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Abstract 
  Anthelmintic resistance in parasitic nematodes of small ruminants is widespread 
and, in some parts of the world, threatens the sustainability of sheep production.  The 
mechanisms whereby parasitic nematodes become resistant to anthelmintics, particularly 
ivermectin, remain to be determined.  The majority of studies to date have investigated 
target site mutations; relatively little attention has been paid to the role of gene expression 
changes.    The  present  study  focused  on  Teladorsagia  circumcincta;  the  predominant 
parasitic  gastrointestinal  nematode  species  in  the  UK  and  the  predominant  resistant 
species.    The  role  of  changes  in  gene  expression  were  investigated  in  an  ivermectin-
susceptible isolate (CVL) and a multidrug resistant isolate (MOTRI), utilising a range of 
molecular biological techniques. 
 
  In the first experiment, a panel of novel putative ivermectin resistance genes were 
identified from T. circumcincta, comprising 11 partial P-glycoprotein (Pgp) and 3 partial 
Cytochrome P450  (CYP) sequences.  Both Pgps and CYPs have been implicated in the 
handling and metabolism of xenobiotics in other biological systems, but have not been 
investigated  in  T.  circumcincta  to  date.    Initial  results,  using  semi-quantitative  PCR 
identified changes in expression of this panel of genes between the CVL and MOTRI 
isolates.   
 
  Constitutive differences in expression of the Pgps and CYPs between CVL and 
MOTRI were determined using the ʔʔCt TaqMan
® real-time PCR method.  A statistically 
significant increase in expression was observed for TeciPgp-9 NBD2 across all life-cycle 
stages but most notably in eggs (55-fold increase).  A statistically significant reduction in 
expression  of  TeciPgp-2  NBD2  was  observed  in  all  but  the  adult  stages  of  MOTRI 
compared to CVL.  Analysis of a 208 base pair sequence of TeciPgp-9 NBD2 identified 
high levels of polymorphism, with at least four non-coding SNPs evident in the MOTRI 
isolate.  These results merit further investigation.  
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  Inducible changes in the expression of the Pgps and CYPs were investigated in 
MOTRI  before  and  after  ivermectin  treatment,  using  real-time  PCR.    Statistically 
significant fold changes in expression in most of the genes occurred in at least one life-
cycle  stage.    Inducible  expression  of  TeciPgp-2  NBD2  and  TeciPgp-9  NBD2  was 
investigated further by comparing adult MOTRI parasites with those recovered three days 
after in vivo ivermectin exposure, and by exposing pools of MOTRI xL3 to ivermectin in 
the  larval  migration  inhibition  test.    The  survivors  of  ivermectin  exposure  exhibited  a 
statistically significant reduced 13.68-fold expression of TeciPgp-2 NBD2 compared to 
MOTRI.  Similarly, the MOTRI xL3 able to migrate in the presence of ivermectin in the 
LMIT had a 1.88-fold reduction in TeciPgp-2 NBD2 expression compared to MOTRI xL3 
unexposed  to  ivermectin.    These  results  indicate  that  inducible  changes  in  TeciPgp-2 
NBD2 and TeciPgp-9 NBD2 expression can occur, but the experimental design is critical 
to being able to identify the changes.   
 
  In a more global approach, the transcriptomic response of MOTRI adults to in vitro 
ivermectin  exposure  was  investigated  using  Roche  454  sequencing,  generating  98,685 
novel  EST  sequences,  providing  an  important  resource  for  a  genome  resource-poor 
organism.    Objective  bioinformatic  analysis  of  the  two  datasets  revealed  statistically 
significant differences in the mean expression levels of the KEGG orthologous groups for 
„translation‟,  „amino  acid  metabolism‟  „carbohydrate  metabolism‟  and  „xenobiotic 
degradation and metabolism‟.  On combining the two datasets, and through application of a 
novel  statistical  method, 16 clusters of ESTs were identified as  containing statistically 
significant differences in the mean proportion of exposed reads compared to unexposed 
reads  under  the  conservative  model,  whilst  a  further  355  clusters  were  found  to  have 
statistically significant differences under the liberal model.   
 
  One-way suppression subtractive hybridisation (SSH) was used to identify genes 
exhibiting increased expression in MOTRI adults compared to CVL adults.  28 contiguous 
sequences were identified from the SSH experiment; 6 contiguous sequences were selected 
for validation; 5 of these results were confirmed using semi-quantitative PCR.  Each contig 
was BLAST searched against the Roche 454 dataset; contig SSH14 aligned most closely to 
one of the statistically significant clusters in the conservative model, SSHs 5, 6, 10 and 23 4 
aligned most closely to statistically significant clusters in the liberal model.  This suggests 
that changes in expression in these sequences occur both constitutively, between CVL and 
MOTRI isolates, and inducibly, following ivermectin exposure.   
 
  This  work  has  shown  that  changes  in  gene  expression,  particularly  the 
constitutively  reduced  expression  in  TeciPgp-2  NBD2  and  the  constitutively  increased 
expression in TeciPgp-9 NBD2 (coupled with the presence of SNPs) could play a role in 
allowing multidrug resistant T. circumcincta to survive ivermectin exposure.  Roche 454 
sequencing and SSH approaches  identified  gene expression changes  associated with  in 
vitro ivermectin exposure and ivermectin resistance.  These could form the basis of a novel 
panel of candidate resistance genes whose altered expression profiles may allow multidrug 
resistant  T.  circumcincta  to  survive  ivermectin  exposure  by  some,  as  yet  identified, 
mechanism.    Finally,  we  have  also  shown  that  a  multidrug  T.  circumcincta  isolate  is 
affected by ivermectin exposure and that changes in gene expression could have a role to 
play  in  the  ivermectin  resistance  phenotype  in  T.  circumcincta.    The  genetic  changes 
underpinning these changes in gene expression remain to be elucidated, and need to be 
investigated  in  other  isolates.    These  changes  could  form  the  basis  of  an  ivermectin 
resistance  molecular  marker,  to  monitor  the  spread  of  resistance,  and  to  evaluate 
management practices aimed at delaying its spread.   
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Chapter 1: General Introduction 
1.1: Parasitic gastroenteritis (PGE) 
Parasitic  gastroenteritis  (PGE)  is  caused  by  the  presence  of  large  numbers  of 
gastrointestinal (GI) nematode parasites in the stomach and intestines of ruminants, leading 
to reduced liveweight gain, anaemia, and in some cases, death.  Clinical signs of PGE 
include diarrhoea, lethargy and, in more severe cases, anaemia and submandibular oedema 
(Urquhart  et  al.,  1996;  Sargison,  Jackson,  &  Scott,  2002;  Nieuwhof  &  Bishop,  2005; 
Taylor, Coop, & Wall, 2007).  There is a range of costs associated with PGE in sheep, both 
for the farmers and the animals, such as loss of efficient production of meat, milk and wool 
and a reduction in the animals‟ welfare level (Boyne, Stott, & Gunn, 2006; Broughan & 
Wall, 2007).  It is difficult to accurately quantify the economic costs of PGE as the effects 
of nematode infection can cause either clinical or sub-clinical disease, yet parasitism is 
seen as the single most important cause of production losses in small ruminants around the 
world (Molento, 2009).  The cost of GI nematode infection in the UK sheep industry was 
estimated by Nieuwhof & Bishop (2005) to be £84 million per annum, with the range in 
estimates being £48M to £120M.  This is calculated as the cost to the industry due to 
reduced  lamb  growth  rates  plus  treatment  and  prevention  measures.    It  has  also  been 
estimated  that  ovine  nematodes  inflict  the  greatest  net  cost  to  the  Australian  grazing 
industry (McLeod, 1995).   
 
PGE in sheep is caused by individual or concurrent infections with the nematode 
parasites  Teladorsagia  circumcincta,  Haemonchus  contortus,  Trichostrongylus  spp, 
Nematodirus spp and Cooperia spp.  In cool temperate regions, the principal cause of PGE 
is  T.  circumcincta  whilst  in  tropical  and  subtropical  regions,  H.  contortus  is  more 
important (Sargison, Jackson, & Scott, 2002; Sargison et al., 2005; Stear et al., 2006; 
Taylor, Coop, & Wall, 2007).  PGE caused by T. circumcincta (teladorsagiosis) in sheep 
results in a hyperplastic gastritis which can be loosely described as two different types 
(analogous  to  type  I  and  type  II  bovine  ostertagiosis  caused  by  Ostertagia  ostertagi) 
(Urquhart et al., 1996; Sutherland & Scott, 2010).  Type I is found in lambs in their first 
grazing  season  usually  between  August  and  October,  and  is  due  to  the  ingestion  and 
maturation of large numbers of infective larvae from the pasture.  The rarer type II occurs 
during late winter and early spring and is caused by the delayed maturation of worms 23 
which had been ingested the previous autumn and entered a period of arrested development 
in  the  host  (Gibbs,  1986;  Urquhart  et  al.,  1996).    Alternatively,  larvae  that  have 
overwintered  on  pasture  may  also  cause  type  II  teladorsagiosis  (Sargison,  Jackson,  & 
Scott, 2002).  Type I is a more acute disease whilst type II was generally seen as a sub-
clinical disease leading to production losses (Abbott, Taylor, & Stubbings, 2004).   
 
Surveillance reports have suggested that cases of PGE in sheep are increasing in 
Scotland, and are mostly due to T. circumcincta infection.  It is thought that this is possibly 
due  to  a  combination  of  climate  change,  an  increase  in  anthelmintic  resistance  and 
extensive  animal  movement,  especially  post  Foot  and  Mouth  Disease 
(http://www.defra.gov.uk/vla/reports/rep_surv.htm).  In South East Scotland there has been 
a 20% increase in annual rainfall and a 1ºC increase in average monthly temperatures 
between 1961 and 2004 which has led to an extended herbage growing i.e. grazing season 
of 4 weeks (Barnett et al., 2006).  This means that conditions for survival and development 
of the larval stages of nematodes such as T. circumcincta in the environment are becoming 
more favourable.  Type II teladorsagiosis is now becoming more common in South East 
Scotland than in previous years; PGE outbreaks also appear to be becoming more severe 
(Sargison et al., 2007a; Kenyon et al., 2009a). 
 
1.1.1: Immunity to GI nematodes 
PGE is  principally  a disease of  young animals.  Regular  exposure to  moderate 
burdens of parasites allows the lamb to develop an immune response which prevents the 
parasite from establishing in the host in large numbers (Colditz et al., 1996; Stear et al., 
2009).  Repeated ingestion of larvae by lambs over a period of two to four months from the 
age of four to five months gradually allows a protective immunity to develop  (Abbott, 
Taylor, & Stubbings, 2004).  Immunity to T. circumcincta takes two grazing seasons to 
become fully established and adult sheep will generally only harbour a few adult worms 
(Urquhart  et  al.,  1996;  Taylor,  Coop,  &  Wall,  2007),  suggesting  the  immunity  which 
develops  is  not  a  completely  sterile  immunity  (Abbott,  Taylor,  &  Stubbings,  2004; 
Sutherland & Scott, 2010).  The level of immunity appears to vary with age, the genotype 24 
of the sheep and also the reproductive status of the ewe (McNeilly, Devaney, & Matthews, 
2009). 
 
GI nematode infection has been associated with an increase in IgE and peripheral 
and  mucosal  eosinophils  (Miller,  1996;  Huntley  et  al.,  1998a;  Huntley  et  al.,  1998b; 
Sutherland  &  Scott,  2010).    Infection  with  GI  nematodes  causes  a  specific  humoral 
immune response leading to the production of the Th2 subset of CD4+ helper T cells 
characterised  by  the  expression  of  the  cytokines  IL-4,  -5,  -10  and  -13  (Miller,  1996; 
McNeilly, Devaney, & Matthews, 2009; Sutherland & Scott, 2010).  This suggests that the 
worm  burden is  regulated, in  part, in  immune sheep by an immediate hypersensitivity 
reaction (Stear et al., 1995; Urquhart et al., 1996; McNeilly, Devaney, & Matthews, 2009).  
In abomasal  lymph  node cells  from  immune sheep there is  a greater predominance of 
mRNA transcripts encoding the Th2 associated cytokines, IL-4, -5 and -13 compared to 
parasite naïve sheep  (McNeilly, Devaney, & Matthews, 2009).  A negative correlation 
between anti-larval excretory/ secretory specific mucus IgA levels and the number of GI 
nematodes  which  establish  in  the  abomasum  has  been  shown  (Smith  et  al.,  2009).  
Increased mucosal IgA levels, in both natural and experimental infections, has been shown 
to negatively correlate with adult worm length, adult worm burden and faecal egg count 
(Stear  et  al.,  1995;  Miller,  1996;  Beraldi  et  al.,  2008;  Stear  et  al.,  2009;  McNeilly, 
Devaney, & Matthews, 2009).  Overall, the immune response to GI nematode infection 
appears  to  affect  the  parasites  in  a  number  of  ways:  preventing  the  establishment  of 
incoming infective third larval stages (L3s); slowing or arresting larval development within 
the wall of the abomasum; affecting the ability for adult worms to grow and reproduce to 
their full potential and increasing the rate at which adult parasites are killed or expelled 
from the abomasum (Taylor, Coop, & Wall, 2007; McNeilly, Devaney, & Matthews, 2009; 
Sutherland & Scott, 2010). 
 
1.2: T. circumcincta 
T. circumcincta is a nematode parasite of small ruminants and is classified in the 
Order  Strongylida,  Superfamily  Trichostrongyloidea  and  Family  Trichostrongylidae 
alongside  the  other  sheep  nematode  parasites;  H.  contortus,  Trichostrongylus  spp, 25 
Nematodirus spp and Cooperia spp (Taylor, Coop, & Wall, 2007).  T. circumcincta was 
previously classified as Ostertagia circumcincta but is also known by its common name, 
the brown stomach worm.  T. circumcincta has a worldwide distribution (Taylor, Coop, & 
Wall, 2007) and in temperate regions is the predominant nematode species parasitizing 
sheep  (Sargison,  Jackson,  &  Scott,  2002;  Bartley  et  al.,  2003;  Sargison  et  al.,  2005; 
Broughan & Wall, 2007).  T. circumcincta is a bursate nematode with the adults appearing 
as  red-brown  slender  worms  up  to  10mm  long  in  the  mucosa  on  the  surface  of  the 
abomasum  (Urquhart  et  al.,  1996).    T.  circumcincta  can  be  distinguished  from  other 
species by morphological features such as absence of proconus, bursal ray pattern and, in 
adult males, by the spicules at the posterior end of the worm (Denham, 1969; Lichtenfels 
& Hoberg, 1993; Taylor, Coop, & Wall, 2007). 
 
1.2.1: T. circumcincta life-cycle 
  The  direct  life-cycle  of  T.  circumcincta,  as  shown  in  Figure  1.1,  is  typical  of 
trichostrongylid nematodes.  Eggs are laid by female worms living on the surface of the 
abomasum in the definitive sheep host and are subsequently excreted onto the pasture in 
the faeces.  Eggs develop in the faecal pat to the first larval stage (L1) then moult to the 
second and third larval  stages (L2 and  L3) in  approximately two weeks  under optimal 
conditions.  Ideal conditions for parasite development are 18-26°C and a relative humidity 
of  approximately  60%  (Gruner  &  Suryahadi,  1993;  Urquhart  et  al.,  1996;  O'Connor, 
Walkden-Brown, & Kahn, 2006).  T. circumcincta is more tolerant of low temperatures 
than H. contortus and can complete development from the egg to L3 stage between 1°C and 
35°C.  The increasing average monthly temperatures recorded between 1961 and  2004 
means that there is now a longer period of the year where temperatures exceed 10°C, 
giving the parasites a longer period to develop through to the infective stage (Kenyon et 
al., 2009a; van Dijk et al., 2010).  Once at the L3 stage, the parasite is less susceptible to 
changes in climatic conditions due to the retained L2 sheath and can over-winter on the 
pasture for up to two years and still be infective (Kerboeuf, 1985; O'Connor, Walkden-
Brown, & Kahn, 2006; Stenhouse, 2007).  The L3 migrate from the faecal pat to the pasture 
where they are ingested by the host.  Rainfall increases the infectivity of the pasture by 
allowing easier migration of L3 from the faecal pat to the pasture and by reducing the 
chance of desiccation of the larval stages.  However, immersion of the eggs in water is 26 
detrimental to their viability (Gruner & Suryahadi, 1993; Abbott, Taylor, & Stubbings, 
2004). 
 
After  ingestion,  the  L3  exsheath  in  the  rumen  of  the  sheep  and  migrate  to  the 
abomasal glands where they can be found three to four days post infection (Michel, 1974).  
Once established, the parasite develops through the L4 stage to the final adult stage.  It is 
not possible to distinguish between male and female worms until the L4 stage is reached 
(Denham, 1969).  On emergence from the abomasal glands, the adult parasites become 
sexually mature on the mucosal surface.  Emergence of parasites from the glands causes 
cytolysis  and  sloughing  of  the  epithelium  of  the  abomasum,  which  causes  the  normal 
secretory cells of the gastric glands to be replaced by hyperplastic cells.  This results in the 
loss of the specialised secretory function and junctional integrity of the cells (Scott et al., 
1998), leading to leakage of proteins into the GI tract, resulting in hypoalbuminaemia and 
increased plasma pepsin levels (McKellar, 1993; Sutherland & Scott, 2010).  The time 
taken from ingestion of L3 to the parasites producing eggs, the pre-patent period, is around 
18 days.  The entire life-cycle of T. circumcincta can be completed in as little as three 
weeks (Urquhart et al., 1996). 
 
  Once in the abomasal glands, T. circumcincta can undergo a process known as 
hypobiosis, or arrested larval development.  This is defined as the temporary cessation of 
development, occurring in certain circumstances and times of the year until more suitable 
environmental conditions prevail.  Hypobiosis often only affects a proportion of the worm 
population (Michel, 1974; Urquhart et al., 1996).  In T. circumcincta, a drop in temperature 
in  the  autumn  coincides  with  an  increase  in  the  number  of  hypobiotic  larvae  in  the 
abomasal gland of the sheep.  The larvae develop to the early L4 stage in the abomasal 
glands and then remain at that point for up to three months, or possibly longer (Michel, 
1974; Urquhart et al., 1996).  The synchronised development of these hypobiotic larvae in 
the spring is a major cause of type II teladorsagiosis (Urquhart et al., 1996).  The numbers 
of larvae undergoing arrested/ inhibited development also seems to be correlated with the 
size of the local IgA immune response of the host and the size of the worm burden within 
the host (Stear et al., 1995).  Hypobiosis may also play a part in the peri-parturient rise 
(PPR) seen in ewes, when an increase in nematode eggs excreted in the faeces occurs 27 
around lambing time.  Three mechanisms appear to combine to cause the PPR; a temporary 
relaxation in the immunity to the parasites concurrent with increased prolactin levels in the 
ewe allows hypobiotic larvae to develop; a reduced loss of adult worms and an increased 
establishment  of  new  worms;  and  an  increased  fecundity  of  the  existing  adult  worms 
(Michel, 1974; Urquhart et al., 1996; Taylor, Coop, & Wall, 2007).  The eggs produced 
during the PPR are the source of virtually all the parasites acquired by the lambs; it is these 
parasites  which  cause  type  1  PGE  (Heath  &  Michel,  1969;  Gibson,  1973).    The  PPR 
usually occurs from two weeks before lambing to six weeks post-lambing (Urquhart et al., 
1996) and ensures the pasture is heavily contaminated with eggs, and hence infective L3s, 
at the point when the lambs are most susceptible to infection. 
 
1.3: Control of parasitic gastroenteritis 
  Control of gastrointestinal infections is attempted through various means but the 
principal method of control of PGE in sheep flocks has been the regular strategic use of 
anthelmintics to prevent disease in lambs which have not yet developed natural immunity 
to the parasites (Abbott, Taylor, & Stubbings, 2004; Prichard et al., 2007).  The aim of 
anthelmintic treatment is to prevent clinical or sub-clinical disease, and hence some of the 
costs associated with PGE, whilst allowing the development of natural immunity (Urquhart 
et al., 1996; Molento, 2009).  An increase in anthelmintic resistance, together with the 
growing  popularity  of  organically  produced  food  and  concerns  about  drug  residues 
entering the food chain has generated interest in control strategies that do not solely rely on 
anthelmintics.  However, none of these alternative control strategies discussed below offer 
an  effective  alternative  to  anthelmintics  on  their  own  (Wolstenholme  et  al.,  2004).  
Another method of controlling PGE, which has been the focus of much research, is the 
development  of  vaccines  that  target  antigens  excreted  or  secreted  by  the  parasites,  or 
molecules localised, or hidden, within the parasites.  These alternative control strategies, 
including vaccination, will be discussed first followed by the anthelmintics.   
 
1.3.1: Alternative control strategies 
Other methods of control include breeding to increase host resilience to parasite 
infection.  Resilience is the ability of the host to remain productive whilst infected with GI 28 
nematodes.  Certain breeds of sheep and individuals within a flock appear to be more able 
to sustain growth whilst infected with parasites.  The majority of sheep in a flock will 
harbour  few  parasites  whilst  the  minority  will  harbour  the  majority  of  the  parasite 
population,  this  is  known  as  over-dispersion  (Stear  et  al.,  2006;  Mitreva  et  al.,  2007; 
Stafford,  Morgan,  &  Coles,  2009).    Selective  breeding  for  animals  more  resilient  to 
parasite infection (i.e. those able to cope better with the worm burden) or animals relatively 
resistant  to  parasite  infection  (i.e.  those  that  harbour  fewer  parasites  than  relatively 
susceptible animals) could be used to reduce the impact of GI nematodes (Stear et al., 
2000).  However, this approach is slow and heritability values for traits associated with 
resilience are low and usually come at the expense of more desirable production traits such 
as growth, meat and wool quality  (Bisset  & Morris, 1996; Woolaston & Baker, 1996; 
Waller & Thamsborg, 2004; Stear, Doligalska, & Donskow-Schmelter, 2007). 
 
Nutrition plays a role in the impact of GI nematodes on an animal‟s health status.  
Amino  acids  are  required  by  the  sheep  for  maintenance  of  condition,  development  of 
immunity, growth and reproduction.  There is a loss of protein in the gut due to the damage 
to the epithelium caused by the parasites‟ emergence and a resulting reduction in the ability 
of the sheep to utilize metabolizable energy.  This will, in turn, result in competition for 
resources between the different body systems (Sykes & Coop, 2001; Waller & Thamsborg, 
2004).  There is evidence that dietary supplementation with urea enhances resistance to T. 
circumcincta as measured by a lower establishment rate of worms in the abomasum (Stear 
et  al., 2000).  Lambs  will select  for a high protein  diet when infected with  nematode 
parasites but those on a diet supplemented with urea have been shown to eat a higher 
proportion of the food offered (Stear et al., 2000).  Niezen et al (1998) and Heckendorn et 
al (2007) found that feeding plants containing condensed tannins resulted in reduced levels 
of GI nematode infection whilst also improving the performance of sheep.  Other forages, 
not  containing  condensed  tannins,  also  have  an  effect  on  performance  levels  under 
gastrointestinal nematode challenge.  Lambs grazing chicory compared to a grass/ clover 
mix have been shown to have lower faecal egg counts and a faster growth rate (Waller & 
Thamsborg, 2004; Kidane et al., 2010).  There is increasing interest in the use of plants 
with natural anthelmintic properties, particularly for organic producers or in areas where 
there is not sufficient and reliable access to anthelmintics; studies are ongoing to identify 29 
which plants and plant extracts may be of use.  However trials to date on plants, such as 
Albizia anthelmintica, have not been that successful (Grade et al., 2008).   
 
Trials have been carried out on several nematophagous fungi but principally on 
Duddingtonia  flagrans,  which  is  fed,  as  a  supplement  to  the  host  in  the  form  of 
chlamydospores.  The fungi are then excreted onto the pasture where they destroy the 
parasite larvae before they are able to migrate to the herbage, thus preventing infection of 
the host (Larsen, 1999).  In principle this method has been shown to work but in field trials 
involving D. flagrans against naturally acquired infections in dairy ewes there was shown 
to be no significant parasitological benefit, although productivity was improved compared 
to control groups (Faessler, Torgerson, & Hertzberg, 2007).   
 
Grazing management can be used to reduce the infectivity of the pastures and to 
slow the development of anthelmintic resistance.  Suggested methods in the Sustainable 
Control of Parasites in Sheep (SCOPS) guidelines (Abbott, Taylor, & Stubbings, 2004), 
include grazing sheep and cattle together and grouping animals by age.  Co-grazing sheep 
and  goats  is  not  recommended  as  the  same  parasites  can  infect  both  species.    Other 
methods include reducing stocking densities, alternating pasture with crops to disrupt the 
transmission cycle and rotational grazing (Waller & Thamsborg, 2004; Stear, Doligalska, 
& Donskow-Schmelter, 2007). 
 
1.3.2: Anti-parasite vaccines 
There is a growing interest in the use of vaccines to control parasitic infections.  
Vaccines have some advantages over anthelmintics as they leave no chemical residues that 
would  require  withdrawal  periods  for  food  products  and  are  also  seen  as  more 
environmentally friendly as they are not toxic to dung and marine flora and fauna (Dalton 
& Mulcahy, 2001; Vercruysse et al., 2004; Omura, 2008).  The majority of commercially 
available anti-parasite vaccines are for parasitic protozoa and use live attenuated parasites 
(Dalton & Mulcahy, 2001; Smith & Zarlenga, 2006).  There is only one commercially 
available  nematode  parasite  vaccine,  namely  Bovilis
®  Huskvac  (formerly  known  as 30 
Dictol), for vaccinating calves against the lungworm Dictyocaulus viviparus.  This uses 
irradiation-attenuated L3s from donor calves and has been a financially viable vaccine, 
although there are some ethical concerns about the use of large numbers of donor animals 
(Vercruysse et al., 2004).  The majority of current nematode vaccine work concentrates on 
H. contortus (Sutherland & Scott, 2010). 
 
Natural antigen candidates have been studied to determine whether the immunity 
that develops in sheep following GI nematode infection can be harnessed by exposing the 
sheep to antigens such as those excreted or secreted by the parasite (E/S products).  The 
use of 15kDa and 24kDa proteins from E/S products from adult H. contortus, and thiol-
binding fractions from H. contortus E/S were both found to give strong protective immune 
responses  to  challenge  infections  with  H.  contortus  following  vaccination  (Smith  & 
Zarlenga,  2006).    However,  large  numbers  of  donor  animals  are  required  to  obtain 
sufficient quantities of worms to provide E/S material, so attempts have been made to 
make recombinant versions (Smith & Zarlenga, 2006).  The protective immune responses 
to native antigens have been difficult to replicate with recombinant antigens due to the 
complex  nature  of  the  molecules  involved.    Difficulties  in  replicating  the  correct 
conformation and post-translational modifications of the recombinant molecule in artificial 
expression systems like bacteria and yeast have proved to be too challenging (Smith & 
Zarlenga, 2006). 
 
Current focus for vaccine discovery is on the use of “hidden antigens” that reside 
on  the  gut  surface  of  the  parasites  and  are  not  normally  exposed  to  the  host  immune 
response (Knox & Smith, 2001).  The hidden antigen approach is particularly effective 
against  blood-feeding  parasites  such  as  the  cattle  tick,  Boophilus  microplus  and  in  H. 
contortus (Willadsen et al., 1995; Smith & Zarlenga, 2006).  This approach aims to raise a 
circulating antibody response in the host which, once the antibodies are ingested by the 
parasite, interferes with the parasite‟s ability to feed normally, leading to starvation and 
expulsion.  Molecules such as H11 from H. contortus have been identified as strongly 
immunogenic,  giving  greater  than  90%  reduction  in  worm  burdens  against  challenge 
infection (Knox & Smith, 2001).  Another candidate antigen from H. contortus is H-gal-
GP, a complex of putative digestive enzymes extracted from a detergent-soluble, integral 31 
membrane protein fraction.  As H11 and H-gal-GP are hidden antigens, repeated doses of 
vaccine have to be given to maintain protection as the antigens are not immunologically 
recognised by the sheep following H. contortus infection (Smith, Van Wyk, & van Strijp, 
2001).  Recombinant versions of H11, expressed in bacterial and insect cell lines, and H-
gal-GP expressed in bacterial, Pichia and insect cell lines, have, however, failed to elicit 
protection in animal trials (Smith & Zarlenga, 2006).  Native homologues of H11 and H-
gal-GP  have  had  limited  success  in  T.  circumcincta  vaccine  trials  to  date  as  T. 
circumcincta is a mucosal browser so the parasites are not exposed to sufficiently high 
levels  of the effector antibodies;  TcH11 and  TcH-gal-GP  were shown to  be protective 
against  H. contortus  proving their immunogenicity  (Knox & Smith,  2001;  Smith,  Van 
Wyk, & van Strijp, 2001; Sutherland & Scott, 2010).   
 
To compete against anthelmintics, a commercially viable vaccine would have to be 
developed with a broad spectrum of activity, giving protection against at least the three 
major parasites of sheep, namely H. contortus, T. circumcincta and Trichostrongylus spp 
(Dalton & Mulcahy, 2001).  Modelling studies have suggested that a vaccine need only 
have 60% efficacy in 80% of the flock for substantial benefits in terms of reduced lamb 
mortality to be observed so a vaccine does not need to compete against anthelmintics in 
terms of efficacy (Barnes, Dobson, & Barger, 1995).  Developing anti-parasite vaccines 
which are as efficacious as anthelmintics is proving to be problematic.  This is due, in part, 
to the limited availability and complicated nature of the antigens required, difficulties in 
expressing  these  antigens  in  recombinant  form,  antigenic  variation  and  diverse  gene 
expression exhibited by the different life-cycle stages of GI nematodes (Vercruysse et al., 
2004).  In the case of mucosal browsers such as T. circumcincta, it is considerably more 
difficult to deliver antibodies effectively as the parasites are not ingesting serum antibodies 
in sufficient quantities to have the desired effect (Vercruysse et al., 2004; Sutherland & 
Scott, 2010).  Also, delivering the antigens to surfaces such as the gut mucosa in sufficient 
quantities to elicit a mucosal immune response is proving to be difficult (Knox & Smith, 
2001). 
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1.3.3: Anthelmintics 
Anthelmintics are the cornerstone of modern GI nematode control.  Until recently, 
there  have  been  three  main  chemical  families  of  broad  spectrum  anthelmintics 
commercially available to treat GI nematode infections, namely; the benzimidazoles (BZs); 
levamisole and other imidazothiazoles (LEV); and the macrocyclic lactones (MLs).  These 
are  also  known,  respectively,  as  the  “white  drenches”,  “yellow  drenches”  and  “clear 
drenches”  (Abbott,  Taylor,  &  Stubbings,  2004).    A  new  class  of  drugs,  the  amino-
acetonitrile derivatives (AADs) have recently been discovered (Kaminsky et al., 2008).  
The AADs have been launched onto the small ruminant market in New Zealand and more 
recently in the UK.  Each group of anthelmintics appears to have a different mode of 
action, as discussed below.   
 
The  BZs,  such  as  albendazole  (ABZ),  thiabendazole  (TBZ)  and  fenbendazole 
(FBZ), were introduced in the 1960s.  BZs are effective against a broad range of parasites 
and also have wide safety margins, working at dosages of mg/kg bodyweight (McKellar & 
Jackson, 2004).  Their mode of action appears to be mediated through binding to β-tubulin 
within the parasite, thus inhibiting the formation of microtubules that are central to the 
form and function of the parasite‟s cells.  This prevents various essential cellular processes 
such as the transport of secretory granules and enzymes in the cell cytoplasm, resulting in 
cell lysis, with knock-on detrimental effects on motility and feeding (McKellar & Jackson, 
2004; Mitreva et al., 2007; von Samson-Himmelstjerna et al., 2007).  
 
A decade later, another broad spectrum anthelmintic, LEV, was released onto the 
market.  Like the BZs, the dose is also in the mg/kg bodyweight range, however, LEV also 
acts on the host so care has to be taken with the dosage (McKellar & Jackson, 2004).  LEV 
is a member of the imidazothiazole/ tetrahydropyrimidine class of anthelmintics, which 
also includes pyrantel (PYR) (McKellar & Jackson, 2004).  LEV is a cholinergic agonist at 
the nicotinic neuromuscular junctions that works by first opening and then blocking the 
acetylcholine receptor-mediated cation channels.  This causes a sustained neuromuscular 
depolarisation, leading to a rapid tonic paralysis of the parasite‟s somatic musculature, 
resulting in expulsion from the host (Dobson et al., 1986; Martin et al., 1998; Prichard, 33 
2001; McKellar & Jackson, 2004; Rayes et al., 2004; Kopp et al., 2008; Prichard & Geary, 
2008). 
 
The ML, ivermectin (IVM) was isolated from Streptomyces avermectinius in 1974 
and  released  onto  the  market  in  1981,  and  is  effective  at  doses  of  µg/kg  bodyweight 
(McKellar & Jackson, 2004; Van Zeveren et al., 2007a; Omura, 2008).  IVM was the first 
commercially  available  endectocide,  being  effective  against  helminths,  arachnids  and 
insects (Geary, 2005; Omura, 2008).  IVM was found to have high levels of potency, a 
broad spectrum of activity and good persistence, enabling novel application routes such as 
slow  release  devices  (boluses),  injectable  formulations  and  topically  applied  (pour-on) 
IVM to be developed (Geary, 2005).  When fully effective, IVM has an efficacy of almost 
100%, as a result, it is now the largest selling anti-parasitic drug in livestock and has 
essentially revolutionised the animal health industry (McKellar & Jackson, 2004; Geary, 
2005; Van Zeveren, 2009).  IVM binds irreversibly to γ-aminobutyric acid- (GABA) and 
glutamate-gated  chloride  (GluCl)  channels  causing  the  hyperpolarisation  and  flaccid 
paralysis of pharyngeal and somatic muscle cells, leading to starvation and immobility of 
the worms (Martin et al., 1998; Blackhall et al., 1998a; Blackhall, Prichard, & Beech, 
2003;  Gilleard  &  Beech,  2007;  Prichard  &  Roulet,  2007;  Stenhouse,  2007;  James  & 
Davey, 2008).  Another member of the ML family is moxidectin (MOX), which was also 
isolated from a species of Streptomyces.  MOX appears to have a similar mode of action to 
IVM; the two ML subclasses, the avermectins (e.g. IVM) and milbemycins (e.g. MOX), 
have been shown to competitively displace each other from a GluCl channel in C. elegans 
(Ardelli et al., 2009).  MOX and IVM share the same central ML ring core, only differing 
at the side chains (Lespine et al., 2007; Ardelli et al., 2009).  Compared to IVM, MOX is 
more  lipophilic,  allowing  it  to  be  absorbed  faster  and  persist  longer  within  the  host 
(Lespine et al., 2007; Lifschitz et al., 2010). 
 
The AADs are the first new anthelmintic class since the MLs and appear to have a 
novel  mode  of  action,  targeting  nicotinic  acetylcholine  receptors  that  are  unique  to 
nematodes (Kaminsky et al., 2008; Prichard & Geary, 2008).  The AADs cause the hyper-
contraction of nematode somatic muscle cells, leading to paralysis.  They also cause the 
spasmodic contraction of the anterior portion of the pharynx.  Both these effects ultimately 34 
lead  to  the  parasite‟s  death  (Kaminsky  et  al.,  2008).    The  AADs  appear  to  have  low 
toxicity against mammals whilst also being efficacious against both the larval and adult 
stages (Besier, 2009). 
 
1.4: Anthelmintic resistance 
Anthelmintic  treatment  applies  a  selection  pressure  on  parasitic  populations;  an 
inevitable  consequence  of  the  regular  prophylactic  use  of  anthelmintics  has  been  the 
parasites  developing  resistance.    Anthelmintic  resistance  is  defined  as  the  ability  of 
parasites to survive a dose of drug that would normally kill them; it is heritable and non-
reversible (Barton, 1983; Jackson & Coop, 2000; Wolstenholme et al., 2004).  Phenotypic 
resistance can either be seen as a heritable decline in a drug‟s effectiveness or a reduction 
in the length of time that a drug is able to exert its effects on the parasites within the host 
(James, Hudson, & Davey, 2009).  A parasite resistant to one anthelmintic in a drug class 
will  usually  be  resistant  to  all  anthelmintics  within  that  class;  this  is  known  as  side 
resistance (Kaplan et al., 2007).  The exception to this rule appears to be the ML, MOX, 
which appears to retain efficacy, for several treatment cycles, against parasites exhibiting 
IVM resistance, possibly due to longer persistency within the sheep (Sutherland et al., 
2002; Sutherland et al., 2003; Lespine et al., 2007; Wilson & Sargison, 2007; Lifschitz et 
al., 2010).  Drug resistance has developed rapidly to the three currently available classes of 
drugs, for example within three years of launch for IVM, and is a major threat to livestock 
production in many parts of the world (Van Wyk & Malan, 1988; Kaplan, 2004; Lespine et 
al.,  2008;  Sutherland,  Shaw,  &  Shaw,  2010).    Anthelmintic  resistance  is  a  global 
phenomenon but is more prevalent in the Southern Hemisphere (Jackson & Coop, 2000; 
Bartley et al., 2004; Kaplan, 2004).  It has been estimated that carrying out a monthly 
preventative treatment regime, using a drug that the parasites are resistant to, results in the 
average price of the finished lamb being 14% lower compared to lambs which had been 
treated monthly with an effective drug (Sutherland, Shaw, & Shaw, 2010).  In the absence 
of alternative control strategies, such as those discussed above, high levels of anthelmintic 
resistance may make it impossible to sustain economic sheep production on some farms, in 
some cases this has already occurred (Jackson & Coop, 2000; Sargison et al., 2005).   
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In the UK, BZ resistant T. circumcincta were first reported in sheep in Cheshire in 
1982 (Britt, 1982; Cawthorne & Whitehead, 1983), with the first report of LEV resistance 
in sheep in 1994.  IVM resistance was only relatively recently identified in sheep in 2001 
(Sargison, Scott, & Jackson, 2001), having previously been identified in goats in 1992 
(Jackson, Jackson, & Coop, 1992).  Resistance to IVM appears to be more common in 
small ruminants than in large ruminants, possibly due to different pharmacokinetics and 
the latter being able to mount a stronger immune response to the parasites and, therefore, 
requiring fewer anthelmintic treatments (Geary, 2005).  The predominant nematode species 
exhibiting resistance in the UK appears to be T. circumcincta (Jackson & Coop, 2000; 
Bartley et  al., 2003).  The true extent of anthelmintic resistance is  not  known  (Coles, 
2005),  as  few  farmers  routinely  check  the  efficacy  of  the  anthelmintics  they  use  and 
resistance  is  often  only  diagnosed  after  the  clinical  failure  of  the  drugs  on  the  farm 
(Stubbings, 2003; Sargison et al., 2007b).  Large-scale anthelmintic surveys are labour 
intensive,  expensive  and  logistically  difficult  to  perform.    Sixty-four  percent  of  farms 
tested in a survey of Scottish sheep flocks had resistance to benzimidazoles (Bartley et al., 
2003), with the prevalence higher in lowland farms compared to upland or hill farms.  This 
survey found no evidence for LEV and IVM resistance in Scottish sheep flocks at that time 
but a later survey, (Bartley et al., 2006), found IVM resistant T. circumcincta in six out of 
seventeen flocks sampled.  No routine surveillance for resistance is carried out, suggesting 
that anthelmintic resistance may be more widespread than stated in the literature (Sargison, 
Scott, & Jackson, 2001). 
 
Multiple anthelmintic resistance is observed when a parasite population is resistant 
to more than one drug class.  Triple resistance to the BZs, LEV and MLs was first recorded 
in the 1980s in H. contortus in South Africa (Van Wyk & Malan, 1988; Kaplan, 2004).  
Multiple anthelmintic resistance is more prevalent in the Southern Hemisphere (Bartley et 
al., 2004).  The first triple resistant parasites of ovine origin in the UK were reported in 
2001  and  triple  resistance  has  now  been  reported  in  at  least  five  UK  sheep  flocks 
(Sargison,  Scott,  &  Jackson,  2001;  Bartley  et  al.,  2004;  Sargison  et  al.,  2007b).    The 
inability to control T. circumcincta infection due to multiple anthelmintic resistance has 
been seen as a contributory factor in the abandonment of sheep farming on at least two UK 
farms (Sargison et al., 2005; Blake & Coles, 2007). 
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The AADs were released onto the market in New Zealand in 2009 and in the UK in 
2010, against a background of parasites already resistant to existing anthelmintics, as such, 
it  will  become  increasingly  important  to  monitor  the  efficacy  of  AAD  anthelmintic 
treatment.    Parasites  that  are  already  multi-drug  resistant  in  the  field,  although  not 
predisposed  to  AAD-resistance  will  inevitably  develop  resistance  to  the  AADs;  AAD-
resistant  H.  contortus  strains  have  been  generated  using  in  vitro  and  in  vivo  selection 
experiments whilst laboratory mutagenic experiments were used to generate AAD-resistant 
C.  elegans.    From  these  resources  putative  AAD  resistance  markers  were  identified 
(Kaminsky et al., 2008).  By identifying and monitoring the spread of AAD resistance 
using the putative AAD resistance markers when it inevitably occurs in the field, we will 
be able to better understand the mechanisms involved in AAD resistance and what causes 
its spread. 
 
1.4.1: Factors affecting the development of anthelmintic resistance 
The development of anthelmintic resistance has occurred relatively rapidly.  It is 
facilitated by the large population size and inherent high genetic variability that is typical 
amongst  nematode  parasites,  and  compounded  by  the  movement  of  their  host  species 
(Blouin et al., 1995; Redman et al., 2008).  It is viewed as the inevitable consequence of 
routine  anthelmintic  use  (Jackson  &  Coop,  2000;  Abbott,  Taylor,  &  Stubbings,  2004; 
James & Davey, 2008).  Suppressive prophylactic parasite control strategies across the 
whole flock, utilising anthelmintics at regular intervals corresponding to the pre-patent 
period of the parasites, have been used to disrupt the parasite life-cycle and prevent clinical 
disease (Stubbings, 2003).  The frequency of treatment determines how rapidly resistance 
will develop (Barton, 1983; Kwa, Veenstra, & Roos, 1994; Prichard, 2001).  Suppressive 
prophylactic parasite control in young lambs has also been shown to prevent the lambs 
from developing a protective immune response to H. contortus meaning they are more at 
risk of developing haemonchosis once the parasites are no longer being controlled by the 
anthelmintics (Colditz et al., 1996).   
 
A study of the sequences  of isotype 1  -tubulin alleles of  H. contortus and T. 
circumcincta from goat farms in France suggests that BZ resistance in small ruminants has 37 
resulted from the selection of pre-existing resistance alleles in addition to spontaneous 
mutations resulting in novel resistance alleles (Silvestre & Humbert, 2002; Silvestre et al., 
2009).  In an open sheep farm in the UK, analysis of the T. circumcincta BZ-resistant 
isolate present on the farm indicated that resistance to BZs has occurred through multiple 
mutations, spread between populations by gene flow as a result of the open nature of the 
UK  sheep  flock  (Skuce  et  al.,  2010).    Resistant  parasites  do  not  appear  to  revert  to 
susceptibility once the selection pressure of anthelmintic treatment is removed, suggesting 
that there is no reduction in fitness in resistant parasites (Coles, 2005; James & Davey, 
2008).  No significant difference in egg production, development rate, establishment in the 
host  or  survival  of  adults  or  larvae  was  found  when  comparing  BZ-resistant  and  -
susceptible T. circumcincta (Elard, Sauve, & Humbert, 1998). 
 
Some control methods advocated in the past have since been proven to be highly 
selective for anthelmintic resistance.  One such recommendation was to dose sheep with 
anthelmintics and move them to clean pasture in an attempt to reduce the numbers of 
infective larvae available to re-infect the sheep (Boag & Thomas, 1973; Morley & Donald, 
1980).  This “dose and move” strategy has been shown to select more rapidly for resistance 
as all the parasites contributing to the next generation will be those which survived the 
anthelmintic treatment  i.e. potentially  resistant  (Silvestre & Humbert, 2000;  Stubbings, 
2003;  Waghorn  et  al.,  2009).    This  practice  is  now  being  actively  discouraged.    It  is 
recommended that sheep are weighed prior to treatment to reduce the chance of under-
dosing and that sheep are withheld from feed for 24 hours prior to treatment to slow the 
flow of digesta through the gut, which can improve drug efficacy.  It is also important to 
ensure  dosing  guns  are  correctly  calibrated  and  the  anthelmintics  are  stored  correctly 
(Barnes, Dobson, & Barger, 1995; Dobson, Le Jambre, & Gill, 1996; Silvestre, Cabaret, & 
Humbert,  2001;  Abbott,  Taylor,  &  Stubbings,  2004).    The  use  of  anthelmintics  with 
persistent activity such as MOX can also hasten the development of anthelmintic resistance 
as the parasites are exposed to declining doses of the drug for a longer period, a process 
called tail selection (Dobson, Le Jambre, & Gill, 1996; Le Jambre et al., 1999).   
 
Another method to increase the bioavailability and, hence, the efficacy of the ML 
anthelmintics, but which has yet to get beyond research applications, is to co-administer an 38 
inhibitor of P-glycoproteins (Pgps) alongside IVM.  In the in vitro larval feeding inhibition 
test (LFIT), the use of Pgp interfering agents such as ketoconazole, verapamil and quercitin 
has been shown to drive BZ and IVM resistant T. circumcincta and H. contortus isolates 
towards a susceptible phenotype, as shown by a shift to the left on the dose response curve, 
indicating more larvae are affected by the drug at a lower concentration (Bartley et al., 
2009).    In  vivo,  it  has  also  been  shown  that  ketoconazole  increases  the  plasma 
concentration of IVM in sheep by reducing the Pgp mediated IVM efflux (Alvinerie et al., 
2008). 
 
A  certain  proportion  of  the  parasite  population  will  not  be  exposed  to  the 
anthelmintic during treatment, these parasites are said to be in refugia, and include the 
environmental stages of the parasite (eggs to L3), encysted larvae in the abomasal glands 
and parasites in sheep which are left untreated (Abbott, Taylor, & Stubbings, 2004).  The 
principle of refugia is now seen as the most important factor in delaying the spread of 
anthelmintic resistance by providing a source of susceptible parasites to dilute out resistant 
individuals (Soulsby, 2007).  Allowing part of the sheep flock to remain untreated, for 
example ewes which have built up natural immunity to parasites, or only treating those 
animals  showing  clinical  symptoms  of  PGE  will  increase  the  numbers  of  parasites  in 
refugia and slow the development of resistance (Abbott, Taylor, & Stubbings, 2004).  The 
use of targeted selective treatment (TST) regimes is being investigated as a refugia-based 
management strategy aimed at maintaining drug efficacies whilst minimizing the loss of 
productivity caused by PGE.  These strategies use indicators such as milk yield, weight 
gain, level of anaemia and faecal egg count to determine which animals in a flock require 
anthelmintic treatment.  Liveweight gain in lambs has been shown to be a good indicator of 
individuals  requiring  treatment  in  areas  where  T.  circumcincta  predominates,  and  the 
FAMACHA (Faffa Malan Chart) system in tropical climates, using the level of anaemia, 
where  H.  contortus  is  predominant  (Stafford,  Morgan,  &  Coles,  2009;  Kenyon  et  al., 
2009a).  Preliminary results show that the TST approach maintains drug efficacy better 
than  traditional  suppressive  treatment  regimes  whilst  also  having  little  effect  on  lamb 
liveweight  gain  and  only  requiring  approximately  half  the  amount  of  anthelmintic 
(Burgess, Bennett, & Kenyon, 2009; Greer et al., 2009; Kenyon et al., 2009b). 
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Anthelmintic resistance appears to be a genetic phenomenon; resistant worms give 
rise to resistant offspring.  The means by which resistance is inherited will also affect how 
quickly  resistance  develops,  for  example,  anthelmintics  with  multiple,  genetically 
independent sites of action will cause the development of resistance in the parasites to 
occur  more  slowly  compared  to  an  anthelmintic  with  a  single  defined  point  of  action 
(Martin et al., 1998).  If resistance is inherited as a dominant trait or is sex-linked, it will 
spread much more rapidly through a population than if it is a recessive trait.  The genetics 
of  anthelmintic  resistance  is  complex,  with  little  consensus  in  the  literature;  different 
species and sexes of parasites seem to exhibit different patterns of resistance.  Furthermore, 
the different modes of action of the anthelmintic classes is likely to mean each class has a 
distinct mechanism of resistance.  BZ resistance in H. contortus was initially described as 
incompletely dominant and subsequently as a multigenic, recessive autosomal trait whilst 
in T. colubriformis BZ resistance is an incompletely recessive trait (Dobson, Le Jambre, & 
Gill, 1996; Sangster, Redwin, & Bjorn, 1998; Le Jambre et al., 1999; Sutherland & Scott, 
2010).  LEV resistance in T. circumcincta and in T. colubriformis females is a sex-linked 
recessive trait but in H. contortus LEV resistance is an autosomal recessive trait (Dobson, 
Le  Jambre,  &  Gill,  1996;  Sangster,  Redwin,  &  Bjorn,  1998;  Martin  et  al.,  1998; 
Wolstenholme et al., 2004; Sutherland & Scott, 2010).  LEV and TBZ resistance in an 
isolate of H. contortus was proposed to be controlled by more than one gene (Sangster, 
Redwin, & Bjorn, 1998).  ML resistance in H. contortus and T. circumcincta appears to be 
controlled by dominant traits (Dobson, Le Jambre, & Gill, 1996; Le Jambre et al., 1999; Le 
Jambre et al., 2000; Sutherland et al., 2002; Sutherland et al., 2003; Wolstenholme et al., 
2004). 
 
1.5: Detection of anthelmintic resistance 
Currently, detection of anthelmintic resistance relies on in vitro and in vivo tests.  
However, these tests are limited in their use as not all drugs can be tested using each assay, 
they are time-consuming, expensive, labour intensive and in some cases require the use of 
test animals (Coles et al., 1992).  Some of the current diagnostic tests only work when at 
least  25%  of  the  parasite  population  under  test  is  phenotypically  resistant  (Martin, 
Anderson, & Jarrett, 1989; Coles et al., 1992; McKellar & Jackson, 2004).  The exceptions 
to this are DNA-based tests for detecting BZ resistance in which individual parasites and 
pooled  samples  can  be  assayed,  giving  much  higher  sensitivity.    Details  of  how  each 40 
diagnostic test works are given below together with their limitations.  There is a need for 
improved tests for detecting resistance to make the best use of existing anthelmintics, to 
investigate the genetic consequences of different management strategies and ultimately as 
surveillance tools for use in the field. 
 
1.5.1: In vivo tests 
The controlled efficacy test (CET) is seen as the gold standard test to calculate the 
true efficacy of anthelmintics (McKellar & Jackson, 2004; Coles et al., 2006).  Control 
animals are infected with a known number of L3 and then dosed with anthelmintic at a 
range  of  concentrations.    After  a  set  time  period,  the  animals  are  culled  and  worms 
recovered from the abomasum.  Resistance is confirmed when the reduction in worm count 
is less than 90%, or more than 1000 worms survive treatment (Coles et al., 1992; Taylor, 
Hunt, & Goodyear, 2002).  An untreated group is also included as a control.  Details of the 
standardised method for carrying out the CET are given in Wood et al (1995), having 
standardised  methods  allows  drug  efficacy  trials  from  around  the  world  to  be  easily 
compared.  The use of test animals is expensive, time-consuming and labour intensive; 
there are also ethical concerns about the use of experimental animals. 
 
The faecal egg count reduction test (FECRT) compares the faecal egg count of 
individual  animals  before  and  after  anthelmintic  treatment;  it  is  relatively  simple  to 
perform  and  can  be  used  to  test  all  groups  of  anthelmintics  but,  like  the  CET,  it  is 
expensive and time-consuming (Taylor, Hunt, & Goodyear, 2002).  A gap of 10 to 17 days, 
depending on the anthelmintic under test, between treatment and test days is required as a 
drop in egg production occurs directly after anthelmintic treatment.  The inclusion of an 
untreated control group is recommended to identify any natural fluctuations in egg output 
during the test period.  Resistance is confirmed when the reduction in faecal egg count 
post-treatment  is  less  than  95%  and  when  the  lower  95%  confidence  interval  of  the 
reduction in faecal egg count is less than 90%.  Resistance is suspected when only one of 
the two criteria is met (Coles et al., 1992; Bartley et al., 2006; Van Zeveren et al., 2007a). 
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1.5.2: In vitro tests 
The egg hatch test (EHT) only works with the BZs as LEV and the MLs are not 
ovicidal (Coles, 2005).  Eggs collected from faeces are incubated in serial dilutions of TBZ 
and the percentage hatch rate observed, allowing the discriminating dose to be calculated 
from a dose response curve (Le Jambre, 1976; Taylor, Hunt, & Goodyear, 2002).  The 
EHT  performs  best  on  species  of  nematodes  with  rapidly  hatching  eggs  (Coles  et  al., 
1992).  In mixed gastrointestinal nematode infections, species identification of the hatched 
larvae is possible.  Recently, a standardised protocol has been determined to allow easy 
repeatable comparison between laboratories (von Samson-Himmelstjerna et al., 2009b).  
An altered protocol for the egg hatch test is available for the detection of LEV resistance 
(Dobson et al., 1986). 
 
The micro-agar larval development test (MALDT) is used to identify resistance to 
BZs and LEV but cannot be used for the MLs as it is not reliable enough (Coles, 2005).  
The larval development test (LDT) can be used with any anthelmintic group and involves 
the  development  of  L1  into  L3  in  the  presence  of  the  anthelmintic  under  test,  with 
Escherichia coli as a food source (Taylor, Hunt, & Goodyear, 2002).  A commercial larval 
development test called “Drenchrite” has been developed (Coles, 2005). 
 
  The LFIT is used to test for ML and LEV resistance.  Eggs collected from faeces 
are allowed to hatch and the L1 are cultured in serial dilutions of anthelmintic for 2 hours.  
The larvae feed on fluorescein isothiocyanate (FITC)-labelled E. coli and are incubated for 
a further 24 hours.  The numbers of larvae which are fed or unfed at each anthelmintic 
concentration is determined by examining the larvae under a fluorescence microscope and 
this ratio compared to an untreated control group (Alvarez-Sanchez et al., 2005).  Another, 
related, assay for the detection of LEV and ML resistance is the larval migration inhibition 
test (LMIT) (Wagland et al., 1992; Rabel, McGregor, & Douch, 1994).  Like the LFIT, 
exsheathed L3 are incubated in serial dilutions of anthelmintic and then placed, in solution, 
above a 25μm nylon mesh and incubated for a further two hours.  Resistant worms, which 
have not been paralysed by the drug, will be able to actively migrate through the mesh.  By 
counting the number of migrated and non-migrated L3, the percentage migration can be 42 
calculated  and,  hence,  provide  an  idea  of  an  isolate‟s  ability  to  survive  anthelmintic 
treatment. 
 
In vitro assays are easier, faster and cheaper to perform than in vivo tests and do not 
require the use of animals, which also removes any inter-host variation (Dobson et al., 
1986; Dobson, Le Jambre, & Gill, 1996).  The tests described above have different uses, 
primarily due to some of the tests being restricted to testing certain classes of drugs such as 
the MALDT and EHT not detecting ML resistance or the LFIT and LMIT not detecting BZ 
resistance.    Like  in  vivo  tests,  in  vitro  tests  only  work  when  over  25%  of  the  worm 
population under test is resistant (Coles et al., 1992; McKellar & Jackson, 2004).  One 
challenge to all the tests described is when mixed species infections are present; different 
species may have different sensitivities to a drug, making it difficult to interpret results.   
 
1.5.3: Molecular based tests 
As resistance has a genetic basis, either through qualitative changes (mutations) or 
quantitative changes (alterations in expression of genes), the identification of these changes 
could lead to the development of DNA based tests.  Development of sensitive molecular-
based diagnostic tests has enabled the detection of BZ resistance at lower levels compared 
to in vitro methods.  The tests can allow the identification of individual parasites carrying 
resistance  genes  within  a  parasite  population  (Elard,  Cabaret,  &  Humbert,  1999;  von 
Samson-Himmelstjerna,  2006).    The  tests  also  allow  species  identification  in  mixed 
populations,  and  can  be  adapted  to  give  the  prevalence  of  resistance  for  each  species 
(Silvestre  &  Humbert,  2000).    Polymerase  chain  reaction  (PCR)-based  tests  are  only 
available for diagnosis of BZ resistance, where single nucleotide polymorphisms (SNPs), 
such as those discussed below, have been identified that are associated with resistance 
(Kwa, Veenstra, & Roos, 1994; Elard, Cabaret, & Humbert, 1999; Silvestre & Humbert, 
2000).    This  PCR  has  been  developed  further  to  include  PCR-RFLP,  allowing  the 
simultaneous species identification and determination of the resistance status of individual 
T. circumcincta, H. contortus and T. colubriformis L3.  This PCR has also been adapted for 
real-time PCR applications, which are more rapid than conventional PCR and allow the 
simultaneous detection of susceptible and resistant alleles, even in pooled samples (von 43 
Samson-Himmelstjerna,  2006;  Walsh  et  al.,  2007;  von  Samson-Himmelstjerna  et  al., 
2009a).  When using molecular based tests, as for the in vivo and in vitro methods, the 
challenge is the correct identification of resistance in mixed parasite species infections.  
However,  the  reliance  on  only  one  mutation  to  diagnose  resistance  will  not  take  into 
account other non-specific resistance mechanisms which may be enabling populations of 
parasites to exhibit phenotypic resistance (Coles, 2005).  This could mean that a parasite 
not exhibiting a mutation associated with resistance in a molecular-based test may still 
have other gene expression level changes or mutations that enable it to be phenotypically 
resistant.   
 
1.6: Anthelmintic resistance mechanisms 
Resistance is thought to develop in a number of ways (Wolstenholme et al., 2004).  
Firstly, a resistant nematode could have an altered drug target which results in the drug 
being unable to bind, or bind less effectively.  Secondly, there could be a change in the 
metabolism of the drug causing the drug not to be metabolised into its active form, or to be 
removed from its target sites.  Thirdly, a change in distribution of the drug in the parasite 
could  prevent  it  reaching  its  target  site.    Fourthly,  a  change  in  the  drugs  target  gene 
expression could overcome the drugs action.  Alternatively, there could be non-specific 
resistance mechanisms (i.e. a mechanism not related to the precise mode of action of the 
drug) such as changes in the expression level of non-target proteins used by the parasite to 
handle  drugs  and  toxins  (Wolstenholme  et  al.,  2004).    These  mechanisms  should  be 
identifiable as quantitative and qualitative genetic changes. 
 
Genetic studies have identified a point mutation, a substitution of tyrosine (Tyr) for 
phenylalanine (Phe) at codon 200 (Phe200Tyr or F200Y) in the isotype 1  -tubulin gene, 
which  is  the  major  genetic  determinant  of  BZ  resistance  in  T.  circumcincta, 
Trichostrongylus colubriformis, H. contortus and Cooperia oncophora (Kwa, Veenstra, & 
Roos, 1994; von Samson-Himmelstjerna et al., 2007).  A second much less common, Phe-
Tyr polymorphism at codon 167 is also associated with BZ resistance, especially in the 
nematode parasites  of equines  (Silvestre  & Cabaret,  2002;  Wolstenholme et  al., 2004; 
Gilleard, 2006; Hodgkinson et al., 2008).  It appears that, in H. contortus, Tyr is required 44 
at codon 200 for BZ resistance but in T. circumcincta, worms can survive BZ treatment 
when Phe/Phe homozygous at codon 200 and either Phe/Tyr heterozygous at codon 167 or 
Tyr/Tyr  homozygous  at  codon  167  (Silvestre  &  Cabaret,  2002;  von  Samson-
Himmelstjerna  et  al.,  2007).    Some  triple-resistant  T.  circumcincta  with  susceptible 
genotypes at codon 200, have been shown to survive BZ treatment in vivo and in vitro, 
suggesting that other resistance mechanisms may also be contributing to the expression of 
BZ resistance (Stenhouse, 2007).  An alternative point mutation in H. contortus capable of 
conferring  BZ  resistance,  was  found  at  codon  198,  a  substitution  of  alanine  (Ala)  for 
glutamic acid (Glu) (Glu198Ala) (Ghisi, Kaminsky, & Maser, 2007; de Lourdes Mottier & 
Prichard,  2008).    This  mutation  and  Phe200Tyr  appear  to  be  mutually  exclusive;  the 
combination  of  the  two  may  be  lethal  to  the  parasites.    Alongside  these  mutations,  it 
appears that binding of BZs to β-tubulin is reduced in resistant compared to susceptible 
isolates (von Samson-Himmelstjerna, 2006). 
 
Resistance  mechanisms  to  LEV  and  the  other  imidazothiazole/ 
tetrahydropyrimidines, including PYR, are less well researched (Kopp et al., 2008).  Three 
genes, unc-38, unc-29 and lev-1, identified in C. elegans appear to be involved in LEV 
resistance  and  were  found  to  encode  nicotinic  acetylcholine  receptors  (nAChRs).  
Mutations in unc-29 or unc-38 caused a complete loss of sensitivity to LEV (Fleming et 
al.,  1997).    A  mutation  from  glutamic  acid  (Glu)  to  glycine  (Gly)  at  amino  acid  153 
(Glu153Gly) in the unc-38 gene of C. elegans is required for LEV resistance (Rayes et al., 
2004; Martin & Robertson, 2007).  LEV is a very weak agonist of mammalian muscle, 
resulting in low toxicity, however, the Glu153Gly mutation increases the efficacy of LEV 
as an agonist against mammalian muscle acetylcholine receptors (Rayes et al., 2004).  The 
mutation in the unc-63 gene, changing a glutamine (Gln) to glycine (Gly) at amino acid 57 
(Gln57Gly)  in  C.  elegans,  appears  to  reduce  the  sensitivity  of  the  receptors  to  PYR 
(Bartos, Rayes,  & Bouzat, 2006).  nAChRs are made up of five glycoprotein subunits 
arranged  around  a  central  ion  channel;  different  subunits  give  the  nAChR  different 
pharmacological properties (Kopp et al., 2008).  In C. elegans, absence of one type of 
nAChR at the neuromuscular junction can cause LEV resistance whilst absence of the L 
subtype of nAChR from Oesophagostomum dentatum was associated with LEV resistance 
(Martin & Robertson, 2007).  LEV resistant H. contortus and T. colubriformis membrane 
preparations were found to have decreased nAChR affinity for LEV (Sangster, Redwin, & 45 
Bjorn, 1998).  A gene fragment, HA17, was found to be differentially expressed between 
LEV-resistant  and  -susceptible  parasites  using  cDNA-AFLP  techniques  and  has  been 
proposed as a potential marker for LEV resistance in H. contortus (Neveu et al., 2007).  
Kopp et al (2008) showed in the dog hookworm, Ancylostoma caninum, that whilst there 
were no polymorphisms of significance in three putative PYR receptor subunits (AAR-29, 
AAR-38 and AAR-63), there was a significantly reduced level of transcription of these 
genes in a highly PYR resistant isolate compared to an isolate with low levels of PYR 
resistance.  These subunits were orthologous to the unc-29, unc-38 and unc-63 genes in C. 
elegans (Kopp et al., 2008). 
 
Genes implicated in IVM resistance are the likely molecular targets of IVM and 
include Glutamate- and GABA- gated Cl channels (Njue et al., 2004;  Gilleard, 2006).  
Changes in allele frequencies of Glu- and GABA- Cl subunits in H. contortus have been 
observed but no single allele has been associated with resistance between different IVM 
resistant  populations  of  H.  contortus  (Blackhall  et  al.,  1998a;  Blackhall,  Prichard,  & 
Beech, 2003).  Only one study has associated a change in an amino acid, from leucine to 
phenylalanine at codon 256, (Leu256Phe) in the GluClα3 subunit of C. oncophora to IVM 
resistance but this has not been found in  H. contortus, T. circumcincta, O. ostertagi or 
other  C.  oncophora  isolates  (Njue  et  al.,  2004;  Van  Zeveren,  2009).    In  C.  elegans, 
mutations  in  several  GluCl  subunit  genes  are  required  for  ML  resistance  (McCavera, 
Walsh, & Wolstenholme, 2007).  Concurrent mutations of three genes encoding GluCl α-
type subunits, avr-14, avr-15 and glc-1 in C. elegans are required to confer high levels of 
IVM resistance; mutation of any of the two genes only confers low or no resistance (Dent 
et al., 2000; Cook et al., 2006).  Avr-15 encodes a GluClα2 which is expressed in the 
pharyngeal  muscle  in  C.  elegans;  avr-14  encodes  a  GluClα3  and  is  expressed  in  the 
extrapharyngeal nervous system:  Significantly, one of the modes of action of IVM is 
starvation of nematodes caused by inhibition of the pharyngeal pump (Dent et al., 2000; 
Cook et  al., 2006).   Parasitic nematodes  have a different  set  of  GluCl  subunit  genes 
compared to C. elegans but do share some, such as avr-14, an orthologue of which, in C. 
oncophora, has a polymorphism making the subunit less sensitive to  IVM  (McCavera, 
Walsh,  &  Wolstenholme,  2007).    The  molecular  basis  of  resistance  to  IVM  in 
trichostrongyle parasites remains to be elucidated (Geary, 2005; Prichard et al., 2007). 
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Even though AADs are a recent discovery and are yet to reach a wider market, 
research has already been carried out to determine if and how resistance to the AADs will 
develop.  AAD resistant populations of C. elegans have been selectively bred by exposing 
them to the drug; this has allowed the AAD target gene to be identified as a nAChR, called 
acr-23 (Prichard & Geary, 2008; Kaminsky et al., 2008; Zarlenga & Gasbarre, 2009).  This 
nAChR is unique to nematodes and is different from those associated with LEV resistance 
(Prichard  &  Geary,  2008).    Three  AAD-resistant  H.  contortus  mutant lines  have  been 
generated which all appear to have lost at least part of the H. contortus des-2 homologue, 
which is part of the nAChR group.  The two fully AAD-resistant H. contortus mutants had 
also lost part of the H. contortus homologue of the acr-23 gene (Kaminsky et al., 2008). 
 
1.7: Candidate ivermectin resistance genes 
  Most  of  the  anthelmintic  resistance  mechanisms  identified  to  date  have  used  a 
candidate gene approach to identify qualitative changes conferring resistance.  The limited 
success  of  this  approach  is  partly  because  classical  genetic  linkage  studies  to  identify 
„resistance genes‟ are difficult, especially where the mode of action of the anthelmintics is 
still not clear.  This makes it difficult to propose candidate resistance genes for further 
study.  Alternative mechanisms of resistance such as changes in gene expression level 
remain largely unexplored, particularly in T. circumcincta and will be the focus of this 
thesis.  Differences in expression levels of genes may be constitutive, where a gene is 
always expressed differentially between anthelmintic susceptible and resistant strains of 
parasites at rest, or inducible, where a change in gene expression is observed between 
parasites that have been treated with or exposed to anthelmintic and those that have not.  
Changes in gene expression pattern may be caused by either up or down -regulation of the 
gene  or  increased  or  decreased  gene  copy  number.    Details  of  two  gene  families,  the 
cytochrome  P450s  and  P-glycoproteins,  which  may  be  linked  to  the  IVM-resistance 
phenotype and appear to play a pivotal role in the handling and metabolism of drugs, are 
given below. 
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1.7.1: P-glycoproteins 
Pgps are large ~170kDa transmembrane proteins which are part of the ATP binding 
cassette (ABC) superfamily of genes.  These are found throughout the phyla  Archaea, 
Eubacteria and Eukarya (Valverde et al., 1992; Kerboeuf, Guegnard, & Le Vern, 2003; 
Jones  &  George,  2005;  Riou  et  al.,  2005).    Pgps  are  involved  in  a  range  of  cellular 
processes, including the transport of endogenous and exogenous hydrophobic molecules 
(Valverde et al., 1992; Sangster et al., 1999a; Kerboeuf, Guegnard, & Le Vern, 2003).  
Pgps  comprise  two  symmetrical  halves,  but  they  can  also  exist  as  half-transporter 
molecules (Sheps et al., 2004; Ardelli, Guerriero, & Prichard, 2006a).  Each half contains a 
transmembrane  domain,  comprised  of  six  transmembrane  α-helices,  and  a  cytoplasmic 
nucleotide binding domain (NBD) at the carboxy end of each half molecule which contains 
an ATP binding site (Sangster, 1994).  Within the cytoplasm of cells, the two halves of the 
molecule are linked by a hydrophilic region of approximately 60 amino acids; together, the 
two transmembrane domains form a membrane channel that acts as a substrate binding site 
(Jones & George, 2005).  The two NBDs are structurally non-identical or functionally 
interchangeable  but  are  highly  conserved  and  show  an  amino  acid  homology  of 
approximately 70% (Sangster, 1994; Higgins et al., 1997; Sangster et al., 1999a).  Within 
the  NBD  there  is  the  so-called  “Walker  motif”,  a  characteristic  amino  acid  sequence, 
LSGGQ, which is the signature sequence of the NBD in ABC transporters (Higgins et al., 
1997; Jones & George, 2005).  A diagram of a typical Pgp is shown in Figure 1.2. 
 
Compared to the amount of information about Pgps in humans and E. coli, the 
amount of data on parasites is much smaller and appears to concentrate on human parasites 
such as Plasmodium falciparum, trypanosomes and Onchocerca volvulus.  Nematode Pgp 
studies have concentrated on C. elegans, O. volvulus and H. contortus (Sangster, 1994; 
Jones & George, 2005).  Nematodes appear to possess more Pgps than mammals, possibly 
due to parasites living in a more hostile environment (Lespine et al., 2008).  For example 
the eggs and larval stages are exposed to a range of toxins and conditions whilst in the 
faeces or on the pasture, such as xenobiotics from fungi, and the adults are exposed to an 
acidic environment and digestive enzymes in the abomasum of the host  (Sutherland & 
Scott, 2010).  Pgps in nematode parasites appear to be expressed in a range of tissues, 
including the pharynx and intestinal tract in H. contortus and C. elegans, sheaths of L3, 
eggshells and cuticles of H. contortus and microfilariae and adults of O. volvulus (Lincke 48 
et al., 1993; Broeks et al., 1995; Kwa et al., 1998; Huang & Prichard, 1999; Smith & 
Prichard, 2002; Kerboeuf, Guegnard, & Le Vern, 2003; Kerboeuf et al., 2003; Riou et al., 
2005; Prichard & Roulet, 2007; Riou et al., 2007; Lespine et al., 2008).  Pgps are thought 
to play a pivotal role in handling xenobiotics as the MLs, such as  IVM, appear to be 
absorbed  into,  distributed  around  and  eliminated  from  parasites  under  the  control  of 
multidrug resistant transporters such as Pgps (Lespine et al., 2008). 
 
Over-expression of Pgps is linked to drug resistance in cancerous tumours, malaria 
parasites and the human immunodeficiency virus (Beugnet, Gauthey, & Kerboeuf, 1997; 
Zhang et al., 1998; Loo & Clarke, 1999; Jones & George, 2005).  In human tumours, such 
as  sarcomas  and  neuroblastomas,  Pgp  expression  correlates  with  a  multidrug  resistant 
(MDR) phenotype in the cancer cells, leading to a lower response to chemotherapy and 
reduced patient survival.  Interestingly, IVM, which is a known substrate of Pgp, can be 
used as a MDR reversing agent (Pouliot et al., 1997; Loo & Clarke, 1999).  An increase in 
Pgp  transcription  has  also  been  observed  in  P.  falciparum  and  is  associated  with 
chloroquine resistance (Ekong et al., 1993), whilst the use of verapamil, a calcium channel 
blocker that binds to Pgp, reverses chloroquine resistant P. falciparum (Martin, Oduola, & 
Milhous, 1987). 
 
As stated previously, Pgps appear to be abundant in nematodes.  Various PCR and 
probe-based approaches have identified at least 2 Pgp genes from O. volvulus, at least 14 
Pgp genes in C. elegans and at least 12 Pgp genes in H. contortus (Kwa et al., 1998; Huang 
& Prichard, 1999; Le Jambre, Lenane, & Wardrop, 1999; Sangster et al., 1999a; Kerboeuf 
et al., 2003; Sheps et al., 2004; Blackhall, Prichard, & Beech, 2008).  To date, no Pgps 
have  been  identified  in  T.  circumcincta;  this  is  despite  ongoing  EST  and  genome 
sequencing projects.  An increase in Pgp mRNA level has been observed in IVM-selected 
H. contortus (Xu et al., 1998) and changes in Pgp allele frequencies and/ or reductions in 
genetic  diversity  have  been  observed  between  IVM-  or  MOX-selected  isolates  of  O. 
volvulus and H. contortus (Blackhall et al., 1998b; Ardelli, Guerriero, & Prichard, 2005; 
Ardelli,  Guerriero,  &  Prichard,  2006a;  Ardelli,  Guerriero,  &  Prichard,  2006b).    These 
observations would suggest that the anthelmintics, particularly the MLs, are placing the 
Pgps under selection pressure.  Expression of OvPgp-1 in O. volvulus negatively correlates 49 
with  stage-specific  sensitivity  to  IVM  as  microfilariae  express  less  Pgp  and  are  more 
sensitive to IVM compared to adults (Huang & Prichard, 1999).  Pgps do appear to be 
implicated in ML resistance, for example, co-administration of verapamil with MOX or 
IVM significantly increases the efficacy of the anthelmintic against a MOX-selected strain 
of H. contortus (Xu et al., 1998).  Resistance to IVM in C. elegans is associated with 
increased expression of Pgps and multidrug resistance proteins, which are members of the 
ABC superfamily, like Pgps (James & Davey, 2008).  No SNPs in Pgps associated with 
ML resistance have been identified thus far, possibly due to the size and number of the 
molecules.  Van Zeveren (2009) showed that there was a 3.4 fold constitutive increase in 
expression of a Pgp, designated PGP2a, in adult O. ostertagi from a laboratory selected 
isolate that was demonstrably resistant to IVM. 
 
Treatment of H. contortus laboratory- and field- isolated populations with BZs also 
appears to exert a selection pressure on Pgp alleles as none of the populations of worms 
were  in  Hardy-Weinberg  equilibrium  at  the  Pgp  locus  (Blackhall,  Prichard,  &  Beech, 
2008).  There may be an element of “cross-talk” between the two resistance mechanisms; 
Pgps may offer an alternative, or additional,  mechanism of resistance to BZs in addition to 
the aforementioned SNPs in  -tubulin (Blackhall, Prichard, & Beech, 2008).  The use of 
Pgp  inhibitors,  such  as  Lens  culinaris  lectin,  causes  an  enhanced  susceptibility  of  H. 
contortus eggs to TBZ (Kerboeuf, Guegnard, & Le Vern, 2002) and the use of verapamil 
increases  the  toxicity  of  TBZ  and  ABZ  to  H.  contortus  eggs  (Beugnet,  Gauthey,  & 
Kerboeuf, 1997).  Inhibitors of Pgps cause a reversal towards a susceptible phenotype of 
resistant strains of T. circumcincta and H. contortus when exposed to IVM in the LFIT.  
These inhibitors, many of which are already used therapeutically, although not for parasitic 
nematode control, included pluronic P85, verapamil (used to treat hypertension and cardiac 
arrhythmia), quercitin, ketoconazole (a broad spectrum anti-fungal agent) and valspodar 
(Virkel et al., 2009; Bartley et al., 2009). 
 
1.7.2: Cytochrome P450s 
Cytochrome  P450s  (CYPs)  are  a  large  superfamily  of  haemproteins  which  are 
found throughout the Animal Kingdom, suggesting an ancestral gene existed before the 50 
divergence  of  prokaryotes  and  eukaryotes  (Nelson  et  al.,  1996;  Berge,  Feyereisen,  & 
Amichot, 1998; Mansuy, 1998; Omura, 1999).  CYPs are the largest gene superfamily 
identified to date and can be classified into over 70 individual families of genes, each 
identified by a number, which have at least 40% amino acid identity.  These can be further 
classified into subfamilies and, finally, genes and alleles (Nelson et al., 1996; Gong et al., 
2005).  Subfamilies are designated by a letter and share at least 55% amino acid identity, 
whilst the numeral at the end of the CYP name denotes the gene (Berge, Feyereisen, & 
Amichot, 1998).   The divergence in protein sequence of alleles is less than or equal to 3% 
(Nelson et al., 1996).  Families of CYPs can be loosely grouped into clans which probably 
represent  genes  that  diverged  from  a  single  common  ancestor  (Nelson,  1998;  Nelson, 
1999). 
 
CYPs  are  single  domain  proteins  which  protrude  into  the  cytoplasm  and  are 
anchored to membranes by an N terminal signal sequence linked to the catalytic domain by 
a highly conserved proline rich region, as shown in Figure 1.3 (Chen & Kemper, 1996; 
Gotoh, 1998; Graham & Peterson, 1999).  In eukaryotes, CYPs are bound to the membrane 
of the endoplasmic reticulum or mitochondria whilst, in most bacteria, CYPs are water 
soluble (Chen & Kemper, 1996; Omura, 1999).  Studies have shown that the structure of 
CYPs  generally  consists  of  four  β-sheets  and  thirteen  α-helices  (Graham  &  Peterson, 
1999).  Only three amino acid positions are conserved across the whole CYP superfamily, 
two  form  the  amino  acid  motif  E-x-x-R  in  one  of  the  α-helices  which  make  up  the 
structural core of the protein whilst the third conserved amino acid is a cysteine that is the 
fifth ligand for the haem ion (Graham & Peterson, 1999).  CYPs catalyse the oxidative and 
reductive  metabolism  of  a  wide  range  of,  predominantly  hydrophobic,  exogenous  and 
endogenous  molecules,  such  as  sterols,  fatty  acids,  prostaglandins,  drugs  and 
environmental  toxins  (Guengerich,  1991;  Nelson  et  al.,  1996;  Amichot  et  al.,  1998; 
Barrett,  1998;  Mansuy,  1998;  Graham  &  Peterson,  1999;  Menzel,  Bogaert,  &  Achazi, 
2001).    One  protein  is  able  to  catalyse  different  reactions  depending  on  the  substrate 
presented.  Also, there is redundancy in the CYP pathways as more than one CYP can 
metabolize the same substrate (Guengerich, 1991; Menzel et al., 2005). 
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In C. elegans, approximately 80 CYPs have been identified as a result of the C. 
elegans genome sequencing project, and are classified into clans 2, 3 and 4 containing 7, 3 
and 3 gene families, respectively (Barrett, 1998; Gotoh, 1998; Menzel, Bogaert, & Achazi, 
2001).  Within clan 3, the CYP13 family appears to be specific to C. elegans (Gotoh, 1998; 
Nelson, 1998; Nelson, 1999).  It is possible that C. elegans has such a large number of 
CYPs to enable the nematode to cope with environmental toxins.  Few studies to date have 
identified CYPs from parasitic nematodes.  Adult helminth enzyme extracts from a range 
of  species,  including  H.  contortus,  Heligmosomoides  polygyrus  and  Fasciola  hepatica, 
were unable to oxidise known CYP substrates and attempts using spectrophotometry or 
CYP-inducing agents failed to identify CYPs in adult nematodes  (Barrett, 1998).  The 
methods used at the time may have lacked the sensitivity to detect CYPs which are only 
present in very low abundance or in the free-living larval stages (Barrett, 1998).  However, 
CYPs  have  since  been  found  in  all  life-cycle  stages  of  C.  elegans,  including  adults 
(Menzel, Bogaert, & Achazi, 2001). 
 
There is some evidence that H. contortus larval stages may possess CYPs, through 
the  identification  of  microsomal  CYP  activity  against  the  substrates  aldrin  and  7-
ethoxycoumarin  that  could  be  inhibited  by  the  CYP  inhibitor,  piperonyl  butoxide,  and 
induced by phenobarbitol (Kotze, 1997; Berge, Feyereisen, & Amichot, 1998).  There is 
also evidence that the efficacy of BZs can be improved by the use of the CYP inhibitors 
piperonyl butoxide, ketoconazole and metyrapone and the administration of BZs has been 
shown to increase the catalytic activity of CYP1A in rat hepatocytes (Baliharova et al., 
2003; McKellar & Jackson, 2004; Virkel et al., 2009).  It has also been suggested that CYP 
activity in H. contortus may be restricted to the free-living stages where oxygen is readily 
available (Kotze, 1997).  The CYP activity in  adult  H. contortus is  10,000-fold lower 
compared to rat liver microsomes, so the assays used may not have been sensitive enough 
to detect this (Kotze, 1997).  Approximately 60 CYP tags have been identified from the H. 
contortus  genome  sequencing  project  database  but  it  is  anticipated  this  will  reduce  in 
number due to the presence of numerous polymorphisms or as tags become assembled (R. 
Laing, Pers. Comm.). 
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It appears that CYPs may also play a role in drug resistance in a range of species 
other than nematode parasites.  Insect CYPs are involved in the metabolism of the majority 
of insecticides, either activating the molecule or as a detoxification mechanism (Berge, 
Feyereisen, & Amichot, 1998).  In insects, over-expression or over-transcription of CYPs 
appear  to  enable  Drosophila  spp,  Anopheles  minimus,  Anopheles  gambiae  and  Culex 
pipiens pallens to exhibit insecticide resistance (Amichot et al., 1998; Daborn et al., 2002; 
Le Goff et al., 2003; Nikou, Ranson, & Hemingway, 2003; Gong et al., 2005; Rodpradit et 
al., 2005; Vontas et al., 2005).  For example, Drosophila spp over-expressing Cyp6g1 are 
resistant to various insecticides such as organophosphates, DDT and growth regulators 
(Ffrench-Constant,  Daborn,  &  Le  Goff,  2004).    Chloroquine  resistance  in  the  malaria 
parasites, P. berghei and P. falciparum, has also been shown to correlate with an increase 
in CYP activity (Ndifor, Ward, & Howells, 1990; Barrett, 1998). 
 
1.8: Summary 
T. circumcincta is the most important nematode parasitizing sheep in the UK and 
contributes significantly to the economic and welfare costs associated with PGE.  In the 
UK, it is also the dominant resistant species yet the full extent of anthelmintic resistance is 
not known due to insensitive diagnostic tests and the absence of active surveillance (Coles, 
2005).  Sheep do eventually build up immunity to  T. circumcincta but lambs are very 
vulnerable  to  infection  and  the  ability  of  lambs  to  reach  slaughter  weight  in  an 
economically  viable  length  of  time  relies  heavily  on  the  use  of  anthelmintics,  without 
which the sheep industry would not be able to survive in its present form (Sargison et al., 
2005; Blake & Coles, 2007).  As such, it is important that the mechanisms of anthelmintic 
resistance, particularly to the MLs are investigated, molecular markers associated with 
resistance are found and improved techniques for the detection of resistance are developed 
(Prichard & Roulet, 2007).  This would allow enhanced anthelmintic usage management 
strategies to be developed with the aim of prolonging the effective life of the available 
classes. 
 
Candidate gene studies looking at specific genes which are assumed to be the target 
site for anthelmintic drugs have only managed to identify SNPs associated with resistance 53 
to the BZs (Gilleard, 2006; von Samson-Himmelstjerna et al., 2007).  As discussed in this 
literature review, other mechanisms of resistance such as changes in gene expression in 
non-target  genes  like  the  CYPs  and  Pgps  remain  to  be  investigated,  particularly  in  T. 
circumcincta.    Alongside  these  classical  candidate  gene  studies  focussing  on  gene 
expression changes as opposed to mutations, the potential of alternative genetic techniques 
such as next generation sequencing and suppression subtractive hybridisation, which do 
not rely on initial assumptions about a gene‟s association with a drug‟s mode of action, 
need  to  be  explored.    Furthermore,  a  greater  understanding  of  the  drug  handling 
mechanisms of MDR T. circumcincta will potentially enable the development of molecular 
markers  for  resistance  which  will  enable  a  more  effective  control  strategy  for  T. 
circumcincta to be developed whilst reducing the rate at which anthelmintic resistance 
develops. 
 
1.9: Aims and objectives 
  The  overall  aim  of  this  research  was  to  gain  an  insight  into  how  MDR  T. 
circumcincta  processes  anthelmintics,  in  particular  IVM,  and  using  molecular  biology 
techniques, to identify the role non-specific drug handling mechanisms, such as CYPs and 
Pgps,  play in  the  expression of resistance with  a view to  developing  sensitive genetic 
markers  for  resistance  detection.    Comparisons  were  made  between  a  T.  circumcincta 
isolate resistant to BZs, LEV and IVM (MOTRI) and the non-related CVL isolate which 
was isolated before exposure to LEV and IVM and is phenotypically BZ susceptible as 
measured by the EHT (D. Bartley, Pers. Comm.).  Alongside this other comparisons were 
made using in vitro and in vivo IVM exposed isolates; further details of the isolates used in 
the different experiments are given in Chapter 2. 
 
  The first objective was to identify a panel of novel Pgp and CYP homologues from 
T. circumcincta for a more detailed genetic analysis.  This was performed on cDNA 
and  EST  datasets  using  bioinformatics  approaches,  and  PCR  using  degenerate 
primers based on available sequences from related nematode species.  At the time 
of  writing,  no  complete  genome  sequence  and  only  a  limited  EST  dataset  was 
available for T. circumcincta.  If T. circumcincta follows the same pattern as C. 54 
elegans and H. contortus, then the numbers of Pgps and CYPs is likely to be large.  
It was not anticipated that all Pgps and CYPs will be identified by this approach. 
 
  The second objective was  to  develop  semi-quantitative or real-time quantitative 
PCR  assays  based  on  the  selected  panel  of  Pgp  and  CYP  genes  to  investigate 
comparative  gene  expression in  three different  T. circumcincta isolates, namely 
susceptible (CVL), triple-resistant (MOTRI) and triple-resistant survivors of in vivo 
IVM treatment (Post IVM MOTRI) and over five life-cycle stages.  The first part of 
this objective was to identify constitutive changes in the expression of the CYPs 
and Pgps between IVM- susceptible and resistant T. circumcincta isolates.  The 
second part of this objective was to identify inducible changes in the expression of 
CYPS and Pgps  by stressing different  isolates  of  T. circumcincta with  IVM to 
identify genes which display altered expression patterns in response to anthelmintic 
exposure.  Two experiments were carried out, to investigate this: (i) exposing the 
parasite  isolates  to  IVM  in  vitro,  utilising  a  modified  LMIA  method,  and  (ii) 
comparing the Post IVM MOTRI isolate with the MOTRI isolate in vivo. 
 
  The third objective used a more global, non-candidate gene approach, to investigate 
gene  expression  changes  in  the  MOTRI  isolate  in  response  to  in  vitro  IVM 
exposure by comparing an unexposed pool of adult parasites to an IVM exposed 
pool.  Using the next generation Roche 454 sequencing approach, a large amount of 
novel sequence data for T. circumcincta was generated.  Bioinformatic analysis of 
this  sequence  data  allowed  the  identification  of  clusters  of  sequences  which 
exhibited altered expression profiles in response to IVM exposure.   
 
  The  final  approach  was  to  use  a  non-hypothesis  driven  one-way  suppression 
subtractive hybridisation method, followed by sequencing of the cloned subtracted 
products to investigate constitutive gene expression differences between the CVL 
and MOTRI adult parasites at rest.  This was to identify which genes in the MOTRI 
adults had increased expression compared to the CVL adults, and could potentially 55 
be  used  as  markers  for  anthelmintic  resistance,  or  gene  expression  changes 
allowing the parasite to exhibit resistance.   
   56 
 
 
Figure 1.1: Life-cycle of T. circumcincta. 
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Figure 1.2: Structure of a typical P-glycoprotein.  The P-glycoprotein has been expanded to aid visualisation 
as  it  normally  forms  a  cylindrical  channel  within  cell  membranes.    The  transmembrane  α  helices  are 
numbered 1 -12, the two nucleotide binding domains labelled NBD 1 and 2 and the hydrophobic linker 
region is shown at the centre of the diagram, protruding into the lipid bilayer. 
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Figure 1.3: Structure of a Cytochrome P450.  Human CYP46a1 showing it binding to a membrane (blue 
line).    Alpha  helices  are  shown  as  red  coils  and  beta  sheets  as  yellow  ribbons.    From: 
http://opm.phar.umich.edu/ protein.php?pdbid=2q9f 59 
Chapter 2: General Parasitological and Molecular Biology Materials and 
Methods 
This  chapter describes  general  parasitological  and molecular biology techniques 
used in the completion of more than one experiment.  Specific materials and methods for 
real-time PCR, Roche 454 sequencing and Suppression Subtractive Hybridisation can be 
found in the relevant chapters.   
 
2.1: General parasitological techniques 
  Sheep were euthanized according to Home Office guidelines by individuals holding 
a Personal Licence permitting them to do so.  All animal experimental procedures listed 
below  had  been  previously  reviewed  and  approved  by  the  Moredun  Internal  Ethics 
Committee prior to commencement. 
 
2.1.1: T. circumcincta isolates 
The  cDNA  initially  used  for  identification  of  genes  was  L4  and  xL3  SMART 
cDNA, and single-stranded adult cDNA, kindly provided by Dr A. J. Nisbet and from the 
known  IVM  susceptible  T.  circumcincta  MTci2  (CVL)  isolate.    The  CVL  isolate  was 
isolated prior to the use of LEV and IVM and, in an EHT for BZ resistance status, was 
shown  to  have  an  estimated  ED50  of  0.09µg/mL  where  the  cut-off  for  resistance  is 
0.1µg/mL, indicating that it is also BZ-susceptible (D. Bartley, Pers. Comm.).  For the 
synthesis of SMART cDNA, T. circumcincta L3 parasites of the same IVM susceptible 
CVL strain were used.  For use in the real-time PCR experiments, three isolates were used; 
the CVL isolate, a triple  IVM, BZ  and  LEV resistant isolate (MOTRI or MTci5) and 
finally a drug-exposed isolate. Controlled efficacy and faecal egg count reduction tests 
revealed that the efficacies of FBZ, LEV and IVM against the MOTRI isolate were 59%, 
88% and 60%, respectively (Bartley et al., 2004).  To obtain the drug-exposed isolate, the 
MOTRI isolate was exposed to a full therapeutic dose of IVM (Oramec ; Merial) at a dose 
of 0.25mg/kg body weight two days after infection.  This isolate was subsequently named 
Post IVM MOTRI.  Eggs, L1, xL3, L4 and adults were obtained from each of the three 
isolates.  MOTRI adult parasites were used in the in vitro drug exposure experiment prior 60 
to  next  generation  sequencing.    For  the  suppression  subtractive  hybridisation  work, 
MOTRI and CVL adults which had previously been collected and stored in liquid nitrogen 
were used.  In vivo IVM survivors were obtained by infecting adult sheep with 30,000 
MOTRI xL3 and then giving the sheep a full therapeutic dose of IVM (Oramec ; Merial) at 
a dose of 0.25mg/kg body weight 28 days post infection.  Three days after IVM treatment 
the sheep were euthanized and adult parasites collected using the method described below.   
 
2.1.2: Recovery of eggs from faeces 
Sheep were orally infected with 10,000 to 15,000 T. circumcincta L3.  Faeces were 
collected by attaching a collection bag via a harness to the rump of male sheep.  Eggs were 
extracted from the faeces by emulsifying the faeces in 5mL tap water per gram of faeces. 
The resulting suspension was washed through a series of sieves with mesh sizes of 1mm, 
212μm, 68μm and 38μm, respectively.  The retentate, containing the parasite eggs, was 
collected and washed from the 38μm sieve, transferred to centrifuge tubes and centrifuged 
at  200  x  g  for  2  mins.    The  supernatant  was  removed  and  the  pellet  re-suspended  in 
saturated sodium chloride solution before being centrifuged for a further 2 mins at 200 x g.  
Using forceps, the meniscus of the tubes was clamped off and poured into a beaker then 
transferred to the 38μm sieve and washed with tap water.  The retentate was collected 
using tap water and centrifuged for 2 mins at 200 x g with the supernatant being removed.  
Tap water was used to return the volume in the centrifuge tube to 10mL and an egg count 
performed. The eggs were centrifuged, the supernatant removed and the eggs re-suspended 
in 1X Phosphate Buffered Saline (PBS) before being stored in liquid nitrogen. 
 
2.1.3: Collection of L1 
Eggs extracted from faeces as described above were used to obtain L1 parasites by 
culturing the eggs according to the following procedure.  Eggs were incubated for 18-24 
hours at 25°C and then transferred into the top of a mini Baermann apparatus with 20-
25μm mesh and cultured for a further 2 hours at 25°C.  Hatched L1 were collected from the 
well of a 6 well plate following their migration through the Baermann apparatus during the 
2 hour incubation period.  L1 were stored in 1X PBS in liquid nitrogen. 61 
2.1.4: Recovery of L3 from faeces 
L3 were obtained by coproculture.  Faeces were collected as described above for 
recovery of eggs.  Macerated faecal material from  T. circumcincta infected sheep was 
mixed with  vermiculite at  a ratio of 10g faeces to  4g vermiculite, placed in  a sample 
container and covered with a plastic bag containing holes to allow gas exchange.  The 
faeces were incubated at 20-27°C for 10 days, the plastic was removed and the vermiculite 
faeces mix flooded with tepid water and incubated at room temperature for 4 hours.  The 
supernatant was then removed and L3 extracted using a Baermann apparatus.  The L3 were 
exsheathed by addition of a 1% sodium hypochlorite solution (Milton sterilising fluid) and 
observed under a microscope until 90% exsheathment had occurred.  Sodium hypochlorite 
was  removed  from  the  solution  by  repeatedly  re-suspending  the  larvae  in  water, 
centrifuging at 200 x g for 2 mins and removing the supernatant.  This procedure was 
repeated at least three times and the parasites were re-suspended in 1X PBS, then stored in 
liquid nitrogen. 
 
2.1.5: Recovery of L4 from abomasum 
Sheep orally dosed with 150,000 L3 were used to obtain L4 from the abomasum.  
Seven days  after infection, the sheep was  euthanized and the abomasum  removed, cut 
along the greater curvature, and the contents washed out by rinsing three times with warm 
saline.  The abomasum was then pinned out onto a polystyrene board and placed in a large 
funnel containing warm saline so that the internal abomasal surface hung down into the 
saline.  The abomasum was left at 37°C for several hours allowing the L4 to migrate to the 
bottom of the funnel where they were collected, re-suspended in 1X PBS and transferred to 
liquid nitrogen for long term storage. 
 
2.1.6: Recovery of adult parasites from abomasum 
Adult T. circumcincta were collected from the abomasum of sheep 21 days post 
infection with 30,000 to 50,000 L3.  The abomasum was removed from an infected sheep 
and  opened  up  along  the  greater  curvature  of  the  abomasum,  collecting  the  abomasal 
contents.  The surface of the abomasum was washed with as little warm saline as possible, 62 
with the abomasal washings in saline being collected with the abomasal contents.  600mL 
of the abomasal contents and washings was mixed with 600mL of 1.8% agarose diluted in 
saline, and allowed to set over a wire mesh at the bottom of a bucket.  Once set, the bucket 
with the agarose-abomasal mix was placed in a large funnel containing warm saline and 
incubated at 37°C for several hours to allow the adults to migrate out of the agarose-
abomasal mix into the saline where they were collected and transferred to liquid nitrogen 
for long term storage 1X PBS. 
 
2.2: In vitro bioassays 
2.2.1: Larval migration inhibition test (LMIT): Standard technique 
  The LMIT works by incubating L3 in serial dilutions of IVM and determining the 
percentage of L3 which are capable of migrating through a mesh submerged in a solution 
containing IVM, as shown in Figure 2.1, part A.  Isolates of parasites most resistant to the 
paralysing effects of IVM will be able to migrate at a greater percentage in a higher dose of 
drug compared to those less resistant isolates (Wagland et al., 1992; Rabel, McGregor, & 
Douch, 1994). 
 
  Approximately  2400  L3  parasites,  obtained  via  coproculture  as  described 
previously, were allowed to migrate through a Baermann chamber for 1 hour at 26°C using 
a double thickness piece of 25μm mesh, attached to a section of a syringe, placed into a 
well  of  a  6-well  plate  containing  10mL  tap  water.    After  the  1  hour  incubation  was 
completed, the tap water containing the migrated L3 was transferred to a centrifuge tube 
and centrifuged for 2 mins at 200 x g.  The volume in the tube was reduced, the L3 were re-
suspended and a second count made to determine the number of L3.  The volume in the 
centrifuge tube was adjusted to give between 10 and 15 L3 per 10μL.  A serial dilution of 
IVM in Dimethyl Sulphoxide (DMSO) was prepared in darkened Eppendorf tubes from a 
stock solution (3000μg/mL) to give four working concentrations of 300μg/mL, 60μg/mL, 
20μg/mL  and  5μg/mL.    In  clean  darkened  Eppendorf  tubes,  10μL  of  each  drug 
concentration or neat DMSO (control) was added to 190μL of the L3 suspension to give 
final concentrations of IVM of 150μg/mL, 15μg/mL, 3μg/mL, 1μg/mL, 0.25μg/mL and 
0μg/mL.  The L3 were incubated for 2 hours at 26°C in the above IVM concentrations.   63 
  A 24-well plate was set up to contain the migration chambers made from small 
plastic tubes covered at one end with a 20μm mesh.  The layout of the plate is shown in 
Figure 2.1, part B.  210μL of the stock or working concentrations of IVM was mixed with 
3801μL tap water in a darkened Bijou to provide 1910μL of solution to fill each of the 
duplicate wells for each drug concentration.  This was calculated to give the same final 
concentrations of IVM as previously described.  90μL of the drug exposed L3 were added 
down  the  side  of  the  migration  chamber  into  the  well  above  the  mesh  and  the  plate 
incubated for a further 2 hours in the dark at 26°C.  Migrated L3 were washed off the 
bottom of the migration chamber back into the well, the migration chamber was tipped 
upside down into the corresponding empty well below it on the plate and non-migrating L3 
washed back through the mesh.  The L3 were stained with helminthological iodine and 
counted under an inverted microscope at x100 magnification.  Percentage migration for 
each well was determined and an average for each drug concentration calculated. 
 
2.2.2: Larval migration inhibition test (LMIT): Modified technique 
  The LMIT technique described above was modified to enable the protocol to be 
scaled up to give sufficient quantities of L3 for use in molecular experiments.  Following 
several  experiments  using  the  standard  LMIT  method,  a  dose  of  2.5μg/mL  IVM  was 
chosen  as  the  previous  results  suggested  this  would  give  a  migration  percentage  of 
approximately  10%.    However,  using  the  protocol  described  below  this  resulted  in  an 
average migration of 0.41%, so subsequently a dose of 1μg/mL IVM was used, which had 
been shown to give an average migration of 24% in the standard migration technique. 
 
  The  first  Baermannisation  step  (1  hour  at  26°C  using  a  25μm  mesh)  was  not 
performed,  instead  the  L3  were  exsheathed  by  addition  of  a  1%  sodium  hypochlorite 
solution  (Milton  sterilising  fluid)  into  a  flask  containing  the  L3  in  70mL  water.    A 
subsample of the L3 were observed under a microscope, and when 90% had exsheathed, 
the L3 were washed as described in Section 2.1.4, counted and re-suspended in 240mL 
warm tap water.   
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A serial dilution of IVM in DMSO was prepared in darkened Eppendorf tubes from 
a stock solution (3000μg/mL) to give a final working concentration of 50μg/mL.  In clean 
darkened Falcon tubes, 2.5mL of IVM or neat DMSO (control) was added to 47.5mL of 
the L3 suspension to give final concentrations of IVM of 1μg/mL, and 0μg/mL.  The L3 
were  incubated  in  the  dark  for  2  hours  at  26°C.    Following  incubation,  the  L3  were 
centrifuged for 5 mins at 1500 x g with the brake off to allow the L3 to pellet to the bottom 
of the Falcon tubes without vortexing back into suspension.  The volume in each Falcon 
tube was reduced to 10mL and the L3 were inverted to re-suspend them.   
 
Five migration chambers were set up using clean glass jam jars of identical size, 
capable of holding 320mL.  The Baermann chamber was made using two sample pots with 
their bottoms cut out, placed one inside the other, holding a piece of 20μm mesh in place 
between them.  These were then placed in the jam jars.  Four of the migration chambers 
were to provide replicates of the drug concentration whilst the fifth was for the no drug 
control.  65.6mL of the working concentration of IVM was mixed with 1205.4mL warm 
tap water in a darkened 2L Duran bottle to provide the solution to fill the jam jars.  Each 
IVM jam jar was filled with 310mL of the drug whilst the control jam jar was set up by 
mixing 294mL of tap water and 16mL DMSO.  10mL of the drug exposed L3 were added 
down the side of the sample pot above the mesh and the jam jars incubated for 2 hours at 
26°C in the dark.   
 
Migrated L3 were washed off the bottom of the migration chamber back into the 
jam  jar,  the  migration  chamber  was  tipped  upside  down  onto  a  Petri  dish  and  non-
migrating L3 washed back through the mesh after removing the mesh from between the 
two  sample  pots  to  ensure  no  non-migrating  L3  were  caught  in  the  mesh  folds.    The 
contents of the jam jars and Petri dishes were sequentially spun down in the centrifuge (2 
mins at 200 x g) until each of the migrating and non-migrating samples were re-suspended 
in a total volume of 10mL.  Five 10μL subsamples from the migrating L3 samples were 
taken  and  the  number  of  L3  present  determined  under  a  microscope.    From  this  the 
percentage migration of each jam jar was calculated.  Each sample was reduced in volume 
and stored in 1X PBS in liquid nitrogen. 65 
2.3: General molecular biological techniques 
2.3.1: Extraction of RNA 
The  Trizol
®  method  was  used  to  extract  total  RNA  from  parasite  material.  
Parasites removed from storage in liquid nitrogen were placed in a pre-chilled pestle and 
mortar  (-80°C)  and  ground  to  a  fine  powder  using  liquid  nitrogen  to  ensure  parasites 
remained frozen.  The liquid nitrogen was allowed to evaporate and 8mL Trizol
® reagent 
(Invitrogen) added.  Once solidified, the Trizol-parasite mix was ground up until liquid 
then transferred into 1mL aliquots in Eppendorf tubes and allowed to incubate at 15-30°C 
for 5 mins.  200μL chloroform was added to each Eppendorf tube and the Eppendorf tubes 
shaken vigorously and incubated at 15-30°C for 2 mins, then centrifuged at 12000 x g for 
15 mins at 2-8°C.  The RNA was precipitated from the Trizol mix by transferring the 
colourless upper aqueous phase from the Eppendorf tube into a clean Eppendorf tube, 
adding 500μL isopropanol,  mixing and incubating for 10 mins  at  15-30°C.  A second 
centrifugation  at  12000  x  g  for  10  mins  at  2-8°C  was  performed  and  the  supernatant 
removed without dislodging the RNA pellet.   The RNA was washed by adding 1mL 75% 
ethanol, vortexing and centrifuging at 7500 x g for 5 mins at 2-8°C.  The ethanol was 
removed and the pellet allowed to air dry to remove all traces of the ethanol.  The RNA 
was re-suspended in up to 75μL nuclease free water and stored at -80°C.  Confirmation of 
RNA quality was obtained by running 5μL on a 1% agarose gel to identify the 18S band 
and  by  determining  the  RNA  concentration  using  the  NanoDrop
®  ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc).  RNA extracted later in the project had 
1μL  RNAse  OUT  (Invitrogen)  added  prior  to  storage  at  -80°C  to  prevent  possible 
degradation of RNA. 
 
2.3.2: Synthesis of cDNA 
To enable the identification of candidate resistance genes, single-stranded cDNA 
was synthesised from RNA using the Invitrogen Superscript reverse transcriptase kit with 
oligo  dT  primers,  according  to  the  manufacturer‟s  instructions.    Briefly  2μL  oligo  dT 
primer was mixed with 5μg total RNA and the reaction made up to 12μL with PCR-grade 
water, then incubated at 70°C for 10 mins and chilled on ice.  4μL 5x first strand buffer, 
2μL  0·1M  DTT  and  1μL  10mM  dNTP  mix  was  added  before  the  reaction  mix  was 66 
incubated at 42°C for 2 mins.  1μL Superscript II enzyme was added and the reaction mix 
incubated at 25°C for 10 mins then at 42°C for 50 mins. The enzyme was heat inactivated 
at 70°C for 10 mins and the resulting cDNA stored at -20°C. 
 
The  Switching  Mechanism  At  5‟  End  of  RNA  Template  (SMART
™)  Rapid 
Amplification  of  cDNA  ends  (RACE)  cDNA  amplification  kit  (Clontech)  and  the 
Advantage
® 2 PCR Enzyme System (Clontech) were used to manufacture RACE-ready 
cDNA.  Two separate reactions were performed to make 5‟ and 3‟ RACE-ready cDNA.  
To manufacture 5‟ RACE-ready cDNA 1μL of RNA was mixed with 1μL 5‟-CDS primer 
and 1μL SMART II A oligo and the final volume made up to 5μL with sterile water.  3‟ 
RACE-ready cDNA was prepared by adding 1μL of RNA to 1μL of 3‟-CDS primer A and 
the final volume made up to 5μL with sterile water.  Both reactions were incubated at 70°C 
for 2 mins and then cooled on ice for 2 mins.  To both the 5‟ and 3‟ reaction mixes, 2μL of 
5X First-Strand buffer, 1μL 20mM DTT, 1μL 10mM dNTP Mix and 1μL MMLV Reverse 
Transcriptase was added and the reaction mix incubated at 42°C for 90 mins.  The starting 
concentration of the total RNA was greater than 200ng/μL so 100μL of Tricine-EDTA 
Buffer was added to each reaction and the tubes incubated at 72°C for 7 mins.  Aliquots of 
the RACE-ready cDNA were made and stored at 20°C. 
 
  cDNA for use in real-time PCR was manufactured using the Invitrogen Superscript 
reverse  transcriptase  kit  as  described  above  with  the  following  modifications:  The 
concentration of RNA added in step 1 was 1.5μg total RNA and 2μL random primers were 
used instead of oligo dT primers in the first strand synthesis reaction.  Triplicate cDNA 
synthesis reactions were set up for each isolate and life-cycle stage with the three reactions 
pooled and mixed prior to the cDNA concentration being determined using the NanoDrop
® 
ND-1000 spectrophotometer.  The cDNA was diluted to 50ng/μL and aliquots made prior 
to storage at -20°C. 
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2.3.3: Standard PCR 
Four different types of primers were used: housekeeping gene primers (Table 2.1), 
degenerate primers to identify Pgps and CYPs (Table 2.2), specific primers to amplify Pgp 
and  CYP  sequence  (Table  2.3)  and  standard  primers  for  amplification  of  sequence  in 
cloning vectors (Table 2.4).  Primers were designed using the services on MWG Biotech 
and Primer3 (www.eurofinsdna.com and http://frodo.wi.mit.edu/, respectively) to calculate 
Tm.  Primers were ordered from MWG Biotech and diluted to a stock concentration of 
100μM.  The working concentration of all primers for PCR was 10μM. 
 
Standard  PCR  used  the  Platinum
®  Taq  DNA  polymerase  kit  (Invitrogen)  and 
dNTPs (Roche).   Standard PCR reactions were carried out by combining 12·75μL dH2O 
with 2·5μL 10X PCR buffer, 0·75μL 50mM MgCl2, 1·0μL 10mM dNTP, 0·5μL Platinum
® 
Taq DNA Polymerase and 2·5μL each of the forward and reverse primers and template to 
give  a  total  reaction  volume  of  25μL.    All  PCR  reactions  were  run  on  an  Applied 
Biosystems 2720 thermal cycler as follows: 5 mins at 94°C for a denaturing step followed 
by 40 cycles of 94°C for 30 secs, X°C for 30 secs and 72°C for 30 secs, (where X is the 
Tm of the primers minus 5°C), followed by 10 mins at 72°C and then a hold at 4°C.  The 
PCR results were visualised by running the whole PCR reaction mix on a 1% agarose gel 
as described below. 
 
2.3.4: Rapid amplification of cDNA ends (RACE) PCR 
RACE PCR primers (Table 2.5) were designed, as described above, to extend the 5‟ 
gene sequence of specific Pgps.  RACE PCR reactions were set up by combining 34·5μL 
PCR grade water with 5μL 10X Advantage 2 PCR buffer, 1μL 10mM dNTP mix, 1μL 50X 
Advantage 2 Polymerase Mix, 2·5μL 5‟ RACE ready cDNA, 5μL 10X Universal Primer 
Mix and 1μL of the specific primer to give a total reaction volume of 50μL.  A touchdown 
PCR protocol was used as follows: 5 cycles of 94°C for 30 secs and 72°C for 3 mins 
followed by 5 cycles of 94°C for 30 secs, 70°C for 30 secs and 72°C for 3 mins followed 
by 25 cycles of 94°C for 30 secs, 68°C for 30 secs and 72°C for 3 mins followed by a hold 
at 72°C for 7 mins and then a hold at 4°C.  The results of the RACE PCR were visualised 
as for the standard PCR, as described below.  PCR product sizes on agarose gels were 68 
estimated by comparing the position of the band on the gel to the sizes of bands of the 
DNA Molecular Weight Marker X (Roche) which has a size range of 0.07 to 12.2 kbp. 
 
2.3.5: Semi-quantitative PCR 
  Semi-quantitative PCR was performed by setting up a PCR using the gene-specific 
primers designed for CYPs 1, 2 and 3 and PGPs 2, 3, 5, 6, 7 and 9 (Table 2.3), the actin 
and β-tubulin control primers (Table 2.1) and cDNA generated using random primers from 
eggs, L1, xL3, L4 and adults of the CVL and MOTRI T. circumcincta isolates as follows:  
36µL  of  nuclease-free  water  was  combined  with  5µL  10X  PCR  buffer,  1.5µL  50mM 
MgCl2, 1·0μL dNTP, 0·5μL Platinum
® Taq DNA Polymerase, 1μL each of the forward and 
reverse primers, and 4μL template cDNA diluted to  250ng/µL to  give a total  reaction 
volume of 50μL.  The PCR reaction conditions were 5 mins at 94°C followed by 30 cycles 
of 94°C for 30 secs, 55°C for 30 secs and 72°C for 30 secs, followed by 10 mins at 72°C 
and then held at 4°C.  After 15, 20, 25 cycles and upon completion of the PCR, 5µL of the 
reaction mix was removed from each tube and stored at 4°C prior to all the samples being 
visualised on an agarose gel as described below. 
 
2.3.6: Visualisation of PCR products: 
  To visualise PCR products between 5μL and the full volume of the PCR reaction 
was loaded onto a 1% agarose gel (containing TAE and Gel Red as described below) 
which  had  been  submerged  in  an  electrophoresis  tank  filled  with  1  x  TAE  buffer.  
Electrophoresis was carried out on the 1% agarose gels at 70-110V for between 30 to 60 
mins to allow separation of any PCR products according to molecular weight.  The gel was 
examined  under  UV  light  and  the  size  of  the  bands  present  determined  against  DNA 
Molecular Weight Marker X (Roche) which has a size range of 0.07 to 12.2 kb or against 
the TrackIt
™ 
1Kb Plus DNA Ladder (Invitrogen) which has a size range of 0.1 to 12 kb.  
Reagents used were prepared as follows: 
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Tris-acetic acid-ethylenediaminetetraacetic acid (TAE) buffer  
A 50X stock solution of TAE was prepared by dissolving 242g Tris base in 500mL 
distilled  water  (dH2O),  to  which  57.1mL  glacial  acetic  acid  and  100mL  0·5M 
ethylenediaminetetraacetic acid (EDTA) (pH8) was added and the volume topped up to 1L 
with dH2O.  For use as an agarose gel tank buffer the 50X stock solution was diluted to 1X 
in dH2O. 
 
Agarose gel 
  1%  agarose  gel  was  prepared  by  dissolving  4g  agarose  and  8mL  50X  TAE  in 
392mL of dH2O using a microwave.  20μL 10000X Gel Red (Biotium Inc) was added to 
enable visualisation of DNA under UV light. 
 
2.3.7: Cloning of PCR products 
Bands visualised under UV on 1% agarose gels were excised using a clean scalpel 
and purified following the protocol for the QIAquick Gel Extraction Kit (Qiagen).  Briefly, 
the gel slice was dissolved in Buffer QG at a ratio of 300μL per 100mg of gel in an 
Eppendorf tube placed in a water bath at 50°C.  The DNA in Buffer QG was bound to the 
spin column by centrifugation at 17900 x g for 1 minute.  The DNA on the column was 
washed by addition of 500μL of buffer QG, centrifuged for 1 minute, addition of 750μL of 
Buffer PE and then centrifuged for 1 minute.  Waste was removed from the collection tube 
between each step and a final centrifugation step of 1 minute carried out to remove all 
residues of Buffer PE.  Purified DNA was eluted by adding 30μL dH2O to the spin column, 
which was allowed to stand for 1 minute before a final centrifugation for 1 minute.  The 
eluted DNA was stored at -20°C. 
 
  Purified PCR product was ligated into pGEM
®-T vector on ice as follows: 5μL 2X 
ligation buffer was mixed with 1μL pGEM
®-T vector, 1μL T4 DNA ligase and 3μL of 
purified PCR product.  The ligation mixture was incubated at 4°C overnight.  On day two, 
JM109  competent  cells  (Stratagene)  were  transformed  with  the  pGEM
®-T  vector 70 
containing the purified PCR product as follows: On ice, 3μL of the ligation mix was added 
to 27μL of JM109 competent cells and incubated on ice for 30 mins.  The cells were heat-
shocked at 42°C in a water bath for 1 minute and returned to ice for 2 mins.  200μL of 
SOC  medium  was  added  to  each  Eppendorf  tube  and  the  cells  placed  in  a  shaking 
incubator at 37°C for two hours.  After two hours, 150μL of the cell suspension was spread 
onto LB AMP XI plates (manufactured as described below) using an ethanol-sterilised 
glass spreader and the plates placed in a 37°C incubator for overnight culture.  White 
colonies, containing the pGEM
®-T vector with purified PCR product insert, were selected 
from the plates using sterile pipette tips and placed in glass universals, containing 10mL 
LB  broth  and  20μL  25mg/mL  AMP,  and  cultured  overnight  at  37°C  in  the  shaking 
incubator. 
 
  Overnight  cultures  were  pelleted  by  pouring  off  the  supernatant  following 
centrifugation of the universals at 3000 x g for 15 mins.  The plasmids were extracted from 
the cells following the protocol for the Wizard
® Plus SV Miniprep DNA purification kit 
(Promega).  Briefly, the cells were re-suspended in 250μL Cell Resuspension Solution and 
transferred to an Eppendorf tube.  The cells were lysed by addition of 250μL Cell Lysis 
solution, mixing, addition of 10μL Alkaline Protease Solution, mixing and incubating at 
room  temperature  for  5  mins.    The  reaction  was  neutralized  by  addition  of  350μL  of 
Neutralization Solution and then centrifuged at 14000 x g for 10 mins at room temperature 
to pellet the cell debris.  The supernatant was carefully removed from the Eppendorf tube 
and placed into the spin column.  Binding of the plasmid to the column was achieved by 
centrifugation of the spin column at 14000 x g for 1 minute, with the waste from the 
column being removed from the collection tube after each step.  Two washes of the column 
were carried out by adding 750μL of Column Wash Solution, centrifuging for 1 minute, 
adding 250μL Column Wash Solution and centrifuging for 1 minute, with the waste being 
removed from the collection tube after each step.  A final centrifugation step for 2 mins at 
14000 x g removed all traces of Column Wash Solution.  The purified plasmid was eluted 
from the column by adding 50μL dH2O and centrifuging at 14000 x g for 1 minute.  The 
extracted  plasmid  DNA  concentration  was  determined  using  the  NanoDrop
®  ND-1000 
spectrophotometer and the purified plasmid stored at -20°C.  Reagents used for cloning 
were prepared or obtained as shown below: 
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Cells 
JM109 competent cells (Stratagene) and the pGEM
®-T vector system (Promega) 
were used to clone PCR products. 
 
Luria Bertani (LB) broth 
  LB broth was prepared by dissolving in 1L dH2O, 10g Bacto
®-tryptone, 5g Bacto
®-
yeast extract and 5g sodium chloride.  Sterilisation was achieved through autoclaving at 
121°C for 15 mins. 
 
Luria Bertani (LB) agar 
  LB agar was prepared from LB broth by dissolving 15g Bacto
®-agar in 1L LB 
broth and autoclaving. 
 
SOC medium 
SOC medium (pH7) was prepared as follows.  1g Bacto
®-tryptone, 0·25g Bacto
®-
yeast  extract,  0·5mL  1M  sodium  chloride  and  0·125mL  1M  potassium  chloride  was 
dissolved in 48·5mL dH2O, autoclaved and allowed to cool.  0·5mL 2M filter-sterilised 
Mg
2+ and 0·5mL 2M filter-sterilised glucose was added and the final volume increased to 
50mL with dH2O.  The pH was adjusted to pH7 and the SOC medium divided into 5mL 
aliquots and stored at -20°C. 
 
Ampicillin solution 
  A 25mg/mL stock solution of ampicillin (AMP) was prepared by dissolving a 25mg 
ampicillin tablet (Stratagene) in 1mL dH2O and was stored at -20°C. 
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Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
  1M IPTG was made by adding 238mg IPTG to 1mL dH2O, vortexing and storing at 
-20°C. 
 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) 
  50mg/mL X-gal in dimethylformamide was obtained from Promega. 
 
LB agar plates containing ampicillin, X-gal and IPTG 
  LB AMP XI plates were prepared by melting LB agar and cooling to 50°C in a 
water bath.  1mL of ampicillin stock solution was added per 500mL LB agar, mixed and 
then poured into 9cm diameter Petri dishes and left to set.  Plates were stored upside down 
at 4°C until required, for a maximum of 2 weeks.  Immediately prior to use, 40μL of 1M 
IPTG and 40μL of X-gal was spread on the surface of the LB agar using an ethanol-
sterilised glass spreader and allowed to absorb into the LB agar at 37°C. 
 
2.3.8: Kits for purification of PCR and cloning products 
Purification  of  PCR  products  from  agarose  gels  was  performed  using  the 
QIAquick
®  Gel  Extraction Kit  (Qiagen).  Purification of the  remaining PCR products, 
which  had  not  been  run  on  agarose  gels,  was  performed  using  the  QIAquick
®  PCR 
purification kit (Qiagen).  Extraction of plasmids from JM109 cell cultures was performed 
using the Wizard
® Plus SV Miniprep DNA purification system (Promega). 
 
2.3.9: Sequencing 
  Purified  plasmids  were  submitted  for  sequencing  to  either  MWG  or  GATC 
according to the instructions specified on the companies‟ websites (www.eurofinsdna.com 
and www.gatc-biotech.com, respectively).  The primers chosen were generally either M13 73 
For, M13 Rev, M13 Uni, SP6 or T7, as shown in Table 2.4, which amplify the pGEM
®-T 
vector across the insertion site.  The majority of sequencing used the M13 Uni, SP6 and T7 
primers.  Occasionally, purified PCR products were sequenced directly without first being 
cloned into the pGEM
®-T vector.  In these cases, the primer chosen for the sequencing 
reaction was the gene specific forward primer for that PCR product. 
 
2.3.10: Analysis of sequencing data 
Sequence  data  received  in  ABI  format  following  cloning  and  sequencing  was 
analysed using SeqMan (DNASTAR Lasergene version 8) to enable the accuracy of base 
calls  to  be  checked,  to  align  sequences  into  contigs  and  to  remove  plasmid  sequence.  
Consensus sequence was used as the query in BLAST X search engines on EMBL-EBI 
(www.ebi.ac.uk/blast2/parasites.html)  and  NCBI  (www.ncbi.nlm.nih.gov/blast/Blast.cgi) 
(Altschul et al., 1990).  Novel sequences generated using the degenerate primer, cloning 
and  sequencing  approach  with  homology  to  Pgps  or  CYPs  from  these  databases  were 
numbered  sequentially.    Translated  protein  sequences  and  open  reading  frames  were 
generated  using  The  Sequence  Manipulation  Suite 
(http://www.ualberta.ca/~stothard/javascript/index.html).  Clustal W analysis, to generate 
alignment files for both nucleotide and protein sequence, was carried out using EMBL-EBI 
(http://www.ebi.ac.uk/Tools/clustalw2/). 
 
Electronic searches to identify potential Pgp and CYP ESTs in  T. circumcincta 
were  carried  out  on  the  following  webpages:  Nembase2; 
(http://xyala.cap.ed.ac.uk/nematodeESTs/search.php)  (Parkinson  et  al.,  2004a),  NCBI; 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore&itool=toolbar)  (Wheeler  et  al., 
2008)  and  EMBL-EBI  (http://srs.ebi.ac.uk/srsbin/cgi-bin/wgetz?-page+top).    Keywords 
such as P-glycoprotein, Pgp, Cytochrome P450, CYP450 and Teladorsagia circumcincta 
were used as search terms. 
 
Individually, the novel Pgp nucleotide sequences, generated using the degenerate 
primers  as  described  above,  were  aligned  against  the  15  full-length  C.  elegans  Pgp 74 
nucleotide sequences using the very accurate alignment option in CLC DNA Workbench 
version  5.6.1  (www.clcbio.com).    The  names  and  GenBank  accession  numbers  of  the 
protein sequences  of the 15  C. elegans Pgps  are shown in  Table 2.6  below and  were 
obtained from Sheps et al (, 2004).  The link to the protein sequence was used to trace back 
to the nucleotide sequence.  The alignments were visually inspected and trimmed to only 
display the part of the alignment containing the T. circumcincta Pgp sequence and then 
used to generate phylogenetic trees to enable the closest matching C elegans Pgp sequence 
to be identified for each individual T. circumcincta Pgp.  This was to enable the correct 
naming of the Pgps as suggested in the guidelines on the Caenorhabditis genetics centre 
website  (http://www.cbs.umn.edu/CGC/nomenclature/index.html).    Phylogenetic  trees 
were  generated using the neighbour-joining (NJ) and Un-weighted Pair Group Method 
with Arithmetic mean (UPGMA) methods using a bootstrap value of 1000. 
 
2.3.11: Identification of single nucleotide polymorphisms (SNPs) 
  Using cDNA generated from pools of adult T. circumcincta, SNPs were identified 
by using gene-specific primers (Table 2.3) to selectively amplify cDNA for PGPs 3, 5, 6, 7 
and 9, using the SuperScript
™ III One-Step RT-PCR System with Platinum
® Taq DNA 
Polymerase.  The actin primers (Table 2.1) were used as positive controls.  The template 
was CVL and MOTRI adult RNA extracted as described in Section 2.3.1, and the reaction 
was  set  up as  follows: 25µL of the 2X Reaction Mix was  combined with  1µL of the 
Reverse Transcriptase/ Platinum
® Taq Mix, 1µL each of the forward and reverse primers 
and 21µL dH2O.  1µL RNA was added to give a total reaction volume of 50µL and the 
PCR reactions run on an Applied Biosystems 2720 thermal cycler programmed as follows: 
50ºC for 30 mins, 94ºC for 2 mins followed by 40 cycles of 94ºC for 15 secs, 55ºC for 30 
secs and 72ºC for 1 minute, followed by 72ºC for 10 mins and a hold at 4ºC.  Following 
the identification of bands on an agarose gel loaded with 10µL PCR product (Section 2.3.6 
above),  the  remaining  40µL  PCR  product  was  cleaned  up  using  the  QIAquick
®  PCR 
purification  kit  (Qiagen),  eluting  into  30µL  water.    The  RNA  concentration  was 
determined using the NanoDrop
® ND-1000 spectrophotometer and the samples submitted 
for sequencing as described above (Section 2.3.9). 
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Analysis of the sequence data was carried out by first confirming the sequence was 
for  the  correct  Pgp  by  aligning  it  against  the  Pgp  consensus  sequences  in  Lasergene 
Seqman.  Subsequently, the pairs of sequences for each Pgp in raw .abi file format (CVL 
and  MOTRI)  were  entered  into  the  online  SeqDoC  programme 
(http://research.imb.uq.edu.au/seqdoc/) to identify the presence of SNPs by comparing the 
sequence  chromatograms.    Where  SNPs  were  observed,  the  individual  nucleotide 
sequences from both CVL and MOTRI were translated into protein sequence using the 
Sequence Manipulation Suite (http://www.bioinformatics.org/sms2/).  The nucleotide and 
translated protein sequences were used to determine whether any of the SNPs represented 
coding  changes  by  carrying  out  Clustal  W  analysis  using  EMBL-EBI 
(http://www.ebi.ac.uk/Tools/clustalw2/). 76 
Table 2.1: Primers used to amplify T. circumcincta housekeeping genes. 
Primer 
name 
Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target 
Tci actin F  Sense  GTT GCT GCT CTT GTG GTT GA  57.3  T. circumcincta actin 
Tci actin R  Antisense  GGA GAG CAC AGC CTG GAT AG  61.4  T. circumcincta actin 
Tci 60S F  Sense  AAA CAA TGG GTC GCC GGA  56.0  T. circumcincta 60S 
Tci 60S R  Antisense  GCA GCA ACA ACG GTG CT  55.2  T. circumcincta 60S 
Tci_BTubF  Sense  TTCCATTCCCTCGTCTTCAC  60.0  T.circumcincta β-tubulin 
Tci_BTubR  Antisense  AGCCATTTTCAATCCACGAG  60.0  T.circumcincta β-tubulin 
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Table 2.2: Degenerate primers used to identify Pgps and CYPs from T. circumcincta cDNA.  * means the Tm was calculated approximately using W instead of I. 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target  Source 
1S  Sense  AGY GGI TGY GGN AAR AGY AC  58.3*  H. contortus Pgp  (Sangster et al., 1999b) 
2S  Sense  AGY GGI TGY GGN AAR TCN AC  58.3*  H. contortus Pgp  (Sangster et al., 1999b) 
3S  Sense  TCI GGI TGY GGN AAR AGY AC  57.3*  H. contortus Pgp  (Sangster et al., 1999b) 
4S  Sense  TCI GGI TGY GGN AAR TCN AC  57.3*  H. contortus Pgp  (Sangster et al., 1999b) 
1A  Antisense  AGI GCI GAN GTN GCY TCR TC  59.4*  H. contortus Pgp  (Sangster et al., 1999b) 
2A  Antisense  AGI GCR CTN GTN GCY TCR TC  60.4*  H. contortus Pgp  (Sangster et al., 1999b) 
3A  Antisense  AAI GCI GAN GTN GCY TCR TC  57.3*  H. contortus Pgp  (Sangster et al., 1999b) 
4A  Antisense  AAI GCR CTN GTN GCY TCR TC  58.3*  H. contortus Pgp  (Sangster et al., 1999b) 
5A  Antisense  ATI GCD ATI CGY TGY TTY TGN CC  59.5*  H. contortus Pgp  (Sangster et al., 1999b) 
6A  Antisense  ATI GCD ATY CTY TGY TTY TGN CC  58.6*  H. contortus Pgp  (Sangster et al., 1999b) 
13A-1  Sense  CAA GAM GAA GTR GAY ARA GAA TG  57.1 
C. elegans CYP13A 
(Menzel, Bogaert, & 
Achazi, 2001)  13A-2  Antisense  CCC ATC TYT CIG GYY TRA AC  57.3 
31A-1  Sense  TCA AGC GGA ACT GGA TGA AG  57.3 
C. elegans CYP31A 
(Menzel, Bogaert, & 
Achazi, 2001)  31A-2  Antisense  GAG CCA TGA TGA CCT TCT CT  57.3 
33C-1  Sense  ATG CAK GAA AAI ATY CTD ATD GA  52.9 
C. elegans CYP33C 
(Menzel, Bogaert, & 
Achazi, 2001)  33C-2  Antisense  TAM GGW AGA TYA TTY TTA TCA  49.1 
35A-1  Sense  ATA TGG GRG TTG GDA ARG AT  53.9 
C. elegans CYP35A 
(Menzel, Bogaert, & 
Achazi, 2001)  35A-2  Antisense  GCA TGR CGT TGA ATY TCT CC  57.3 
DegenTcP450For  Sense  TTG AYY TWT GGA TWG CWG GTC A  56.5  T. circumcincta CYP EST 
 
CypGrp2 Deg For  Sense  TGG NTN GCT GGT MWD GAR AC  58.0 
T. circumcincta CYP clan2 
  CypGrp2 Deg Rev  Antisense  TCC TKW CGA GCN ANC CAH ARA TC  61.2 78 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target  Source 
CypGrp3 Deg For  Sense  GGT GTR GGW CCW MGR CAD TGT  61.4 
T. circumcincta CYP clan3 
  CypGrp3 Deg Rev  Antisense  ACA CAH TGY CKW GGW CCY ACA  59.5 
CypGrp4 Deg For  Sense  TGG ADA VRT CGV CGA AAR ATG  57.2 
T. circumcincta CYP clan4 
  CypGrp4 Deg Rev  Antisense  TGG DGT NAD CAT YTT TCG BCG A  59.0 79 
Table 2.3: Gene specific T. circumcincta primers. 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target  Amplicon 
length (bp) 
Specificity 
Pgp1Tc Rev  Antisense  GCT CAA TTT CCT CCT GAG AAC  57.9  T. circumcincta PGP1     
Pgp1Tc IntFor  Sense  GAA GGT GGC ATG TAC CGG  61.4  T. circumcincta PGP1     
Pgp1Tc IntRev  Antisense  GAG GTT CCT GTG CTG CAG CAC  63.7  T. circumcincta PGP1     
P1TcF  Sense  GTG CTG CAG CAC AGG AAC  58.2 
T. circumcincta PGP1  676  Failed to amplify 
P1TcR  Antisense  GCG GCG TGC TCA ATT TCC  58.2 
Pgp2Tc Int For  Sense  CGA AAA CAT CAG AAA CAT GA  51.2  T. circumcincta PGP2     
Pgp2Tc Int Rev  Antisense  AAT GTT CTC AAG GAT CGT ACA  54  T. circumcincta PGP2     
P2TcF  Sense  GAA AGA GCC TCA TCG GGA G  58.8 
T. circumcincta PGP2  649  PGP2 specific 
P2TcR  Antisense  GGA AGG TTT AGG GTC GTC C  58.8 
P3TcF  Sense  CCA ATG CAT CCC TGG CTC  58.2 
T. circumcincta PGP3  618  PGP3 specific 
P3TcR  Antisense  CCT CGT CTG TGG CTG AC  57.6 
Pgp4Tc Int For  Sense  ACG GTG TGG AAA TCG ACA AG  57.3  T. circumcincta PGP4     
P4TcF  Sense  GGA AGA CGG CAA ATC GAC  56 
T. circumcincta PGP4  662  Not specific 
Pgp4Tc Int Rev  Antisense  CCG TGA TTT CAG CAT CTG TG  57.3 
P5TcF  Sense  CAA GGT TTG AGG CAG CGT TG  59.4 
T. circumcincta PGP5  688  PGP5 specific 
P5TcR  Antisense  GCT TCC TGG ACC TCT TCC  58.2 
P6TcF  Sense  GCY TTG GAC GGT TCT GTG G  59.9 
T. circumcincta PGP6  259  PGP6 specific 
P6TcR  Antisense  GCG CTC CCT TTT CTC CTG  58.2 
P7TcF  Sense  GTG CGT ACG CCG ACA AG  57.6 
T. circumcincta PGP7  699 
Not specific, 
redesigned  P7TcR  Antisense  CGT TTG ACT GCT CTG CAG C  58.8 80 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target  Amplicon 
length (bp) 
Specificity 
P7TcF2  Sense  CGT ACG CCG ACA AGA TTT ACG  59.8 
T. circumcincta PGP7  663  PGP7 specific 
P7TcR2  Antisense  CCT CGG TGA TTT TAT CGG GG  59.4 
P8TcF  Sense  CTG TGG CTG GTG CTG TG  57.6 
T. circumcincta PGP8  315 
Not specific, 
redesigned  P8TcR  Antisense  CTT TCG GGT TAC GGA TCA C  56.7 
P8TcF2  Sense  GTT CGA TGA AGT GGA TGC TC  57.3 
T. circumcincta PGP8  246  Not specific 
P8TcR2  Antisense  CCA CCG GAC AGC ATG CTA  58.2 
P9TcF  Sense  CTT GTT GGA CTA CTT CTT CGC  57.9 
T. circumcincta PGP9  352  PGP9 specific 
P9TcR  Antisense  GCA GAA TTC GCG GAT TTC TC  57.3 
P10TcF  Sense  CGC CAG TTT ATT GAT GGG C  56.7 
T. circumcincta PGP10  331 
Not specific, 
redesigned  P10TcR  Antisense  CTC GAC CAG CAC GCG C  59.4 
P10TcF2  Sense  TAT TGA TGG GCT ATT ACC CGC  57.9 
T. circumcincta PGP10  283  Not specific 
P10TcR2  Antisense  CCA ACT GAG AGA TTA TTC CCC  57.9 
P11TcF  Sense  CGT TGT GTA AAC CTG CTG G  56.7 
T. circumcincta PGP11  347 
Not specific, 
redesigned  P11TcR  Antisense  CAC AGC AAT ACT TTG GGA TTG C  58.4 
P11TcF2  Sense  CAG GAA CTG ACC ACG CTG  58.2 
T. circumcincta PGP11  213  Not specific 
P11TcR2  Antisense  GTA GCC ATC ATG CTT ATC GC  57.3 
Cyp1For  Sense  CAG CAC GGG TAG AGG AG  57.6 
T. circumcincta CYP1  366  CYP1 specific 
Cyp1Rev  Antisense  GTT CTG CYT GAG CAA GTG  54.8 
Cyp2For  Sense  CAA AAA TCC TGA GGT CAT GC  55.2 
T. circumcincta CYP2  323  CYP2 specific 
Cyp2Rev  Antisense  GCT GTT CCA GTG TCT TAC C  56.7 
Cyp3For  Sense  CGT ATG GTT GTT CTA TGC G  54.5 
T. circumcincta CYP3  467  CYP3 specific 
Cyp3Rev  Antisense  CCT GTA ATG GTC TTC GTA G  54.5 81 
Table 2.4: Standard primers used to amplify sequence from cloned cDNA.   
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target 
T7  Sense  TAA TAC GAC TCA CTA TAG GG  53.2  pGEM
®-T vector 
SP6  Antisense  CAT TTA GGT GAC ACT ATA G  50.2  pGEM
®-T vector 
M13 For  Sense  AGC GGA TAA CAA TTT CAC ACA GGA  47.0  pGEM
®-T vector 
M13 Rev  Antisense  CGC CAG GGT TTT CCC AGT CAC GAC  48.0  pGEM
®-T vector 
M13 Uni (-21)     TGT AAA ACG ACG GCC AGT  53.7  pGEM
®-T vector 
TrplX for  Sense  TCG GGA AGC GCG CCA TT  57.6  Phagemid vector 
TrplX rev  Antisense  TGC GGC CGC ATG CAT AAG  58.2  Phagemid vector 
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Table 2.5: RACE PCR primers used to extend 5‟ sequence of Pgps. 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target 
Pgp1Tc 5'race  Antisense  GTG CGG CGT GCT CAA TTT CCT CCT GAG AAC  70.9  T. circumcincta PGP1 
Pgp2Tc 5'race  Antisense  CTC GTA GGA AGG TTT AGG GTC GTC CAG TCC  70.9  T. circumcincta PGP2 
Pgp3Tc 5'race  Antisense  CTC GTC TGT GGC TGA CGG GCG ACC AAA GC  73.7  T. circumcincta PGP3 
Pgp4Tc 5'race  Antisense  CGG AGT GCC GCC GTG ATT TCA GCA TCT G  71.0  T. circumcincta PGP4 
Pgp5Tc 5'race  Antisense  GCA ATA CGA CAA GCT TCC TGG ACC TCT TCC  69.5  T. circumcincta PGP5 
Pgp6Tc 5'race  Antisense  CTA ACG GAW CCT GGW GGR AGR CCG TAG TGG  72.2  T. circumcincta PGP6 
Pgp7Tc 5'race  Antisense  CGA GAG CGT TTG ACT GCT CTG CAG CCT C  71.0  T. circumcincta PGP7 
Pgp8Tc 5'race  Antisense  GGG CGT TGG CCA GTC TAG CGG CAT CCT CG  75.2  T. circumcincta PGP8 
Pgp9Tc 5'race  Antisense  GCC GCG AAA TGT CCA CCC GTC CCA AGC GG  75.2  T. circumcincta PGP9 
Pgp10Tc 5'race  Antisense  CGC GTT CTT CGG AGA TAT CCC GCC CCA GCG  75.0  T. circumcincta PGP10 
Pgp11Tc 5'race  Antisense  CCA GCT CCA GCG GCA GAG CCA CGT TGC C  75.4  T. circumcincta PGP11 83 
Table 2.6: C elegans Pgp genes and accession numbers used for phylogentic analysis.  All were obtained 
from Sheps et al., 2004 
Gene name  GenBank Accession number 
Pgp-1  CAB01232 
Pgp-2  AAB52482 
Pgp-3  CAA91467 
Pgp-4  CAA91463 
Pgp-5  CAA94202 
Pgp-6  CAA94220 
Pgp-7  CAA94219 
Pgp-8  CAA94203 
Pgp-9  CAB03973 
Pgp-10  AAC48149 
Pgp-11  CAA88940 
Pgp-12  CAA91799 
Pgp-13  CAA91800 
Pgp-14  CAA91801 
Pgp-15  CAA91802 84 
A       
 
 
 
 
 
 
 
 
B 
Figure 2.1: Larval migration inhibition test A: Diagram showing a side view of the migration chamber used 
in the LMIT.  The dotted line represents the mesh which L3 have to actively migrate through whilst exposed 
to a solution of IVM. Larvae affected by IVM are represented by a straight line and larvae resistant to IVM 
by a curved line.  B: Layout of the plate in the standard LMIT.  Non migrating L3 are washed into the empty 
wells below each drug migration well prior to counting. 
Negative 
control
Negative 
control
0.25μg/mL 0.25μg/mL 1μg/mL 1μg/mL
3μg/mL 3μg/mL 15μg/mL 15μg/mL 150μg/mL 150μg/mL
Negative 
control
Negative 
control
0.25μg/mL 0.25μg/mL 1μg/mL 1μg/mL
3μg/mL 3μg/mL 15μg/mL 15μg/mL 150μg/mL 150μg/mL85 
Chapter 3: Identification of Candidate Ivermectin Resistance Genes 
3.1: Introduction 
Macrocyclic lactone anthelmintics, and IVM in particular, have been used to treat 
sheep infected with parasitic nematodes like T. circumcincta for over twenty-five years, yet 
the mechanisms of resistance to IVM have yet to be determined (Geary, 2005; Omura, 
2008).    The  majority  of  research  on  drug  resistance  in  parasitic  nematodes  has  been 
focused on identifying target site mutations associated with resistance, for example, the 
Phe200Tyr SNP which confers resistance to BZs (Wolstenholme et al., 2004; von Samson-
Himmelstjerna et al., 2007).  IVM binds to GABA and GluCl channels and causes the 
hyperpolarisation  and  flaccid  paralysis  of  the  pharyngeal  and  somatic  muscle  cells 
(Blackhall et al., 1998a; Blackhall, Prichard, & Beech, 2003), leading to starvation and 
immobility of the worms.  Changes in allele frequencies of these genes in H. contortus 
have been associated with IVM resistance, but no single allele has been shown to confer 
resistance  in  more  than  one  isolate  or  population  (Blackhall  et  al.,  1998a;  Blackhall, 
Prichard, & Beech, 2003).  In C. elegans, three concurrent mutations in GluCl subunits 
(namely, avr-14, avr-15 and glc-1) are required for high levels of IVM resistance.  The 
orthologue of avr-14 in C. oncophora (the GluClα3 subunit) also carries a functional SNP 
(Leu256Phe), which makes the channel less sensitive to IVM (Dent et al., 2000; Njue et 
al., 2004; McCavera, Walsh, & Wolstenholme, 2007).   
 
As has been shown in Chapter 1, candidate IVM resistance genes such as Pgps and 
CYPs have been studied in a range of organisms, although, as  yet, there is very little 
information on these genes in T. circumcincta.  They could offer alternative, non-target 
gene mechanisms for parasites to survive drug exposure, either through increased drug 
efflux  or  metabolism  (Wolstenholme  et  al.,  2004).    Pgps  are  transmembrane  proteins 
involved in  the active transport of endogenous  and exogenous  hydrophobic molecules, 
whilst  CYPs  catalyse  the  metabolism  of  a  wide  range  of  molecules  such  as  drugs, 
environmental  toxins  and  sterols  (Mansuy,  1998;  Sangster  et  al.,  1999a).    As  such, 
although not definitive targets of IVM, changes in the expression levels of these genes (and 
their gene products) might enable parasites to survive IVM exposure.  Pgps have been 
identified in the model nematode C. elegans and the parasitic nematode H. contortus, along 
with  some  parasitic  nematodes  of  humans  such  as  O.  volvulus,  yet  none  have  been 86 
identified in T. circumcincta to date (Huang & Prichard, 1999; Jones & George, 2005).  
However a number of experiments have suggested they are implicated in IVM resistance.  
For example, the use of Pgp inhibitors has been shown to cause a shift towards an IVM-
susceptible phenotype in an IVM-resistant T. circumcincta isolate using the LFIT (Bartley 
et al., 2009).  Also, changes in the expression levels or allelic frequencies of Pgps have 
been described in IVM-selected H. contortus, O. volvulus and C. elegans (Xu et al., 1998; 
Blackhall et al., 1998b; James & Davey, 2008), indicating that changes in the expression 
levels of non-target genes could play a role in expression of an IVM-resistance phenotype.   
 
CYPs have been identified in all life-cycle stages of C. elegans, with approximately 
80 identified through the C. elegans genome project (Barrett, 1998; Menzel, Bogaert, & 
Achazi, 2001).  Identification of CYPs in parasitic nematodes has not been so fruitful, in 
Barrett (1998), the author went as far as to claim there was no experimental evidence for 
CYPs in adult helminths, based on mono-oxygenase enzyme activity, but that they may be 
present in low abundance in larval stages.  However, the H. contortus genome sequencing 
project has identified 60 CYP ESTs to date, although these could reduce in number as the 
sequence is further assembled (R. Laing, Pers. Comm.).  No CYPs have been identified in 
T. circumcincta in the literature to date.  In the LFIT experiment described above, the T. 
circumcincta IVM-resistant isolate also showed a shift towards susceptibility when CYP 
inhibitors were used, suggesting the presence of CYPs in T. circumcincta (Bartley et al., 
2009). 
 
In this Chapter, the candidate gene approach was used to investigate the role of 
differential  gene  expression  of  Pgps  and  CYPs  in  the  IVM-resistant  phenotype  in  T. 
circumcincta.  Firstly, a panel of novel Pgp and CYP homologues from T. circumcincta 
were  identified  prior  to  a  more  detailed  genetic  analysis.    This  was  performed  using 
degenerate PCR and sequencing interfaced with bioinformatics approaches applied to the 
available EST datasets, as described in Chapter 2.  At the time this work was carried out, 
no complete genome sequence was available for T. circumcincta and there was only a 
limited EST dataset available, thus degenerate primers designed to amplify Pgps from H. 
contortus were employed from (Sangster et al., 1999a) and degenerate primers to amplify 
CYPs were designed utilising other nematode CYP sequences.  If T. circumcincta follows 87 
the same pattern as C. elegans and H. contortus, then the estimated numbers of Pgps and 
CYPs  is  likely  to  be  large.    It  was  not  anticipated  that  all  Pgps  and  CYPs  would  be 
identified by this approach. 
 
3.2: P-glycoproteins 
3.2.1: Identification of novel P-glycoprotein sequences 
  Identification  of  Pgps  was  performed  using  the  degenerate  H.  contortus  PCR 
primers which target the NBD of the Pgp molecule (as shown in Table 2.2, sequences 
obtained from Sangster et al (1999a)).  These were employed in a standard PCR reaction 
followed by cloning and sequencing, as described in Sections 2.3.3 and 2.3.6 to 2.3.10.  
The template for these reactions was L4 and xL3 SMART cDNA, and single-stranded adult 
cDNA (all kindly provided by Dr A. J. Nisbet) and from the known IVM susceptible T. 
circumcincta CVL isolate.  Eleven novel sequences, ranging in size from 395bp to 407bp, 
with BLAST homology to Pgps from H. contortus, O. volvulus, Cyathostomum spp and 
Caenorhabditis  briggsae  were  identified.    None  of  the  BLAST  hits  aligned  to  T. 
circumcincta sequence suggesting that all 11 Pgp sequences are novel sequences, which 
are  not  yet  in  the  public  domain,  even  in  EST  databases.    Sequences  were  numbered 
sequentially as they were identified (i.e. PGP1 to PGP11).  The nucleotide sequence was 
translated into the corresponding protein sequence and identification of the correct reading 
frame  made.    As  the  primers  used  targeted  the  NBD  of  Pgps,  the  presence  of  the 
characteristic Walker motif (LSGGQ) of ABC transporters in the protein sequence was 
used  to  confirm  the  BLAST  results  (Higgins  et  al.,  1997;  Jones  &  George,  2005).  
Additional cloning and sequencing of PCR products was carried out to derive consensus 
sequences, to improve the accuracy of the sequencing results and to resolve any multiple 
base calls.   
 
3.2.2: Elongation of P-glycoprotein sequence using RACE PCR 
None of the sequences amplified using the degenerate primers encoded a full-length 
coding sequence for any given gene; potentially two sequences could be the two separate 
NBDs of the same  gene.  RACE-ready cDNA was  synthesised in  order  to  extend the 88 
sequences in the 5‟ and 3‟ directions, to provide longer sequence reads and to determine if 
any of the NBDs were parts of the same gene.  The nucleotide sequences identified above 
were aligned in Clustal W (http://www.ebi.ac.uk/Tools/clustalw/index.html) and used to 
design gene-specific RACE primers as shown in Table 2.5.  All the RACE primers were 
designed for 5‟ RACE; NBDs are situated more closely to the 3‟ end so 5‟ RACE would be 
more likely to generate significantly longer products compared to 3‟ RACE.  Use of the 
RACE primers followed by cloning and sequencing enabled the sequences for PGPs 1, 2, 
3, 4, 5 and 7 to be extended whilst also improving the sequence accuracy.  The RACE 
primers for PGPs 6, 8, 9, 10 and 11 were found to be non Pgp-specific (i.e. none of the 
selected clones aligned with Pgp sequence) or to produce no PCR product.  The RACE 
product for PGP1 was cloned into the pGEM
®-T vector and, when sequenced from both 
ends  using  the  M13  uni  and  SP6  primers,  did  not  produce  a  contiguous  sequence  so 
primers  Pgp1Tc  IntFor  and  Pgp1Tc  IntRev  (Table  2.3)  were  designed  and  used  in  a 
sequencing  reaction to  enable  a  complete sequence of the PGP1  RACE product  to be 
obtained.  The lengths of the Pgps and the numbers of sequences making up each Pgp 
consensus sequence are shown in Table 3.1. 
 
Individually, each Pgp protein sequence was aligned using Clustal W against H. 
contortus PgpA (Accession number AF003908) and against O. volvulus PGP1 (AF083642) 
to discover whether the region amplified aligned more closely to NBD1 or NBD2.  All, 
apart from PGP1, aligned more closely to either NBD1 or NBD2 whilst PGP1 was found 
to contain both NBDs as shown in Table 3.1.  As eight of the consensus sequences appear 
to align to NBD1 (PGPs 1, 3, 4, 5, 7, 8, 9 & 11), this suggests that there could be at least 
eight Pgps in T. circumcincta, and probably more. 
 
On translating the nucleotide sequence for PGP7, it was discovered that a frame 
shift  occurs  approximately  between  amino  acids  272  and  277,  equating  to  between 
nucleotides 814 and 829.  Analysis of the nucleotide sequence was unable to identify if a 
sequencing error had caused a deletion or insertion of a nucleotide in the sequence at this 
point.  As a result, no full length protein sequence in one continuous reading frame could 
be  made;  thus  the  Clustal  W  protein  alignment  (Appendix  2)  contains  two  entries  for 
PGP7, one in each of the reading frames.  The nucleotide and protein alignments of the 11 89 
T. circumcincta Pgps are shown in the Appendix.  Even though there are some sequences 
for each of the NBDs and one sequence that spans both NBDs, as described above, when 
aligned together, all 11 Pgp sequences align to NBD2. 
 
3.2.3: Design and validation of P-glycoprotein specific primers 
In order to determine the gene expression profiles of the 11 Pgps in the different 
isolates  and  life-cycle  stages  of  T.  circumcincta,  pairs  of  gene-specific  primers  were 
designed for each Pgp using the Pgp nucleotide alignment (Appendix 1).  The primers 
were designed to give as large an amplicon as possible to increase the coverage of any 
sequence  data  generated  whilst  also  providing  sufficient  sequence  data  to  confirm  the 
identity of any Pgp sequences generated.  The gene-specific primers and size of amplicons 
are shown in Table 2.3. 
 
The primers were firstly validated against a panel of known Pgp-containing purified 
plasmids to determine whether the primers were specific for the Pgp they were designed 
against.  The gels showing the outcome of this validation are shown in Figure 3.1.  The 
sizes of each of the bands visualised on the gel was estimated by comparing to the Mx 
marker lane and were found to be of the anticipated size.  The primers designed against 
PGP 1, 2, 3, 4, 5, 6, 7 and 9 exclusively amplified their corresponding Pgp plasmids, whilst 
the PGP8 primers also weakly amplified PGPs 6 and 9, and the PGP 10 and 11 primers 
were completely non-specific, amplifying all the PGP-containing plasmids.  Attempts were 
made to optimise the respective reactions by altering the reaction conditions for the PGP 8, 
10 and 11 primers; however, this failed to improve their specificity.  These gene-specific 
primers were redesigned as shown in Table 2.3 but on repeated validation against the Pgp-
containing plasmids, the same pattern of non-specificity was observed (data not shown), so 
these Pgps were excluded from further analysis.   
 
The  next  stage  of  the  validation  of  the  Pgp-specific  primers  was  to  determine 
whether the primers would selectively amplify their particular Pgp from T. circumcincta 
cDNA.  PCRs on IVM-susceptible T. circumcincta exsheathed L3 and L4 SMART cDNA 90 
and single-stranded adult cDNA were set up using the primer pairs for PGPs 1, 2, 3, 4, 5, 6, 
7, 9 (Table 2.3) and T. circumcincta actin (Table 2.1) as a positive control.  The results of 
this validation are shown in Figure 3.2, part A.  Only one weak band was identified from 
the PGP1 primers against L3 and no bands were amplified from PGP4 or PGP9.  All the 
main bands identified on the gel were of the anticipated size with the exception of the 
lower band from PGP5 versus adult cDNA and the lowest arrowed band from PGP7 versus 
L4 cDNA.  A second PCR was set up for PGP4 and PGP9 using IVM susceptible adult T. 
circumcincta 5‟ RACE-ready cDNA as template.  The results of this validation are shown 
in Figure 3.2, part B.  Both the PGP4 and PGP9 primers resulted in a single strong band on 
the agarose gel of the expected size. 
 
The bright bands and the three weak bands (arrowed) were excised from the gels in 
Figure  3.2,  parts  A  and  B  with  a  clean  scalpel,  cleaned  up  using  the  QIAquick  Gel 
Extraction Kit (Qiagen), and cloned into pGEM-T vector in JM109 cells and sequenced, as 
described previously, to determine if the bands were the correct Pgp.  The results of this 
cloning experiment are shown in Table 3.2.  The specificity of the primers was determined 
after sequence analysis by firstly excluding any clones which did not contain an insert.  
Next, the remaining sequences were trimmed in SeqMan (DNASTAR Lasergene, version 
8) to remove any vector sequence and the resulting sequence aligned against the consensus 
sequences for the 11 Pgps.  Any sequences failing to align with the Pgp sequences were 
BLAST searched to give a putative identity.  A primer pair was determined to be non-
specific if a clone which should have aligned to that particular Pgp was found to not have 
that identity, and the primer sequences were found at the start and end of the sequence.  
After several attempts at validation, the PGP1-specific primers were discarded as PCR 
products were either not amplified or failed to clone successfully.  The original primers for 
PGP7 (P7Tc F&R) were not sufficiently specific and so these were redesigned, validated 
against  the  plasmids  and  against  the  life-cycle  stage  cDNA  from  the  CVL  isolate  as 
described above.  Although one of the subsequent clones from the xL3 PCR product did not 
align to PGP7 (Table 3.2), these primers were determined to be specific as neither the 
P7TcF2 or P7TcR2 primer sequence was present at the ends of the cloned sequence.  The 
identity of this clone was a ribosomal protein of only 241bp in length compared to the PCR 
product size of ~650bp and, along with the absence of the primer sequences, this suggested 91 
that the insert was a contaminant of the cloning process.  The primer pairs for PGPs 2, 3, 5, 
6 and 9 were also shown to be gene-specific as shown in Table 3.2.   
 
3.2.4: Semi-quantitative PCR using P-glycoprotein specific primers 
  Using the gene-specific primers for PGPs 2, 3, 5, 6, 7 and 9 (Table 2.3) and for 
both the actin and β tubulin control genes (Table 2.1), a semi-quantitative PCR, using 
cDNA from eggs, L1, xL3, L4 and adults from the CVL and MOTRI isolates, was set up 
with aliquots of the PCR product collected after 15, 20, 25 and 30 cycles.  The PCR 
products were run on a 1% agarose gel and visualised under UV as shown in Figure 3.3.  
The  gel  shows  that  the  expression  of  the  control  genes  (actin  and  β  tubulin)  is 
approximately  equal  between  the  CVL  and  MOTRI  isolates,  however,  there  is  some 
variation  in  the  cycle  number  where  the  bands  became  visible  between  the  life-cycle 
stages.  No bands were present in either isolate, across all life-cycle stages for PGP2.  The 
expression of PGPs 3 and 7 showed no discernable difference between the two isolates 
although there was some variation in band intensity between the life-cycle stages.  The 
band intensity of PGP5 for the adult stage was also approximately equal between CVL and 
MOTRI but in the egg, L1 and xL3 stages the CVL isolate showed a greater intensity 
compared to the MOTRI isolate at 30 cycles.  In the L4 stage for PGP5, the MOTRI band 
at 30 cycles was more intense than the CVL band.  Across all life-cycle stages for PGP6, 
the intensity of the band from MOTRI cDNA was greater than the band from CVL cDNA.  
No bands were present using the PGP9 primers in the egg, xL3 and adult life-cycle stage 
whilst in the L1 and L4 stages the bands from MOTRI cDNA were more intense compared 
to the bands from CVL cDNA.   
 
3.2.5: Correct nomenclature of T. circumcincta P-glycoproteins 
  Phylogenetic analysis of the contiguous T. circumcincta Pgp sequences against C. 
elegans Pgp homologues, as described in Section 2.3.10, was carried out to determine the 
correct nomenclature for the 11 Pgp genes.  The results of this analysis are summarised in 
Table 3.3.  PGP1 aligned most closely to CePgps- 3 and -4 with bootstrapping values of 
1000 for both trees (Figure 3.4).  However, because it aligned equally well to both  C. 
elegans sequences this sequence will still be referred to as PGP1.  PGP2 aligned most 92 
closely to NBD2 in CePgp-2 with bootstrapping values of 1000 for both trees (Figure 3.5) 
and so from now on will be referred to as TeciPgp-2 NBD2.  PGP4 aligned most closely to 
the NBD1 in CePgp-9 (NJ bootstrap value 887, UPGMA bootstrap value 1000; Figure 3.6) 
and from now on will be referred to as TeciPgp-9 NBD1.  Like TeciPgp-2 NBD2, PGP5 
aligned  most  closely  with  CePgp-2  with  bootstrapping  values  of  1000  for  both  trees 
(Figure 3.7) however, PGP5 aligned against the NBD1.  As a result, PGP5 will now be 
known as TeciPgp-2 NBD1.  Like TeciPgp-9 NBD1, PGP6 aligned most closely with 
CePgp-9 (NJ bootstrap value 850, UPGMA bootstrap value 983; Figure 3.8) however, 
PGP6 aligned against the NBD2.  As a result, PGP6 will now be known as TeciPgp-9 
NBD2.  Like PGP1, PGP9 aligned closest to two C. elegans genes; CePgps -1 and -9 (NJ 
bootstrap value 529, UPGMA bootstrap value 390) and so this sequence will still be called 
PGP9 as it could not be determined which it aligned more closely to.   The alignments 
generated for PGPs 3, 7, 8, 10 and 11 were quite poor, resulting in the T. circumcincta 
sequences being broken up into lots of small sections spread across both NBD areas of the 
C. elegans Pgp nucleotides sequences.  As a result, the trees generated did not indicate 
which C. elegans Pgp was the closest match so these genes will still be referred to by their 
sequence names.  Interestingly, the major sections of the PGP8 sequence aligned in the 
NBD2 region as opposed to the NBD1 region of H. contortus PgpA (Accession number 
AF003908) and O. volvulus PGP1 (AF083642) it had aligned to previously, as described in 
Section 3.2.2.   
 
3.2.6: Identification of single nucleotide polymorphisms 
  Using the gene-specific primers as described in Table 2.3 and the one-step PCR 
protocol described in Section 2.3.11, gene-specific PCR products were obtained from adult 
CVL and MOTRI T. circumcincta pooled RNA for PGP3, TeciPgp-2 NBD1, TeciPgp-9 
NBD2, PGP7 and PGP9.  The resultant PCR products were purified using the QIAquick
® 
PCR purification kit (Qiagen) and submitted for direct sequencing as described in Section 
2.3.9.  Aligning  the sequences using the SeqDoC programme, as  described in  Section 
2.3.11, showed that for PGP3, TeciPgp-2 NBD1, PGP7 and PGP9 the sequences were 
highly conserved with no significant SNPs over the length of the sequence available for 
analysis.  However, TeciPgp-9 NBD2 proved to be highly polymorphic, with several SNPs 
visible  between  the  CVL  and  MOTRI  sequences.    Figure  3.9  shows  a  representative 
section of PGP3 and a section of TeciPgp-9 NBD2 where at least four major SNPs are 93 
present.  Figure 3.10 shows the nucleotide and protein Clustal W alignments for TeciPgp-9 
NBD2 comparing the CVL and MOTRI sequences.  This shows that, although there are 
SNPs  in this  gene, they are silent  or non-coding and do not  result in  any  amino acid 
changes, although this does not preclude the presence of coding SNPs elsewhere in the 
sequence.  The alignments in Figure 3.10 only show the section of the TeciPgp-9 NBD2 
which was amplified using the gene-specific primers.  As such, the four SNPs are (CVL to 
MOTRI)  as  follows;  A  to  G  at  nucleotide  138,  C  to  T  at  nucleotide  177,  A  to  T  at 
nucleotide  201  and  A  to  C  at  nucleotide  216.    Other  smaller  peaks  also  indicate 
polymorphic sites in the TeciPgp-9 NBD2 gene. 
 
3.3: Cytochrome P450s 
3.3.1: Identification of novel Cytochrome P450 sequences 
The first attempt at amplifying CYPs from T. circumcincta utilised the degenerate 
CYP primers from Menzel et al, (2001) as shown in Table 2.2.  These primers failed to 
amplify any CYPs from T. circumcincta cDNA, possible because the primers were not 
sufficiently degenerate, so EST CYP sequences from Ancylostoma ceylanicum, A. caninum 
and  O.  ostertagi  were  aligned  and  used  to  design  a  new  degenerate  primer, 
DegenTcP450For.  The use of this primer (Table 2.2) in conjunction with the TrplX Rev 
vector primer (Table 2.4) followed by cloning into the pGEM
®-T vector and sequencing of 
the resultant product, identified a CYP from T. circumcincta L4 SMART cDNA.  Whilst 
designing the DegenTcP450For primer, a second sequence from an xL3 enriched SSH EST 
dataset generated at Moredun Research Institute (Nisbet et al., 2008) was found to have 
BLAST  similarities  to  CYPs  from  other  nematodes.    Finally,  a  bioinformatics  search 
identified  a  third  EST  (accession  number  CB037767)  from  the  Nembase  cluster 
TDC01265 from a mixed sex T. circumcincta adult cDNA library.  A summary of the 
CYPs found in T. circumcincta is shown in Table 3.4, again sequences were numbered 
sequentially as they were identified (CYP1 to CYP3).   
 
Three further pairs of degenerate CYP primers were designed using a panel of CYP 
EST sequences from a range of nematodes species, such as A. caninum, C. elegans, O. 
ostertagi and T. circumcincta, with each pair of primers being specific for CYP clans 2, 3 94 
and 4 (Table 2.2), respectively, in an attempt to increase the chance of finding further T. 
circumcincta CYP sequences.  Again, these primers failed to amplify further CYPs from T. 
circumcincta cDNA. 
 
Alignments of the nucleotide sequences and translated protein sequences for the 
three T. circumcincta CYPs were performed using Clustal W and are shown in Appendices 
3  and  4.    The  nucleotide  sequences  for  the  three  T.  circumcincta  CYPs  were  aligned 
against  a  panel  of  CYP  sequences  from  H.  contortus,  C.  elegans,  A.  caninum  and  O. 
ostertagi using CLC DNA Workbench version 5.6.1 (www.clcbio.com).  The alignment 
was used to generate phylogentic trees as shown in Figure 3.11.  Part  A shows a tree 
generated using the UPGMA distance matrix with a bootstrap value of 1000 whilst part B 
shows a tree generated using the NJ distance matrix with a bootstrap value of 1000. 
 
3.3.2: Design and validation of Cytochrome P450 specific primers 
Specific primers were designed, using the nucleotide alignment in Appendix 3, for 
each of the three CYPs to enable their amplification from T. circumcincta cDNA.  The 
primer sequences, melting temperature and expected size of PCR product are shown in 
Table  2.3.    These  three  primer  pairs  were  used  in  PCRs  on  IVM  susceptible  T. 
circumcincta  exsheathed  L3  and  L4  SMART  cDNA  and  single-stranded  adult  cDNA 
alongside the T. circumcincta actin primers as a positive control.  Figure 3.12 shows the 
PCR  products  run  on  a  1%  agarose  gel,  showing  the  presence  of  single  bands  of  the 
expected sizes.  The bands were excised from the gel with a clean scalpel, the gel product 
cleaned up and sent for sequencing.  The results of the sequencing are shown in Table 3.5 
below.  These results show that the primers designed successfully amplified the CYPs from 
cDNA and are specific, only amplifying the CYP they were designed against. 
 
3.3.3: Semi-quantitative PCR using CYP specific primers 
As described previously for the Pgp work, semi-quantitative PCR was set up to 
investigate the relative expression of CYPs 1, 2 and 3 in five life-cycle stages of the CVL 95 
and MOTRI isolates of T. circumcincta compared to actin and β-tubulin controls.  Samples 
of the PCR reaction mix were taken after 15, 20, 25 and 30 cycles.  The agarose gels, 
visualised under UV, are shown in Figure 3.13.  As discovered previously, the expression 
levels of actin and β tubulin were approximately equal between the two isolates.  The 
expression  of  all  three  CYP  genes  was  low  with  the  majority  of  the  life-cycle  gene 
combinations only giving identifiable bands after 30 cycles.  For CYP1, only three very 
weak bands were apparent in the 30 cycle samples, these indicated that expression of this 
gene in the xL3 stage was greater in the CVL isolate compared to the MOTRI isolate and 
the expression in the L4 stage was approximately equal.  No bands were visible in the egg 
and L1 stages for CYP2 and only very weak bands of equal intensity were visible in the L4 
and adult stage.  Bright bands were visible in the xL3 stage but, like those in the L4 and 
adult stage, there was no difference between the CVL and MOTRI samples.  No bands 
were present for CYP3 in the egg, L1 or adult life-cycle stages.  Weak bands were present 
in the xL3 and L4 stages for CYP3; in both cases the MOTRI band was more intense than 
the CVL band.   
 
3.4: Discussion 
  Candidate  IVM  resistance  genes  such  as  the  Pgps  and  CYPs  have  not  been 
investigated  previously  in  T.  circumcincta  despite  extensive  investigation  in  other 
nematodes  such as  C. elegans, H. contortus and O. volvulus (Nelson,  1998;  Huang  & 
Prichard, 1999; Sangster et al., 1999a; Sheps et al., 2004; Ardelli, Guerriero, & Prichard, 
2005).  Both have generalised roles within cells; Pgps are involved in the transport of 
endogenous and exogenous hydrophobic molecules whilst CYPs catalyse the metabolism 
of hydrophobic molecules, such as drugs and environmental toxins (Barrett, 1998; Mansuy, 
1998; Sangster et al., 1999a; Kerboeuf, Guegnard, & Le Vern, 2003).   
 
Pgps have been shown to be involved in drug resistance in cancerous tumours, 
malaria parasites and the human immunodeficiency virus (Beugnet, Gauthey, & Kerboeuf, 
1997; Zhang et al., 1998; Loo & Clarke, 1999; Jones & George, 2005), where an increase 
in expression of Pgps allows a drug-resistant phenotype to develop.  It is also known that 
the anthelmintic, IVM, is a substrate of Pgps (Pouliot et al., 1997).  Changes in mRNA 96 
levels,  allele  frequencies  and  expression  of  Pgps  in  H.  contortus,  O.  ostertagi  and  O. 
volvulus have been observed following IVM selection, or in isolates resistant to IVM (Xu 
et  al.,  1998;  Blackhall  et  al.,  1998b;  Ardelli,  Guerriero,  &  Prichard,  2005;  Ardelli, 
Guerriero, & Prichard, 2006a; Ardelli, Guerriero, & Prichard, 2006b; Van Zeveren, 2009).  
Inhibitors of Pgps have been shown to cause a reversal towards a susceptible phenotype in 
resistant strains of T. circumcincta and H. contortus when exposed to IVM, as measured by 
the LFIT (Bartley et al., 2009).   
 
In this Chapter, the use of degenerate PCR primers, previously utilised to identify 
Pgps  in  H.  contortus  (Sangster  et  al.,  1999a)  against  cDNA  generated  from  IVM-
susceptible  T.  circumcincta  has  allowed  the  identification  of  eleven  novel  partial  Pgp 
sequences.  These partial gene sequences are the first time Pgps have been identified in T. 
circumcincta.  Out of the eleven genes identified, seven aligned to the NBD1 from H. 
contortus PgpA and O. volvulus PGP1, three aligned against NBD2 and one sequence 
(PGP1) contained both NBDs, as shown in Table 3.1.  This originally suggested that the 
potential number of Pgps in T. circumcincta was at least eight.  By aligning each individual 
T. circumcincta against the fifteen C. elegans Pgp sequences from Sheps et al (2004), it 
was determined that the two genes that had originally been called PGPs 2 and 5 were both 
the closest homologues of CePgp-2.  As a result, these were re-named TeciPgp-2 NBD2 
and TeciPgp-2 NBD1, respectively.  CePgp-2 has been shown to be homologous to PgpA 
in H. contortus, as such, TeciPgp-2 NBD2 and TeciPgp-2 NBD1 can be assumed to be 
homologous to this gene.  The two partial genes, PGPs 4 and 6 were shown to align most 
closely  to  CePgp-9  and  were  subsequently  renamed  TeciPgp-9  NBD1  and  TeciPgp-9 
NBD2, respectively.  If these four partial gene fragments prove to be each half of the 
respective  genes,  this  would  indicate  T.  circumcincta  has  at  least  nine  Pgps.    In  H. 
contortus at least twelve Pgp genes have been identified, whilst at least two have been 
identified in O. volvulus, and at least fifteen in C. elegans; the identification of eight or 
nine in T. circumcincta seems to fit this pattern (Kwa et al., 1998; Huang & Prichard, 
1999; Le Jambre, Lenane, & Wardrop, 1999; Sangster et al., 1999a; Kerboeuf et al., 2003; 
Blackhall, Prichard, & Beech, 2008).  Unequivocally defining the final number of Pgps 
requires the completion of the genome sequence of T. circumcincta.   
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Although  not  a  main  component  of  this  thesis,  the  identification  of  SNPs  in 
TeciPgp-9 NBD2 using SeqDoc analysis is interesting.  TeciPgp-9 NBD2 appears to be 
considerably more polymorphic than the other Pgps identified.  Four main SNPs were 
identified in the 208bp of sequence analysed, although the sequence chromatogram for 
TeciPgp-9 NBD2 does show other minor polymorphisms (Figure 3.9, part B).  The four 
main SNPs are A138G, C177T, A201T and A216C; the numbering of these SNPs is based 
on their position in the gene sequence currently available; when the full length sequence is 
obtained these numbers will change.  All of these SNPs are silent; as shown in Figure 3.10, 
part B, the protein sequence remains unchanged between CVL and MOTRI.  However, as 
previously stated, this does not preclude the presence of coding SNPs elsewhere in this 
gene.  Other polymorphisms in TeciPgp-9 NBD2 could also be SNPs but neither CVL nor 
MOTRI  are  clonal  populations;  the  presence  of  individual  worms  exhibiting  a  greater 
degree of resistance in the CVL isolate, or the presence of individual worms exhibiting a 
lesser degree of resistance in the MOTRI isolate, could result in some of the nucleotide 
positions being identified as polymorphic within an individual isolate when they are, in 
fact, a SNP between resistant and susceptible worms.  Identifying the presence of a highly 
polymorphic region in TeciPgp-9 NBD2 (the left hand portion of Figure 3.9, part B) could 
also  explain  why  the  RACE  primer  for  TeciPgp-9  NBD2  failed  to  work;  the  primer, 
Pgp6Tc 5'race, aligns to nucleotides 180 to 208 which includes the silent SNP A201T 
alongside other polymorphisms.  The presence of SNPs, whether silent or coding, could be 
a useful marker to distinguish between susceptible and resistant isolates. They may only 
prove to be isolate-specific so it would be interesting to determine whether these silent 
SNPs are also present in other isolates of T. circumcincta.  Interestingly Kimchi-Sarfaty et 
al (2007) have also found silent, or synonymous, SNPs in a haplotype of the Multidrug 
Resistance 1 (MDR1) gene expressed in a range of cell lines; the MDR1 gene is associated 
with multidrug resistance in cancer cells.  The Pgp encoded by MDR1 exhibits altered drug 
and  inhibitor  interactions,  yet  the  mRNA  and  protein  levels  remain  unchanged.    The 
authors hypothesise that the silent SNPs result in the use of rare codons during translation 
that could lead to altered protein translation kinetics which, in turn, affects co-translational 
folding and the structure of substrate and inhibitor interaction sites (Kimchi-Sarfaty et al., 
2007; Komar, 2007).   
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As a first step to determining whether there are changes in the expression of the 
Pgps, as measured by their mRNA levels, which correlate to the resistance status of the T. 
circumcincta isolate, a semi-quantitative PCR approach was adopted (Figure 3.3).  This 
experiment showed that the expression of the six Pgp genes, to which there were validated 
gene-specific  primers  available,  was  not  uniform  across  all  life-cycle  stages.    Pgp 
expression was evident in all life-cycle stages, which correlates with results from other 
nematodes,  as  reported  in  the  literature.    For  example,  the  expression  of  Pgps  in  H. 
contortus  has  been  shown  in  eggs,  L1,  L3  and  adults  using  gene  probes  and  in  situ 
hybridisation (Kwa et al., 1998; Smith & Prichard, 2002; Riou et al., 2005).  TeciPgp-2 
NBD2 (PGP2) was not detected in the semi-quantitative PCR experiment (Figure 3.3), 
however, this may be related to the low expression level of Pgps in general and this one in 
particular.  In the original PCR experiment to identify Pgps, expression of these genes was 
often only evident after 40 PCR cycles.  There were also discernable differences in the 
expression levels between the MOTRI and CVL isolates.  There was no uniform pattern of 
expression of the Pgps; some appeared to be expressed equally between the CVL and 
MOTRI  isolates  (PGPs  3  and  7)  whilst  TeciPgp-9  NBD2  (PGP6)  exhibited  increased 
expression in MOTRI compared to CVL.  Caution needs to be applied when analysing 
these results, however, as inaccuracies in the method such as pipetting error or amount of 
starting cDNA added to each well prior to PCR cycling could have caused some of the 
slight differences in band intensity observed.  In the case of TeciPgp-2 NBD2 and other 
genes, where no expression was observed at certain life-cycle stages, it may be necessary 
to repeat the experiment with more PCR cycles before it is assumed that these genes are 
not expressed in these life-cycle stages.  Alternatively, the use of methods such as real-time 
PCR could allow the quantification of these genes more accurately.   
 
  Like the Pgps, the CYPs have also been implicated in drug resistance.  In mosquito 
species such as An. minimus, An. gambiae and C. p. pallens, over-expression or over-
transcription  of  CYPS  enables  the  insects  to  exhibit  resistance  to  insecticides  (Nikou, 
Ranson,  & Hemingway, 2003;  Rodpradit  et  al., 2005;  Gong et  al., 2005).   In malaria 
parasites such as P. berghei and P. falciparum, an increase in CYP activity correlates with 
chloroquine  resistance  (Ndifor,  Ward,  &  Howells,  1990).    Over  80  CYPs  have  been 
identified  in  C.  elegans  in  all  life-cycle  stages  but  their  identification  in  parasitic 
nematodes  has  not  been  so  straightforward,  until  the  increase  in  genome  sequence 99 
availability in recent years (Menzel, Bogaert, & Achazi, 2001).  Barrett (1998)  claimed 
that there was no evidence of the presence of CYPs in adult parasitic nematodes, based on 
biochemical measurements of mono-oxygenase enzyme activity and that they would only 
be present at low abundance in larval stages, if present at all.  In a LFIT experiment, 
Bartley  et  al  (2009)  were  able  to  show  that  CYP  inhibitors  caused  a  shift  towards  a 
susceptible  phenotype  in  T.  circumcincta,  and  so  CYPs  may  be  implicated  in  the 
mechanism of IVM resistance in this species.  The efficacy of BZs can also be improved 
by  the  use  of  the  CYP  inhibitors,  piperonyl  butoxide  and  metyrapone  (McKellar  & 
Jackson, 2004), possibly hinting at some generic (i.e. not linked to mutations in β-tubulin) 
resistance mechanisms.   
 
  Using a combination of degenerate PCR, bioinformatic searches of NEMBASE, 
and an EST dataset at Moredun, three distinct CYPs were identified, one each from L3, L4 
and adult T. circumcincta (Table 3.4).  None of the sequences obtained were full-length 
coding sequences.  The presence of a CYP in a mixed sex adult cDNA library contradicts 
the statement from Barrett (1998) that adult parasitic nematodes do not possess CYPs.  
Unlike some of the Pgps, it has not been possible to identify which C. elegans CYP gene is 
the nearest homologue.  The CYP gene superfamily is very large and assigning the correct 
nomenclature to a newly identified CYP is carried out through the P450 Nomenclature 
Committee; as such the sequences identified here remain named as CYP 1, 2 and 3 (Nelson 
et al., 1996).  Identifying the three partial CYPs from T. circumcincta was problematic and 
is possibly due to the low levels at which they are expressed.  Kotze (1997) measured the 
CYP activity towards aldrin and 7-ethoxycoumarin in H. contortus microsomes and found 
it to be 10,000-fold lower compared to rat liver microsomes.  Gene-specific primers were 
designed  for  each  of  the  three  CYPs  identified  and  validated  by  sequencing  the  PCR 
products obtained from amplification of L3, L4 and adult cDNA (Figure 3.12).  This proved 
that the primers designed solely amplified their specific CYP target.   
 
  As with the Pgps, the gene-specific primers were used to determine the expression 
profile of the three CYPs across the life-cycle stages (eggs, L1, xL3, L4 and adults) of the 
CVL and MOTRI isolates, compared to the actin and β-tubulin control genes in a semi-
quantitative PCR.  This experiment showed that the level of CYP expression was low; 100 
most of the bands obtained were very weak, compared to the bands for actin and β-tubulin, 
even after 30 cycles.  In fact, none of the three genes were amplified from egg cDNA; 
however, it is not possible to conclude at this stage that they are not expressed in eggs.  
The indication that CYP1 was expressed more in CVL xL3 than in MOTRI xL3 and CYP3 
was expressed more in MOTRI L4 compared to CVL L4 (Figure 3.13) suggests that the 
CYP  genes  are  worthy  of  further  investigation  in  the  context  of  IVM  resistance  in  T. 
circumcincta.  Using real-time PCR would allow a more accurate measure of whether these 
genes  do  exhibit  an  altered  gene  expression  profile  between  CVL  and  MOTRI;  semi-
quantitative PCR only allows a subjective measure of expression differences.   
 
The identification of 11 novel partial Pgp gene fragments and 3 partial CYP gene 
fragments from T. circumcincta gives a good panel of candidate resistance genes for use to 
investigate whether altered expression patterns of these generic drug handling molecules 
have a role to play in the expression of the IVM-resistance phenotype.  Semi-quantitative 
PCR has revealed demonstrable differences in mRNA expression levels for both the CYPs 
and Pgps between a multi-drug resistant and susceptible T. circumcincta isolates; more 
accurate quantification of these genes using real-time PCR is required.  The differences 
observed  in  the  expression  of  TeciPgp-9  NBD2,  indicating  a  constitutive  increase  in 
expression across all life-cycle stages in the MOTRI isolate compared to CVL coupled 
with  the  observation  of  SNPs  in  the  same  gene,  make  this  the  priority  for  further 
investigations.   101 
Table 3.1: Length and number of sequences aligning to each of the 11 novel Pgp sequences identified from T. 
circumcincta cDNA. 
Pgp name 
Size  of  nucleotide 
sequence (bp) 
Number  of  sequences  in 
alignment 
Predicted  region 
of Pgp 
PGP1  2322  13  NBD 1 & NBD 2 
PGP2  1041  14  NBD 2 
PGP3  945  17  NBD 1 
PGP4  1501  18  NBD 1 
PGP5  935  5  NBD 1 
PGP6  405  4  NBD 2 
PGP7  1892  5  NBD 1 
PGP8  398  2  NBD 1 
PGP9  398  2  NBD 1 
PGP10  395  3  NBD 2 
PGP11  395  2  NBD 1 102 
Table 3.2: Results of cloning of Pgp gene-specific primers to determine their specificity.  The sequence of the primers is shown in Table 2.3.  * Remaining clone was a contaminant as no 
P7TcF2 and P7TcR2 primers were present in the sequence and sequence was not correct length compared to original band size on agarose gel. 
Band 
name 
Template  Band size 
(approx bp) 
Primers  Clone results 
(# correct ID) 
Specificity 
P1L3  CVL xL3 SMART cDNA  650  P1TcF & P1TcR  0/0  Cloning failed 
P1  CVL adult 5‟ RACE  650  P1TcF & P1TcR  0/0  Cloning failed 
P2L3  CVL xL3 SMART cDNA  600  P2TcF & P2TcR  2/2 
PGP2 specific  P2L4  CVL L4 SMART cDNA  600  P2TcF & P2TcR  3/3 
P2Ad  CVL single-stranded adult cDNA  600  P2TcF & P2TcR  3/3 
P3L3  CVL xL3 SMART cDNA  600  P3TcF & P3TcR  3/3 
PGP3 specific  P3L4  CVL L4 SMART cDNA  600  P3TcF & P3TcR  3/3 
P3Ad  CVL single-stranded adult cDNA  600  P3TcF & P3TcR  3/3 
P4  CVL adult 5‟ RACE  600  P4TcF & P4TcR  6/7  Not specific 
P5L4  CVL L4 SMART cDNA  600  P5TcF & P5TcR  3/3 
PGP5  specific  if 
band of correct size 
P5Ad 1  CVL single-stranded adult cDNA  600  P5TcF & P5TcR  3/3 
P5Ad 2  CVL single-stranded adult cDNA  500  P5TcF & P5TcR  0/3 
P6L3  CVL xL3 SMART cDNA  250  P6TcF & P6TcR  3/3 
PGP6 specific 
P6L4  CVL L4 SMART cDNA  250  P6TcF & P6TcR  3/3 
P7L3  CVL xL3 SMART cDNA  650  P7TcF & P7TcR  3/3 
Not specific 
P7L4 1  CVL L4 SMART cDNA  700  P7TcF & P7TcR  1/1 
P7L4 2  CVL L4 SMART cDNA  650  P7TcF & P7TcR  3/3 
P7L4 3  CVL L4 SMART cDNA  250  P7TcF & P7TcR  1/3 
P7Ad  CVL single-stranded adult cDNA  650  P7TcF & P7TcR  2/3 103 
Band 
name 
Template  Band size 
(approx bp) 
Primers  Clone results 
(# correct ID) 
Specificity 
P7L3  CVL xL3 SMART cDNA  650  P7TcF2 & P7TcR2  2/3* 
PGP7 specific  P7L4  CVL L4 SMART cDNA  650  P7TcF2 & P7TcR2  1/1 
P7Ad  CVL single-stranded adult cDNA  650  P7TcF2 & P7TcR2  3/3 
P9  CVL adult 5‟ RACE  350  P9TcF & P9TcR  9/9  PGP9 specific 
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Table 3.3: Results of the phylogenetic analysis of the 11 T. circumcincta Pgp genes to determine their correct gene identification. * denotes sequence which were reduced in size slightly 
when the alignment was trimmed due to a small proportion of the T. circumcincta sequence aligning a very large distance away from the remaining part of the sequence.   
Gene 
name 
Sequence 
size 
NBD  UPGMA 
result 
UPGMA 
bootstrap value 
Neighbour- 
joining result 
Neighbour-  joining 
bootstrap value 
Notes  Accession 
number 
PGP1  2273*  1&2  CePgp-3or 4  1000  CePgp-3 or 4  1000  Keeps temporary name  FR691845 
PGP2  936*  2  CePgp-2  1000  CePgp-2  1000  Gene now called TeciPgp-2 NBD2  FR691846 
PGP3  945  1  Not clear  -  CePgp-10  1000  Alignment poor quality, keeps temporary name  FR691847 
PGP4  1501  1  CePgp-9  1000  CePgp-9  887  Gene now called TeciPgp-9 NBD1  FR691848 
PGP5  935  1  CePgp-2  1000  CePgp-2  1000  Gene now called TeciPgp-2 NBD1  FR691849 
PGP6  405  2  CePgp-9  983  CePgp-9  850  Gene now called TeciPgp-9 NBD2  FR691850 
PGP7  1892  1  Not clear  -  CePgp-10  646  Alignment poor quality, keeps temporary name  FR691851 
PGP8  398  1  Not clear  334  CePgp-10  166  New alignment shows it to be NBD2  FR691852 
PGP9  398  1  CePgp-9or 1  390  CePgp-9 or 1  529  Keeps temporary name  FR691853 
PGP10  395  2  Not clear  -  CePgp-10  -  Alignment poor quality, keeps temporary name  FR691854 
PGP11  395  1  Not clear  -  CePgp-10  -  Alignment poor quality, keeps temporary name  FR691855 105 
Table 3.4: A summary of T. circumcincta CYPs found using PCR and bioinformatics approaches. 
CYP Name  Identification 
method 
Life cycle stage  Size of nucleotide 
sequence (bp) 
CYP 1  Degenerate PCR  L4  724 
CYP 2  EST dataset  L3  647 
CYP 3  Bioinformatics  Mixed sex adult  681 106 
Table 3.5: Results of cloning of CYP PCR products to determine the specificity of the specific T. circumcincta CYP primers. 
Primers 
Template 
cDNA 
No. clones 
submitted 
Expected size 
of product 
Actual size 
of product 
Notes 
Primer 
specificity 
CYP 1  L3  6  365  366  100-95% sequence identity to CYP1 
Yes 
CYP 1  L4  6  365  366  100-95% sequence identity to CYP1 
CYP 2  L3  1  323  323  97% identity to CYP2  Yes 
CYP 3  L3  1  467  468  95% identity to CYP3 
Yes 
CYP 3  L4  2  467  468  95% identity to CYP3 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: 1% agarose gel electrophoresis of PCR products to determine whether the T. circumcincta Pgp-
specific  primers  only  amplified  their  target  Pgps  using  plasmids  containing  the  respective  partial  Pgp 
sequences as template DNA.  The primers designed against PGPs 1, 2, 3, 4, 5, 6, 7 and 9 were specific for 
their target whilst PGP 8, 10 and 11 primers were amplifying non target Pgps.  Each of the bands on the 
agarose gel was the expected size of the PCR product as stated in Table 2.3.  Positive and negative controls 
are not shown.   
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Figure 3.2: 1% agarose gel electrophoresis of PCR products to determine whether the Pgp specific primers 
only amplified their target Pgps.  A: IVM susceptible T. circumcincta exsheathed L3 and L4 SMART cDNA 
and single-stranded adult cDNA used as template against primers for PGPs 1, 2, 3, 4, 5, 6, 7 and 9.  Weak 
bands have been arrowed to aid identification.  B: IVM susceptible adult 5‟ RACE-ready cDNA used as 
template against primers for PGPs 4 and 9. 
Mx PGP 4 PGP 9
Mx
PGP 1               PGP 2             PGP 3              PGP 4  PGP 5
L3   L4   Ad    L3   L4    Ad    L3   L4    Ad    L3   L4   Ad   L3   L4   Ad
Mx
PGP 6                   PGP 7                  PGP 9       Actin
L3    L4      Ad      L3      L4     Ad     L3     L4     Ad     L3     L4     Ad
Mx
PGP 1               PGP 2             PGP 3              PGP 4  PGP 5
L3   L4   Ad    L3   L4    Ad    L3   L4    Ad    L3   L4   Ad   L3   L4   Ad Mx
PGP 1               PGP 2             PGP 3              PGP 4  PGP 5
L3   L4   Ad    L3   L4    Ad    L3   L4    Ad    L3   L4   Ad   L3   L4   Ad
Mx
PGP 6                   PGP 7                  PGP 9       Actin
L3    L4      Ad      L3      L4     Ad     L3     L4     Ad     L3     L4     Ad Mx
PGP 6                   PGP 7                  PGP 9       Actin
L3    L4      Ad      L3      L4     Ad     L3     L4     Ad     L3     L4     Ad109 
 
Figure 3.3: 1% agarose gel of the semi-quantitative PCR products using the Pgp gene specific primers.  Each set of primers was used to amplify cDNA from eggs, L1, xL3, L4 and adult T. 
circumcincta of either the CVL (C) or MOTRI (M) isolate.  5µL of PCR product was removed after 15, 20, 25 and 30 cycles. A negative control (-) was included for each lifecycle stage –
primer combination and the gel marker lane (Mx) containing TrackIt
™ 1Kb Plus DNA Ladder (Invitrogen) is on the left. 110 
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Figure 3.4: Phylogenetic trees generated using the CLC DNA Workbench package showing the relationship 
of T. circumcincta PGP1 to 15 C. elegans Pgp genes.  A: Tree generated using the UPGMA distance matrix 
with  a  bootstrap  value  of  1000.  B:  Tree  generated  using  the  Neighbour-joining  distance  matrix  with  a 
bootstrap value of 1000.  Both trees indicate T. circumcincta PGP1 is closest to CePgp-3 and CePgp-4. 
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Figure 3.5: Phylogenetic trees generated using the CLC DNA Workbench package showing the relationship 
of T. circumcincta PGP2 to 15 C. elegans Pgp genes.  A: Tree generated using the UPGMA distance matrix 
with  a  bootstrap  value  of  1000.  B:  Tree  generated  using  the  Neighbour-joining  distance  matrix  with  a 
bootstrap value of 1000.  Both trees indicate T. circumcincta PGP2 is closest to CePgp-2.  PGP2 will now be 
known as TeciPgp-2 NBD2.   
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Figure 3.6: Phylogenetic trees generated using the CLC DNA Workbench package showing the relationship 
of T. circumcincta PGP4 to 15 C. elegans Pgp genes.  A: Tree generated using the UPGMA distance matrix 
with  a  bootstrap  value  of  1000.  B:  Tree  generated  using  the  Neighbour-joining  distance  matrix  with  a 
bootstrap value of 1000.  PGP4 will now be known as TeciPgp-9 NBD1 as it aligns most closely in both trees 
to CePgp-9.   
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Figure 3.7: Phylogenetic trees generated using the CLC DNA Workbench package showing the relationship 
of T. circumcincta PGP5 to 15 C. elegans Pgp genes.  A: Tree generated using the UPGMA distance matrix 
with  a  bootstrap  value  of  1000.  B:  Tree  generated  using  the  Neighbour-joining  distance  matrix  with  a 
bootstrap value of 1000.  Due to this analysis PGP5 will now be known as TeciPgp-2 NBD1 as it aligns most 
closely to CePgp-2.   
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Figure 3.8: Phylogenetic trees generated using the CLC DNA Workbench package showing the relationship 
of T. circumcincta PGP6 to 15 C. elegans Pgp genes.  A: Tree generated using the UPGMA distance matrix 
with  a  bootstrap  value  of  1000.  B:  Tree  generated  using  the  Neighbour-joining  distance  matrix  with  a 
bootstrap value of 1000.  PGP6 will now be known as TeciPgp-9 NBD2 as it aligns most closely to CePgp-9. 
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Figure 3.9: SeqDoC alignments comparing sequence generated from CVL and MOTRI adult T. circumcincta for PGP3 and TeciPgp-9 NBD2.  A: Partial SeqDoc alignment for PGP3. 
B: Partial SeqDoc alignment for TeciPgp-9 NBD2. In each alignment the top chromatogram was the CVL sequence and the lower chromatogram the MOTRI sequence. The middle 
trace indicates where a SNP has occurred between the two sequences (difference profile).  The regions shown in this figure are not the same parts of the Pgp molecule.   117 
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Figure 3.10:  Clustal W alignments of the nucleotide and protein sequences of TeciPgp-9 NBD2 comparing 
the  sequences  derived  from  adult  T.  circumcincta  from  the  MOTRI  and  CVL  isolates.    A:  Nucleotide 
alignment with the SNPs highlighted in red text. B: Protein alignment of translated coding sequence showing 
that the respective SNPs identified are synonymous. 
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Figure 3.11: Phylogenetic trees showing the relationship of T. circumcincta CYPs to CYP sequences from H. 
contortus (Hc), C. elegans (Ce), A. caninum (Ac) and O. ostertagi (Oo).  The T. circumcincta (Tc) sequences 
are named in the order they were discovered.  The C. elegans CYPs are given their official family name 
whilst  A.  caninum  and  O.  ostertagi  sequences  are  named  according  to  their  accession  number.  A:  Tree 
generated using the UPGMA distance matrix with a bootstrap value of 1000. B: Tree generated using the 
CLC DNA Workbench package using the Neighbour-joining distance matrix with a bootstrap value of 1000. 
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Figure 3.12: 1% agarose gel showing the specific bands for the three T. circumcincta CYP specific primers.  
The white arrows denote bands which were analysed further.  A very weak band could also be observed from 
CYP2 versus L4 
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Figure 3.13: 1% agarose gel of the semi-quantitative PCR products using the CYP gene specific primers.  Each set of primers was used to amplify cDNA from eggs, L1, xL3, L4 and adult T. 
circumcincta of either the CVL (C) or MOTRI (M) isolate.  5µL of PCR product was removed after 15, 20, 25 and 30 cycles. A negative control (-) was included for each lifecycle stage –
primer combination and the gel marker lane (Mx) containing TrackIt
™ 1Kb Plus DNA Ladder (Invitrogen) is on the left. 121 
Chapter  4:  Quantitative  TaqMan
®  Real-Time  PCR  to  Measure  the 
Expression  of  Candidate  Ivermectin  Resistance  Genes  in  Teladorsagia 
circumcincta Isolates 
4.1: Introduction 
  The role of candidate IVM resistance genes, such as the Pgps and CYPs, in the 
expression  of  resistance  to  the  anthelmintics,  has  not  been  investigated  to  date  in  T. 
circumcincta.  This is despite these genes being implicated in drug resistance in other 
systems,  for  example,  over-expression  of  Pgps  linked  to  drug  resistance  in  cancerous 
tumours and over-expression of CYPs associated with drug-resistance in mosquitoes (Loo 
& Clarke, 1999; Nikou, Ranson, & Hemingway, 2003).  Alongside this, work carried out 
in related parasitic nematodes such as H. contortus and O. volvulus has also suggested that 
differences in expression of these genes could play a role in the IVM-resistant phenotype, 
as described below.   
 
  The likely molecular targets of IVM appear to be the GABA and GluCl channels; 
concurrent mutations in three GluCl α-type subunits in C. elegans confer high levels of 
IVM resistance (Dent et al., 2000; Njue et al., 2004; Gilleard, 2006).  However, more 
generic  drug  handling  mechanisms,  such  as  the  Pgps  also  seem  to  play  a  role  in  the 
expression  of  an  IVM  resistance  phenotype  as  shown  by  various  studies  utilising  Pgp 
inhibitors.  The co-administration of verapamil (a Pgp inhibitor) with MOX or IVM has 
been  shown  to  significantly  increase  anthelmintic  efficacy  against  MOX-selected  H. 
contortus and the use of Pgp inhibitors in the LFIT caused reversion towards susceptibility 
in IVM-resistant H. contortus and T. circumcincta (Xu et al., 1998; Bartley et al., 2009).  
IVM or MOX selection in H. contortus and O. volvulus appear to place the Pgps under 
selection pressure as indicated by changes in allele frequencies and/ or loss of genetic 
diversity (Blackhall et al., 1998b; Ardelli, Guerriero, & Prichard, 2005; Ardelli, Guerriero, 
& Prichard, 2006b).  An increase in PgpA mRNA level has also been observed in IVM-
selected H. contortus (Xu et al., 1998).   
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  CYPs  are  a  large  family  of  membrane-anchored  proteins  involved  in  the 
metabolism  of  a  range  of  predominantly  hydrophobic,  exogenous  and  endogenous 
compounds, including drugs (Guengerich, 1991; Mansuy, 1998).  CYPs appear to play a 
role  in  insecticide  resistance  in  mosquitoes  and  Drosophila  spp  (Daborn  et  al.,  2002; 
Nikou, Ranson, & Hemingway, 2003; Le Goff et al., 2003), whilst chloroquine resistance 
in malaria parasites also appears to be associated with increased CYP activity  (Ndifor, 
Ward, & Howells, 1990; Barrett, 1998).  Their role in drug resistance, particularly to IVM, 
which is hydrophobic, has not been extensively investigated in parasitic nematodes.  This 
is possibly due to the enzymatic assays previously used not being sufficiently sensitive to 
detect CYP activity (Kotze, 1997; Barrett, 1998).  The use of the CYP inhibitors, piperonyl 
butoxide and metyrapone has also been shown to increase the efficacy of BZ anthelmintics 
(McKellar & Jackson, 2004), providing further evidence of their role in generic xenobiotic 
metabolism.   
 
If Pgps and CYPs are involved in generic drug handling mechanisms, for example, 
by preventing IVM from reaching its target sites in the pharyngeal and somatic muscle 
cells or by metabolising IVM into an inactive form, then changes in the expression profile 
of these genes would be expected when comparing drug–resistant and –susceptible isolates 
(Gilleard & Beech, 2007; Prichard & Roulet, 2007; Blackhall, Prichard, & Beech, 2008).  
Increased  or  reduced  expression  levels,  reflected  in  mRNA  levels,  could  be  identified 
depending on the specific role of that particular candidate resistance gene in the parasite.  
A panel of candidate resistance genes, comprising 11 partial Pgp and 3 partial CYP gene 
sequences was identified from T. circumcincta, as described in Chapter 3.  Initial semi-
quantitative  PCR  results,  also  described  in  Chapter  3,  indicated  that  differences  in 
expression  of  these  genes  were  evident  when  comparing  well-characterised  T. 
circumcincta isolates with known IVM resistance status.   
 
The expression of the Pgp and CYP genes in the CVL, MOTRI and Post IVM 
MOTRI T. circumcincta isolates was investigated further, using the relative quantification 
(or ʔʔCt) real-time PCR method, as described below.  In this method, the Ct for the test 
gene is normalised to the actin Ct values for the same isolate and life-cycle stage on the 
same reaction plate.  Next, the expression of the gene in MOTRI is expressed relative to 123 
the expression in CVL and the expression in Post IVM MOTRI expressed relative to the 
expression in MOTRI.  The value obtained gives a relative fold change in expression.  The 
first comparison (CVL vs. MOTRI) investigated constitutive expression differences i.e. 
those  found  between  the  IVM–susceptible  and  –resistant  isolates  “at  rest”  whilst  the 
second  comparison  (MOTRI  vs.  Post  IVM  MOTRI)  investigated  inducible  expression 
differences i.e. those found between the pre- and post-IVM exposure isolates.   
 
4.2: Materials and methods 
4.2.1: Design of primers and probes 
TaqMan
® primers and TaqMan
® Minor Groove Binder (MGB) fluorogenic probes 
were designed using the Primer Express
® software version 3.0 (Applied Biosystems).  The 
consensus sequence for each gene, generated using standard and RACE PCR as described 
previously, was entered into Primer Express, and 10 combinations of forward and reverse 
primers and probes designed by the software.  Default parameters were chosen to give 
short amplicons of less than 150bp, primers with a Tm of 58- 60°C, the difference in Tm 
between the primers to be less than 2°C and the primers to have a high G-C content.  
Default parameters were also chosen for the probes, briefly, the probe Tm was designed to 
be 8-10°C higher than the primers, to have no G on the 5‟ end, and to have a maximum of 
30 bases between the primer and the probe.  The primer and probe sets chosen for each 
gene are shown in Table 4.1. 
 
The specificity of the primers and probes was validated by BLASTN searching the 
sequences against the EBI database (http://www.ebi.ac.uk/Tools/blast2/parasites.html) to 
determine if they would align to any other T. circumcincta sequence.  The primer and 
probe sequences were also searched against the Lasergene EditSeq (DNASTAR Lasergene 
version 8) files generated for each of the Pgp and CYP specific gene sequences from the 
Seqman  sequence  alignments  to  confirm  they  were  specific  for  the  gene  they  were 
designed to target.   
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Primers  and  probes  were  ordered  from  Applied  Biosystems 
(http://www3.appliedbiosystems.com).  The primers were supplied lyophilised and were 
re-suspended  in  HPLC  water  (Sigma)  to  give  a  stock  concentration  of  100μM.    The 
working dilution was 10μM and the primers were stored at -20°C in individual reaction 
aliquots.  FAM labelled MGB probes were supplied in solution at 100μM, again a working 
dilution of 10μM was made, aliquots made and stored at -20°C. 
 
Real-time PCR reagents 
  TaqMan
® Gene Expression Master Mix, MicroAmp
™ Optical 96-well plate and 
MicroAmp
™ Optical adhesive film were obtained from Applied Biosystems. 
 
4.2.2 Real-time PCR protocol 
  Real-time  PCR  reactions  were  set  up  by  combining  10μL  TaqMan
®  Gene 
Expression Master Mix, 1μL each of the forward and reverse primers, 0.25μL of the MGB 
probe and 5.75μL of water to give a total master mix volume of 18μL per reaction.  Due to 
the light sensitivity of MGB probes, these were allowed to thaw in the dark and only 
briefly exposed to light whilst making up the master mix.  The master mix was kept in the 
dark whilst being transferred to the PCR workstation area where it was dispensed into the 
96-well PCR plate in 18μL aliquots.  To each well of the plate, 2μL template, either cloned 
purified  PCR  product  or  T.  circumcincta  cDNA  (diluted  previously  to  50ng/μL)  was 
added.  Duplicate wells were set up for each template used.  Following the addition of the 
template, the plate was sealed with an adhesive film, ensuring that the film was pressed 
down firmly to prevent contamination and evaporation of the PCR reactions. 
 
All real-time PCR runs were carried out on an ABI 7000 sequence detection system 
(Applied  Biosystems).    The  reaction  conditions  were  as  follows:  95°C  for  12  mins 
followed by 40 cycles of 95°C for 15 secs and 60°C for 60 secs.  Collection of data, by 
detection of the FAM dye attached to the probe, occurred during the final phase of each 
cycle; this enabled a crossing threshold (Ct) value to be determined for each well.  This 125 
value shows at how many PCR cycles the linear phase of the PCR reaction crossed a pre-
determined threshold.  Triplicate real-time PCR runs were carried out for each gene under 
test.    The  baseline  and  threshold  for  each  of  the  three  runs  for  each  gene  were  set 
identically and the Ct values recalculated to enable direct comparisons between the run 
data to be made, as described below. 
 
4.2.3: Validation of efficiency of real-time primers and probes 
  To determine the efficiency of the primers and probes, individual gene fragments 
were cloned into pGEM
®-T vectors, amplified and purified to provide sufficient plasmid 
template  for  the  real-time  PCR  reactions.    The  gene  sequences  used  to  determine  the 
efficiency of the primer and probe sets are shown in Table 4.2.  Using the concentration of 
the plasmid and the plasmid size, the copy number for each gene specific plasmid was 
determined.  A 10-fold dilution series (10
^8 to 10
^3 copies) for each plasmid was set up to 
enable the efficiency of the primers and probes to be calculated.   
 
Initial PCR reactions using the plasmid standards as template were carried out as 
described  previously.    From  these  reactions,  a  standard  curve  was  generated  for  each 
primer and probe set.  From the standard curve, a correlation coefficient (R
2) and value 
representing the slope of the standard curve were generated.  An R
2 value of >0.99 was 
determined as  showing  the individual data points  on the standard curve fitted the line 
sufficiently.  From the slope value, the efficiency of the reaction could be calculated and 
expressed as a percentage as follows: 
 
  Efficiency = (10 
^ (-1/slope) -1) x 100 
 
Ideally, the efficiency of the reaction should be 100%, this is achieved if the value 
of the slope is -3.33.  If the efficiency was found to be too low or too high then that 
specific gene was removed from further analysis. 126 
4.2.4: Analysis of real-time data 
  Relative  quantification  of  the  gene  expression  level  was  carried  out  using  the 
comparative Ct (ʔʔCt) method.  The raw Ct values for the Pgp or CYP (target) gene and 
the actin (endogenous control) gene for the three parasite isolates (CVL, MOTRI, Post 
IVM MOTRI) and five life-cycles stages (eggs, L1, xL3, L4 and adults) were exported from 
the ABI 7000 SDS program into Excel (Microsoft Windows XP).  The relative fold change 
in  expression  of  a  particular  gene,  as  reflected  in  cDNA  level,  between  two  different 
isolates (either CVL vs. MOTRI or MOTRI vs. Post IVM MOTRI) was calculated for each 
life-cycle stage by following the three steps below: 
 
  Firstly,  for  each  isolate  and  life-cycle  stage  combination,  the  target  gene  was 
normalised to the endogenous control: 
 
    ʔCt = Ct target gene – Ct endogenous control 
 
  Next, the sample was normalised to the calibrator sample:  In CVL vs. MOTRI 
comparison, the calibrator was CVL and the sample MOTRI.  In the Post IVM MOTRI vs. 
MOTRI comparison, the calibrator was MOTRI and the sample Post IVM MOTRI.   
 
    ʔʔCt = ʔCt sample – ʔCt calibrator 
 
  Finally, the relative fold change in expression between the two isolates, normalised 
to the endogenous control, was calculated using the formula: 
 
    Fold change = 2 
–ʔʔCt 127 
4.2.5: Statistical analysis of the real-time results 
  Triplicate real-time runs were carried out for each gene.  To analyse the multiple 
real-time runs, the data were converted to a log scale to control for occasions when one 
replicate could be up-regulated and the next down-regulated.  If the fold changes were 
averaged, a false reading would result. For example:  Replicate 1 = 5-fold up-regulation, 
replicate 2 = 5-fold down-regulation (≈0.2).  Average fold change = (5 + 0.2) / 2 = 2.6 
average fold up-regulation, which is incorrect.  Taking the log of the two fold changes 
shown above gives the following equation (C.-D. Mayer, Pers. Comm.), which calculates 
the correct average: 
 
    Log (5) + log (1/5) = log (5) – log (5) = 0 fold change in expression. 
 
  The ʔCt values were log transformed as follows, where A is the sample and B the 
calibrator: 
 
    Expression A / Expression B = 2^ (-(ʔA – ʔB) 
 
  Applying log2 to each side gives: 
 
    Log2 (Expression A) − Log2 (Expression B) = (-ʔA) - (-ʔB) 
 
  This means to log transform the ʔCt values, a positive ʔCt value becomes negative 
and vice versa.  Hence, the log transformed values for 2 
–ʔʔCt were calculated as follows:  
Firstly, the average of the triplicate results was obtained by calculating the average log 
transformed ʔCt value for both the sample and calibrator.  The average log ratio was 
calculated by: 128 
 
    Average log ratio = Average log expressionA – Average log expressionB 
 
  The average fold change was calculated as: 
 
    2^ 
Average log ratio 
 
  A  two  tailed  T-Test  was  performed  in  Excel  (Microsoft  Windows  XP)  on  the 
triplicate log transformed ʔCt values to generate a P-value. 
 
4.3: Validation of real-time primers and probes 
  Each primer and probe set (Table 4.1) was validated against a duplicate 10-fold 
serial  dilution,  calculated  to  give  10^8  to  10^3  gene  copies,  of  pGEM
®-T  plasmids 
containing the target gene.  The standard curve, generated using the threshold crossing 
values (Ct) for each plasmid copy number, was used to calculate the efficiency of the 
reaction using the efficiency calculation, as described earlier.  A representative plot of raw 
data obtained for PGP7 from the ABI 7000 sequence detection system is shown in Figure 
4.1 alongside the standard curve generated from the Ct values for PGP7.  Each gene‟s 
primer  and  probe  sets  (PGP1,  TeciPgp-2  NBD2,  PGP3,  TeciPgp-9  NBD1,  TeciPgp-2 
NBD1, TeciPgp-9 NBD2, PGP7, PGP8, PGP9, PGP10, PGP11, CYP1, CYP2 and CYP3) 
were quantified on a reaction plate alongside the actin containing plasmids.  This allowed 
the relative efficiency of the amplification of the genes to be compared to actin both by 
visual inspection of the standard curves and also by comparing the efficiency values.  The 
efficiency values for the test genes are shown in Table 4.3; actin has more than one set of 
values as it was validated several times against the other genes.  Efficient primer and 
probes sets have an efficiency value close to 100%, indicating that the amount of product 
doubles with each real-time cycle (Bustin et al., 2009).  The TeciPgp-9 NBD1 primer and 
probes were validated twice as the efficiency value for the first run was so low, compared 129 
to the other genes.   An example of the difference in standard curves for TeciPgp-9 NBD1 
compared  to  actin  is  shown  in  Figure  4.2.    Due  to  the  relatively  low  efficiency,  the 
expression of this transcript in T. circumcincta was not investigated further.   
 
  Each experimental plate quantified the expression of one of the test genes and actin 
for each isolate and life-cycle stage combination in duplicate alongside a 10-fold serial 
dilution of the actin plasmids.  The serial dilution was made up fresh from a frozen aliquot 
of the actin plasmid for each experimental run.  The efficiency of the actin standards was 
calculated  for  each  run  to  monitor  if  there  were  any  significant  changes  over  time.  
Alongside this, the duplicate actin Ct values for each isolate and life-cycle stage were 
recorded and a graph (Figure 4.3) produced showing the average actin Ct values and the 
standard  deviation.    To  be  able  to  trust  the  fold  changes  obtained  using  the  relative 
quantification method, the Ct values for the control gene between the sample and calibrator 
need to be comparable.  From Figure 4.3, it is possible to see that comparisons between 
life-cycle  stages  were  not  feasible  due  to  the  variation  in  actin  Ct  values.    Also,  the 
comparison between MOTRI and Post IVM MOTRI in the L4 stage cannot be made due to 
the large difference in actin Ct values between the two samples.   
 
4.4: Relative quantification of expression of P-glycoproteins in T. circumcincta 
4.4.1: Constitutive Pgp expression: CVL vs. MOTRI 
  The  expression  of  Pgps  in  CVL  and  MOTRI  was  compared  to  investigate  the 
constitutive expression of these genes in T. circumcincta.  Using CVL as the calibrator, the 
expression of each gene in MOTRI was calculated as a fold change in expression.  The 
expression of each gene in the CVL isolate was, therefore, always 1, whilst a value greater 
than 1 for MOTRI indicated that the gene had increased expression in MOTRI and a value 
between 0 and 1 for MOTRI indicated that the gene had reduced expression in MOTRI.  
The  closer  the  relative  fold  change  in  expression  is  to  1,  the  more  equal  the  level  of 
expression between the MOTRI and CVL isolate.  Statistical analysis of triplicate runs for 
each gene generated an average fold change in expression together with a P-value; these 
results are shown in Table 4.4.   130 
These results show that there was a statistically significant constitutive increase in 
expression of  TeciPgp-9 NBD2 across all life-cycle stages,  the most dramatic being  a 
55.27-fold  increase  (P<0.01),  a  5.06-fold  increase  (P<0.05),  a  17.49-fold  increase 
(P<0.01), a 14.04-fold increase (P<0.05) and a 6.75-fold increase (P<0.01) of TeciPgp-9 
NBD2  in  MOTRI  compared  to  CVL  eggs,  L1,  xL3,  L4  and  adults,  respectively.    The 
average  fold  change  in  expression  of  TeciPgp-9  NBD2  in  MOTRI  relative  to  CVL  is 
shown  in  Figure  4.4;  the  lines  for  each  bar  of  the  graph  show  the  range  in  relative 
expression of TeciPgp-9 NBD2 in MOTRI from the triplicate real-time runs.   
 
There was a statistically significant constitutive reduction in expression of TeciPgp-
2  NBD2  of  6.02-fold  (P<0.05),  8.50-fold  (P<0.01),  7.61-fold  (P<0.05)  and  7.12-fold 
(P<0.01)  in  MOTRI  eggs,  L1,  xL3  and  L4  compared  to  CVL,  respectively,  whilst  the 
reduced  expression  of  TeciPgp-2  NBD2  in  adults  was  not  statistically  significant.  
However, the expression of TeciPgp-2 NBD1 did not follow the same expression pattern as 
TeciPgp-2 NBD2 as shown in Figure 4.5, parts A and B.  The relative fold change in 
expression of TeciPgp-2 NBD1 was a 1.04-fold reduction, a 1.37-fold reduction, 1.07-fold 
increase, 1.37-fold increase and 1.78-fold increase in MOTRI eggs, L1, xL3, L4 and adults 
compared  to  CVL,  respectively,  however  none  of  these  changes  in  expression  were 
statistically  significant,  although  the  change  in  expression  in  the  adult  stage  was 
approaching significance at the 5% level.   
 
  Alongside the changes in gene expression across all life-cycle stages observed for 
TeciPgp-9  NBD2  and  TeciPgp-2  NBD2,  there  were  also  changes  in  the  constitutive 
expression  of  other  genes  in  individual  life-cycle  stages,  as  shown  in  Table  4.4.    For 
example, the expression of PGP1 in MOTRI eggs was 3.9-fold greater than in CVL eggs 
(P<0.05) whilst in MOTRI L4, the expression of PGP1 was 1.46-fold lower than in CVL 
L4.  In PGP3, only one life-cycle stage had a statistically significant difference (P<0.05) in 
expression between MOTRI and CVL; MOTRI eggs were shown to have a 2-fold increase 
in expression compared to CVL eggs.  The expression of PGP9 in MOTRI L1 was 1.36-
fold higher than in CVL L1 (P<0.05) whilst in MOTRI L4 the expression was 2-fold higher 
than CVL L4 (P<0.01).  The expression of PGPs 10 and 11 in MOTRI varied between life-
cycle stages.  In the xL3 stage, there was a 1.88-fold increase in PGP10 expression in 131 
MOTRI compared to CVL (P<0.05) whilst in the L4 stage there was a 3.99-fold reduction 
in PGP10 expression in MOTRI compared to CVL (P<0.01).  In the L4 stage there was a 
2.68-fold reduction in PGP11 expression in MOTRI compared to CVL (P<0.05), whilst in 
the adult stage, there was a 1.6-fold increase in PGP11 expression in MOTRI compared to 
CVL (P<0.05).   
 
4.4.2: Confirmation of primer specificity for TeciPgp-2 NBD2 and TeciPgp-9 NBD2 
  As  the  most  significant  results  for  the  constitutive  gene  expression  differences, 
showing statistically significant expression differences across all the life-cycle stages, the 
identity of the real-time PCR products for TeciPgp-2 NBD2 and TeciPgp-9 NBD2 needed 
to be confirmed.  Two real-time PCR products from each of the TeciPgp-2 NBD2 and 
TeciPgp-9 NBD2 real-time runs were selected at random, cloned into pGEM
®-T vector 
and transformed into JM109 cells as described in Section 2.3.7.  Two white colonies were 
selected  for  each  PCR  product  and,  following  overnight  culture  in  LB  broth,  purified 
plasmids were submitted for sequencing.  The sequences obtained were trimmed to remove 
vector  sequence  and  aligned  against  the  consensus  sequences  for  the  eleven  partial  T. 
circumcincta Pgps identified in Chapter 3, using SeqMan (DNASTAR Lasergene version 
8), as shown in Table 4.5.  Of the four sequences from TeciPgp-2 NBD2 real-time PCR, 
three aligned exclusively to the TeciPgp-2 NBD2 consensus sequence whilst the fourth 
was found not to contain an insert.  Of the three sequences from TeciPgp-9 NBD2, all three 
aligned exclusively to TeciPgp-9 NBD2.  This confirmed the specificity of the TeciPgp-2 
NBD2 and TeciPgp-9 NBD2 primer and probe sets.   
 
4.4.3:  Biological  replicates  of  constitutive  TeciPgp-2  NBD2  and  TeciPgp-9  NBD2 
expression 
  Biological replicates, comprising different pools of T. circumcincta MOTRI and 
CVL  eggs,  xL3  and  adults  to  those  used  in  the  original  experiments  were  obtained, 
processed as described previously, and used to quantify the expression of TeciPgp-2 NBD2 
and  TeciPgp-9  NBD2,  to  confirm  the  original  results.    The  actin  Ct  values  for  these 
biological replicates were compared to the original actin Ct values as is shown in Figure 
4.6.  This comparison indicated that the actin Ct values for the biological replicates of the 132 
CVL and MOTRI eggs were not comparable to each other and also were different to the 
original average actin Ct values.  As such, the constitutive gene expression of TeciPgp-2 
NBD2 and TeciPgp-9 NBD2 in eggs in the biological replicates was excluded from further 
analysis.  The actin Ct values for the xL3 and adult stages between MOTRI and CVL were 
sufficiently close to each other to allow the relative fold changes in expression of TeciPgp-
2 NBD2 and TeciPgp-9 NBD2 in the biological replicates to be calculated, as is shown in 
Table 4.6.  The expression of TeciPgp-2 NBD2 in MOTRI xL3 was 14.71-fold lower than 
in CVL xL3 (P<0.05), compared to the 7.61-fold decrease found in the original triplicate 
results.  The expression of TeciPgp-2 NBD2 in MOTRI adults was 13.28-fold lower than 
in CVL adults (P<0.01), compared to the original 2.72-fold decrease in the original results.  
There was a 14.93-fold increased expression of TeciPgp-9 NBD2 in MOTRI xL3 compared 
to MOTRI (P<0.01) which was similar to the 17.49-fold increased expression in this gene 
found  in  the  original  results.    The  result  for  TeciPgp-9  NBD2  for  adult  constitutive 
expression in the biological replicate samples was not statistically significant.   
 
4.4.4: In vivo inducible Pgp expression: MOTRI vs. Post IVM MOTRI 
  Inducible  expression  of  Pgps  was  investigated  by  carrying  out  the  relative 
quantification of these genes in the T. circumcincta Post IVM MOTRI isolate compared to 
the  MOTRI  isolate.    This  was  to  see  whether  adult  parasites  which  survived  in  vivo 
exposure to IVM, as described in Chapter 2, expressed the Pgp genes at a different level 
compared to unselected parasites of the same isolate.  In the same way that the CVL isolate 
was used as a calibrator in the constitutive gene expression comparison above, the MOTRI 
isolate was used as the calibrator in this comparison, such that the expression of the Pgps 
in the Post IVM MOTRI samples was described as a fold change relative to the MOTRI 
sample.  The results of this comparison are shown in Table 4.7.  Due to the difference in 
actin Ct values between MOTRI and Post IVM MOTRI L4 (Figure 4.3), this comparison 
was excluded from any further analysis.   
 
Unlike  the  constitutive  gene  expression  comparison,  there  were  no  changes  in 
expression of any one gene across all life-cycle stages.  All the statistically significant 
changes  in  the  larval  stages  reflected  increases  in  expression,  whilst  the  statistically 133 
significant expression changes observed in the adult stage all showed reduced expression 
in the Post IVM MOTRI isolate compared to the MOTRI isolate.  In the L1 stage, there 
was a 3.42-fold increase in TeciPgp-2 NBD2 expression (P<0.05), a 1.58-fold increase in 
PGP3 expression (P<0.05) and a 3.16-fold increase in TeciPgp-2 NBD1 expression in Post 
IVM MOTRI compared to MOTRI (P<0.01).  In the xL3 stage, there was a 1.67-fold 
increase in PGP1 expression (P<0.01), a 1.54-fold increase in TeciPgp-9 NBD2 expression 
(P<0.01) and a 3.84-fold increase in PGP8 expression in Post IVM MOTRI compared to 
MOTRI (P<0.01).  In the adult stage, there was a 1.78-fold reduction in PGP7 expression 
(P<0.05), a 2.12-fold reduction in PGP8 expression (P<0.05) and a 2.27-fold reduction in 
PGP11 expression in Post IVM MOTRI compared to MOTRI (P<0.05).   
 
4.4.5: In vivo inducible TeciPgp-2 NBD2 and TeciPgp-9 NBD2 expression: IVM survivors  
  Surviving adult parasites of the MOTRI isolate were collected from the abomasum 
of donor sheep three days after a full therapeutic dose of IVM, as described in Sections 
2.1.1 and 2.1.6.  This was to investigate whether the expression of Pgps was transiently 
altered during the period of IVM exposure in vivo.  The average actin Ct values for the 
IVM survivors, original CVL and MOTRI adults and the biological replicates CVL and 
MOTRI adults are shown in Figure 4.7.  The biological replicate MOTRI adults were 
chosen as the calibrator sample due to the similarity of their actin Ct values, as shown in 
Figure 4.7, and because they were of the same isolate to the IVM survivors.  The relative 
fold change in expression of TeciPgp-2 NBD2 and TeciPgp-9 NBD2 in the IVM survivors 
was calculated compared to the MOTRI adult biological replicate sample, as shown in 
Figure 4.8.  In the adult IVM survivors there was a 13.68-fold reduction in expression of 
TeciPgp-2  NBD2  relative  to  the  expression  in  the  biological  replicates  MOTRI  adults 
(P<0.05)  whilst  the  1.82-fold  increase  in  expression  of  TeciPgp-9  NBD2  in  the  IVM 
survivors  compared  to  the  biological  replicates  MOTRI  adults  was  not  statistically 
significant.   
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4.4.6:  In  vitro  inducible  TeciPgp-2  NBD2  and  TeciPgp-9  NBD2  expression:  Larval 
migration inhibition test 
  The in vitro inducible expression of TeciPgp-2 NBD2 and TeciPgp-9 NBD2 was 
investigated in MOTRI L3 by utilising the LMIT.  Using the standard LMIT method, as 
described  in  Section  2.2.1,  a  concentration  of  2.5µg/mL  IVM  was  chosen  as  the 
discriminating  dose  to  allow  approximately  10%  of  the  L3s  of  the  MOTRI  isolate  to 
migrate through a Baermann chamber in the presence of the drug.  However, on scaling up 
the method (Section 2.2.2) and with the larvae also being subsequently exsheathed, this 
concentration was found to be too high as the percentage migration was less than 1%.  
Thus, a lower concentration of 1µg/mL IVM was used.  Three pools of xL3 were obtained 
from this experiment; one pool (unexposed) comprised the xL3s which had successfully 
migrated through the control (no IVM) Baermann chamber, the second pool (migrators) 
comprised the xL3s which had successfully migrated through the Baermann chamber in the 
presence of 1µg/mL IVM and the third pool (non-migrators) comprised the xL3s which 
failed to migrate through the Baermann chamber in the presence of 1µg/mL IVM.  The 
percentage of xL3s  which migrated in  the presence of  IVM was  38.75% whilst  in  the 
control sample the proportion of xL3s which migrated was 96.25%.   
 
  Real-time PCR was carried out to quantify the expression of TeciPgp-2 NBD2 and 
TeciPgp-9 NBD2 in these three samples and also against the biological replicate MOTRI 
xL3  sample.    For  TeciPgp-2  NBD2,  there  was  no  statistically  significant  difference  in 
expression between the migrators and non-migrators or between the non-migrators and 
unexposed samples.  There was a statistically significant 1.88-fold increase in TeciPgp-2 
NBD2 expression in the unexposed sample compared to the migrators sample (P<0.05).  
For  TeciPgp-9  NBD2,  there  was  no  statistically  significant  difference  in  expression 
between the unexposed, migrators or non-migrators.  When compared to the biological 
replicate MOTRI sample, there was no statistically significant difference in expression of 
TeciPgp-2 NBD2 in any of the three LMIT samples and for TeciPgp-9 NBD2, the only 
statistically significant difference was a 1.69-fold increase in expression in the unexposed 
sample compared to the MOTRI xL3 biological replicate sample.   
 135 
4.5: Relative quantification of expression of Cytochrome P450s in T. circumcincta 
4.5.1: In vivo constitutive Cytochrome P450 expression: CVL vs. MOTRI 
  As  with  the  Pgps,  the  relative  constitutive  expression  of  CYP1,  2  and  3  was 
investigated  in  eggs,  L1,  xL3,  L4  and  adults  of  the  CVL  and  MOTRI  T.  circumcincta 
isolates using real-time PCR.  The specific primers and probes for the three CYP genes are 
shown in Table 4.1.  Following triplicate real-time runs, the data were statistically analysed 
to determine the average fold change in expression of the genes in the MOTRI isolate 
compared to the CVL isolate, the statistical significance of each result and the range in 
relative expression.  As before, a value greater than 1 for MOTRI indicated that the gene 
had increased expression compared to the CVL isolate, whilst a value between 0 and 1 for 
MOTRI indicated that the gene had reduced expression in MOTRI.  The closer the relative 
fold change in expression was to 1, the more equal the level of expression between the 
MOTRI and CVL isolate.  The results of this analysis are shown in Table 4.8.  Statistically 
significant  increases  in  expression  of  11.73-fold  for  CYP1  (P<0.01)  and  5.25-fold  for 
CYP2  (P<0.01)  were  observed  when  comparing  CVL  and  MOTRI  eggs.    Statistically 
significant reductions in expression of 1.56-fold for CYP1 (P<0.05), 1.98-fold for CYP2 
(P<0.05) and 2.32-fold for CYP3 (P<0.05) were observed in the L1 stage.  In MOTRI 
adults  there  was  a  statistically  significant  2.82-fold  increase  in  expression  of  CYP1 
(P<0.01) and a 2.60-fold increase in expression of CYP2 compared to CVL adults.   
 
4.5.2: In vivo inducible Cytochrome P450 expression: MOTRI vs. Post IVM MOTRI 
  The relative inducible expression of the three CYP genes in T. circumcincta Post 
IVM MOTRI was determined compared to the MOTRI isolate.  No comparison was made 
between the L4 stage of these isolates as the average actin control gene Ct values, used to 
normalise the CYP gene data, was not comparable between the isolates as shown in Figure 
4.3.  As shown in Table 4.9, there were statistically significant reduced relative expression 
levels of 1.88-fold for CYP1 (P<0.05) and 1.86-fold for CYP2 (P<0.05) in Post IVM eggs 
compared to MOTRI eggs.  For the same two CYP genes, in the L1 stage there was an 
increase in relative expression of 2.91-fold (P<0.05) and 3.23-fold (P<0.01), respectively.  
The only statistically significant change in expression in the xL3 stage was a 1.38-fold 
(P<0.05)  increase  in  relative  expression  of  CYP3  in  Post  IVM  MOTRI  compared  to 136 
MOTRI.  Statistically significant reduced fold changes in expression of CYP1, 2 and 3 
when comparing the adult Post IVM MOTRI to adult MOTRI of 1.23-fold (P<0.05), 3.08-
fold (P<0.01) and 2.07-fold (P<0.05) were also observed.   
 
4.6: Discussion 
  Using the relative quantification, or ʔʔCt, real-time PCR method, the expression of 
11 Pgp and 3 CYP genes in three T. circumcincta isolates was investigated.  Real-time 
PCR has advantages over standard PCR methods, being quicker to perform and also being 
considerably  more  sensitive,  allowing  the  detection  of  smaller  changes  in  expression, 
particularly in genes expressed at low levels (Pfaffl, 2001; Bustin et al., 2009).  The use of 
a reference gene (in this case actin) in the experimental procedure allows the results of the 
test gene to be normalised to take into account any potential variation in cDNA level, thus 
eliminating sample variation error (Van Zeveren et al., 2007b).  For the ʔʔCt method to be 
valid, the efficiencies of the target and control gene need to be approximately equal (Livak 
& Schmittgen, 2001).  As shown above, this was not the case for TeciPgp-9 NBD1 which 
was, therefore, excluded from further analysis.  At the time of carrying out this experiment, 
actin was chosen as the control gene as it appeared to be more stably expressed between 
different T. circumcincta isolates compared to β-tubulin, as shown in the semi-quantitative 
PCR results in Chapter 3.  However, since carrying out these experiments, the preferred 
method for performing relative quantification of gene expression has recommended that a 
panel of reference genes is investigated and that at least two of the most stably expressed 
genes are then used to normalise the test genes results (Van Zeveren et al., 2007b; Strube 
et  al.,  2008;  Bustin  et  al.,  2009).    One  such  method  is  the  GeNorm  approach  which 
assumes that minimally regulated, stably transcribed genes stay in a constant ratio to each 
other and, therefore, provide a better baseline for normalising relative expression data to 
(Van Zeveren et al., 2007b).  Due to stage-specific variation in the control gene chosen for 
this experiment, no comparison of Pgp and CYP expression could be made across the 
respective life-cycle stages, however, this did not preclude the investigation of the relative 
expression between isolates.  Such variability between life-cycle stages is not surprising 
given the extreme physiological changes observed in parasites as they develop from free-
living to parasitic stages (Nisbet et al., 2008).   
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These real-time data have shown that differences in expression of the Pgps and 
CYPs  occur  both  between  IVM-susceptible  and  -resistant  T.  circumcincta  isolates 
(constitutive  expression  differences)  and  between  pre-  and  post-IVM  treated  T. 
circumcincta isolates (inducible expression differences) as revealed through the range of in 
vivo and in vitro drug exposure experiments described above.  Importantly, the constitutive 
expression differences found for TeciPgp-2 NBD2 and TeciPgp-9 NBD2 were (with the 
exception of TeciPgp-2 NBD2 in the adult stage) statistically significant across all life-
cycle stages.  The expression of TeciPgp-2 NBD2 is between 6.02 and 8.50-fold lower in 
the  MOTRI  isolate  compared  to  the  CVL  isolate,  whilst  the  expression  of  TeciPgp-9 
NBD2 is between 5.06 and 55.27-fold greater in the MOTRI isolate compared to the CVL 
isolate.  Adult, L4 and xL3 parasites are exposed to IVM in the gut, eggs will be transiently 
exposed as they are excreted; whilst in the faecal pat, eggs and larval stages will remain 
exposed to IVM as 90% of the administered dose of IVM is excreted in faeces (Canga et 
al., 2009).  Therefore, altered expression of TeciPgp-2 NBD2 and TeciPgp-9 NBD2 across 
all life-cycle stages could allow resistant parasites to survive continued IVM exposure.   
 
Pgps  are  membrane  transporters  and  IVM  is  known  to  be  a  potential  substrate 
(Sangster et al., 1999a; Prichard & Roulet, 2007).  As such, an increase in the expression 
of  TeciPgp-9  NBD2  in  the  triple  drug-resistant  MOTRI  isolate  could  represent  the 
mechanism by which resistant parasites remove the drug, either from inside their bodies or 
away from the IVM target sites, such as the somatic and pharyngeal muscles (Gilleard & 
Beech, 2007; Prichard & Roulet, 2007; Blackhall, Prichard, & Beech, 2008).  The reduced 
expression  of  TeciPgp-2  NBD2,  like  the  increased  expression  of  TeciPgp-9  NBD2 
associated with the resistant phenotype of MOTRI, could also be related to the parasites 
preventing IVM reaching its target sites.  Pgps are involved in transport of a range of 
endogenous and exogenous hydrophobic molecules into and out of cells, and are therefore 
not  specifically  designed  to  transport  IVM  (Kerboeuf,  Guegnard,  &  Le  Vern,  2003; 
Lespine et al., 2008).  Potentially, different Pgps could have different affinities for IVM 
and a parasite could reduce the expression of a particular Pgp with a high affinity to IVM, 
thus preventing the IVM from reaching its target site within the parasite‟s cells.  Recent 
work, using fluorescent protein reporters in transgenic C. elegans, has shown that both 
Pgp-9 and Pgp-2 are expressed in the first and second bulbs of the pharynx and in the 
intestine (Zhao et al., 2004) (http://wormbase.sanger.ac.uk/).  Further work by Schroeder et 138 
al (2007) and Nunes et al (2005), showed that in RNAi C. elegans Pgp-2(-) mutants, there 
was  a  dramatically  reduced  ability  of  the  worms  to  store  lipids;  Pgp-2  was  shown  to 
localise to the gut granules in the intestines of C. elegans, which are the site of fat storage.    
In  this  present  study,  TeciPgp-2  NBD2  shows  reduced  expression  in  the  resistant  T. 
circumcincta isolate; it would be interesting to investigate whether this is linked to reduced 
storage of lipids in these parasites.  Interestingly, experiments in H. contortus eggs have 
shown a link between the degree of anthelmintic resistance and cholesterol content; the 
lipid  content  of  membranes  appears  to  affect  Pgp  activity  and  transport  of  lipophilic 
molecules such as IVM (Riou et al., 2003; Riou, Koch, & Kerboeuf, 2005; Riou et al., 
2007).  Cholesterol depletion in H. contortus eggs resulted in an increase in TBZ resistance 
as measured by EHT (Riou et al., 2003).  Conversely free cholesterol concentration in H. 
contortus  eggs  was  significantly  higher  in  resistant  isolates  compared  to  susceptible 
isolates,  and  the  presence  of  Pgps,  as  measured  with  monoclonal  antibodies,  was 
significantly correlated with the amount of free cholesterol (Riou et al., 2007).  It appears 
from  these  studies  that  Pgp  function  is  dependent  on  the  lipid  environment  of  the 
membrane within which they are localised, yet the functional studies in C. elegans implied 
that, in the case of Pgp-2, at least, changes in expression affected the lipid environment 
(Riou, Koch, & Kerboeuf, 2005; Nunes et al., 2005; Schroeder et al., 2007).  The 55.27-
fold increase in expression of TeciPgp-9 NBD2 in eggs in MOTRI compared to CVL is 
very  interesting,  especially  as  an  increase  in  fluorescent  staining  with  monoclonal 
antibodies  for  human  and  mouse  multidrug  resistance  -1  (mdr1)  was  observed  in 
anthelmintic  resistant  H.  contortus  eggs  compared  to  susceptible  eggs  (Kerboeuf, 
Guegnard, & Le Vern, 2003).  In a similar experiment in T. circumcincta, fluorescence of 
MOTRI  eggs  was  three  times  greater  than  in  susceptible  (Moredun  Ovine  Susceptible 
Isolate, MOSI) eggs (P. Skuce. Pers. Comm.).  In C. elegans, mdr1 is orthologous to Pgp-2 
(http://wormbase.sanger.ac.uk/).  However, none of the studies on H. contortus, mentioned 
above, investigated individual Pgp genes, and it was not possible to ascertain the Pgp-
specificity of the immunofluorescence observed.  It would be interesting to investigate, in 
the T. circumcincta isolates used in this thesis, the localisation of TeciPgp-2 NBD2 and 
TeciPgp-9 NBD2, possibly through transgenic fluorescent protein reporter studies or the 
generation of specific monoclonal antibodies, and the effect that changes in expression of 
these genes  could  have on the lipid  content of membranes,  using RNAi,  ultimately to 
elucidate further the role they play in IVM resistance.   
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An increase in  PgpA (orthologous  to  C. elegans Pgp-2) mRNA level  has  been 
demonstrated  using  Northern  blotting  in  IVM-selected  H.  contortus  and,  in  adult  O. 
ostertagi, a 3.4-fold increase in expression of a Pgp2 orthologue was found using real-time 
PCR from a laboratory selected IVM resistant isolate (Xu et al., 1998; Van Zeveren, 2009).  
More  importantly,  TeciPgp-9  has  been  identified  as  playing  a  major  role  in  the  IVM 
resistant  phenotype  in  a  T.  circumcincta  near-isogenic  anthelmintic-resistant  line 
developed  in  New  Zealand  (Bisset,  2007).    The  near-isogenic  line  was  developed  by 
backcrossing an inbred multi-drug resistant isolate with an inbred anthelmintic susceptible 
isolate, with IVM selection at each generation.  This research was conducted independently 
of the present study, and the results only became available at the time of writing.  As in the 
present  study,  Bisset  (2007) found increased polymorphisms  in  TeciPgp-9 in  the  IVM 
resistant line.  For example, individual resistant worms possessed three or four TeciPgp-9 
haplotypes compared to no more than two haplotypes in susceptible worms.  Moreover, 
using real-time PCR, resistant worms exhibited a higher expression level of  TeciPgp-9 
than susceptible worms, indicative of an increased gene copy number.  Alongside this, 
amino acid substitutions were found when comparing TeciPgp-9 coding sequences from 
resistant and susceptible worms.  Unfortunately, we are not in a position to determine 
whether the same coding SNPs are implicated in our IVM-resistant MOTRI isolate at this 
stage because the regions of the gene where these amino acid substitutions are found in the 
New  Zealand  T.  circumcincta  lines  are  not  covered  by  the  sequence  generated  in  this 
thesis.    These  amino  acid  substitutions  may  also  be  present  in  UK  IVM-resistant  T. 
circumcincta  isolates.    The  generation  of  a  full-length  coding  sequence  for  TeciPgp-9 
would be an obvious starting point for further work to investigate this.  If found, they could 
form the basis of a molecular marker for IVM resistance.   
 
Finding significant fold changes in expression in all life-cycle stages of TeciPgp-9 
NBD2 when comparing two, non-related UK isolates; one multi-drug resistant and the 
other drug-susceptible, becomes far more important in the light of the work carried out in 
New Zealand.  Changes in the expression of TeciPgp-9 could be caused by an increase in 
copy number, as found in the New Zealand study, or as a result of a mutation or change in 
the  gene  promoter  or  upstream  regulatory  element  controlling  the  transcription  of  that 
gene.  The cause of the change in expression of  TeciPgp-9 remains to be determined.  
Regulation of expression is dependent on regions of DNA either upstream of the gene in 140 
question or in intronic regions; areas which would need to be investigated to determine 
how the fold change in expression of TeciPgp-9 NBD2 between CVL and MOTRI occurs; 
very little is currently known about these regulatory sequences in nematodes (Prichard & 
Roulet, 2007).  Even though the change in expression of TeciPgp-9 NBD2 associated with 
IVM  resistance  has  been  found  in  both  the  UK  and  New  Zealand,  the  next  step  in 
developing these changes into a marker for IVM resistance is to confirm the presence of 
the expression differences, or the amino acid substitutions, in other UK field isolates of T. 
circumcincta resistant to IVM and potentially in other parasites species too.   
 
Another important step in fully investigating the role TeciPgp-9 NBD2 plays in 
IVM  resistance  in  the  UK  would  be  determining  whether  TeciPgp-9  NBD1  (formerly 
PGP4) exhibits the same expression profile as TeciPgp-9 NBD2, this was not possible in 
this investigation as the primers and probes for TeciPgp-9 NBD1 were not sufficiently 
efficient and so the gene was excluded from the real-time PCR experiments described in 
this Chapter.  More importantly, the generation of a full-length sequence for TeciPgp-9 
would confirm that they are genuinely two halves of the same gene.  Ten NBD1 haplotypes 
and  four  NBD2  haplotypes  for  TeciPgp-9  were  identified  in  the  New  Zealand  near-
isogenic T. circumcincta lines, some of which were found exclusively or predominantly in 
the resistant lines.  Some NBD1 haplotypes appeared to correspond to particular NBD2 
haplotypes but have yet to be shown to be parts of the same haplotype (Bisset, 2007).  This 
could be the same with TeciPgp-9 NBD1 and TeciPgp-9 NBD2 if they are found to have a 
different expression profile; the two parts, although potentially from the same gene may, in 
fact, have developed through a gene duplication event and therefore not have been under 
the same selection pressure.  According to the alignments of T. circumcincta sequences 
against  the  C.  elegans  Pgps  in  Chapter  3,  TeciPgp-2  NBD1  (formerly  PGP5)  should 
represent  the  5‟  end  of  the  same  Pgp  molecule  as  TeciPgp-2  NBD2,  yet  the  gene 
expression  profile  of  these  two  genes  following  triplicate  real-time  PCR  runs  was  not 
identical.  Indeed, for the xL3, L4 and adult stages there were non-statistically significant 
increased expression of TeciPgp-2 NBD1 whilst for TeciPgp-2 NBD2 in these stages there 
was  decreased  expression  in  the  MOTRI  isolate  compared  to  the  CVL  isolate.    As 
described for TeciPgp-9 from New Zealand, there could be different haplotypes of the two 
NBDs, and so, although both TeciPgp-2 NBD1 and TeciPgp-2 NBD2 aligned most closely 
to the C. elegans Pgp-2; they could be fragments of two copies of the TeciPgp-2 gene.   141 
Changes in expression of other genes including the CYPs were also observed, these 
changes were not evident across all life-cycle stages and generally represented smaller fold 
changes  than those found for  TeciPgp-2 NBD2 and  TeciPgp-9 NBD2.   As such, their 
importance in the role of expressing an IVM-resistant phenotype may not be as  great.  
Interestingly, compared to the general pattern of expression of the panel of Pgp genes, the 
CYPs seemed to follow a similar pattern of expression to each other, as shown in Tables 
4.8 and 4.9.  For example, the expression of the three CYPs when comparing CVL and 
MOTRI L1 all showed a statistically significant reduction in expression.     
 
The  first  comparison  described  in  this  Chapter,  investigating  constitutive 
expression differences between the IVM-susceptible CVL and IVM-resistant MOTRI T. 
circumcincta isolates, was the same comparison as that carried out in Chapter 3 using 
semi-quantitative PCR.  Comparing the semi-quantitative and real-time PCR data shows 
that the real-time PCR confirms the majority of the changes in gene expression identified 
whilst also identifying changes not visible in the semi-quantitative PCR, particularly where 
the expression of the genes was too low to be identified using semi-quantitative PCR.  
TeciPgp-2 NBD2 (originally called PGP2 in the semi-quantitative experiment) was not 
amplified  using  semi-quantitative  PCR  but  in  the  real-time  PCR  experiment,  reduced 
expression was found in all life-cycle stages of the MOTRI isolate compared to the CVL 
isolate.  PGP3 and PGP7 were the most stably expressed between CVL and MOTRI in the 
semi-quantitative PCR (Figure 3.3) and showed no statistically significant differences in 
expression in the real-time experiment (Table 4.4).   
 
It was hypothesised that a stepwise change in expression going from the IVM-
susceptible  (CVL)  isolate,  through  the  IVM-resistant  (MOTRI)  isolate  to  the  IVM 
survivors (Post IVM MOTRI) isolate might be observed.  With the exception of TeciPgp-9 
NBD2 in the xL3 stage, where the change in expression between CVL and MOTRI was a 
17.49-fold increase and the change in expression between MOTRI and Post IVM MOTRI 
was  a  1.54-fold  increase,  this  was  found  not  to  be  the  case.    This  suggests  that  any 
increases in constitutive expression in resistant isolates were not enhanced when a resistant 
isolate was further selected with IVM treatment to remove any parasites within that isolate 
exhibiting  a  drug-susceptible  phenotype.    In  fact,  with  the  three  CYP  genes,  it  was 142 
observed that when statistically significant increases in fold change in expression were 
observed between the CVL and MOTRI isolates, a corresponding statistically significant 
reduction in fold change in expression was observed between the MOTRI and Post IVM 
MOTRI (Tables 4.8 and 4.9).   
 
To fully investigate the changes in expression found in isolates of T. circumcincta 
resistant to IVM, various experiments utilising both in vivo and in vitro approaches to IVM 
exposure were carried out.  In all of these comparisons, parasites from the MOTRI isolate 
were  compared  to  parasites  of  the  same  isolate  which  had  undergone  some  form  of 
selection with, or exposure to, IVM.  As described above, the comparison between the Post 
IVM MOTRI (in vivo IVM treatment survivors) and MOTRI isolates did not show that 
parasites surviving IVM treatment exhibited any further change in expression of any given 
gene  following  on  from  the  CVL-MOTRI  constitutive  gene  expression  comparison.  
Therefore, it was  decided to  determine whether any transient  inducible changes  in  the 
expression of TeciPgp-9 NBD2 and TeciPgp-2 NBD2 could be identified.  Utilising a 
modified LMIT method, a four way comparison between (i) MOTRI xL3 able to migrate in 
the presence of IVM, (ii) those unable to migrate in the presence of IVM, (iii) those that 
migrated through a Baermann chamber whilst not exposed to IVM and (iv) the biological 
replicate xL3 MOTRI isolate, was made.  The only statistically significant differences in 
expression were a 1.88-fold increase in TeciPgp-2 NBD2 expression in the unexposed 
sample compared to the migrators sample and a 1.69-fold increase in TeciPgp-9 NBD2 
expression  in  the  unexposed  sample  compared  to  the  MOTRI  xL3  biological  replicate 
sample.    Potentially,  the  LMIT  method  and  the  IVM  dose  chosen  for  this  experiment 
(1µg/mL IVM) may not have been sufficient to induce any changes in expression of the 
two genes investigated.  Alternatively, the non-migrator xL3 could have also been killed by 
the exposure to IVM and, as such, would not have exhibited altered TeciPgp-2 NBD2 and 
TeciPgp-9 NBD2 expression profiles.  However, the actin Ct values between the three 
LMIA samples, and when compared to the biological replicate MOTRI xL3 sample, were 
similar (data not shown); dead or dying parasites would have been expected to have altered 
levels of mRNA.   
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As a final experiment, donor sheep were infected with MOTRI parasites which 
were allowed to develop to the adult stage prior to treatment with a full therapeutic dose of 
IVM.    Three  days  after  drug  administration,  adult  parasites  were  collected  from  the 
abomasa, as described previously.  This time course was chosen to give any adults affected 
by the IVM treatment a chance to be expelled by the host whilst those able to resist IVM 
treatment would still be exposed to IVM.  Gill & Lacey  (1998) found that 25% of T. 
circumcincta  were  expelled  8-10  hours  after  exposure  with  the  rest  remaining  in  the 
abomasum for at least 14 hours post treatment whilst the half-life of IVM is between 61 
and 178 hours (Prichard et al., 1985a; Marriner, Mckinnon, & Bogan, 1987; Canga et al., 
2009).  The statistically significant relative fold change in expression of TeciPgp-2 NBD2 
was  13.69-fold  lower  in  the  IVM  survivors  compared  to  MOTRI  whilst  the  1.82-fold 
increase in expression of TeciPgp-9 NBD2 in the IVM survivors compared to MOTRI was 
not  statistically  significant.    This  experiment  gives  an  indication  that  inducible  gene 
expression  changes  may  occur  in  response  to  IVM  treatment;  however,  the  biggest 
challenge  when  carrying  out  these  experiments  is  determining  whether  any  changes 
observed  are  due  to  the  IVM  exposure  or  a  generalised  response  to  the  experimental 
procedure.  Roulet and Prichard (2006) showed that over-expression of five H. contortus 
Pgps occurred 24 hours after in vivo IVM exposure.  As such, the experimental protocol 
chosen to investigate the inducible expression of Pgps in T. circumcincta may need to be 
altered to identify changes in expression which occur rapidly following IVM exposure.  
For example, the incubation and processing periods when carrying out the LMIT may have 
allowed altered gene expression patterns to return to baseline levels.   
 
  This work has shown that, in a panel of candidate resistant genes comprising of 
Pgps and CYPs, significant differences in gene expression were evident when comparing 
T.  circumcincta  isolates  resistant  and  susceptible  to  IVM,  as  well  as  following  IVM 
exposure.  Significantly, the constitutive expression differences in TeciPgp-2 NBD2 and 
TeciPgp-9  NBD2  were  found  across  all  life-cycle  stages  and  the  differences  found  in 
expression levels of TeciPgp-9 NBD2 were reinforced by similar findings in the same gene 
in laboratory-derived T. circumcincta isogenic lines in New Zealand.  These differences in 
expression,  alongside  SNPs  identified  in  TeciPgp-9  NBD2  (Chapter  3)  need  further 
investigation to determine whether they occur in other isolates of T. circumcincta, in other 
parasitic  species  exhibiting  IVM  resistance,  to  determine  what  is  the  cause  of  the 144 
differences in expression observed and what is their functional significance.  If found in 
other isolates exhibiting IVM resistance, these differences in expression could form the 
basis of a molecular test for IVM resistance in parasitic nematodes. 145 
Table 4.1: Table showing primers and probes designed for real-time PCR.  All probes were fluorescently labelled with FAM. 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target 
ActinQTcFor  Sense  ACG ACG AGG TTG CTG CTC TT  59 
T. circumcincta actin  ActinQTcProbe  NA  TGG TTG ACA ATG GAT CC  69 
ActinQTcRev  Antisense  GAA TCC GGC TTT GCA CAT TC  59 
P1QTcFor  Sense  GTG TGG AAA GAG CAC CGT GAT  59 
T. circumcincta PGP1  P1QTcProbe  NA  CAG CTC GTC GAG AGG T  69 
P1QTcRev  Antisense  GCC ACA CAA GGC GTC GTA A  59 
P2QTcFor  Sense  TGC AAA TGC AGT TCG GTA AGA  58 
T. circumcincta PGP2  P2QTcProbe  NA  AAT GCG GGA CAC AGA A  68 
P2QTcRev  Antisense  TGC CAG CCT CCT CCA GAA  59 
P3QTcFor  Sense  CGA GTT GCA ATT GAG AGA TTT CA  58 
T. circumcincta PGP3  P3QTcProbe  NA  TGG CTG AAT GGC G  69 
P3QTcRev  Antisense  AGC CAG GGA TGC ATTGGA  59 
P4QTcFor  Sense  GAA CGT TGG TGA CCG AGG AA  60 
T. circumcincta PGP4  P4QTcProbe  NA  TGT CTG GTG GCC AAA A  70 
P4QTcRev  Antisense  GCG GGC AAT GGC TAT ACG  59 
P5QTcFor  Sense  TCA TCA GCG ACC CAA CAT TG  59 
T. circumcincta PGP5  P5QTcProbe  NA  ACC GTG GCC GGA TT  69 
P5QTcRev  Antisense  CAC CGC GAA GAA CAC AGT GA  59 
P6QTcFor  Sense  GAC GGT TCT GTG GAA GTT GAT G  58 
T. circumcincta PGP6  P6QTcProbe  NA  CTC ATC TAC GTG CCC ATA T  70 
P6QTcRev  Antisense  TCG GCT CTT GCG ATA CCA A  59 
P7QTcFor  Sense  TCC GGC TCT CTG CCA AGT  58 
T. circumcincta PGP7  P7QTcProbe  NA  ATG TTT GTT GTG ATT CCG  69 
P7QTcRev  Antisense  CGG CGA AAG TTC CAA CCA TA  60 
P8QTcFor  Sense  AAG TGG ATG CTC GTG AAC TGA A  58 
T. circumcincta PGP8 
P8QTcProbe  NA  TTG AGG CAC CTT CG  68 146 
Primer name  Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target 
P8QTcRev  Antisense  CCC GCT AGG GAG ATT TGT GA  59 
P9QTcFor  Sense  TCA GGA GCC GGC GTT GT  60 
T. circumcincta PGP9  P9QTcProbe  NA  TGC TGA TAC AGT TGA AAA T  70 
P9QTcRev  Antisense  CCC GTC CCA AGC GGA TAT  59 
P10QTcFor  Sense  CCG CTA ACG GAA GGT GAG ATT  59 
T. circumcincta PGP10  P10QTcProbe  NA  CCT TGA TGG TCG TCC AT  69 
P10QTcRev  Antisense  GCG CTG TGA CTT AGC GAA CTT  58 
P11QTcFor  Sense  CCG CTG GAG CTG GAC AAC  59 
T. circumcincta PGP11  P11QTcProbe  NA  CAC CGA AAG ACG AGG TC  70 
P11QTcRev  Antisense  TTC CGT CAC GCG ACG TT  58 
C1QTcFor  Sense  AAC TGC TCA CGC TCA CAA AGG  59 
T. circumcincta P450 1  C1QTcProbe  NA  ACA ACG CCT ACT CTC  69 
C1QTcRev  Antisense  AGT GTT CGG TCT GTC CAC GAT  58 
C2QTcFor  Sense  CGT TGT CGG TGG ACA TTC TG  59 
T. circumcincta P450 2  C2QTcProbe  NA  CCC AAA AGG CAC TCC A  69 
C2QTcRev  Antisense  TTA TTA CCG ACA ATT CAG CTG CAA  60 
C3QTcFor  Sense  TTT GGA AAG AAC AAC GAC GTG TA  58 
T. circumcincta P450 3 
C3QTcProbe  NA  CAC TCC AAA TAC TTC G  68 147 
Table 4.2: Table showing the plasmids used to validate the efficiency of the gene specific real-time primer 
and probe sets.   
Gene  Plasmid name  Plasmid 
size (bp) 
Concentration 
(ng/µL) 
Actin  Actin race a  3436  401.19 
PGP1  P1 race 40 1b  3640  308.07 
PGP2  29 Nov 11c  3799  320.18 
PGP3  P3_2a  3752  285.31 
PGP4  (17 Oct) P5b  3368  349.22 
PGP5  25 Mar P5 3Ar  3772  295.69 
PGP7  25 Mar P7 1a  4013  311.81 
PGP6  2S2A1  3402  263.59 
PGP8  1S2A1  3398  328.03 
PGP9  1S1A1  3398  224.39 
PGP10  Pgp1sm1  3395  333.7 
PGP11  Pgp2sm1  3395  616.26 
CYP1  Jan16C3a  3606  332.87 
CYP2  C2L3a  3323  219.99 
CYP3  C3L3a  3468  276.81 148 
Table 4.3: Table showing the efficiencies of the reactions for each primer and probe set, as calculated from 
the standard curves.  The percentage efficiency was calculated from the slope of the standard curve using the 
formula described in 2.4.3 whilst the R2 value gives an indication of how close the data points fit to the 
standard curve and the intercept is the point at which the standard curve crosses the y axis (number of real-
time cycles).   
Gene  Slope  Intercept  R2 value  Efficiency of 
reaction (%) 
Actin  -3.4381  43.1010  0.9939  95.37 
Actin  -3.4206  44.1108  0.9977  96.04 
Actin  -3.1195  40.6668  0.9981  109.2 
Actin  -3.1008  39.9113  0.9989  110.13 
PGP1  -3.2210  41.6619  0.9930  104.39 
TeciPgp-2 NBD2  -3.2791  41.7425  0.9991  101.81 
PGP3  -2.9697  39.8586  0.9964  117.13 
TeciPgp-9 NBD1  -3.6202  51.7543  0.9112  89.5 
TeciPgp-9 NBD1  -4.4088  58.1673  0.9931  68.58 
TeciPgp-2 NBD1  -3.2707  41.2686  0.9859  102.18 
TeciPgp-9 NBD2  -3.3026  39.6582  0.9975  100.81 
PGP7  -3.3170  42.2188  0.9993  100.21 
PGP8  -3.2373  38.3497  0.9979  103.65 
PGP9  -3.3567  39.4773  0.9964  98.568 
PGP10  -3.5396  43.4254  0.9769  91.65 
PGP11  -3.3911  42.1324  0.9982  97.19 
CYP1  -3.3458  39.6981  0.9977  99.01 
CYP2  -3.3274  42.8249  0.9973  99.77 
CYP3  -3.2538  39.5755  0.9963  102.92 149 
Table 4.4: Relative constitutive expression of the Pgp genes in T. circumcincta MOTRI compared to CVL.  The fold change in expression in CVL equals 1 and the expression in 
MOTRI is expressed relative to this.  The statistical significance (at either P<0.05 or P<0.01) of each result is shown in brackets below the fold change in expression.  n.s. means the 
result is not statistically significant.   
  PGP1  TeciPgp-2 
NBD2 
PGP3  TeciPgp-2 
NBD1 
TeciPgp-9 
NBD2 
PGP7  PGP8  PGP9  PGP10  PGP11 
Eggs 
3.90 
(P<0.05) 
0.17 
(P<0.05) 
2.00 
(P<0.05) 
0.96 
(n.s.) 
55.27 
(P<0.01) 
1.07 
(n.s.) 
3.50 
(n.s.) 
1.58 
(n.s.) 
1.07 
(n.s.) 
0.39 
(n.s.) 
L1 
0.73 
(n.s.) 
0.12 
(P<0.01) 
0.70 
(n.s.) 
0.73 
(n.s.) 
5.06 
(P<0.05) 
0.64 
(n.s.) 
1.45 
(n.s.) 
1.36 
(P<0.05) 
1.00 
(n.s.) 
0.87 
(n.s.) 
xL3 
0.82 
(n.s.) 
0.13 
(P<0.05) 
1.17 
(n.s.) 
1.07 
(n.s.) 
17.49 
(P<0.01) 
1.11 
(n.s.) 
0.99 
(n.s.) 
0.65 
(n.s.) 
1.88 
(P<0.05) 
0.82 
(n.s.) 
L4 
0.68 
(P<0.01) 
0.14 
(P<0.01) 
0.61 
(n.s.) 
1.37 
(n.s.) 
14.04 
(P<0.05) 
0.90 
(n.s.) 
3.39 
(n.s.) 
2.00 
(P<0.01) 
0.25 
(P<0.01) 
0.37 
(P<0.05) 
Adults 
1.35 
(n.s.) 
0.37 
(n.s.) 
1.07 
(n.s.) 
1.78 
(n.s.) 
6.75 
(P<0.01) 
1.11 
(n.s.) 
1.12 
(n.s.) 
0.86 
(n.s.) 
1.51 
(n.s.) 
1.60 
(P<0.05) 150 
Table 4.5: Table showing the results of sequencing to confirm the specificity of the T. circumcincta TeciPgp-
2 NBD2 and TeciPgp-9 NBD2 real-time primers.  The primers and probes used to determine the expression 
of  TeciPgp-2  NBD2  were  P2QTcFor,  P2QTcProbe  and  P2QTcRev  and  for  TeciPgp-9  NBD2  were 
P6QTcFor, P6QTcProbe and P6QTcRev as shown in Table 4.1.  The percentage identity of each clone to the 
consensus sequence is shown in brackets.   
Clone Name  Sequence Result 
P2A1a  Aligned to TeciPgp-2 NBD2 (95% identity) 
P2A1b  No insert 
P2C9a  Aligned to TeciPgp-2 NBD2 (95% identity) 
P2C9b  Aligned to TeciPgp-2 NBD2 (96% identity) 
P6A7a  Aligned to TeciPgp-9 NBD2 (94% identity) 
P6A7b  Aligned to TeciPgp-9 NBD2 (100% identity) 
P6B3a  Aligned to TeciPgp-9 NBD2 (100% identity) 151 
Table  4.6:  Relative  constitutive  expression  of  the  TeciPgp-2  NBD2  and  TeciPgp-9  NBD2  in  biological 
replicates of T. circumcincta MOTRI compared to CVL.  The fold change in expression in CVL equals 1 and 
the expression in MOTRI is expressed relative to  this.   The statistical significance (at either P<0.05 or 
P<0.01) of each result is shown in brackets below the fold change in expression.  n.s. means the result was 
not statistically significant.   
  TeciPgp-2 NBD2  TeciPgp-9 NBD2 
xL3 
0.07 
(P<0.05) 
14.93 
(P<0.01) 
Adults 
0.08 
(P<0.01) 
1.00 
(n.s) 152 
Table 4.7: Relative inducible expression of the Pgp genes in T. circumcincta Post IVM MOTRI compared to MOTRI.  The fold change in expression in MOTRI equals 1 and the 
expression in Post IVM MOTRI is expressed relative to this.  The statistical significance (at either P<0.05 or P<0.01) of each result is shown in brackets below the fold change in 
expression.  n.s. means the result is not statistically significant.   
  PGP1  TeciPgp-2 
NBD2 
PGP3  TeciPgp-2 
NBD1 
TeciPgp-9 
NBD2 
PGP7  PGP8  PGP9  PGP10  PGP11 
Eggs 
0.53 
(n.s.) 
1.67 
(n.s.) 
1.34 
(n.s.) 
1.53 
(n.s.) 
1.10 
(n.s.) 
1.38 
(n.s.) 
0.76 
(n.s.) 
1.93 
(n.s.) 
1.17 
(n.s.) 
1.42 
(n.s.) 
L1 
1.24 
(n.s.) 
3.42 
(P<0.05) 
1.58 
(P<0.05) 
3.16 
(P<0.01) 
1.71 
(n.s.) 
1.33 
(n.s.) 
1.17 
(n.s.) 
0.81 
(n.s.) 
1.60 
(n.s.) 
1.79 
(n.s.) 
xL3 
1.67 
(P<0.01) 
1.25 
(n.s.) 
0.94 
(n.s.) 
0.93 
(n.s.) 
1.54 
(P<0.01) 
0.99 
(n.s.) 
3.84 
(P<0.01) 
0.73 
(n.s.) 
0.84 
(n.s.) 
0.80 
(n.s.) 
Adults 
0.63 
(n.s.) 
0.76 
(n.s.) 
0.49 
(P<0.01) 
0.74 
(n.s.) 
0.69 
(n.s.) 
0.56 
(P<0.05) 
0.47 
(P<0.05) 
0.94 
(n.s.) 
0.65 
(n.s.) 
0.44 
(P<0.05) 153 
Table 4.8: Relative constitutive expression of the CYP genes in T. circumcincta MOTRI compared to CVL.  
The fold change in expression in CVL equals 1 and the expression in MOTRI is expressed relative to this.  
The statistical significance (at either P<0.05 or P<0.01) of each result is shown in brackets below the fold 
change in expression.  n.s. means the result is not statistically significant.   
  CYP1  CYP2  CYP3 
Eggs 
11.73 
(P<0.01) 
5.25 
(P<0.01) 
0.95 
n.s. 
L1 
0.64 
(P<0.05) 
0.51 
(P<0.05) 
0.43 
(P<0.05) 
xL3 
1.09 
n.s. 
1.19 
n.s. 
1.09 
n.s. 
L4 
1.16 
n.s. 
1.89 
n.s. 
1.10 
n.s. 
Adults 
2.82 
(P<0.01) 
2.60 
(P<0.05) 
0.78 
n.s. 
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Table 4.9: Relative inducible expression of the CYP genes in T. circumcincta Post IVM MOTRI compared to 
MOTRI.  The fold change in expression in MOTRI equals 1 and the expression in Post IVM MOTRI is 
expressed relative to this.  The statistical significance (at either P<0.05 or P<0.01) of each result is shown in 
brackets below the fold change in expression.  n.s. means the result is not statistically significant.   
  CYP1  CYP2  CYP3 
Eggs 
0.53 
(P<0.05) 
0.54 
(P<0.05) 
0.92 
n.s. 
L1 
2.91 
(P<0.05) 
3.23 
(P<0.01) 
1.92 
n.s 
xL3 
1.56 
n.s. 
1.33 
n.s. 
1.38 
(P<0.05) 
Adults 
0.81 
(P<0.05) 
0.32 
(P<0.01) 
0.48 
(P<0.05) 
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Figure 4.1: Graphs showing typical results from the validation of the real-time primer and probe sets.  A: 
Representative graph of the results for PGP7 showing the duplicate results for each of the dilutions in the 
calibration curve.  The point where the amplification curves cross the green line is the Ct value.  B: The 
standard curve for PGP7 generated using the Ct values from the graph in part A.  The standard curve is used 
to calculate the efficiency of the reaction.  Graphs generated using the ABI 7000 sequence detection system. 
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Figure 4.2: Standard curves for TeciPgp-9 NBD1 and actin.  These show that the TeciPgp-9 NBD1 primers 
and probes did not efficiently amplify the plasmid containing the TeciPgp-9 NBD1 gene, meaning accurate 
comparisons between the actin control gene and the TeciPgp-9 NBD1could not be made.  Graphs generated 
using the ABI 7000 sequence detection system.   
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Figure 4.3: Graph showing the average actin Ct values for each isolate and life-cycle combination.  The 
results are a combination of triplicate real-time run carried out to quantify the expression of the ten Pgp and 
three CYP genes in T. circumcincta.  The error bars on the graph show the standard deviation of the actin Ct 
values 158 
 
Figure 4.4: Graph showing the relative constitutive expression of TeciPgp-9 NBD2 in T. circumcincta.  The 
stars above the graph indicate the statistical significance of the relative fold change in expression of TeciPgp-
9 NBD2 in MOTRI compared to CVL.  P<0.01 is represented by *** and P<0.05 is represented by **.  The 
lines for each bar on the graph represent the range in relative expression.  
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Figure  4.5:  Graphs  showing  the  relative  constitutive  expression  of  TeciPgp-2  NBD  1  and  2  in  T. 
circumcincta.  A: Expression of TeciPgp-2 NBD1. B: Expression of TeciPgp-2 NBD2.  The stars above the 
graph indicate the statistical significance of the relative fold change in expression of TeciPgp-2 in MOTRI 
compared  to  CVL.    P<0.01  is  represented  by  ***  and  P<0.05  is  represented  by  **,  statistically  non-
significant results are indicated with n.s.  The lines for each bar on the graph represent the range in relative 
expression.  
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Figure 4.6: Graph showing the average actin Ct values for the biological replicates of the constitutive gene 
expression comparison between MOTRI and CVL T. circumcincta compared to the corresponding (original) 
isolate and life-cycle average actin Ct values.  The error bars on the graph show the standard deviation of the 
actin Ct values.   
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Figure 4.7: Graph showing the average actin Ct values for the adult T. circumcincta IVM survivors compared 
to the Ct values for the adult CVL and MOTRI T. circumcincta biological replicates and original adult CVL 
and MOTRI T. circumcincta.  The error bars on the graph show the standard deviation of the actin Ct values.   
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Figure 4.8: Graphs showing the relative fold change in expression between MOTRI adults and IVM survivor 
MOTRI adults.  A: Relative expression of TeciPgp-2 NBD2.  B: Relative expression of TeciPgp-9 NBD2.  
P<0.05 is represented by **, statistically non-significant results are indicated with n.s.  The lines for each bar 
on the graph represent the range in relative expression. 163 
Chapter  5:  Roche  454  Sequencing  Analysis  Comparing  in  vitro 
Ivermectin-Exposed  and  Ivermectin-Unexposed  Teladorsagia 
circumcincta Adults* 
5.1: Introduction 
  Anthelmintics are the principal method of control for PGE, yet their mode of action 
and the underlying genetic determinants of resistance exhibited by the parasites are still not 
adequately understood.  Most of the studies in this area to date have used a “candidate gene 
approach” to look for key genetic changes, such as target site mutations, in related parasitic 
species or in the model nematode, C. elegans (Wolstenholme et al., 2004).  However, this 
has largely not been a fruitful exercise (Gilleard, 2006; von Samson-Himmelstjerna et al., 
2007).  Classical  genetic linkage studies  to  identify  „resistance  genes‟ are challenging, 
particularly in nematode parasite populations made up of individuals with differing levels 
of resistance, where there are no parental anthelmintic-susceptible isolates to compare to 
the resistant populations, and especially when the mode of action of the anthelmintic is still 
not  clearly  understood  (Gilleard,  2006).    This  makes  it  difficult  to  propose  candidate 
resistance genes for further study.  An overview of the current understanding of the modes 
of action of the anthelmintics and the mechanisms of resistance are given below, more 
detail is provided in Chapter 1.   
 
The BZs bind to β-tubulin within the parasite, disrupting various essential cellular 
processes  and  resulting  in  cell  lysis  (McKellar  &  Jackson,  2004;  von  Samson-
Himmelstjerna et al., 2007; Mitreva et al., 2007); resistance to the BZs is associated with 
point  mutations  at  codon  200  (Phe200Tyr),  codon  167  (Phe167Tyr)  and  codon  198 
(Glu198Ala) in the isotype 1 β-tubulin gene (Silvestre & Cabaret, 2002; Wolstenholme et 
al.,  2004;  Ghisi,  Kaminsky,  &  Maser,  2007;  de  Lourdes  Mottier  &  Prichard,  2008).  
However, some T. circumcincta isolates have been shown to survive BZ treatment in vivo 
and in vitro when they have susceptible genotypes at codon 200, suggesting other, as yet 
unidentified  mechanisms,  are  enabling  the  parasites  to  exhibit  resistance  (Stenhouse, 
2007).   
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LEV, as a cholinergic agonist at the nicotinic neuromuscular junctions, opens and 
blocks  the  acetylcholine  receptor-mediated  cation  channels  resulting  in  the  rapid  tonic 
paralysis of the somatic muscles (McKellar & Jackson, 2004; Rayes et al., 2004; Prichard 
& Geary, 2008).  Three nAChR receptors subunits, unc-38, unc-29 and lev-1, identified in 
C. elegans appear to be involved in LEV resistance (Kopp et al., 2008).  Mutations in unc-
29 or unc-38 caused a complete loss of sensitivity to  LEV (Fleming et al., 1997).  A 
mutation from glutamic acid (Glu) to glycine (Gly) at amino acid 153 (Glu153Gly) in the 
unc-38 gene of C. elegans was necessary for LEV resistance (Rayes et al., 2004; Martin & 
Robertson, 2007).   
 
IVM binds irreversibly to GABA and GluCl channels causing the hyperpolarisation 
and flaccid paralysis of pharyngeal and somatic muscle cells leading to starvation and 
immobility of the worms (Martin et al., 1998; Blackhall et al., 1998a; Blackhall, Prichard, 
& Beech, 2003; Prichard & Roulet, 2007; Stenhouse, 2007; James & Davey, 2008).  In C. 
elegans, concurrent mutations in several GluCl α-type subunit genes, avr-14, avr-15 and 
glc-1, are required to confer high levels of IVM resistance; mutations of any two of the 
three  genes  only  confers  low  or  no  resistance  (Dent  et  al.,  2000;  Cook  et  al.,  2006; 
McCavera, Walsh, & Wolstenholme, 2007).  The molecular basis of resistance to IVM in 
trichostrongyle parasites, such as T. circumcincta, remains to be elucidated (Geary, 2005; 
Prichard et al., 2007). 
 
  Alternative mechanisms of resistance to those described above, such as changes in 
gene expression levels, remain largely unexplored.  As previously stated in Chapter 1, 
differences in expression levels of genes may be constitutive, where a gene is always 
expressed  differentially  between  anthelmintic-susceptible  and  -resistant  isolates  of 
parasites at rest, or inducible, where a change in gene expression is observed between 
parasites that have been exposed to anthelmintic and those that remain unexposed.  Again, 
most research in this area has adopted a “candidate gene approach”, concentrating on genes 
that are suspected of being involved in drug efflux or metabolism, for example the Pgps 
and CYPs (Kotze, 1997; Prichard & Roulet, 2007).  However other, as yet unidentified, 
genes may also be involved in resistance; this provides an opportunity to use a more global 
approach to identify changes in gene expression, which has potentially not been prejudiced 165 
by selectively looking for particular  genes.   “Next  generation” sequencing approaches, 
such as Roche 454, Illumina Solexa and ABI SOLiD technologies, offer an alternative to 
the  candidate  gene  approach  as  they  can  offer  an  unbiased  and  global  analysis  of 
quantitative and qualitative genetic changes associated with a particular phenotype or in 
response to treatment (Marguiles et al., 2005).  The digital readout (Expressed Sequence 
Tag; EST) from the sequenced cDNA reflects the mRNA expression level of that particular 
gene or contiguous sequence (Nagaraj, Gasser, & Ranganathan, 2007).  All of these next 
generation  sequencing  technologies  offer  advantages  over  the  traditional  Sanger 
sequencing method (Sanger, Nicklen, & Coulson, 1977), in terms of cost, throughput and 
amount of data generated, however, the length of the reads produced may be significantly 
shorter (Pop & Salzberg, 2008; Shin et al., 2008; Shendure & Ji, 2008).   
 
  Roche  454  sequencing  amplifies  cDNA  strands  which  have  been  attached  to 
agarose  beads  in  a  picolitre  sized  emulsion-based  pyrosequencing  reaction;  at  each 
sequencing cycle a single type of nucleotide is added, followed by the substrate luciferin 
which causes light to be emitted from the beads where a nucleotide has been incorporated.  
Roche 454 sequencing generates hundreds of thousands of sequences of between 200 and 
400 nucleotides in length in a single run with an average accuracy of 96% (Marguiles et 
al.,  2005;  Graveley,  2008;  Mardis,  2008;  Rothberg  &  Leamon,  2008).    Like  the  454 
platform, the ABI SOLiD (Sequencing by Oligo Ligation and Detection) also uses the 
emulsion PCR method, utilising ligase instead of polymerase.  The cDNA is captured on 
paramagnetic beads, immobilized in a solid substrate for the sequencing reaction stage 
which utilises a fluorescently labelled octamer that generates a signal corresponding to 
base 5 of the octamer.  The octamer is then cleaved between bases 5 and 6, removing the 
fluorescent part of the octamer.  Further cycles enable the sequencing of every 5
th base.  
The rest of the sequence is generated using other octamers which target different bases 
(Shendure  &  Ji,  2008).    SOLiD  sequencing  generates  3-4  gigabases  of  sequences  in 
approximately  five  days  with  an  average  read  length  of  25-50  bases  (Graveley,  2008; 
Mardis, 2008).  Illumina Solexa attaches pieces of cDNA, which are flanked with adaptors, 
to a solid substrate.  These are clonally amplified by bridge PCR to generate a cluster of 
identical  amplicons  which  are  then  linearized  to  generate  single  stranded  cDNA.  
Sequencing  by  synthesis  is  carried  out  utilising  fluorescently  labelled  dNTPs  with  a 
terminating  moiety  that  only  allows  a  single  nucleotide  to  attach  at  each  cycle.    The 166 
fluorescence  is  measured  and  then  the  terminating  moiety  removed,  allowing  the  next 
dNTP  to  attach  (Mardis,  2008;  Shendure  &  Ji,  2008).    This  process  generates  large 
numbers of sequences (1300Mb sequence/ run) of a similar length to those generated using 
the SOLiD method (Shendure & Ji, 2008; Graveley, 2008).   
 
  Utilizing these next generation sequencing approaches allows the rapid generation 
of  databases  containing  novel  sequences.    This  is  particularly  important  for  genomic 
resource-poor organisms such as T. circumcincta, where the amount of sequence data is 
limited; currently the T. circumcincta genome project has generated 14Mb of sequence 
(http://www.sanger.ac.uk/Projects/T_circumcincta/;)  and  only  ~6,000  ESTs  are  in  the 
public  domain  (http://www.ncbi.nlm.nih.gov/dbEST/dbEST_summary.html).    Although 
the cost of Roche 454 sequencing is higher compared to SOLiD or Solexa sequencing, 
using this method to investigate the transcriptome of T. circumcincta is preferable at this 
point in time as it increases the chance of generating meaningful data with sufficient read 
length to enable correct assembly and identification of ESTs when a genome sequence is 
not available to use as a scaffold (Shendure & Ji, 2008).  The inducible transcriptomic 
response of the MOTRI multi-drug resistant isolate of T. circumcincta (MTci5) following 
in vitro IVM exposure was therefore investigated using Roche 454 sequencing.  In vitro 
IVM exposure was chosen as very little is known about how drug-resistant T. circumcincta 
responds  to  IVM  exposure  (Prichard  et  al.,  2007).    As  the  market  leader  in  terms  of 
anthelmintic sales in  the livestock market,  it is  especially important  to determine how 
parasites are able to survive IVM treatment  (Van Zeveren, 2009).  Using the methods 
described below, two pools of adult parasites were incubated for 5 hours, one pool exposed 
to IVM and the other pool as an unexposed control.  RNA was extracted from each pool 
and subjected to Roche 454 sequencing and bioinformatic analysis of the subsequent EST 
dataset.  
 
5.2: Materials and methods 
5.2.1: In vitro exposure to ivermectin 
Adult  MOTRI  T.  circumcincta  were  collected  from  the  abomasum  of  a  sheep 
previously  infected  with  15000  L3  21  days  P.I  using  a  modification  to  the  method 167 
described previously in Section 2.1.6.  After removal of the abomasum and collection of 
the abomasal contents and washings, individual worms were identified under a compound 
microscope using the x10 objective.  These were removed from the abomasal contents 
using a hypodermic needle bent into an L shape.  Parasites were inspected to confirm they 
were  not  damaged  and  sexed  under  a  microscope  before  being  placed  in  Petri  dishes, 
containing  9850μL  RPMI  and  100μL  penicillin/streptomycin  (final  concentration  1%), 
with an approximate 50:50 sex ratio, a total of approximately 100 parasites in each of 4 
dishes.  50μL DMSO (final concentration 0.05%) was added to two of the petri dishes to 
act as the unexposed controls and 50μL DMSO/ IVM (final concentration DMSO = 0.05%, 
final concentration IVM = 5μg/mL) was added to the other two dishes.  The petri dishes 
were placed in an incubator at 37°C in 5% CO2 for 5 hours before the parasites were 
removed from the culture medium, placed in 1x PBS, and snap frozen in liquid nitrogen. 
 
5.2.2: 454 sequencing reaction 
Total  RNA  was  extracted  from  one  IVM-exposed  and  one  -unexposed  pool  of 
parasites  using  Trizol  reagent  (Invitrogen)  according  to  the  manufacturer‟s 
recommendations,  as  described  in  Section  2.3.1.    Confirmation  of  RNA  integrity  was 
obtained by agarose gel electrophoresis and by determining the RNA concentration using a 
NanoDrop
® ND-1000 spectrophotometer.  1µg total RNA from the IVM-exposed and -
unexposed samples was supplied to Cogenics (www.cogenics.com) for cDNA synthesis 
and  Roche  454  sequencing.    Adaptors  were  ligated  onto  cDNA  transcribed  from  the 
respective samples to aid subsequent transcript identification (exposed vs unexposed) and 
the  cDNA  subjected  to  a  quarter  plate  Roche  454  sequencing  run  on  a  GS-FLX  454 
genome sequencer.  The basic technique is as described in Marguiles et al (2005).  Briefly, 
individual fragments of the cDNA library were captured onto beads inside an oil emulsion 
containing the PCR reagents.  Following PCR amplification, the emulsion was broken and 
a picolitre- sized pyrosequencing reaction set up for each bead containing amplified DNA 
on a fibre-optic slide.  The light emitted by the individual pyrosequencing reactions in each 
well is converted into a digital read of sequence data.   
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5.2.3: Bioinformatics 
Whole genome sequencing assembly was carried out using the proprietary Roche 
454 Newbler Assembler software.  The identity of contiguous sequences (contigs) was 
sought  using  BLAST  [Basic  Local  Alignment  Search  Tool  (Altschul  et  al.,  1990)], 
searching against three databases; Swissprot, Wormpep and the “est_others” nucleotide 
database curated by NCBI.  Functional classification was also carried out on the contigs on 
the basis of homology with the KEGG genomes orthology database using KAAS (KEGG 
Automatic Annotation Server: http://www.genome.jp/tools/kaas/) (Kanehisa & Goto, 2000; 
Moriya et al., 2007) with the single direction hit option.  Contigs could be represented in 
more than one functional group.   
 
Comparison of EST abundance was carried out by tagging contigs with identifiers 
to distinguish their origin (IVM-exposed or -unexposed) then pooling and assembling these 
sequences using SeqMan (DNASTAR Lasergene version 8) with the ProAssembler option.  
Sequences with a better than 95% match were assembled into clusters, manually curated 
and/or trimmed to resolve any conflicts arising from sequencing artefacts.  The consensus 
sequences of the clusters were BLAST searched in the NCBInr database to give a putative 
identity.   
 
5.2.4: Statistical analysis of 454 dataset 
A  2 2  Fisher‟s  Exact  test  was  conducted  to  test  for  differences  between  the 
proportions  of  exposed  and  unexposed  contigs  for  each  functional  classification  as 
identified by KEGG analysis.  The estimated p-values for all functional groups were then 
adjusted using the False Discovery Rate (FDR) approach (Benjamini & Hochberg, 1995) 
to take into account multiple comparisons of treatments. 
 
The methodology used to identify clusters indicated that there was likely to be 
excess clustering or overdispersion in the data.  However, with a single replicate for each 
combination of cluster and treatment, it was not possible to quantify this effect.  Therefore 169 
an approach was adopted which combined information from two statistical models that 
together spanned the range of results which would arise from the more appropriate model.  
 
The baseline statistical model was a saturated model that assumed that differences 
observed  between  treatments  for  all  clusters  were  fully  explained  as  arising  from  the 
differences  in  the  treatment  means.    This  involved  fitting  a  generalised  linear  model 
(GLM) with a binomial error distribution and logit link function (with cluster, treatment 
and a cluster by treatment interaction as fixed effects) or conducting a Fisher‟s Exact test 
for the number of reads in each cluster where a GLM was inappropriate.  The p-values 
from  this  model were liberal.   The estimated p-value indicating the level  of statistical 
significance for differences between the exposed and unexposed groups in the numbers in 
each  cluster  was  recorded.    These  p-values  were  adjusted  using  the  FDR  approach  as 
discussed earlier.  Subsequently, an estimate of the overdispersion in the data was obtained 
by  refitting  the  GLM  with  only  a  treatment  effect,  assuming  that  all  other  observed 
differences  were  caused  by  excess  clustering.    This  gave  an  overestimate  of  the  true 
overdispersion in the data. 
 
Finally, an alternative model was fitted, with over-dispersion fixed at the value 
obtained  previously.    This  involved  refitting  the  GLM  with  cluster,  treatment  and  the 
cluster by treatment interaction as fixed effects, and overdispersion fixed at the previous 
estimate or conducting a Fisher‟s Exact test for the number of reads in each cluster and 
adjusting the resulting p-value for the previously estimated overdispersion.  These p-values 
were adjusted using the FDR approach as mentioned earlier.  The p-values from this model 
were conservative. 
 
The  FDR  adjusted  p-value  for  a  cluster  is  the  minimum  FDR  for  which  the 
observed difference between the mean expression level of exposed and unexposed worms 
would be accepted as statistically significant.  It is possible to interpret these adjusted p-
values  as  the  expected  probabilities  of  the  clusters  being  assessed  as  showing  no 
statistically significant differences, given the unadjusted p-values and a random choice of 
FDR threshold.  The adjusted p-values from the two models were used to categorise each 170 
cluster into one of three classes: clusters with statistically significant p-values under the 
conservative model were of prime scientific interest; clusters with non-significant p-values 
under the liberal model were unlikely to be of interest; other clusters were of indeterminate 
status, but could be prioritised for further work with respect to either set of p-values. 
 
All  statistical  analyses  were  carried  out  using  the  12
th  Edition  of  the  GenStat 
statistical package (Payne et al., 2009) except the Fisher‟s Exact test which was performed 
in  the  R  software  system  version  2.9.2  (R  Development  Core  Team,  2009:  www.R-
project.org) 
 
5.3: Results 
  From the two samples (IVM –exposed and –unexposed) submitted for Roche 454 
sequencing, a total of 98,685 reads (= ESTs) were obtained. A summary of these results is 
shown in Table 5.1.  For the IVM-exposed sample, 55,341 individual sequence reads were 
obtained, of which 68.3% were assembled into 2,049 contigs with the remaining 15,488 
reads not aligning to any other sequence (singletons).  For the unexposed sample, a total of 
43,344 individual sequence reads was obtained, of which 65% were assembled into 1,659 
contigs with the remaining 13,857 reads as singletons.   The average read length for the 
exposed and unexposed samples was 251 base pairs (Figure 5.1).  Singletons which failed 
to form a contig were found to be either short sequences of poor quality (but with good 
homology to the sequencing primer); to have a high occurrence of repeats, or to contain 
sequencing errors and so were excluded from any further analyses.   
 
Candidate resistance genes were absent from either dataset with the exception of 
one contig (contig 1062, containing 2 reads and 241bp long) in the IVM-exposed dataset 
with BLAST homology to an ABC transporter; subfamily B (MDR/TAP); member 1.  The 
nucleotide sequence for this contig was aligned against the 11 available T. circumcincta 
Pgp sequences  described in  Chapter 3  and  also  against the 15 known  C. elegans Pgp 
sequences.  Phylogenetic trees were generated from these alignments using both the NJ and 
UPGMA distance matrices.  Figure 5.2 shows the relationships between contig 1062 and 171 
the  11  partial  T.  circumcincta  Pgps  previously  identified,  whilst  Figure  5.3  shows  the 
relationship between contig 1062 and the 15 C. elegans Pgps.   Contig 1062 does not align 
exclusively to any individual sequence suggesting it may be a novel member of the T. 
circumcincta  Pgp  family  or  possibly  a  different  part  of  one  of  the  genes  previously 
identified.   
 
5.3.1: Comparison of transcript levels based on KEGG functional groups 
Figure 5.4 shows the functional classification of each contig as identified using the 
KEGG genomes orthology database.  56.2% of the exposed and 55.8% of the unexposed 
samples were shown as having no orthologous hit.  In the exposed sample 12.6% of the 
contigs were in the group „energy metabolism‟, 8.6% of the contigs were in the group 
„circulatory system‟ and 13% of the contigs in the group „neurodegenerative disease‟.  In 
the  unexposed  sample,  the  percentages  for  these  same  groups  were  12.8%,  8.9%  and 
13.1%, respectively.  There was no statistically significant difference between the mean 
proportion of reads in exposed and unexposed samples for these four largest groups so they 
were removed from the data presented (Figure 5.4) to allow for easier visualisation of the 
smaller functional groups.  However, all groups were included in the statistical analysis.  
The KEGG orthologous group for „translation‟ showed a statistically significant increase in 
expression  in  the  IVM-exposed  sample  compared  to  the  IVM-unexposed  sample 
(P<0.001), whereas the orthologous groups for „amino acid metabolism‟, „carbohydrate 
metabolism‟ and „xenobiotic degradation and metabolism‟ showed statistically significant 
(P=0.001, P=0.022 and P=0.042 respectively) decreases in mean proportion of reads in the 
IVM-exposed sample compared to the -unexposed sample.  All other groupings, including 
those with no orthologous hits, were found to have no statistically significant difference in 
the mean proportion of reads between the IVM-exposed and IVM-unexposed samples. 
 
5.3.2: Comparison of transcript levels within clusters 
  2,570  clusters  were  obtained  when  the  exposed  and  unexposed  contigs  were 
combined; individual clusters varied in size from 2 to 5,823 reads per cluster.  Sixteen 
clusters  were  found  to  have  statistically  significant  differences  in  expression  level 
(P<0.0001) between the mean proportion of exposed and unexposed reads in the cluster 172 
under the conservative statistical model.  Under the liberal statistical model, a further 355 
clusters were found to have statistically significant differences (P<0.05) between the mean 
proportion of exposed and unexposed reads in the cluster.  The remaining 2,199 clusters 
were not statistically significant under either model. 
 
Of the sixteen statistically significant clusters under the conservative model, half of 
these clusters had an increased mean proportion of exposed reads compared to unexposed 
reads.  The change in read numbers and putative identities of these sixteen clusters is 
shown in Table 5.2.  Four of the clusters had no BLAST homology assigned and two were 
un-named or hypothetical proteins.  A further four clusters were identified as vitellogenin, 
however, there was no consistency in expression as one cluster showed an increased mean 
proportion of exposed reads whilst the three other vitellogenin clusters showed a reduced 
mean proportion of exposed reads, compared to unexposed reads.  Cytochrome C oxidase 
subunits were also represented four times, three were of subunit type I and one was a 
subunit  type  III.    Of  the  four  cytochrome  C  oxidase  subunits,  half  showed  a  reduced 
number of exposed reads compared to unexposed reads.  The remaining two clusters were 
identified as a major sperm protein, showing a reduced mean proportion of exposed reads, 
and a NADH dehydrogenase subunit 4, showing an increased mean proportion of exposed 
reads.   
 
  Of the 355 statistically significant clusters under the liberal model, 228 (64%) of 
these clusters showed a reduced mean proportion of exposed reads compared to unexposed 
reads.  Of the 355 clusters, 89 (25%) had no BLAST identity whilst 138 (39%) were 
hypothetical,  predicted  or  putative  proteins.    Some  cluster  identities  featured  more 
commonly  than  other  clusters;  the  majority  of  cluster  identities  were  only  represented 
once.  Nine of the clusters were identified as heat shock proteins (HSPs), five showing an 
increased number of exposed reads and four a reduced number of exposed reads.  The next 
most common identities were six clusters representing C-type single domain activation 
associated secreted proteins (ASPs).  Apart from one cluster, all showed a reduced mean 
proportion of exposed reads compared to unexposed reads.  Another five clusters were 
identified as secreted protein precursors; four had a reduced mean proportion of exposed 
reads compared to unexposed reads and were secreted protein 5 precursors.  One showed 173 
an increased mean proportion of exposed reads compared to unexposed reads but, unlike 
the  previous  four  secreted  protein  precursors,  was  identified  as  a  secreted  protein  6 
precursor.  Like the clusters with the statistically significant results under the conservative 
model, vitellogenin also featured in the significant results in the liberal model, with four 
clusters  again  being  assigned  this  identity  and  following  the  same  expression  pattern.  
Three  more  clusters  were  also  identified  as  cytochrome  C  oxidase  subunits,  two  were 
subunit type I and one subunit type III.  However, compared to the statistically significant 
clusters with the same identity in the conservative model, all of these clusters showed an 
increase in the mean proportion of exposed reads.  The identities of the 355 clusters are 
provided in Appendix 5. 
 
5.4: Discussion 
Limited sequence data are available for T. circumcincta and, although a genome 
sequencing  project  is  underway  (http://www.sanger.ac.uk/Projects/Helminths/),  it  is 
unlikely that an annotated genome sequence will be available in the near future.  Currently, 
the  T.  circumcincta  genomic  resource  represents  ~6,000  ESTs 
(http://www.ncbi.nlm.nih.gov/dbEST/dbEST_summary.html).    Currently,  it  is  estimated 
that parasitic nematodes have approximately 20,000 genes; in C. elegans the genome is 
approximately  100  megabases  in  size  whilst  in  H.  contortus,  due  to  bigger  and  more 
numerous introns, the genome is estimated to be 200-350 megabases long, although the 
exact genome size has not yet been determined.  The T. circumcincta genome is more 
likely to mirror that of H. contortus as both are parasitic species, although Leroy, Duperray 
&  Morand  (2003)  estimated  the  genome  size  of  T.  circumcincta  to  be  59  megabases.  
Currently,  the  T.  circumcincta  genome  sequencing  stands  at  14  megabases 
(http://www.sanger.ac.uk/Projects/T_circumcincta/) (Parkinson et al., 2004b; Sutherland & 
Scott, 2010).  Although not providing full coverage of the transcriptome, the generation of 
a  total  of  98,685  novel  reads  (i.e.  ESTs)  provides  a  valuable  resource  to  allow  the 
investigation  of  whether  inducible  gene  expression  changes  have  a  role  to  play  in 
resistance to anthelmintics.   
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The majority of the KEGG genome functional classification groups, including the 
largest „no hits‟ group were equally represented in both exposed and unexposed datasets.  
The scale of changes observed following IVM exposure is very different to those observed 
when comparing the gene expression profile of T. circumcincta during profound changes 
in the worms‟ physiology, e.g. transition to a different life cycle stage (Nisbet et al., 2008).  
A statistically significant increase in the expression of genes linked to translation in the 
exposed  sample  suggests  that  one  of  the  responses  to  IVM  exposure  is  a  generalised 
increase in protein production.  As expected, translation was one of the larger functional 
groups shown in Figure 5.4; most of the contigs in this group were of ribosomal origin.  
All of the groups showing a statistically significant reduction in expression appear to be 
linked to metabolism, including „amino acid metabolism‟, „carbohydrate metabolism‟ and 
„xenobiotic degradation and metabolism‟.  One way the parasites could be trying to survive 
exposure  to  IVM  could  be  to  stop  any  non-essential  cellular  processes;  however  the 
general reduction in metabolic processes could also indicate the parasites being paralysed 
or killed by IVM.   
 
The functional group „xenobiotic degradation and metabolism‟ showed a reduction 
in expression in the exposed group.  This was where any candidate resistance genes such as 
cytochrome  P450s  would  be  expected  to  sit,  and  an  increase  in  expression  of  genes 
potentially involved in generalised drug handling mechanisms was anticipated.  Genes of 
this class are generally expressed at low levels so the majority are likely to be missing from 
this transcriptomic analysis (Kotze, 1997; Barrett, 1998).  This is because an EST dataset is 
subject to sampling bias which leads to under-representation of rare transcript (Nagaraj, 
Gasser, & Ranganathan, 2007).  Interestingly, the only contig identified as a candidate 
resistance gene (IVM-exposed contig 1062) was identified as an ABCB1 which according 
to the KEGG functional classifications used was classified in the „membrane transport‟ 
group not in the „xenobiotic degradation and metabolism‟ group.  This contig was aligned 
against Pgp sequences from both C. elegans and T. circumcincta as Pgps are also part of 
the B subfamily of ABC transporters (Sheps et al., 2004).  The alignment trees (Figures 5.2 
and 5.3) did not indicate that contig 1062 was the same or closely related to any of the T. 
circumcincta previously identified, nor did it align to any particular C. elegans Pgp.   
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None of the putative target genes implicated in IVM resistance, such as the GABA 
and  GluCl  channels  described  in  the  Chapter  introduction,  were  present  in  the  cluster 
analysis.  A more targeted approach such as real-time PCR, or more in-depth sequencing, 
would be required to assay all genes in this class and to provide statistically meaningful 
data on differential expression of these genes.  It is also important to remember that the 
MOTRI isolate represents a spectrum of resistant phenotypes and will include a proportion 
of susceptible individuals that will undoubtedly be killed by the IVM exposure in vitro.  It 
is  possible  that  the  level  of  IVM  exposure  chosen  caused  the  death  of  the  relatively 
susceptible parasites and induced stress responses in the more resistant parasites.  The 
contribution of dead or dying individuals may have masked the expression of generalised 
drug handling mechanisms such as Pgps and CYPs. 
 
Analysis  of  the  functional  classification  of  the  contigs  in  the  exposed  and 
unexposed  datasets  revealed  only  slight  differences  between  the  two  datasets.    This 
suggested that any differences in expression levels were subtle and were more likely to be 
found  within  clusters  rather  than  within  functional  groups.    HSPs  show  increased 
expression  when  cells  are  exposed  to  heat  or  other  environmental  stresses  (Lindquist, 
1986).  However four of the nine clusters identified as HSPs showed a reduced mean 
proportion of exposed reads when exposed to IVM.  Six of the clusters were identified as 
C-type single domain ASPs and the majority were shown to have reduced expression in the 
exposed sample compared to the unexposed sample.  ASPs are nematode-specific proteins 
and are believed to have roles in parasite establishment and maintenance and may also act 
as allergens (Visser et al., 2008).  A reduced expression of these proteins in response to 
IVM could be the adult parasites down-regulating activity associated with their parasitic 
behaviour.   
 
More  than  one  cluster  was  identified  as  vitellogenin  or  cytochrome  C  oxidase 
subunits; however, no clear pattern of increased or decreased expression of these cluster 
identities  could  be  identified.    Cytochrome  C  oxidases  are  part  of  the  mitochondrial 
electron transport chain; changes in expression may be due to changes in the parasite‟s 
respiration  rate  in  response  to  drug  exposure.    The  majority  of  clusters  identified  as 
vitellogenin (six out of the eight identified as having statistically significant differences in 176 
read numbers between the two samples) showed a decreased expression in the exposed 
sample, suggesting a reduction in egg production in response to IVM exposure. 
 
  Unfortunately, we do not have access to the parental susceptible population of T. 
circumcincta  from  which  MOTRI  was  selected  in  the  field.    This  makes  meaningful 
genetic comparisons of susceptible and resistant isolates difficult as they do not share a 
common genetic background.  However, in this study we have explored global changes in 
gene expression within one isolate following exposure to IVM in vitro.  This experiment 
has shown that next generation sequencing approaches can be used to investigate gene 
expression changes in pools of complex nematode parasites such as T. circumcincta, for 
which genomic resources are limited.  This small-scale study has facilitated the generation 
of  two  new  sets  of  ESTs  from  a  multiple  drug-resistant  T.  circumcincta  isolate,  and 
allowed a comparative investigation into the transcriptomic response of this isolate to IVM 
exposure.  Results clearly show that not all the observed expression changes reflect up-
regulation, many of the changes involved down-regulation.  Results also show that the 
MOTRI isolate, which exhibits an IVM efficacy of 60%, is still affected by IVM treatment. 
 
  In  terms  of  understanding  the  genetic  basis  of  resistance,  next  generation 
sequencing approaches have great potential to contribute to this area of research.  These 
high-throughput  sequencing  technologies  now  routinely  require  very  small  amounts  of 
starting material, making them ideal for studies of parasitic helminths for which biological 
material can be limiting.  However, care also needs to be taken when using EST datasets to 
estimate  gene  numbers;  the  fragmented  nature  of  the  sequence  generated  (particularly 
those generated using Solexa and SOLiD) can cause over-representation of a gene when 
two  non-overlapping  fragments  of  the  same  gene  are  taken  to  be  two  separate  genes 
(Abubucker  et  al.,  2009).    This  may  be  the  case  with  the  dataset  described  above, 
especially in the case of vitellogenin which is a very long transcript (Nisbet & Gasser, 
2004).  Until a full genome is available for T. circumcincta, it will not be possible to 
definitively say whether the gene expression changes identified in this Chapter are real or a 
result of erroneous gene fragmentation.   
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Although not exploited in this study, the assembly of large sequence datasets into 
contigs allows a precise analysis of qualitative genetic changes, for example SNPs and 
indels, which may be linked to resistance.  Furthermore, detailed network analysis of large 
EST datasets such as those generated by next generation sequencing may contribute to 
making biological sense of complicated inter-related gene expression changes.  The biggest 
challenge  when  generating  large  amounts  of  EST  data  is  the  correct  application  of 
downstream bioinformatic and statistical analysis to answer biologically relevant questions 
(Pop & Salzberg, 2008; Shendure & Ji, 2008).  In this research we have developed a two-
model based statistical method to allow the categorization of a large dataset into more 
refined groups, aiding the identification of the most significant changes.  The application 
of next generation sequencing approaches when applied to the most appropriate biological 
resource  should  ultimately  help  identify  the  genuine  genetic  determinants  underlying 
anthelmintic resistance. 
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Table 5.1: Summary of the results of the Roche 454 sequencing carried out on two pools of MOTRI mixed-
sex T. circumcincta adults, one exposed to ivermectin in vitro and one as an unexposed control. 
Sample  Number 
of reads 
%  reads 
assembled 
Number of 
contigs 
Largest contig 
length (BP) 
Number of 
singletons 
IVM exposed  55,341  68.3  2,049  3,735  15,488 
IVM unexposed  43.344  65.0  1,659  2,872  13,857 
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Table 5.2: The sixteen clusters with statistically significant differences in gene expression between IVM-
exposed and –unexposed worms under the conservative model.  The columns show the cluster identity used 
in the analysis (cluster), the number of reads within that cluster (U reads = unexposed and T reads = 
exposed), whether gene expression up (+) or down (-) regulated compared to unexposed reads (change) and 
what the putative cluster identity was (Best BLAST identity). 
Cluster  U reads  T reads  Change  Best BLAST identity 
1782  0  863  + 
Cytochrome c oxidase subunit I [Ancylostoma caninum] 
YP_002725710.1 
210  508  1439  + 
Cytochrome  c  oxidase  subunit  I  [Steinernema  rarum] 
AAY22431.1 
538  1893  3930  + 
Hypothetical  protein  Bm1_17870  [Brugia  malayi] 
XP_001895031.1 
1621  0  176  + 
NADH dehydrogenase subunit 4 [Cooperia oncophora] 
NP_851330.1 
378  0  62  +  No hits found 
1747  0  253  +  No hits found 
175  271  836  + 
Unnamed  protein  product  [Macaca  fascicularis] 
BAE89779.1 
1746  0  291  + 
Vitellogenin-6;  Flags:  Precursor  [Oscheius 
brevesophaga] Q94637.1 
2557  516  0  - 
Cytochrome  oxidase  subunit  I  [Cooperia  oncophora] 
BAE72507.1 
409  347  12  - 
Cytochrome  oxidase  subunit  III  [Ancylostoma 
duodenale] CAD10435.1 
672  348  199  - 
Major  sperm  protein  [Dictyocaulus  viviparus] 
ACC64398.1 
2550  283  0  -  No hits found 
2558  46  0  -  No hits found 
574  182  0  -  Vitellogenin [Haemonchus contortus] AF305957_1 
102  418  241  - 
Vitellogenin structural genes (yolk protein genes) family 
member  (vit-2)  [Caenorhabditis  elegans] 
NP_001123117.1 
653  783  299  - 
Vitellogenin-6;  Flags:  Precursor  [Oscheius 
brevesophaga] Q94637.1 180 
 
Figure 5.1: Graph showing the average read length of the sequences generated by Cogenics using the two 
pools of RNA generated from MOTRI T. circumcincta adults, one exposed to ivermectin and one unexposed 
in vitro.  Reproduced from 454 run report from Cogenics 
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A   
 
 
B   
Figure 5.2: Relationship of contig 1062 from the IVM-exposed dataset to the 11 partial Pgp gene sequences 
identified in Chapter 3.  A: Tree generated using the UPGMA distance matrix with a bootstrap value of 1000. 
B: Tree generated using the NJ distance matrix with a bootstrap value of 1000. 
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A   
 
 
B   
Figure  5.3:  Relationship  of  contig  1062  from  the  IVM-exposed  dataset  to  the  15  C.  elegans  Pgp  gene 
sequences.  A: Tree generated using the UPGMA distance matrix with a bootstrap value of 1000. B: Tree 
generated using the NJ distance matrix with a bootstrap value of 1000. 
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Figure  5.4:  Functional  classification  of  reads  from  454  sequencing  of  (A)  in  vitro  ivermectin  exposed 
MOTRI T. circumcincta adults and (B) unexposed MOTRI T. circumcincta adults identified using KAAS.  
Not shown in the Figure are the 56.2% of exposed reads and 55.8% of unexposed reads with no known hits, 
the 12.6% of exposed reads and 12.8% of unexposed reads in the functional group „energy metabolism‟, the 
8.6% of exposed reads and 8.9% of unexposed reads in the functional group „circulatory system‟ and the 
13% of exposed reads and 13.1% of unexposed reads in the functional group „neurodegenerative disease‟.  
Individual reads may be present in more than one functional group. 184 
Chapter 6: Suppression Subtractive Hybridisation Comparison of Gene 
Expression in CVL and MOTRI Teladorsagia circumcincta Isolates  
6.1: Introduction 
Candidate resistance gene studies aimed at identifying the genes associated with 
IVM  resistance  in  parasitic  nematodes  such  as  T.  circumcincta  have  not  definitively 
identified either the genes involved nor markers associated with resistance (Gilleard, 2006; 
von Samson-Himmelstjerna et al., 2007).  Most of the studies to date have looked for 
mutations  associated with  IVM resistance,  yet  other mechanisms  of resistance such as 
changes in expression levels of genes potentially involved in drug handling or metabolism 
have largely been ignored.  The work described in Chapters 3 and 4 has investigated the 
role  differential  gene  expression  of  Pgps  and  CYPs  could  play  in  the  IVM  resistance 
phenotype  exhibited  by  certain  isolates  of  T.  circumcincta.    However,  as  discussed  in 
Chapter 5, changes in the expression of other genes, not classified as candidate resistance 
genes, could potentially enable T. circumcincta to exhibit IVM resistance.  The use of a 
more  global  “non-hypothesis”  driven  approach  to  identify  genes  exhibiting  altered 
expression profiles in response to IVM exposure (see Chapter 5) or in a IVM-resistant 
isolate  could  enhance  the  knowledge  of  how  IVM-resistant  T.  circumcincta  is  able  to 
handle the drug and also survive drug exposure.  One such technique, which can be used to 
investigate changes in gene expression, is described below.   
 
Suppression subtractive hybridisation (SSH) was first described by Diatchenko et 
al (1996) as a method to allow the identification and isolation of differentially expressed 
genes between two pools of cDNA.  Firstly, normalisation of the tester cDNA sample 
equalises the abundance of the cDNAs within that pool, then sequences common to both 
samples are removed by hybridising the driver cDNA to the tester cDNA.  A final PCR 
step  selectively  amplifies  only  those  cDNAs  which  are  unique  to  the  tester  cDNA 
population whilst preventing the amplification of non-unique transcripts.  Identification of 
the unique transcripts in the tester population is then achieved by cloning and sequencing 
the resultant PCR products.  The method is especially useful for identifying transcripts 
with  low  abundance  as  the  first,  normalisation,  step  equalises  the  abundance  of  the 
transcripts,  whilst  the  suppressive  PCR  step  means  single-stranded,  non-differentially 
expressed double-stranded or driver specific cDNAs fail to amplify.  SSH has advantages 185 
over  previous  methods,  such  as  differential  display,  as  it  is  less-time  consuming  and 
requires less starting material (Gasser & Newton, 2000; Cottee et al., 2006).  Compared to 
standard EST library construction, SSH also produces fewer redundant sequences, made up 
of common, abundantly expressed genes and enables the identification of genes expressed 
at low levels by selectively amplifying them (Diatchenko et al., 1996; Nisbet & Gasser, 
2004; Cottee et al., 2006).   
 
Few studies to date have utilised SSH to investigate differences in gene expression 
in parasitic nematodes. Where it has been employed, SSH has been used to investigate 
stage-specific changes in gene expression, particularly those changes associated with the 
transition  between  the  free-living  and  parasitic  stages,  whilst  other  studies  have 
investigated  gender  differences  in  expression.    Two-way  (identifying  increased  and 
reduced expression of genes between the tester and driver cDNA) stage-specific expression 
of  genes  has  been  investigated  in  Trichinella  spiralis,  where  comparisons  were  made 
between newly hatched larvae, day 3 adults and day 5 adults; in An. caninum, where genes 
with differential expression between free-living and parasitic larval stages were identified 
and, finally, in T. circumcincta, where gene expression was compared between xL3 and 
early L4 parasites (Liu et al., 2007; Nisbet et al., 2008; Datu et al., 2008).  Comparisons of 
gene expression between male and female adult parasites, using SSH, have been carried 
out in O. dentatum and T. vitrinus (Nisbet & Gasser, 2004; Cottee et al., 2006).  Uniquely, 
one study in T. spiralis has used SSH to investigate differential expression in life-cycle 
stages and between the parasite sexes.  This study investigated the genes induced in T. 
spiralis following in vitro heat shock  and identified 12 genes induced in infective larvae 
following exposure to 43ºC, as compared to 37ºC (Mak, Sun, & Ko, 2001).  No studies, to 
date  have  employed  SSH,  in  parasitic  nematodes  to  investigate  the  gene  expression 
changes associated with anthelmintic resistance.   
 
The investigation of constitutive expression differences has, until now, focused on 
the  panel  of  candidate  resistance  genes  as  described  in  Chapters  3  and  4.    The  final 
comparison in this thesis was to use a „non-hypothesis‟ driven one-way SSH approach to 
identify genes with increased expression in the resistant MOTRI T. circumcincta isolate 
compared to the susceptible CVL isolate.  This was to complement the Roche 454 dataset 186 
generated in Chapter 5 comparing the inducible expression of genes in the MOTRI isolate 
which  had  been  exposed  to  IVM  in  vitro.    The  SSH  method  was  chosen  because  it 
amplifies unique transcripts with low abundance whereas the methods used prior to SSH 
were inefficient at amplifying transcripts of low abundance (Diatchenko et al., 1996).  To 
identify genes with increased expression in, or unique to MOTRI, MOTRI cDNA was 
chosen as the tester sample while the CVL cDNA was the driver sample.   
 
6.2: Materials and methods 
6.2.1: Extraction of RNA 
  RNA was extracted from two pools of adult worms, one from the known IVM-
susceptible T. circumcincta CVL (MTci2) isolate and the other from the triple BZ, LEV 
and IVM-resistant T. circumcincta isolate (MOTRI or MTci5) using the Trizol
® method, as 
described previously (Section 2.3.1).  Estimations of the concentration of the RNA were 
made  using  a  NanoDrop
®  ND-1000  spectrophotometer.    From  these  readings  it  was 
decided that the subtraction experiment would utilise cDNA made using total RNA as 
there were insufficient quantities of total RNA to purify sufficient poly A
+ RNA for the 
subtraction experiment. 
 
6.2.2: Synthesis of cDNA 
  cDNA  was  synthesised  from  the  above  total  RNA  using  the  SMARTer
™  PCR 
cDNA Synthesis kit (Clontech).  First strand synthesis was carried out by combining, for 
each of the two isolates, 1µg total RNA with 1µL 3‟ SMART™ CDS Primer II A and 
nuclease free water to give a total volume of 4.5µL.  This was incubated at 72ºC for 3 mins 
followed by 42ºC for 2 mins in an Applied Biosystems 2720 thermal cycler.  While this 
reaction was incubating, a master mix for the two reactions was set up by combining; 4µL 
5X First-Strand Buffer, 0.5µL 100mM DTT, 2µL 10mM dNTP mix, 2µL 12µM SMARTer 
II A Oligonucleotide, 0.5µL RNase Inhibitor and 2µL 100U SMARTScribe™ Reverse 
Transcriptase.  5.5µL of the master mix was transferred by pipette into each of the reaction 
tubes as soon as the thermal cycling was completed and the tubes incubated for 90 mins at 
42ºC.  The incubation time was extended to 90 mins to ensure full-length cDNAs were 187 
obtained.  The reaction was terminated by heating the tubes to 70ºC for 10 mins and the 
first strand reaction product diluted in 40µL TE buffer. 
 
  cDNA amplification, using long distance PCR, utilised 30µL of each of the first 
strand reaction mixes. A master mix comprising of 666µL sterile deionised water, 90µL 
10X Advantage 2 PCR Buffer, 18µL 50X 10mM dNTP mix, 18µL 12µM 5‟ PCR Primer II 
A and 18µL 50X Advantage 2 Polymerase Mix was set up with 270µL aliquots of this 
master mix placed into each of the two tubes containing the first strand reaction mix.  The 
resulting PCR reaction mix was split into three aliquots of 100µL, labelled A, B, and C, for 
each of the two samples and thermal cycling commenced in an Applied Biosystems 2720 
thermal cycler pre-heated to 95ºC.  Cycling parameters were 95ºC for 1min followed by 15 
cycles of 95ºC for 15 secs, 65ºC for 30 secs and 68ºC for 6 mins.  After the 15 cycles had 
finished, 30µL from each of the tubes labelled C was removed for PCR optimisation, 5µL 
of which was kept for gel analysis, whilst the remainder of tubes C and all of tubes A and 
B were stored at 4ºC.  Further PCR cycles were carried out on the 30µL aliquots from 
tubes C, using the conditions described above.  After 18, 21, 24 and 27 cycles, 5µl aliquots 
were taken for gel analysis.  All of the 5µL aliquots were run on a 1.2% agarose gel and 
the gel visualised under UV.  The results of this gel determined that the samples A, B and 
the  remainder  of  C  did  not  require  further  PCR  cycles;  15  cycles  was  optimal  for 
amplification of the PCR products. 
 
6.2.3: Rsa I digestion of cDNA 
The  three  tubes  for  each  of  the  samples  were  combined  and  the  PCR  product 
cleaned up using the QIAquick
® PCR purification kit (Qiagen), eluting into 50µL nuclease 
free water.  The DNA was diluted to give a total volume of 322.5µL with 10µL set aside 
for later analysis (pre-digestion sample).  To each sample, 36µL 10X  Rsa I restriction 
buffer and 1.5µL Rsa I were added and the samples incubated at 37ºC for three hours.  
Another 10µL aliquot (post-digestion sample) was removed and the rest of the sample 
stored at 4ºC while the pre- and post-digestion samples were run on a 1.2% agarose gel.  
The gel confirmed the Rsa I digestion had worked so the reactions were terminated by the 
addition of 8µL 0.5M EDTA.  The digested cDNA was cleaned up using the QIAquick
® 188 
PCR purification kit (Qiagen), eluting into 30µL, and the concentration determined using a 
NanoDrop
® ND-1000 spectrophotometer.  The more concentrated CVL sample was diluted 
using  nuclease  free  water  to  the  same  concentration  as  the  MOTRI  sample,  namely 
276ng/µL, which was deemed suitable for the subtraction experiment. 
 
6.2.4: Subtraction reaction 
A one-way subtraction was carried out with the MOTRI Rsa I digested cDNA as 
the tester sample and the CVL Rsa I digested cDNA as the driver sample.  The aim of this 
subtraction was to identify sequences which exhibited increased expression in the MOTRI 
sample as compared to the CVL sample.  The kit used for this experiment was the BD 
PCR-Select cDNA Subtraction Kit (Clontech), following the manufacturer‟s protocol.  A 
diagram of the subtraction experiment is shown in Figure 6.1.   
 
Firstly, the tester cDNA underwent adaptor ligation; 1µL of the tester cDNA was 
diluted in 5µL sterile water and a master mix set up by combining 9µL sterile water, 6µL 
5X Ligation Buffer and 3µL T4 DNA Ligase.  Two reactions were set up as follows; for 
tester1-1,  2µL  diluted  tester  cDNA  were  mixed  with  2µL  10mM  Adaptor  1  and  6µL 
master mix whilst for tester 1-2, 2µL diluted tester cDNA were mixed with 2µL 10mM 
Adaptor 2R and 6µL master mix.  For the unsubtracted tester control, 1-c, 2µL of tester 1-1 
and 2µL of tester 1-2 were combined.  The three tubes (1-1, 1-2 and 1-c) were incubated 
overnight at 16ºC.  The samples were stored at -20ºC whilst ligation efficiency analysis 
was  carried out.   To stop  and inactivate the ligation  step, 1µL 0.2M  EDTA/ 1mg/mL 
glycogen mix was added to each tube, mixed and the samples heated at 72ºC for 5 mins.   
 
  Ligation efficiency was evaluated by PCR amplification of the T. circumcincta β-
tubulin housekeeping gene.  This gene was chosen as the amplicons obtained using the β-
tubulin forward and reverse primers (Table 2.1) did not contain any Rsa I digestion sites.  
The master mix for the reactions was set up by combining 92.5µL sterile water, 12.5µL 
10X PCR reaction buffer, 2.5µL 10mM dNTP mix and 2.5µL 50X BD Advantage cDNA 
Polymerase Mix.  1µL of each of tester 1-1 and tester 1-2 was diluted in 200µl nuclease 189 
free water and four PCR reactions set up.  In reaction tube 1, 1µl each of diluted Tester 1-
1, β-tubulin  reverse primer and PCR Primer 1 was mixed with  22µL master mix.   In 
reaction tube 2, 1µl each of diluted Tester 1-1, β-tubulin reverse primer and β-tubulin 
forward primer was mixed with 22µL master mix.  In reaction tube 3, 1µl each of diluted 
Tester 1-2, β-tubulin reverse primer and PCR Primer 1 was mixed with 22µL master mix.  
Finally, in reaction tube 4, 1µl each of diluted Tester 1-2, β-tubulin reverse primer and β-
tubulin forward primer was mixed with 22µL master mix.  The four reaction tubes were 
subjected  to  PCR  on  an  Applied  Biosystems  2720  thermal  cycler  with  the  following 
reaction conditions; 94ºC for 30 secs followed by 25 cycles of 94ºC for 10 secs, 59ºC for 
30 secs and 68ºC for 2 mins 30 secs.  5µL of each of the four PCR reactions was analysed 
on a 2% agarose gel. 
 
The first  hybridisation  between the tester samples (1-1 and 1-2) and the driver 
(CVL) cDNA was carried out by combining the two pools of DNA.  In hybridisation tube 
1, 1.5µL of the Rsa I-digested driver (CVL) cDNA from Section 6.2.3 above was mixed 
with  1.5µL  tester  1-1  and  1µL  4X  hybridisation  buffers  which  had  previously  been 
incubated at room temperature for 15 mins.  In hybridisation tube 2, 1.5µL of the Rsa I-
digested driver (CVL) cDNA from Section 6.2.3 above was mixed with 1.5µL tester 1-2 
and 1µL 4X hybridisation buffer which had previously been incubated at room temperature 
for 15 mins.  Both samples were overlaid with a drop of mineral oil and incubated on an 
Applied Biosystems 2720 thermal cycler at 98ºC for 1 min 30 secs followed by 8 hours at 
68ºC. 
 
  The second hybridisation involved the addition of fresh denatured driver cDNA to 
the combined reaction mixes of tubes 1 and 2.  To do this, fresh driver cDNA (CVL from 
Section 6.2.3) was firstly denatured by combining 1µL of the driver cDNA with 1µL of 
room temperature 4X Hybridisation buffer and 2µL of sterile water.  This was overlaid 
with a drop of mineral oil and incubated on a thermal cycler at 98ºC for 1 min 30 secs.  A 
pipette and pipette tips were warmed to 45ºC and the sample in hybridisation tube 2 drawn 
up into the pipette tip followed by a small amount of air and then the freshly denatured 
driver cDNA.  Finally, the contents of the pipette tip were transferred into hybridisation 
tube 1, mixed and incubated in an Applied Biosystems 2720 thermal cycler set at 68ºC 190 
overnight.  These steps were carried out as quickly as possible, removing the tubes only 
briefly  from  the  thermal  cyclers  set  at  68ºC  to  prevent  the  denatured  cDNA  from  re-
annealing.  After overnight incubation, 200µL pre-warmed dilution buffer was added to the 
sample and mixed; the sample was then heated at 68ºC for 7 mins and stored at -20ºC. 
 
  Amplification of cDNA was carried out by a two-step nested PCR.  In the first PCR 
reaction, a 1µL aliquot of the subtracted cDNA and a 1µL aliquot of the 1-c sample (from 
the  adaptor  ligation  step,  which  had  been  diluted  in  1mL  of  water)  were  placed  into 
separate tubes.  24µL of the master mix, made by mixing 58.5µL sterile water with 7.5µL 
of 10X PCR reaction buffer, 1.5µL 10mM dNTP mix, 3µL 10µM PCR primer 1 and 1.5µL 
50X Advantage cDNA Polymerase mix, was added to each reaction tube.  The reaction 
conditions for the PCR were; 75ºC for 5 mins, 94ºC for 25 secs followed by 27 cycles of 
94ºC for 10 secs, 66ºC for 30 secs and 72ºC for 1 min 30 secs.  On completion of the PCR, 
8µL aliquots were taken from each reaction tube for analysis, and a further 3µL of each of 
the amplified cDNAs diluted in 27µL sterile water.  1µL of the resulting diluted cDNAs 
were transferred to a fresh PCR tube ready for the second PCR reaction and the rest of the 
cDNA stored at -20ºC.  The second master mix was made by mixing 55.5µL sterile water, 
7.5µL 10X PCR reaction buffer, 1.5µL 10mM dNTP mix, 3µL 10µM Nested PCR primer 
1, 3µL 10µM Nested PCR primer 2R and 1.5µL 50X Advantage cDNA Polymerase mix.  
24µL  of  the  master  mix  was  aliquoted  into  the  two  PCR  reaction  tubes  which  were 
subjected to 11 cycles of 94ºC for 10 secs, 68ºC for 30 secs and 72ºC for 1 min 30 secs in 
an Applied Biosystems 2720 thermal cycler.  8µL of the amplified cDNA was removed 
and analysed on a 2% agarose gel alongside the earlier samples.  The final PCR product 
was  cleaned up using the QIAquick
® PCR purification kit (Qiagen), eluting in  a final 
volume of 30µL and stored at -20ºC. 
 
6.2.5: Cloning and sequencing 
  Cloning  of  the  SSH  products  from  the  previous  section  was  carried  out  using 
JM109  competent  cells  (Stratagene)  and  the  pGEM
®-T  vector  system  (Promega),  as 
described in Sections 2.3.7 and 2.3.8.  Initially, 10 white colonies were selected from each 
of two plates of transformed cells, set up from the ligation mix containing the purified 191 
hybridised cDNA.  These were grown up in glass universals containing 10mL LB broth 
and 20μL 25mg/mL AMP, the plasmids purified and sent for sequencing using the T7 
plasmid primer, as described in Section 2.3.9.  Subsequently, a further 10 white colonies 
from each of the two plates were cloned and sequenced. 
 
6.2.6: Analysis of results 
  Analysis  of  the  sequence  data  was  carried  out  using  SeqMan  (DNASTAR 
Lasergene version 8) to enable the accuracy of base calls to be checked, to align sequences 
into contigs and to remove plasmid and adaptor sequence.  Consensus sequences were used 
to  perform  a  tBLASTx  search  on  NCBI  (www.ncbi.nlm.nih.gov/blast/Blast.cgi)  and  a 
BLASTn  search  on  EMBL-EBI  (www.ebi.ac.uk/blast2/parasites.html).    Consensus 
sequences were BLAST searched, using the local BLAST server, against the Roche 454 
sequencing  dataset  (Chapter  5)  to  determine  if  any  of  the  sequences  with  constitutive 
expression  differences  between  MOTRI  and  CVL  also  exhibited  inducible  expression 
differences under IVM exposure in vitro.   
 
6.2.7: Confirmation of results using semi-quantitative PCR 
  Specific primers for six of the sequences obtained were designed to allow semi-
quantitative PCR to be carried out to confirm the validity of the SSH results.  The protocol 
was as follows:  32µL of nuclease free water was combined with 5µL 10X PCR buffer, 
1.5µL 50mM MgCl2, 2μL dNTP, 0·5μL Platinum
® Taq DNA Polymerase, 2μL each of the 
forward and reverse primers, and 5μL template cDNA to give a total reaction volume of 
50μL.  The template for the PCR reaction was either CVL and MOTRI cDNA, synthesised 
from  the  original  RNA  generated  for  the  SSH  experiment,  using  random  primers  as 
described in Section 2.3.2, diluted to 10ng/μL, or the purified Rsa I digested CVL and 
MOTRI cDNA from Section 6.2.3 which had been diluted to 10ng/µL.  The PCR reaction 
conditions were 5 mins at 94ºC followed by 30 cycles of 94ºC for 30 secs, 58ºC for 30 secs 
and 72ºC for 30 secs, followed by 10 mins at 72ºC and a hold at 4ºC.  After 15, 20, 25 
cycles and on completion of the PCR, 5µL of the reaction mix was removed from each 
tube and stored at 4ºC prior to all the samples being visualised on a 1% agarose gel as 
described previously.  ʒ tubulin primers (Table 2.1) were used as a positive control and the 192 
primers used to amplify the SSH products are shown in Table 6.1.  The protocols described 
above required the following reagents which were not supplied as parts of the kits used: 
 
Agarose gel 
2% agarose gel was prepared by dissolving 8g agarose and 8mL 50X TAE in 392mL of 
dH2O using a microwave.  20μL 10000X Gel Red (Biotium Inc) was added to enable 
visualisation of DNA under UV light.  
1.2% agarose gel was prepared by dissolving 4.8g agarose and 8mL 50X TAE in 392mL of 
dH2O using a microwave.  20μL 10000X Gel Red (Biotium Inc) was added to enable 
visualisation of DNA under UV light.  
 
0.5M Ethylenediaminetetraacetic acid (EDTA) 
18.61g EDTA was diluted in water to a final volume of 100mL.   
 
1M TrisHCl, pH8.0 
12.11g TrisHCl was diluted in water to a final volume of 100mL. The pH was adjusted to 
pH8.0 using sodium hydroxide. 
 
TE buffer (10mM Tris [pH8.0], 0.1mM EDTA) 
1mL of the 1M TrisHCl and 20µl of the 0.5M EDTA was diluted to give a total volume of 
100mL. 
  Other  reagents  required  during  the  SSH  experiment,  such  as  TAE  buffer  and 
cloning reagents have been previously described in Chapter 2. 
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6.3: Results 
6.3.1: Genes identified using SSH 
  On completion of the subtraction experiment and the cloning of the resultant PCR 
product, a total of 40 colonies were sequenced.  One colony (2g) failed the sequencing 
quality control checks and was excluded from any further analysis.  The results of the 
sequence analysis, as described in Section 6.2.6, are shown in Table 6.2 below.  Of the 39 
remaining colonies, one (colony 2k) was found, upon sequence analysis, to not contain an 
insert in the plasmid whilst the remaining thirty-eight aligned into 28 contigs ranging in 
size from 215 to 742 bp in length.  The contigs were named SSH1 to 28, sequentially as 
they  were  identified.    The  majority  of  contigs  contained  a  single  sequence,  with  the 
maximum number of sequences within a contig being 4.  The EBI and NCBI best BLAST 
hits for 12 of the 28 contigs gave similar predicted sequence identities while a further 5 
contigs  did  not  have  a  definitive  BLAST  identity,  being  labelled  as  predicted  or 
hypothetical proteins or the BLAST identities were not sufficiently detailed (e.g. SSH11 in 
Table 6.2).  Of 28 contigs, 3 were identified as heat shock protein (HSP) homologues, 2 of 
these were HSP-16 and the third HSP-20.  Three of the contigs  had  putative BLAST 
identities of ribosomal proteins whilst a further 2 contigs had putative BLAST identities of 
T. circumcincta mitochondrial sequences. 
 
6.3.2: Confirmation of results using semi-quantitative PCR 
  Using  the  primers  in  Table  6.1  and  the  semi-quantitative  PCR  protocol,  as 
described  in  Section  6.2.7  above,  the  SSH  results  for  a  selection  of  the  contigs  were 
confirmed.  The contigs were chosen on the basis of their putative BLAST identities and 
were as follows: SSH3 (axonemal dynein), SSH4 (HSP-16), SSH6 (SXC1), SSH7 (HSP-
16),  SSH12  (HSP-20)  and  SSH17  (Cathepsin  B).    The  expression  of  these  genes  was 
compared to the control gene, β-tubulin (Table 2.1).  The amplification of SSH 6, 7 and 12 
was  very  weak  and  for  SSH17  not  visible  at  all  after  completion  of  the  first  semi-
quantitative PCR, so a second semi-quantitative PCR was set up, with the number of cycles 
extended to 35 cycles.   The results of the semi-quantitative PCR experiments are shown in 
Figure  6.2.    For  SSH  3  and  4,  the  MOTRI  sample  showed  a  greater  band  intensity 
compared to the CVL sample at 20 cycles whilst even after 35 cycles and using Rsa I-194 
digested  cDNA  as  template,  no  band  could  be detected  in  either  the  MOTRI  or  CVL 
sample for SSH17.  The first bands visible for SSH 6 and 12 both appeared in the MOTRI 
sample lane after 30 cycles, whilst the difference in intensity of the two bands present at 30 
cycles for SSH7 indicates that this gene was more highly expressed in the MOTRI sample 
compared  to  the  CVL  sample.    Therefore,  with  the  exception  of  SSH17,  where  no 
expression of the gene could be demonstrated, the semi-quantitative PCR results confirm 
the SSH results, indicating that for SSH 3, 4, 6, 7, and 12, there is increased expression in 
the MOTRI T. circumcincta isolate compared to the CVL isolate.   
 
6.3.3: Comparison of SSH results with Roche 454 sequencing results (Chapter 5). 
  BLAST searches of the nucleotide sequences obtained from the SSH analysis were 
made against the contigs generated using the Roche 454 sequencing platform (Chapter 5) 
to determine whether any of the sequences exhibiting increased expression in MOTRI also 
exhibited an altered expression profile following in vitro IVM exposure of the MOTRI 
isolate.  Once the top BLAST hit (or hits if more than 1 shared the top E score) was 
determined, the identity of the cluster containing that contig was made and the number of 
exposed and unexposed reads in that cluster determined by searching the cluster database 
generated in Chapter 5.  Table 6.3 shows the results of this analysis; from this it is possible 
to see that the E scores for the BLAST searches of SSH 3, 8, 15, 16, 21, 22, 24 and 27 
against the 454 dataset were very poor and so these SSH sequences are not discussed 
further.  The identities for the top BLAST cluster hit in the 454 dataset for the remaining 
SSH contigs was generally very similar to the BLAST hits generated when searching the 
SSH nucleotide sequences against the EBI and NCBI databases.  The exception to this was 
SSH7, which did not align to a HSP as the top 454 cluster BLAST hit; however, other 
clusters  with  similar  E  scores  to  the  top  cluster  BLAST  hit  were  identified  as  HSPs.  
SSH14, when BLAST searched against the 454 dataset, aligned most closely to cluster 
538, which was one of the 16 clusters in Chapter 5 with a statistically significant difference 
in gene expression in exposed and unexposed reads in the conservative statistical model.  
The results for this gene indicate that it exhibits both inducibly and constitutively increased 
expression in response to IVM.  SSH 5, 6, 10 and 23 aligned most closely to clusters in the 
454 dataset which were statistically significant under the liberal statistical model (clusters 
464, 674, 2274 and 494, respectively), indicating that the genes represented by these SSH 
sequences could exhibit constitutive and, potentially, inducible differences in expression in 195 
response to IVM.  However, despite all SSH sequences showing increased expression in 
MOTRI compared to CVL, 2 (SSH 6 and 10) showed decreased numbers of exposed reads 
compared to unexposed reads in the Roche 454 dataset.   Of the remaining SSH sequences, 
13 (SSH 1, 2, 4, 7, 11, 12, 17, 18, 19, 20, 25, 26 and 28) had top BLAST identities of 
clusters exhibiting non statistically significant increases in number of exposed compared to 
unexposed  reads  whilst  1  top  cluster  BLAST  identity  (SSH13)  showed  no  change  in 
number  of  reads  and  a  further  1  top  cluster  BLAST  identity  (SSH9)  showed  a  non 
statistically significant decrease in number of exposed compared to unexposed reads.   
 
6.4: Discussion 
The SSH method has identified a panel of 28 sequences exhibiting constitutively 
increased expression in the MOTRI T. circumcincta isolate compared to the CVL isolate.  
BLAST searches in both EBI and NCBI have given putative identities for these sequences.  
In some cases, more than one sequence had the same BLAST identity (e.g. SSH 4 and 7), 
this could be an artefact of the SSH process; cDNA is digested using Rsa I so the two 
sequences may be non-overlapping parts of the same gene.  However, Rsa I digestion is 
recommended as longer cDNA fragments may not hybridise as effectively and smaller 
cDNA  fragments  also  provide  a  better  representation  of  the  genes  (Diatchenko  et  al., 
1996).    The  sequence  generated  was  BLAST  searched  against  the  454  datasets  also 
generated in this thesis (Chapter 5) to determine whether any constitutive changes in gene 
expression between MOTRI and CVL T. circumcincta adults were mirrored by inducible 
changes  in  expression  as  determined  by  the  statistical  analysis  of  the  454  dataset.  
Encouragingly, many of the SSH sequences aligned very closely to sequences generated 
using the 454 sequencing platform, suggesting (particularly in the cases of SSH 5, 6, 10, 14 
and  23,  which  aligned  most  closely  to  clusters  identified  as  exhibiting  statistically 
significant differences in the 454 dataset) that both inducible and constitutive changes in 
gene  expression  could  play  a  role  in  the  IVM-resistance  phenotype  in  MOTRI  T. 
circumcincta.  Unfortunately, the function of SSH14 (and cluster 538) is not known and, 
due to the significance in the change observed in the 454 study, alongside the current 
observation,  this  gene  (and  others  identified  in  this  SSH  work)  could  merit  further 
investigation to determine the role its expression plays in the IVM-resistant phenotype in 
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The accuracy of the SSH results was confirmed using semi-quantitative PCR, this 
is  an  important  step  because,  if  the  tester  and  driver  samples  are  very  similar  (as  is 
potentially the case when comparing two adult stage T. circumcincta isolates), the SSH 
technique is  more prone to  generating false positives (where  a sequence is  selectively 
subtracted despite being present in equal proportions in both the tester and driver samples).  
The  results  for  SSH  3,  4,  6,  7  and  12  were  all  confirmed  by  semi-quantitative  PCR.  
Unfortunately,  amplification  of  SSH17  failed  despite  using  the  Rsa  I-digested  cDNA, 
which had already been amplified as part of the SSH protocol and, therefore, should have 
been enriched for rare transcripts.  Confirmation of the differential expression of SSH17 is 
still required.  The confirmatory results for SSH 3, 4, 6, 7 and 12 suggests that the other 
gene changes here may also be reliable, however, these results would have to be confirmed 
by real-time or semi-quantitative PCR before any further conclusions are made.  These 
genes were chosen for semi-quantitative PCR partially based on their BLAST identities 
and merit further discussion.   
 
SSH 4, 7 and 12 had BLAST identities of HSPs; these are a large gene family 
present in a range of species, including parasitic nematodes.  HSPs are believed to act as 
molecular chaperones, binding and stabilising proteins during folding, assembly, transport 
across  membranes  and  degradation  (Vercauteren  et  al.,  2006).    HSPs  are  both 
constitutively expressed in a range of life-cycle stages and induced in response to heat 
shock and exposure to heavy metals, organic compounds and oxidants (Hartman et al., 
2003; Vercauteren et al., 2006).  Constitutively increased expression of these genes in a T. 
circumcincta  isolate  resistant  to  IVM  could  enable  these  parasites  to  more  efficiently 
manufacture  and  transport  other  proteins  required  to  metabolise  and  handle  the 
anthelmintics.  Alternatively, it could be indicative of a generalised up-regulation of genes 
associated with the parasite‟s stress response, a preconditioning of the resistant parasites 
enabling them to cope with the anthelmintics more easily and rapidly. 
 
SSH3 was also chosen for confirmation of the SSH result with semi-quantitative 
PCR because of its apparent homology with an intermediate chain 1 axonemal dynein; 
however, this identity needs to be used cautiously due to the low E score of the NCBI 
BLAST hit and also because the best EBI and 454 dataset BLAST hits did not support this 197 
BLAST identity.  However, dynein may have a role to play in the IVM-resistant phenotype 
and, as such, merits further discussion.   Dynein has been shown to be required for the 
correct structure and function of amphidial neurones which are located on either side of the 
pharynx in nematodes (Wicks et al., 2000; Freeman et al., 2003).   Mutations in dynein 
genes, such as CHE-3, have caused disruption in the structure of these amphidial neurones 
leading to disrupted chemotaxis and reduced uptake of lipophilic dyes (Wicks et al., 2000; 
Freeman et al., 2003; Bisset, 2007).   IVM is a lipophilic drug and disrupted amphidial 
neurones have been associated with IVM-resistant isolates in C. elegans and H. contortus, 
however, this phenomenon appears to be more associated with cytoplasmic dynein rather 
than axonemal dynein (the BLAST identity of SSH3), which appears to have a role in the 
beating of flagella and cilia (Wicks et al., 2000; Freeman et al., 2003; Lespine et al., 2007; 
Bisset, 2007).   
 
Six cysteine (SXC) motif-containing genes (the putative BLAST identity of SSH6) 
are short amino acid sequences with six conserved potentially disulphide-bonded cysteines.  
SXCs  are  suggested  to  act  as  signalling  ligands  or  are  involved  in  protein-protein 
interactions (Blaxter, 1998; De Maere et al., 2002).  They can exist in several forms, as 
genes containing only the SXC motif, as mucin-like genes or with an enzymatic domain 
flanked  by  SXC  motifs.    Those  with  enzymatic  domains  have  been  identified  as 
tyrosinases, myeloperoxidases and astacin-like zinc metalloproteases (Blaxter, 1998; De 
Maere et al., 2002).  SXC genes were first identified in Toxocara canis in surface coat 
proteins and are part of the small secreted protein class; as such they are seen as a potential 
vaccine  candidate  (Daub  et  al., 2000;  De Maere et  al., 2002).  Why  IVM-resistant  T. 
circumcincta adults exhibit constitutively increased expression of an O. ostertagi SXC1 
homologue is not clear but, like the HSPs, this observation could be linked to the role of 
SXC1 in protein interactions and signalling pathways, allowing the parasites to respond 
more rapidly to IVM exposure. 
 
Finally, cathepsin B (the putative identity of SSH17) is a peptidase and part of the 
C1 family of the CA clan of cysteine proteases (Ranjit et al., 2008; Atkinson, Babbitt, & 
Sajid, 2009).  The functions of cysteine proteases include protein processing and turnover, 
degradation  of  host  protein  (for  example,  extracellular  dermal  matrix  during  skin 198 
penetration  by  Necator  americanus),  hydrolysis  of  haemoglobin  (particularly  in  blood 
feeders like H. contortus and N. americanus) and inhibition of the host protective immune 
responses (Ranjit et al., 2008).  Nisbet et al (2008) identified a cathepsin B-like sequence 
which was highly represented in the L4-specific SSH dataset, whilst immunoscreening of a 
H. contortus  cDNA expression library  with  the protective S3 TSBP fraction identified 
three cathepsin B homologues which localised to the gut microvilli (Skuce et al., 1999).  
Like the SXC genes, cathepsin B molecules are seen as good potential vaccine targets 
(Knox  &  Smith,  2001;  Ranjit  et  al.,  2008).    Again,  why  genes  with  potentially 
immunogenic  and  protein  interaction  roles  exhibit  increased  expression  in  the  IVM-
resistant MOTRI isolate is  not  clear but  potentially  could  be a  result of a  generalised 
increase in the turnover of all proteins enabling the parasites to cope better with IVM 
exposure.   
 
Greater depth, and potential accuracy of the sequences generated could have been 
achieved  through  re-sequencing  of  the  forty  selected  clones,  whilst  selecting  further 
colonies from the plates or repeated cloning of the SSH PCR product could have enabled 
the  identification  of  further  sequences  exhibiting  increased  expression  in  the  MOTRI 
isolate compared to the CVL isolate.  However, the amount of novel sequence generated 
would have become increasingly small as more sequencing was carried out.  As a result, 
the number of sequences selected was capped at forty.  In comparison, a two-way SSH 
experiment looking at differential gene expression between xL3 and L4 T. circumcincta 
generated 361 and 472 unique sequences, respectively (Nisbet et al., 2008).  This result 
illustrates the scale of gene expression changes associated with the transition from the free-
living xL3 stage to the parasitic L4 stage (Nisbet et al., 2008), in comparison with the more 
subtle gene expression changes associated with an IVM resistance phenotype in the adult 
stage.   
 
One of the challenges  in  making comparisons between different  isolates of the 
same species of parasite which have been identified from different geographical regions is 
proving whether any differences observed are due to the different genetic backgrounds of 
the isolates or are due to the differences in their drug resistance status.  The effective size 
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determines  the  population  genetic  structure  (Blouin  et  al.,  1995).    Population  genetic 
studies of T. circumcincta, using mitochondrial sequence data and microsatellite markers, 
have indicated that the majority of genetic diversity in T. circumcincta is found within the 
populations  rather  than  between  populations  (Blouin  et  al.,  1995;  Grillo  et  al.,  2007).  
Animal movement  determines,  to  a certain  extent,  how much gene flow occurs  in  the 
parasite population they harbour and is seen as a major risk factor in the development and 
spread of anthelmintic resistance in the UK (Skuce et al., 2010).  The population genetic 
structure of T. circumcincta suggests that the comparison of different isolates, not sharing a 
common genetic background, is scientifically valid.  As such, identifying constitutively 
expressed  differences  between  the  MOTRI  and  CVL  isolates,  utilising  the  “non-
hypothesis” driven SSH approach, has enabled the identification of 28 gene fragments 
which  could  form  the  basis  of  further  investigations  into  how  IVM  resistant  T. 
circumcincta is able to survive anthelmintic exposure.   
 
These  results  could  be  investigated  further,  through  increasing  the  amount  of 
sequence generated from this SSH experiment or by carrying out the SSH experiment in 
the opposite direction (CVL as  the tester and  MOTRI  as  the driver) to  identify  genes 
exhibiting  constitutive  decreased  expression  in  the  IVM-resistant  MOTRI  isolate.  
Utilising the real-time PCR approach, as used for the candidate resistance genes, the Pgps 
and CYPs, in Chapter 4, could provide relative quantification of the expression of the panel 
of 28 sequences identified in this chapter in MOTRI.  The close homology of some of the 
sequences  identified  in  this  SSH  dataset  with  sequences  generated  using  the  454 
sequencing  approach  also  indicates  that  the  “non-hypothesis”  driven  approach  is  a 
worthwhile addition to understanding the role of gene expression in IVM resistance.  The 
SSH genes also exhibiting statistically significant changes in inducible gene expression 
(SSH 5, 6, 10, 14 and 23) would be the priority for any future studies.   
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Table 6.1: Primers used to amplify T. circumcincta SSH products from the Rsa I digested cDNA. 
Primer 
name 
Primer 
direction 
Sequence  Melting 
temp (ºC) 
Target  Expected size of 
PCR product (bp) 
SSH3 For  Sense  CTA CTC CGA TGC CGT TAG GA  59.4 
SSH3  127 
SSH3 Rev  Antisense  TCC AGA TCG GGA CAA TTG AG  57.3 
SSH4 For  Sense  TTT TCT GGT AGG GTC CAT CG  57.3 
SSH4   202 
SSH4 Rev  Antisense  AAG CGC TAA GCG GAC AAT TA  55.3 
SSH6 For  Sense  CAG TGG CAA CCG GTA ACA AT  57.3 
SSH6  191 
SSH6 Rev  Antisense  CAA TTA GCC TTC GCA AGA CC  57.3 
SSH7 For  Sense  TGG ATT GGG ATG GTT CTA GC  57.3 
SSH7  200 
SSH7 Rev  Antisense  GGC CAA ATC CTT ACC ATT GA  55.3 
SSH12 For  Sense  CAA GCA GGA GCA CAA AAC TG  57.3 
SSH12  194 
SSH12 Rev  Antisense  TCT GTG GAG CAG CCA CTA TG  59.4 
SSH17 For  Sense  CAA TGG CTC GAC CGT TAG TG  59.4 
SSH17  191 
SSH17 Rev  Antisense  GAC GGC AGC AGT CCT TTT TA  57.3 
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Table 6.2: Results of cloning and sequencing of the PCR product generated from a one-way suppressive subtractive hybridisation of CVL from MOTRI T. circumcincta adults.   
Contig 
name 
Contig 
length 
(bp) 
No. 
seqs 
Best EBI BLAST hit  EMBL  acc 
no. 
E score  Best NCBI tBLASTx hit  NCBI acc no.  E Score 
SSH1  322  1 
Ostertagia ostertagi L4 pAMP1 v1 
cDNA 5' similar to SW:KAG1_CAEEL 
Q10454 probable arginine kinase 
BM896907   1.4e-60  
Caenorhabditis briggsae 
Hypothetical protein CBG11000  XM_002644962.1  7E-63 
SSH2  302  2 
Necator americanus L3 cDNA clone 
Na_L3_40B03 5' similar to F57B10.3 
CE11302 phosphoglycerate mutase 
status 
BU666597    1.20E-36 
Brugia malayi 2,3-
bisphosphoglycerate-independent 
phosphoglycerate mutase partial 
mRNA 
XM_001892376.1  2E-52 
SSH3  215  3 
Steinernema feltiae IS6 - desiccation 
stress related ESTs cDNA clone S24-3   BQ579856   1.00E-08 
Predicted: Taeniopygia guttata 
similar to dynein, axonemal, 
intermediate chain 1 
XM_002189680.1  1.1 
SSH4  679  4 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_32D04 5' similar 
to P06582 Heat shock protein HSP16-2. 
Caenorhabditis elegans 
CB037306   2.00E-89 
Angiostrongylus cantonensis 
mRNA for putative Heat Shock 
Protein (hsp-16.1b)  FM207717.1  7E-24 
SSH5  401  2 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_24G11 5' similar 
to O62337 R06C1.4 protein. 
Caenorhabditis elegans 
CB036677   2.80E-45 
Caenorhabditis briggsae 
Hypothetical protein CBG18692  XM_002640484.1  3E-22 
SSH6  296  1 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_36B08 5' similar 
to Q9GNW3 SXC1 protein Ostertagia 
ostertagi 
CB037620   4.00E-53 
Ostertagia ostertagi partial 
mRNA for SXC1 protein  AJ302944.1  1E-13 
SSH7  430  1 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_32F06 5' similar 
to P06582 Heat shock protein HSP16-2. 
Caenorhabditis elegans 
CB037332   7.2e-44  
Angiostrongylus cantonensis 
mRNA for putative Heat Shock 
Protein (hsp-16.1b gene)  FM207717.1  9E-11 202 
Contig 
name 
Contig 
length 
(bp) 
No. 
seqs 
Best EBI BLAST hit  EMBL  acc 
no. 
E score  Best NCBI tBLASTx hit  NCBI acc no.  E Score 
SSH8  429  1 
Brugia malayi L3 subtracted cDNA 
library clone SWBmL3SA163  AA933193   0.21 
Brugia malayi 
Phosphatidylinositol 3- and 4-
kinase family protein partial 
mRNA 
XM_001901052.1  7E-54 
SSH9  452  1 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_50B08 5'  CB038796   1.8e-91  
Drosophila mojavensis GI14783 
mRNA  XM_002010235.1  0.00001 
SSH10  449  1 
Strongyloides ratti L2 pAMP1 v1 
Chiapelli McCarter cDNA 5' similar to 
60S acidic ribosomal protein P1 
BI073294   7.20E-09 
Streptococcus equi subsp. equi 
4047, complete genome  FM204883.1  0.8 
SSH11  462  1 
Pristionchus pacificus mixed stage SL2b 
TOPO cDNA 5'  CN656930    1.40E-07 
Homo sapiens 3 BAC RP11-
143P4 (Roswell Park Cancer 
Institute Human BAC Library) 
complete sequence 
AC092966.6  0.09 
SSH12  536  1 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_44E08 5' similar 
to Q07160 Heat shock protein homolog 
(HSP20) Nippostrongylus  
CB038331   1.1e-82  
Ostertagia ostertagi mRNA for 
heat shock protein 20  AJ310811.2  1E-42 
SSH13  597  1 
Caenorhabditis briggsae mRNA for 
cyclophilin 4 isoform   AJ004826   1.7e-46  
Caenorhabditis elegans 
cyclophilin MOG-6  AF421146.1  9E-76 
SSH14  485  2 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_02B09 5' similar 
to AAB81938.1 non-functional folate 
binding protein - Homo sapiens 
BM052010   1.2e-97  
Trichostrongylus colubriformis 
18S rRNA gene  AJ920350.1  2E-85 
SSH15  423  1 
Teladorsagia circumcincta L3 library 
cDNA clone Tc_L3_18A02 5' similar to 
T27E9.2 CE14265 ubiquinol-
cytochrome c reductase complex 
CB035418   2.4e-52  
Caenorhabditis elegans 
hypothetical protein (T27E9.2)  NM_067380.3  2E-23 203 
Contig 
name 
Contig 
length 
(bp) 
No. 
seqs 
Best EBI BLAST hit  EMBL  acc 
no. 
E score  Best NCBI tBLASTx hit  NCBI acc no.  E Score 
SSH16  248  1 
Caenorhabditis briggsae contig 
cb25.fpc2220   CAAC0100
0044   0.94 
Pig DNA sequence from clone 
CH242-240L11 on chromosome 
13 
CU468995.15  2.1 
SSH17  248  1 
Ostertagia ostertagi partial mRNA for 
putative cathepsin B.4 (catB.4 gene)   AJ296147   6.10E-21 
Ostertagia ostertagi partial 
mRNA for cathepsin B.2  AJ401373.2  1.00E-36 
SSH18  300  1 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_29H04 5'  CB037096   1.80E-58 
Teladorsagia circumcincta 
mitochondrion  GQ888720.1  2.00E-41 
SSH19  303  1 
Teladorsagia circumcincta adults library 
2 cDNA clone Tc_ad2_40H03 5' similar 
to P53014 Myosin, essential light chain 
CB038013   1.5e-60  
Caenorhabditis briggsae CBR-
MLC-3 protein  XM_002646977.1  4.00E-43 
SSH20  263  1 
Nippostrongylus brasiliensis uni-zap 
adult library cDNA clone 
Nb_ad1_06A11 5' 
BM279355   9.90E-28 
Teladorsagia circumcincta 
mitochondrion  GQ888720.1  7.00E-33 
SSH21  521  1 
Caenorhabditis briggsae contig 
cb25.fpc0091 
CAAC0100
0022   1.6e-10  
Caenorhabditis briggsae CBR-
MIG-1 protein  XM_002638736.1  2.00E-57 
SSH22  489  1 
Teladorsagia circumcincta L4 library 
cDNA clone Tc_L4_18E09 5',  CB043721   7.0e-33  
Hirschia baltica ATCC 49814 
CP001678.1  0.26 
SSH23  409  1 
Haemonchus contortus cDNA clone 
Hc_ad_41B01 5',  CB012573   7.4e-12  
Dictyostelium discoideum AX4 
actin binding protein  XM_641035.1  8.00E-06 
SSH24  742  1 
Ostertagia ostertagi L4 SL1 TOPO v1 
cDNA similar to keratins in a glycine-
rich region 
BQ100330   7.5e-78  
Ostertagia ostertagi partial 
mRNA for keratin  AJ429146.1   5.00E-56 
SSH25  656  1 
Ostertagia ostertagi L3 SL1 TOPO v2 
cDNA 5' similar to SW:RHOA_CAEEL 
Q22038 RAS-like GTP-binding protein 
RHOA 
BQ625968   7.4e-50  
Caenorhabditis briggsae CBR-
RHO-1 protein  XM_002632397.1  3.00E-20 204 
Contig 
name 
Contig 
length 
(bp) 
No. 
seqs 
Best EBI BLAST hit  EMBL  acc 
no. 
E score  Best NCBI tBLASTx hit  NCBI acc no.  E Score 
SSH26  241  2 
Haemonchus contortus cDNA clone 
Hc_L4_24H05 5' similar to F28D1.7 
CE05747 locus:rps-23 ribosomal protein 
S23 
CA994729   2.20E-47 
Caenorhabditis elegans 
Ribosomal Protein, Small subunit 
family  NM_069964.4  4.00E-32 
SSH27  295  2 
Meloidogyne chitwoodi female SL1 
pGEM cDNA 5' contains PTR5 
repetitive element 
CF801743   3.50E-06 
Mus musculus BAC clone RP23-
377L13 from chromosome 17  AC134908.5  1.7 
SSH28  231  1 
Haemonchus contortus cDNA clone 
Hc_L4_02B08 5' similar to 
NP_001021.1 ribosomal protein S27 
(metallopanstimulin 1) 
BF186770   9.30E-44 
Ancylostoma duodenale ribosomal 
protein S27e mRNA  EF490130.1   3.00E-27 
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Table 6.3: Table showing the top BLAST cluster hits when the nucleotide sequences for each of the SSH contigs was BLAST searched against the contigs generated in the Roche 454 
sequence analysis (Chapter 5).  ∞ represents an E score where the value was so small it registered as 0.00 (to 2 decimal places).  The change in cluster reads indicates whether there 
were more unexposed (-) or exposed (+) or equal (=) reads in the cluster, whilst the statistical significance indicates whether the change in number of reads in that cluster was 
statistically significant under the conservative statistical model (1), statistically significant under the liberal statistical model (2) or not statistically significant under either statistical 
model (3).  If more than one cluster has an identical E score as the best BLAST hit for a particular SSH sequence, then all the clusters with that E score are shown.   
SSH 
sequence 
Best BLAST 
hit (Cluster 
number) 
E score  NCBI Cluster best BLAST hit  Change in 
cluster 
reads 
Statistical 
significance 
SSH1  215  ∞  Hypothetical protein F46H5.3 Caenorhabditis elegans  +  3 
SSH2  1007  e^-115  Independent phosphoglycerate mutase Onchocerca volvulus  +  3 
SSH3  634  0.84  S60004 hypothetical protein  - common roundworm retrotransposon 
R4 
+  3 
SSH4  680  e^-123  Heat shock protein 20 Haemonchus contortus  +  3 
SSH5  464  e^-177  Hypothetical protein CBG18692 Caenorhabditis briggsae AF16  +  2 
SSH6  674  e^-104  SXC1 protein Ostertagia ostertagi  -  2 
SSH7  110  e^-128  Hypothetical protein CBG18371 Caenorhabditis briggsae AF16  +  3 
SSH8 
1756  1.70  No hits found  +  3 
1720  1.70  Hypothetical protein Bm1_02090 Brugia malayi  +  3 
918  1.70  eXPOrtin (nuclear export receptor) family member (xpo-1)  +  2 
SSH9  575  ∞  GH24252 Drosophila grimshawi  -  3 
SSH10  2274  e^-109  No hits found  -  2 
SSH11  136  e^-124  Hypothetical protein TGME49_048900 Toxoplasma gondii  +  3 
SSH12  131  e^-148  Heat shock protein 20 Ostertagia ostertagi  +  3 
SSH13  152  e^-130  CYclophyliN family member (cyn-4) Caenorhabditis elegans  =  3 
SSH14  538  ∞  Hypothetical protein Bm1_17870 Brugia malayi  +  1 
SSH15  537  0.43  Pre-mRNA cleavage complex II protein Clp1 Brugia malayi  +  2 
SSH16  369  0.25  Hypothetical protein F40A3.3 Caenorhabditis elegans  +  3 
SSH17  201  8e^-60  Cathepsin B-like cysteine proteinase 1  +  3 
SSH18  10  8e^-39  NADH dehydrogenase subu3t 4L Necator americanus  +  3 206 
SSH 
sequence 
Best BLAST 
hit (Cluster 
number) 
E score  NCBI Cluster best BLAST hit  Change in 
cluster 
reads 
Statistical 
significance 
SSH19  88  e^-147  C. briggsae CBR-MLC-3 protein Caenorhabditis briggsae  +  3 
SSH20  10  4e^-28  NADH dehydrogenase subunit 4L Necator americanus  +  3 
SSH21 
121  0.14  Putative zinc metallopeptidase precursor; MEP1b Haemonchus  -  3 
654  0.14  Hypothetical protein CBG20630 Caenorhabditis briggsae AF16  -  3 
SSH22 
2140  0.50  Integrin alpha cytoplasmic region family protein Brugia malayi  -  3 
349  0.50  No hits found  -  3 
SSH23  494  ∞  No hits found  +  2 
SSH24 
100  0.77  Hypothetical protein CBG03794 Caenorhabditis briggsae AF16  +  3 
114  0.77  Hypothetical protein Y66H1B.2 Caenorhabditis elegans  +  3 
SSH25  1160  ∞  RAS-like GTP-binding protein RhoA Brugia malayi  +  3 
SSH26  1649  e^-117  Ribosomal Protein, Small subunit family member (rps-23)  +  3 
SSH27 
399  1.20  Hypothetical protein CBG22942 Caenorhabditis briggsae AF16  +  3 
1744  1.20  No hits found  +  3 
768  1.20  Hypothetical protein Plasmodium yoelii yoelii str. 17XNL  +  3 
SSH28  391  e^-123  Ribosomal protein S27e Ancylostoma duodenale  +  3 207 
 
Figure 6.1: Diagram showing the steps involved in the subtraction reaction. cDNA 1 (tester) was MOTRI and 
cDNA  2  (driver)  was  T.  circumcincta  CVL.    Both  the  driver  and  tester  cDNA  was  Rsa  I  digested,  as 
described in Section 6.2.3 prior to the subtraction experiment.  Diagram modified from the BD PCR-select
™ 
cDNA subtraction kit user manual (http://www.clontech.com/images/pt/PT1117-1.pdf). 208 
 
Figure 6.2: 1% agarose gel electrophoresis of semi-quantitative PCR products for SSHs 3, 4, 6, 7, 12 and 17 against the T. circumcincta CVL (C) or MOTRI (M) isolate.  5µL PCR 
product was removed after 15, 20, 25, 30 and (for SSHs 6, 7, 12 and 17) 35 cycles.  A negative control (-) was included for each gene and the gel marker lane (Mx) containing TrackIt
™ 
1Kb Plus DNA Ladder (Invitrogen) is on the left. 209 
Chapter 7: General Discussion and Conclusions 
  This  study  examined  the  potential  role  of  changes  in  gene  expression  in  the 
anthelmintic  resistant  phenotype  of  T.  circumcincta,  particularly  in  relation  to  IVM 
resistance.  To understand the role of gene expression in the IVM-resistance phenotype of 
T. circumcincta, a range of experimental approaches were employed.  Identification of the 
expression profile of “candidate resistance” genes potentially involved in drug handling 
and  metabolism  in  different  isolates  of  T.  circumcincta,  both  IVM-resistant  and  –
susceptible, and IVM-exposed and -unexposed, was carried out using semi-quantitative 
and real-time PCR as described in Chapters 3 and 4, respectively.  Alongside this, two 
further experiments were carried out, as described in Chapters 5 and 6, utilising the Roche 
454 sequencing platform to investigate the expression of genes following in vitro IVM 
exposure,  and  SSH  to  identify  genes  with  constitutively  increased  expression  in  the 
MOTRI isolate compared to the CVL isolate.  These two approaches were termed “non-
hypothesis” driven as neither technique attempted to focus on particular genes prior to 
carrying out the experiments.   
 
Anthelmintics are the mainstay of modern parasitic nematode control and, in some 
areas  of  the  world,  the  levels  of  resistance  to  the  BZs,  LEVs  and  MLs  exhibited  by 
endoparasites of small ruminants is so high that economically viable farming is becoming 
impossible (Jackson & Coop, 2000; Sargison et al., 2005; Blake & Coles, 2007).  In the 
UK, BZ resistance is widespread, ML resistance is becoming increasingly common and 
MDR  parasite  isolates  are  being  reported  (Bartley  et  al.,  2003;  Bartley  et  al.,  2006; 
Sargison et al., 2007b).  No routine surveillance is carried out, so the levels of resistance 
exhibited by T. circumcincta, the predominant parasitic nematode species on UK farms, to 
the different  classes  of  anthelmintics  is  not  known  (Sargison,  Scott,  &  Jackson,  2001; 
Bartley et al., 2003).  The detection of resistance is problematic; current diagnostic tests, 
using in vivo and in vitro methods such as the FECRT, EHT and LFIT, can be time-
consuming, expensive and lacking in sensitivity (Coles et al., 1992; McKellar & Jackson, 
2004).    Alongside  this,  the  modes  of  action  of  the  anthelmintics  and  mechanisms  of 
resistance employed by the parasites they target are still not fully understood, as described 
in Chapter 1.  Naturally, the genes believed to be the targets of the anthelmintics have been 
prioritised  for  candidate  gene  studies  investigating  the  mechanisms  of  anthelmintic 210 
resistance.  However, to date, this approach has not been very successful and, in the case of 
IVM, has failed to identify any SNPs or mutations conclusively linked to resistance.  As 
such,  it  was  decided  that  alternative  mechanisms  of  resistance  were  worthy  of 
investigation.  One alternative mechanism of resistance could be changes in the expression 
of genes,  for example,  generic drug handling  mechanisms  allowing  T. circumcincta  to 
survive  exposure  to  IVM.    These  changes  would  still  have  a  genetic  basis,  which,  if 
identified, could be developed into a molecular-based test for diagnosis of IVM resistance 
in parasitic nematodes.  Genetic tests have advantages over the current, commonly used, 
diagnostic  tests,  being  quicker  and  easier  to  perform,  more  sensitive  and  able  to  be 
developed into high-throughput formats (von Samson-Himmelstjerna, 2006; von Samson-
Himmelstjerna  et  al., 2009a).  Molecular markers for ML resistance,  developed into a 
diagnostic test, would enable the spread of anthelmintic resistance to be monitored more 
easily and allow the development of management practices such as the TST approach, 
which could  reduce the inevitable spread of anthelmintic resistance, to  be investigated 
more thoroughly (Kenyon et al., 2009b).   
 
  In the first series of experiments, described in Chapters 3 and 4, two families of 
genes in T. circumcincta were investigated; the Pgps and CYPs.  These were chosen for 
investigation due to their possible roles in drug transport and metabolism:  Pgps are large 
transmembrane proteins which transport a range of hydrophobic molecules into and out of 
cells (Valverde et al., 1992; Kerboeuf et al., 2003).  Pgps have been implicated in drug 
resistance in human immunodeficiency viruses, malaria parasites and cancerous tumours 
whilst, in parasitic nematodes, a range of experiments have shown that changes in mRNA 
levels and allele frequencies occur in parasites in response to IVM selection and that co-
administration  of  Pgp  inhibitors  with  IVM  can  increase  the  efficacy  of  IVM  against 
phenotypically IVM-resistant parasites isolates (Beugnet, Gauthey, & Kerboeuf, 1997; Xu 
et al., 1998; Blackhall et al., 1998b; Loo & Clarke, 1999; Jones & George, 2005; Ardelli, 
Guerriero,  &  Prichard,  2006b).    However,  the  majority  of  work  on  Pgps  in  parasitic 
nematodes has focused on H. contortus and O. volvulus, no work on the role of Pgps in the 
anthelmintic  resistant  phenotype  in  T.  circumcincta  has  been  found  in  peer-reviewed 
journals  to  date.    Investigations  into  the  role  of  Pgps  in  anthelmintic  resistance  in  T. 
circumcincta  may  be  hampered  by  the  lack  of  genomic  sequence  for  this  species  in 
publically available databases.  In Chapter 3 of this thesis, eleven novel partial Pgp gene 211 
sequences from T. circumcincta were identified, eight of which appear to align to NBD1 
indicating that there are at least eight Pgp genes in T. circumcincta.  This is similar to what 
has been identified in other nematode species; for example, in O. volvulus at least 2 Pgp 
genes have been identified, at least 12 from H. contortus and 15 from C. elegans (Huang & 
Prichard,  1999;  Sangster  et  al.,  1999a;  Sheps  et  al.,  2004).    Alignment  of  the  T. 
circumcincta  Pgp  sequences  against  the  C.  elegans  Pgp  sequences  was  carried  out  to 
determine the correct nomenclature for these genes, as suggested in the guidelines on the 
Caenorhabditis  Genetics  Centre  website  (http://www.cbs.umn.edu/CGC/nomenclature/ 
index.html).  
 
Eukaryotic CYPs are single domain  membrane-bound proteins  that catalyse the 
metabolism of a range of predominantly hydrophobic molecules, such as IVM (Mansuy, 
1998; Graham & Peterson, 1999).  Like the Pgps, the CYPs appear to play a role in drug 
resistance,  as  over-expression  of  CYPs  or  increased  CYP  activity  has  been  shown  to 
correlate with insecticide resistance in Drosophila spp, An. gambiae, and C. p. pallens and 
chloroquine resistance in P. falciparum and P. berghei (Ndifor, Ward, & Howells, 1990; 
Daborn et al., 2002; Vontas et al., 2005; Gong et al., 2005).  In parasitic nematodes, there 
is some evidence that CYPs play a role in anthelmintic resistance, however, CYP activity 
in parasitic nematodes appears to be difficult to measure (Barrett, 1998).  The use of CYP 
inhibitors, such as piperonyl butoxide, ketoconazole and metyrapone has been shown to 
improve the efficacy of the BZs (Kotze, 1997; McKellar & Jackson, 2004; Bartley et al., 
2009; Virkel et al., 2009).  Changes in “non-specific” drug transport affecting one drug 
class could also have an effect with another drug class.  In Chapter 3, three novel CYPs 
were  identified  from  T.  circumcincta,  using  both  degenerate  PCR  and  bioinformatic 
approaches.  Assigning the correct nomenclature to these partial genes was not attempted; 
the  CYP  superfamily  is  very  large  and  the  naming  of  any  newly  discovered  CYPs  is 
carried out through the P450 Nomenclature Committee, following the recommendations in 
Nelson et al. (1996), and also requires full length gene sequences. 
 
  The first step in determining whether any of the genes identified in Chapter 3 could 
play a role in an IVM-resistant phenotype in T. circumcincta involved the design of semi-
quantitative  PCR  assays.    Validation  of  the  assays  for  PGPs  2  (subsequently  named 212 
TeciPgp-2 NBD2), 3, 5 (subsequently named TeciPgp-2 NBD1), 6 (subsequently named 
TeciPgp-9 NBD2), 7 and 9 and CYPs 1, 2 and 3 were successful.  The results of the PCRs, 
comparing the expression of these genes in the egg, L1, xL3, L4 and adult stages of the 
CVL and MOTRI T. circumcincta isolates, indicated that there were differences in the 
expression levels of some of these genes between the isolates (Figures 3.3 and 3.13).  As a 
result, it was decided that quantifying the expression of the 11 Pgp and 3 CYP genes using 
real-time PCR would give a more accurate result compared to the semi-quantitative PCR 
approach; analysis of the real-time results would determine what changes in expression 
were statistically significant, something that was not possible using semi-quantitative PCR.  
Smaller changes in expression are more easily quantified using real-time PCR compared to 
identifying changes in the intensity of bands on agarose gels; real-time PCR is also faster 
to perform than standard PCR (Pfaffl, 2001; Bustin et al., 2009).   
 
  Using  the  relative  quantitative,  or  ʔʔCt,  real-time  PCR  method,  the  relative 
expression of PGP1, TeciPgp-2 NBD2, PGP3, TeciPgp-2 NBD1, TeciPgp-9 NBD2, PGP7, 
PGP8, PGP9, PGP10, PGP11, CYP1, CYP2 and CYP3 was determined in several isolates 
and following exposure of some of these isolates to IVM in vitro and in vivo.  One concern 
when comparing isolates which do not share a common genetic background (e.g. CVL and 
MOTRI) was that any differences in expression found are a result of the inherent genetic 
variability between the isolates.  However, population genetic studies of T. circumcincta 
have indicated that the majority of genetic diversity occurs within subpopulations rather 
than between subpopulations (Blouin et al., 1995; Grillo et al., 2007).  Comparing the actin 
control gene Ct values for the different isolate and life-cycle stages (Figure 4.3) indicated 
that, with the exception of the MOTRI L4 and Post IVM MOTRI L4 comparison, the actin 
Ct values were sufficiently similar between isolates to allow valid comparisons of the test 
genes.  Likewise, comparing the actin Ct values between the different life-cycle stages also 
indicated that comparing expression of the test genes between life-cycle stages was not 
feasible; normalisation of the test gene Ct values with the actin Ct values would not give 
accurate  results.    However,  although  academically  interesting,  determining  the  relative 
expression of the 3 CYP and 10 validated Pgp genes between life-cycle stages was not part 
of this work.  In future experiments, a different approach to normalising the Pgp and CYP 
expression levels would be recommended.  The GeNorm approach starts with a panel of 
reference  genes  from  which  the  two  most  stably  expressed  genes  are  selected.    This 213 
approach, which has only relatively recently been adopted as the “gold-standard” method, 
assumes that stably transcribed genes stay in a constant ratio to each other and provide a 
better baseline to normalise the test gene expression with  (Van Zeveren et al., 2007b; 
Strube et al., 2008; Bustin et al., 2009). 
 
In  the  first  real-time  experiment,  constitutive  relative  gene  expression  was 
investigated by comparing the CVL and MOTRI isolates at rest; the same comparison as 
was carried out using semi-quantitative PCR.  When comparing the real-time and semi-
quantitative data, the majority of the  results  were in  agreement, with  the exception of 
TeciPgp-2  NBD2  where  no  amplification  across  all  life-cycle  stages  (Chapter  3)  was 
observed using semi-quantitative PCR but amplification of this gene was observed using 
real-time PCR.  This reflects the relative sensitivities of the respective methods.  As shown 
in  Chapter  4,  no  statistically  significant  changes  in  expression  level  were  found  for 
TeciPgp-2  NBD1,  PGP7  and  PGP8  when  comparing  CVL  and  MOTRI;  statistically 
significant differences in expression level of PGP1, PGP3, PGP9, PGP10, PGP11, CYP1, 
CYP2 and CYP3 in individual life-cycle stages were observed when comparing CVL and 
MOTRI; but, more importantly, changes in expression across all life-cycle stages were 
observed for TeciPgp-2 NBD2 and TeciPgp-9 NBD2.  For TeciPgp-2 NBD2 there was a 
statistically  significant  reduction  in  expression  in  the  IVM-resistant  MOTRI  isolate 
compared to the IVM-susceptible CVL isolate, whereas, for TeciPgp-9 NBD2, there was a 
statistically significant increase in expression in the MOTRI isolate compared to the CVL 
isolate.  Biological replicates for xL3 and adult stages of the CVL and MOTRI isolates 
were analysed and, with the exception of a non-statistically significant result for TeciPgp-9 
NBD2  in  the  adult  stage,  confirmed  the  findings  of  the  original  triplicate  real-time 
experiments.  Changes across all life-cycle stages could indicate that genetic changes such 
as  altered  copy  number  underlie  the  expression  differences  observed,  as  opposed  to 
alterations in the regulation of the gene which would be anticipated to only occur in the 
life-cycle stages exposed to IVM.   
 
Interestingly,  despite  the  phylogenetic  analysis  of  the  partial  Pgp  sequences 
indicating that two halves of the same, TeciPgp-2, gene had been identified, the real-time 
PCR results for TeciPgp-2 NBD1 and 2 did not follow the same pattern, as shown in 214 
Figure  4.5.    Further  work  is  required  to  investigate  this;  potentially  the  phylogentic 
analysis and subsequent re-naming of the Pgp sequences could have erroneously classified 
these partial sequences as the two separate NBDs of the same gene.  Unfortunately, the 
relative expression levels of TeciPgp-9 NBD1 could not be determined as the probe and 
primers  designed  did  not  amplify  TeciPgp-9  NBD1  efficiently.    Therefore,  it  was  not 
possible  to  determine  whether  the  two  partial  TeciPgp-9  gene  fragments  (NBD1  and 
NBD2) exhibited the same expression pattern.  The sequencing of the full-length coding 
sequences  of  TeciPgp-2  and  TeciPgp-9  would  conclusively  determine  whether  the 
nomenclature for these genes is correct and would be a priority now that these genes have 
been shown to exhibit statistically significant changes in expression when comparing an 
IVM-resistant and -susceptible T. circumcincta isolate.   
 
It has become apparent, by comparing nucleotide sequences, that TeciPgp-9 NBD2 
is the same gene as identified by Bisset (2007) in New Zealand from laboratory derived 
near-isogenic inbred T. circumcincta lines.  The pattern of allelic, or haplotype, variation 
of TeciPgp -1, -2 and -9 was compared between the drug-susceptible and -resistant lines.  
Analysis of genomic sequence from individual adult male worms showed that five IBDA 
(equivalent to NBD1) and two IBDB (equivalent to NBD2) haplotypes in the New Zealand 
TeciPgp-9  were  under  positive  selection  pressure  in  the  MDR  line  and  of  these  7 
haplotypes, four IBDA and one IBDB were exclusive to the MDR line.  Alongside this, 
Bisset (2007) showed a large number of SNPs in the New Zealand TeciPgp-9 gene, which, 
with  the  exception  of  four,  were  non-coding  or  silent.    The  finding  of  changes  in 
expression levels of TeciPgp-9 NBD2 in UK field-derived isolates becomes even more 
significant in the light of these independent findings from laboratory-derived isolates from 
the other side of the world.  In this present study, we did not attempt to identify whether 
haplotypes  of  TeciPgp-9  were  present  as  the  full-length  genomic  sequence  was  not 
available.  However, as shown in Chapter 3, the presence of at least four silent SNPs 
(A138G,  C177T,  A201T  and  A216C)  in  TeciPgp-9  NBD2  in  the  UK  field-derived, 
unrelated isolates has been shown; unfortunately none of the sequence data obtained from 
the UK isolates for TeciPgp-9 NBD2 covers the regions identified in the New Zealand 
near-isogenic lines  containing the four coding  SNPs.    In work currently on-going, the 
sequence of TeciPgp-9 NBD2 is being extended through 5‟ and 3‟ RACE PCR and has 215 
shown that at least one of the coding SNPs, identified from the New Zealand near-isogenic 
lines, has been identified in the UK CVL and MOTRI isolates (F. Turball, Pers. Comm.).   
 
In the New Zealand study, the expression level of TeciPgp-9 IBDA in individual 
adult male worms was determined using SYBR
® green real-time PCR.  Using the ʔʔCt 
method, there was an average of a 3.4 fold increase in TeciPgp-9 in the resistant worms 
compared to the susceptible worms (Bisset, 2007).  In the present study, using pools of 
mixed sex adult T. circumcincta to generate cDNA, a 6.75 fold increase in expression of 
TeciPgp-9 NBD2 (P<0.01) was observed when comparing CVL to MOTRI, whilst the 
increase in expression for this gene in the other life-cycle stages was 55.27 fold (P<0.01), 
5.06 fold (P<0.05), 17.49 fold (P<0.01) and 14.04 fold (P<0.05) for eggs, L1, xL3 and L4, 
respectively.  As such, the change in expression of TeciPgp-9 NBD2 in IVM-resistant UK 
isolates, compared to IVM-susceptible UK isolates is greater than the change in expression 
observed between the New Zealand isolates.  By comparing the results of the SYBR
® 
green real-time PCR with the haplotype data for the individual worms, Bisset (2007) was 
able to determine that the likely cause of the increase in abundance was an increase in copy 
number of TeciPgp-9 as the MDR worms (exhibiting a higher expression level of TeciPgp-
9)  possessed  3  or  4  different  haplotypes  of  TeciPgp-9  IBDA  compared  to  at  most  2 
haplotypes  in  the  susceptible  worms.    In  fact,  the  presence  of  different  „resistance-
associated‟ haplotypes altered the expression of TeciPgp-9.  For example, the presence of 
IBDA haplotype 10 in resistant worms was related to a 10 fold increase in abundance of 
TeciPgp-9 template in the resistant worms compared to susceptible worms (Bisset, 2007).  
Genes believed to be orthologous to TeciPgp-9 have been studied previously; the gene 
designated as Hcpgp-1 is implicated in ML resistance in H. contortus and ML selection 
was shown to increase the frequency of Hcpgp-1 in a ML-resistant H. contortus isolate 
(Kwa et al., 1998; Le Jambre, Lenane, & Wardrop, 1999; Bisset, 2007).  In C. elegans, 
Pgp-9 has been shown to be expressed in the intestine and the first and second bulbs of the 
pharynx (Zhao et al., 2004) (http://wormbase.sanger.ac.uk/).   
 
  The  identification  of  reduced  TeciPgp-2  NBD2  expression  across  all  life-cycle 
stages, when comparing CVL and MOTRI, was unexpected; the role of Pgps as generic 
detoxification  pumps  suggested  that  increased  expression  of  these  genes  would  be 216 
expected  to  produce  an  IVM-resistant  phenotype  in  T.  circumcincta  (Sangster,  1994; 
Kerboeuf, Guegnard, & Le Vern, 2003).  However, drug resistance could also be mediated 
by reduced uptake of the drug, drug sequestration and/ or by preventing the drug from 
reaching its target site (Wolstenholme et al., 2004; Jones & George, 2005).  TeciPgp-2 
NBD2 could have a high affinity for IVM and so, by reducing expression of this gene (and 
its  gene products) parasites  are able to  reduce the amount of  IVM transported into or 
around  their  tissues.    Although  identified  in  the  New  Zealand  study,  no  real-time 
quantification  of  this  gene  (Tecipgp-2  IBDB)  was  carried  out  so  it  is  not  possible  to 
determine  whether  reduced  expression  of  this  gene  is  also  found  in  New  Zealand.  
Haplotype data for Tecipgp-2 IBDB is available, however, indicating that seven haplotypes 
are present in the New Zealand near-isogenic lines of T. circumcincta, one of which show 
reduced frequencies in the resistant line whilst another was found to be exclusively present 
in the resistant line (Bisset, 2007).  It could be possible that the TeciPgp-2 NBD2 sequence 
obtained in this project is specific for a haplotype which is found more commonly in the 
IVM-susceptible (CVL) isolate than the IVM-resistant (MOTRI) isolate thus, TeciPgp-2 
NBD2 could represent a potential marker for IVM susceptibility.  The PgpA gene from H. 
contortus is believed to be orthologous to C. elegans and T. circumcincta Pgp-2; changes 
in H. contortus PgpA allele frequencies are associated with IVM and MOX resistance and 
this gene is over-expressed in IVM-selected H. contortus (Xu et al., 1998; Blackhall et al., 
1998b; Bisset, 2007).  Interestingly, reduced or disrupted expression of C. elegans Pgp-2, 
which is  localised to  the gut  granule membrane and the first  and second bulbs of the 
pharynx, is associated with impaired fat storage (Zhao et al., 2004; Nunes et al., 2005; 
Schroeder  et  al.,  2007);  in  eggs  of  H.  contortus  cholesterol  depletion  increases  TBZ 
resistance (Riou et al., 2003).  It appears that Pgp function, and hence drug resistance, is 
affected by the concentration of lipids (such as cholesterol) in the membrane within which 
it is localised (Riou, Koch, & Kerboeuf, 2005; Nunes et al., 2005; Schroeder et al., 2007).  
As such, like TeciPgp-9 NBD2, the TeciPgp-2 NBD2 gene warrants further investigation, 
particularly to determine why, in T. circumcincta, a reduced expression of this gene is 
associated with IVM-resistance whilst in H. contortus, this gene is over-expressed in IVM-
selected strains.   
 
  The expression of a panel of “candidate resistance” genes was also investigated in 
T. circumcincta isolates which had been exposed to IVM treatment.  This was to determine 217 
what changes in gene expression were evident in an IVM-resistant isolate (MOTRI) upon 
exposure  to  IVM.    A  range  of  experiments  was  carried  out;  firstly  the  IVM-resistant 
MOTRI isolate was compared to the Post IVM MOTRI isolate, generated by collecting the 
survivors of a full therapeutic dose of IVM.  The rationale behind this experiment was that 
MOTRI  is  known  to  comprise  individuals  displaying  a  range  of  sensitivities  to  IVM; 
treatment  would  select  the  most  resistant  sub-population  within  MOTRI  for  further 
analysis.    Due  to  previously  described  differences  in  actin  Ct  values,  no  comparison 
between  the  MOTRI  and  Post  IVM  MOTRI  L4  stages  was  made.    Fewer  statistically 
significant changes in expression between the isolates were observed and no changes in 
expression of any single gene across all life-cycle stages were observed.  Potentially, the 
MOTRI isolate is  so  resistant  to  IVM that exposing it to  IVM failed  to  further select 
resistant parasites, although this is counter-intuitive as the efficacy of IVM against MOTRI 
is 60% (Bartley et al., 2004).  Alternatively, if parasites do alter expression of resistance-
associated genes, such as the Pgps and CYPs, this change could occur more rapidly and 
only be detectable whilst the parasites are still exposed to the drug.  Thus, the timing of 
IVM exposure and collection of the surviving parasites may be crucial to being able to 
identify inducible expression differences.  To answer this, two further experiments were 
carried out to investigate inducible changes, as described below. 
 
  The  LMIT  can  be  used  to  determine  the  phenotypic  IVM-resistance  status  of 
parasite populations (Wagland et al., 1992; Rabel, McGregor, & Douch, 1994).  By scaling 
up the assay, as described in Chapter 2, it was possible to separate IVM-exposed MOTRI 
T. circumcincta into those able to migrate, or not, in the presence of a discriminating dose 
of IVM.  The expression of TeciPgp-9 NBD2 and TeciPgp-2 NBD2 were compared in 
these  selected  pools  of  xL3  and  a  pool  of  IVM-unexposed  xL3.    Only  one  significant 
change in expression of these genes was found; a statistically significant 1.88-fold increase 
in TeciPgp-2 NBD2 expression in the unexposed sample compared to the migrators sample 
(P<0.05).  Potentially, as described earlier, this could be because the MOTRI isolate is 
constitutively  expressing  these  genes  at  different  levels  and  does  not  alter  expression 
further in response to IVM exposure.  This could be the case with TeciPgp-9 NBD2, if the 
changes in expression are found to be due to an increase in copy number rather than due to 
increased transcription levels.  Alternatively, the design of the experiment may not have 
been  optimal;  for  example,  the  dose  of  IVM  chosen  could  have  been  insufficient,  the 218 
length of time taken to collect the xL3 following exposure may have been too long or it 
might have been better to expose the IVM-susceptible CVL isolate. 
 
  As a final attempt to elucidate whether changes in expression of TeciPgp-9 NBD2 
and TeciPgp-2 NBD2 were inducible, adult T. circumcincta MOTRI in a donor sheep were 
exposed to a full therapeutic dose of IVM and subsequently collected at necropsy three 
days post-treatment.  This time scale was chosen as the half-life of IVM is between 61 and 
102 hours, so the adult worms would still be exposed to IVM but any susceptible worms 
should have been killed and expelled from the abomasum (Canga et al., 2009).  Using this 
approach, it was determined that the expression of TeciPgp-2 NBD2 was reduced in the 
MOTRI  survivors  of  IVM  treatment  and,  although  not  statistically  significant,  the 
expression of TeciPgp-9 NBD2 was increased in the survivors of IVM treatment.   As 
stated  previously,  this  suggests  that  the  correct  design  of  experiments  is  crucial  to 
identifying inducible gene expression differences.  Alongside this, the majority of genes, 
particularly the three CYPs, did not exhibit significant changes in expression, potentially 
subtle changes in gene expression could still have an effect on the ability of parasites to 
survive anthelmintic treatment.  For example, in a study of IVM-resistance in O. ostertagi, 
a 3.4 fold increase in expression of PGP2a was found in laboratory-derived IVM-resistant 
adults compared to IVM-susceptible adults (Van Zeveren, 2009).  It is possible that, as the 
genes were identified in susceptible parasites, and appear to be expressed at low levels, 
resistance-associated genes may be present in susceptible parasites below the threshold of 
detection (Barrett, 1998).  As such other, as yet unidentified Pgps and CYPs (or previously 
unknown genes) could  also be involved in the anthelmintic resistance phenotype in  T. 
circumcincta. 
 
The  fact  that  similar  changes  in  TeciPgp-9  NBD2  have  been  observed  in  T. 
circumcincta isolates from opposite sides of the globe is potentially significant, especially 
given the fact that the IVM-resistant isolates were generated by two completely different 
methods.  In New Zealand, the multi-drug resistant isolate was derived in the laboratory by 
inbreeding and back-crossing, with IVM selection at each generation whereas in the UK, 
MOTRI was naturally selected over many generations by IVM treatment in the field.  This 
suggests that there is some universal commonality in the IVM-resistance mechanisms and 219 
that the polymorphisms and changes in gene expression observed in TeciPgp-9 NBD2 are 
potentially significant in the IVM-resistance phenotype in T. circumcincta.  This study 
provides further evidence that Pgps, especially TeciPgp-9 NBD2, are involved in IVM-
resistance;  increased  expression  of  this  Pgp  is  associated  with  resistance;  anthelmintic 
resistant H. contortus eggs were shown to have increased amounts of Pgps, as measured 
through  the  level  of  fluorescent  monoclonal  antibody,  measured  using  flow  cytometry 
(Kerboeuf, Guegnard, & Le Vern, 2003).  A priority for further studies on TeciPgp-9 and 
its role in the IVM resistant phenotype in T. circumcincta would be the generation of the 
full-length coding and genomic sequence from the CVL, MOTRI and Post IVM MOTRI 
field-derived isolates, respectively.  This would enable the determination of the presence of 
specific  resistance-associated  alleles,  haplotypes  or  coding  SNPs  in  this  gene;  as  have 
already  been  identified  in  the  New  Zealand  laboratory  derived  near-isogenic  lines.  
Alongside this, the changes in gene expression found in TeciPgp-9 NBD2 between the 
CVL and MOTRI isolates need to be investigated in other isolates with differing levels of 
IVM-resistance and from different geographic locations.  If this was found to be the case, 
then the changes in TeciPgp-9 NBD2 could form the basis of a universal molecular test 
(like those available for the BZs) for IVM resistance in T. circumcincta.  The generation of 
a  full-length  coding  sequence  for  this  gene  would  also  help  to  determine  whether  the 
observed  changes  in  gene  expression  are  a  result  of  increased  transcription,  mediated 
through a mutation in an upstream regulatory element, for example, or, like in the New 
Zealand studies, due to an increase in gene copy number.  As has been shown with some in 
vitro inhibitor studies, the use of Pgp inhibitors causes phenotypically IVM-resistant T. 
circumcincta and H. contortus to shift towards an IVM-susceptible phenotype; the further 
knowledge gained during this study, suggesting that the Pgps may play a role  in IVM 
resistance in T. circumcincta, would indicate that studying the co-administration of these 
inhibitors with anthelmintics as a method to overcome MDR parasites could be a viable 
option (Virkel et al., 2009; Bartley et al., 2009).  However, the recently released AAD 
anthelmintic,  monepantel,  has  been  shown  to  be  effective  against  MDR  parasites 
(Kaminsky et al., 2008) and may delay the inevitable loss of ability to control parasites, so 
expensive  animal  trials  involving  Pgp  inhibitors  may  not,  at  this  present  time,  be 
commercially viable. 
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  As  an  alternative  method  to  investigate  more  global  gene  expression  events  in 
relation to IVM resistance, Roche 454 sequencing was used to generate nearly 100,000 
novel sequence reads from two pools of adult T. circumcincta, one of which had been 
exposed to IVM in vitro whilst the other was left unexposed as a control.  The subsequent 
objective bioinformatic and statistical analysis of the in silico sequence data generated, 
enabled  the  sequences  to  be  classified  according  to  the  significance  of  the  change  in 
number of reads (reflecting the mRNA level of that sequence in the two samples) and, for 
many sequences, provided a putative BLAST identity.  Sixteen sequence clusters were 
shown to have the most statistically significant changes in expression between the exposed 
and  unexposed  samples  and  a  further  355  were  shown  to  have  statistically  significant 
changes  in  expression  under  a  more  liberal  statistical  model.    Further  details  of  these 
sequences can be found in Chapter 5 and Appendix 5.  To provide more information on the 
putative function of individual contigs, functional classification was assigned using KAAS; 
from this any statistically significant changes in the proportion of functional groupings was 
identified,  indicating  that  for  the  orthologous  groups  „translation‟,  „amino  acid 
metabolism‟,  „carbohydrate  metabolism‟  and  „xenobiotic  degradation  and  metabolism‟, 
statistically significant changes in the mean proportion of reads within these groupings 
between the two samples was observed.  This work is particularly important for organisms 
like T. circumcincta where the amount of sequence data available in the public domain is 
limited; at present there are only ~6,000 ESTs available on the NCBI dbEST website.  
There are a further 14 megabases of genomic sequence available, generated through the 
genome  sequencing  project,  on  the  Sanger  website 
(http://www.sanger.ac.uk/Projects/Helminths/),  but  candidate  resistance  genes  are 
conspicuously absent to date.  The available sequence does not provide full coverage of the 
T. circumcincta genome; which has been estimated to be in the order of 59 megabases in 
size  (Leroy,  Duperray,  &  Morand,  2003).    The  generation  of  nearly  100,000  novel 
sequences in this project is a valuable genetic resource for studying changes that occur in 
T. circumcincta in response to IVM exposure.   
 
One criticism of the approach used to generate this 454 sequencing EST dataset is 
the lack of candidate resistance genes identified, however this could, like the current size 
of the T. circumcincta genome sequencing project be purely due to the depth of coverage 
achieved.  Even with this relatively limited sequencing dataset, the approach would still be 221 
anticipated  to  identify  the  major  changes  in  gene  expression  associated  with  IVM 
exposure.    Only  one  contig,  containing  2  reads,  was  identified  as  a  Pgp  in  the  IVM-
exposed dataset and the change in expression of this gene was not found to be statistically 
significant.    However,  as  the  approach  was  designed  to  be  „non-hypothesis‟  driven, 
focusing on finding candidate resistance genes such as the Pgps and CYPs could result in 
ignoring other, more significant, changes in gene expression which do enable the parasites 
to  cope  with  IVM  exposure.    As  such,  a  statistically  robust  objective  analysis  of  the 
changes in gene expression enabled a list of potentially interesting genes to be drawn up 
without  any  preconceived  ideas  as  to  their  function  in  the  IVM-resistance  phenotype.  
Mainly for financial reasons, there was only one opportunity to perform this experiment, so 
the experimental design was  selected to  provide the simplest  comparison and the best 
possible  chance  of  identifying  gene  expression  changes  within  an  IVM-resistant  T. 
circumcincta isolate in response to IVM exposure.  The standard therapeutic dose of IVM 
in sheep is 0.25mg/kg body weight, with a half-life of between 61 and 102 hours (Canga et 
al., 2009).  In one experiment, following intra-ruminal dosing with 0.2mg/kg body weight 
IVM,  the  peak  plasma  concentration  was  approximately  17.6ng/mL  (Prichard  et  al., 
1985b) but how this relates to the concentration T. circumcincta is exposed to in vivo in the 
abomasum is not known.  At least a proportion of the MOTRI isolate is able to survive a 
dose of 0.25mg/kg body weight IVM in vivo, so an in vitro IVM exposure concentration of 
5μg/mL was chosen to ensure that the IVM exposed parasites were stressed.   This is 
reflected in the BLAST identies of the most significant changes in read number which 
included  HSPs,  which  have  been  shown  to  increase  expression  in  response  to 
environmental stresses; cytochrome oxidases, which are part of the mitochondrial electron 
transport chain; and vitellogenin,  which is  linked to  egg production  (Lindquist,  1986).  
However, it is possible that some of the changes in gene expression observed could be due 
to the presence of dead or dying adult worms  within the IVM-exposed sample due to 
MOTRI comprising individuals with a range of IVM sensitivities, as previously stated.  
Alternatively,  other  resistance  mechanisms  utilised  by  surviving  worms  in  the  IVM-
exposed sample could have been masked by the contribution from dead or dying worms.  If 
this experiment was to be carried out again, an alternative approach could be to select the 
IVM-exposed survivors by either putting the parasites through a phenotypic assay, such as 
the scaled-up LMIT (Chapter 4), or selecting only adult worms which still appeared to be 
motile or alive following exposure to IVM.  This approach could, however, increase the 
time that the parasites are exposed to IVM, and potentially cause degradation in the RNA 
extracted.  Selection of parasites in this experiment was not carried out as only a limited 222 
number of worms were exposed to IVM and the priority was to ensure there was sufficient, 
good quality RNA extracted as  rapidly as  possible.  This  was  also  to  ensure that any 
transient, inducible gene expression changes could be identified.   
 
Roche  454  sequencing  is  one  of  the  “next-generation”  sequencing  technologies 
which have the potential to revolutionise genome sequencing.  Compared to traditional 
Sanger sequencing, these techniques are cheaper, faster and generate considerably more 
data, although often at the expense of read length, however technical improvements are 
rapidly  beginning  to  overcome  this  (Marguiles  et  al.,  2005;  Pop  &  Salzberg,  2008; 
Shendure & Ji, 2008).  A novel sequencing method called real-time DNA sequencing, has 
recently been described; this could potentially be an improvement on the “next-generation” 
approaches  and could  be used to  investigate gene expression in  genome-poor parasitic 
nematodes, such as T. circumcincta, as the sequence generated is longer compared to the 
current “next generation” approaches (Eid et al., 2009).  The main challenge, however, of 
producing  large  EST  datasets,  such  as  that  described  in  Chapter  5,  is  the  subsequent 
bioinformatic and statistical analysis required to generate meaningful results, in order to 
answer biologically relevant questions.  A novel statistical approach has been applied to 
this  dataset  and  has  allowed  the  identification  of  a  panel  of  genes  showing  altered 
expression profiles in MOTRI in response to in vitro IVM exposure; these genes could 
form  the  basis  of  further  studies  to  identify  how  IVM-resistant  parasites  survive 
anthelmintic treatment.   
 
As a second “non-hypothesis” driven approach to investigate IVM-resistance in T. 
circumcincta,  a  SSH  experiment  was  undertaken  (Chapter  6)  specifically  designed  to 
identify genes exhibiting increased expression in the MOTRI isolate compared to CVL.  
Cloning  of  the  subsequent  products  identified  a  panel  of  28  contiguous  sequences 
exhibiting increased expression in the MOTRI isolate.  Confirmation of the SSH results for 
five out of six selected sequences was obtained by carrying out semi-quantitative PCR, the 
sixth  result  could  not  be  confirmed  as  no  PCR  amplification  occurred.    These  SSH 
sequences were chosen for further investigation based on their BLAST identities, which 
included HSPs, SXC1, dynein and cathepsin B.  Sequences with HSP homology were also 
prominent in the Roche 454 sequencing dataset, and HSPs are known to be constitutively 223 
expressed in a range of parasite life-cycle stages and can be induced in response to various 
physical and chemical challenges (Hartman et al., 2003; Vercauteren et al., 2006).  The 
fact that HSPs have also been identified as exhibiting statistically significant changes in 
expression in response to IVM exposure, as well as in a comparison between IVM-resistant 
and -susceptible T. circumcincta isolates, suggests that this large gene family is worthy of 
further  investigations.    Both  SXC1  and  Cathepsin  B  are  seen  as  potential  vaccine 
candidates in parasitic nematodes; if an effective vaccine was to be developed against these 
genes, it could be even more effective against resistant parasites which have a greater 
expression level of these genes compared to susceptible parasites (Daub et al., 2000; De 
Maere et al., 2002; Ranjit et al., 2008).  The number of sequences identified through this 
subtraction  experiment  is  less  than  those  generated  by  Nisbet  et  al  (2008)  in  a  study 
investigating gene expression associated with the transition from the free-living to parasitic 
stage in T. circumcincta.  However, a second round of cloning and sequencing of the SSH 
products in this experiment indicated that the yield, in terms of novel sequences obtained, 
was  diminishing.    Potentially,  further  rounds  of  sequencing  of  the  SSH  product  could 
identify  other  sequences  exhibiting  increased  expression  in  the  IVM-resistant  isolate 
compared to the IVM-susceptible but, as a method to identify genes for further study, the 
SSH  experiment  has  already  generated  a  panel  of  28  potential  novel  IVM-resistance 
associated genes.   
 
In order to determine whether the two non-candidate approaches had identified any 
of the same, or similar, genes, the sequences identified using SSH were BLAST searched 
against the EST dataset generated using Roche 454 sequencing.  High BLAST E scores for 
some of these searches  indicated that the same molecules may  be present  in  the SSH 
dataset as those identified in the Roche 454 dataset.  One SSH sequence aligned to a contig 
which  was  deemed  to  be  significant  in  the  conservative  statistical  model  of  the  454 
sequencing analysis, whilst a further 5 SSH sequences aligned to contigs deemed to be 
significant in the liberal statistical model of the 454 sequencing analysis.  The fact that 
these gene sequences  appear to  exhibit constitutive expression differences  between the 
CVL and MOTRI T. circumcincta isolates, and inducible expression differences following 
IVM expression suggests that these genes need to be investigated further to determine 
whether they enable the expression of an IVM resistance phenotype in T. circumcincta 
through some as yet unidentified resistance mechanism.   224 
 
One concern whilst undertaking this comparison was that the two isolates used 
(CVL and MOTRI) were isolated independently from different regions of the UK.  This 
could  mean  that  background  genetic  differences  between  the  two  isolates  could  be 
important and lead to the generation of spurious results, linked to the different genetic 
background of the parasites, in the subtraction experiment.  However, using mitochondrial 
sequence  data  and  neutral  microsatellite  markers,  Blouin  et  al  (1995) and  Grillo  et  al 
(2007) were able to determine that the majority of genetic diversity in T. circumcincta is 
found within rather than between populations.  As such, although it is possible to compare 
field-derived isolates, the best possible comparison would still be parental versus field-
derived isolates, or failing that, through the generation of back-crossed near-isogenic lines, 
such as those described in Bisset (2007).  This would enable any non-resistance associated 
gene expression changes to be excluded or, at least, minimised.   
 
The SSH method has proven to be a useful tool to identify a panel of putative IVM-
resistance associated genes for further study.  One criticism of this method is the potential 
to falsely identify differences in gene expression if the tester and driver cDNA are very 
similar to each other (A. Nisbet, Pers. Comm.).  Confirmation of the results using semi-
quantitative PCR is an important control in removing these false positives but whether this 
could be an issue with the comparison described in Chapter 6 is uncertain as the genetic 
relationship of MOTRI and CVL is not known.  If an alternative comparison was to be 
made within an isolate, such as that between the migrators and non-migrators in the LMIT 
experiment, then this tendency of the SSH technique to give false positives could be more 
of a problem.  The panel of genes identified in this SSH experiment provides a starting 
point for further investigations into the role of altered constitutive expression of genes in 
IVM-resistant and -susceptible T. circumcincta isolates.  Following the success of the real-
time PCR assays to determine the relative constitutive expression of a panel of Pgps and 
CYPs in a range of T. circumcincta isolates, this would be the preferred method to fully 
investigate the genes identified through SSH.  It would also be interesting to carry out this 
subtraction experiment in the opposite direction, to identify genes with reduced expression 
in the MOTRI isolate compared to the CVL isolate.  As has been shown using real-time 
PCR, a statistically significant  constitutive reduction in  expression across all life-cycle 
stages of TeciPgp-2 NBD2 was observed; as such constitutive decreased expression of 225 
other, as yet identified, genes could also play a part in the expression of an IVM resistant 
phenotype in T. circumcincta.   
 
Both  the  “non-hypothesis”  driven  Roche  454  sequencing  and  SSH  approaches 
attempted  to  identify  other  genes  which  could  be  associated  with  the  IVM-resistant 
phenotype  either  through  a  change  in  expression  in  response  to  IVM  exposure  or 
constitutively.  The Roche 454 sequencing of IVM-exposed MOTRI adults showed that 
even  a  drug  resistant  isolate  is  affected  by  exposure  to  IVM.    A  novel  method  of 
statistically analysing the results has drawn up a panel of genes which warrant further 
investigation; caution has to be applied however as the relatively short sequences generated 
could mean some of the changes observed are false positives due to gene fragmentation.  
This is also a problem which can also occur following the Rsa I digestion used in the SSH 
experiment.  The SSH experiment has identified other genes, not previously investigated in 
the context of anthelmintic resistance, showing increased expression in MOTRI compared 
to CVL.  Both panels of genes identified using these approaches could form the basis of a 
novel panel of “candidate resistance” genes; their role in expression of a IVM-resistant 
phenotype in T. circumcincta investigated further using real-time PCR, as carried out for 
the panel of Pgp and CYP genes in this thesis.   
 
  The work described in this thesis has shown that changes in expression, both in 
genes putatively associated with IVM resistance and other, non-candidate resistance genes, 
do  occur  as  identified  in  IVM-resistant  and  -susceptible  T.  circumcincta  isolates  and 
following IVM exposure in vitro and in vivo.  The MDR MOTRI isolate is affected by 
exposure to IVM and also shows constitutive differences in expression when compared to 
an  unrelated  drug  susceptible  isolate  (CVL).    Identification  of  changes  in  expression 
associated with IVM resistance could form the basis of a molecular marker for resistance; 
something  which  is  currently  impeding  the  development  of  targeted  control  strategies 
aimed  at  minimising  the  spread  of  IVM  resistance  in  T.  circumcincta  (von  Samson-
Himmelstjerna et al., 2009a).  Maintenance of the efficacy of anthelmintics can only be 
achieved if accurate diagnosis of the resistance status of a parasite population can be made 
(von  Samson-Himmelstjerna,  2006).    Ultimately,  a  sensitive  and  specific  molecular 
diagnostic test for IVM resistance needs to be developed, which can discriminate between 226 
nematode  species  in  natural  infections,  and  identify  the  IVM-resistance  status  of  each 
species.  The identification of the mechanisms of IVM-resistance, and genetic changes 
which control it, would be the first step towards this.  Significantly, in this project, two 
partial Pgp genes, namely TeciPgp-2 NBD2 and TeciPgp-9 NBD2, have been shown to 
exhibit a constitutively altered expression profile between IVM-resistant and -susceptible 
isolates and non-coding SNPs in TeciPgp-9 NBD2 have been identified when comparing 
MOTRI and CVL sequences.  The results for TeciPgp-9 NBD2 are even more significant 
in the light of recent findings from New Zealand, as discussed above.  
 
Important  questions  remain  to  be  answered  before  these  genes  are  heralded  as 
potential  molecular  markers  for  IVM  resistance  in  T.  circumcincta:    The  full-length 
sequence of both these genes needs to be identified so that any further SNPs (silent or 
coding)  and  alleles  or  haplotypes,  associated  with  IVM-resistance,  can  be  identified.  
These genetic changes could form the basis of future molecular markers for resistance and 
would also mean that the cause (either a transcriptional change or a change in gene copy 
number) of the altered gene expression profiles of these genes could be determined.  It 
would be interesting to see whether the numerous  silent SNPs identified in  TeciPgp-9 
NBD2 cause an altered protein conformation which affects its ability to bind to substrates, 
as hypothesised in Kimchi-Sarfaty et al (2007); this would require the codon usage in T. 
circumcincta to be ascertained, if it is not already known.  At the very least, a silent SNP is 
still  a  useful  molecular  marker  for  IVM-resistance,  provided  it  is  shown  to  accurately 
distinguish between resistant and susceptible parasites.  Lastly, and most importantly, the 
changes  found  in  TeciPgp-2  NBD2  and  TeciPgp-9  NBD2,  when  comparing  CVL  and 
MOTRI, need to be confirmed in other isolates of T. circumcincta.  There is no point in 
developing  a  molecular  marker  for  resistance  which  is  subsequently  found  to  only  be 
present in one or a few isolates.  This was the case with the leucine to phenylalanine 
substitution (Leu256Phe) in the GluClα3 subunit of C. oncophora which was subsequently 
not found in any other parasite species or C. oncophora isolates (Njue et al., 2004; Van 
Zeveren, 2009).   
 
  IVM is still the mainstay of many treatment regimes for reducing the burden of 
PGE in livestock worldwide; it is also used in mass drug treatment programmes for human 227 
parasitic nematodes such as O. volvulus (Ardelli, Guerriero, & Prichard, 2006a; Ardelli, 
Guerriero, & Prichard, 2006b; Prichard & Roulet, 2007; Omura, 2008).  As such, the rapid 
development  of  IVM  resistance,  coupled  with  climate  change  potentially  causing  an 
increase in disease incidence is a worrying development.  This is compounded by the lack 
of  rapid,  sensitive  and  cheap  diagnostic  tests  for  IVM  resistance;  the  anthelmintic 
resistance status of parasite populations is generally unknown (Kaplan, 2004; Prichard et 
al., 2007; Kenyon et al., 2009a).  Knowledge of the anthelmintic resistance status of a 
parasite  population  and  the  mechanisms  by  which  the  parasites  exhibit  resistance  is  a 
prerequisite for developing strategies for controlling resistant parasites.  The change in 
gene  expression  observed  in  this  project  could  be  a  step  forward  in  determining  how 
nematode  parasites,  such  as  T.  circumcincta,  are  affected  by  IVM  exposure,  and  how 
resistant parasites are able to survive IVM treatment.  The changes in TeciPgp-2 NBD2 
and TeciPgp-9 NBD2 are particularly noteworthy; further work on these genes is required 
but  the  changes  in  expression  of  these  genes  could  form  the  basis  of  a  much  needed 
molecular marker for IVM resistance.  This would be particularly beneficial in being able 
to understand the implications, at the genetic level, of control and management practices, 
such as targeted selective treatments, aimed at slowing down the inevitable spread of IVM 
resistance (Kenyon et al., 2009b). 228 
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Appendices 
Appendix 1: Clustal W alignment of the nucleotide sequences of the 11 partial Pgp 
genes identified from T. circumcincta 
Pgp1            CTAATACGACTCACTATAGGGCAAGAGTGGTATCAACGCAGAGTACGCGGGGATTCCATT 60 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            ACGAGAATATAATGTGAGGTGGTGGCGTGGAGTAGTCGGCGTTGTTCAGCAGGAACCAGT 120 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            RATATTTCGTGCCACGGTCGCAGAAAATGTTCGAATGGGAGACGACAGCCTAAGTGATGC 180 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            AGATGTTGAAGAAGCGTGTAAAGTTGCGAATGCTTTGGGATTCATCAGGAACCTCAGTGA 240 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GGGCTTCAACACTGYGATCGGTGAGGGTGCCGTGCAGCTGTCAGGTGGTCAGAAACAACG 300 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 250 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            AATCGCTATCGCGAGAGCTCTCGTTAGAAACCCACAGATTTTGCTTCTGGACGAGGCGAC 360 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GAGTGCCCTGGACACAGAAAGCGAACATGCAGTGCAGAAGGCGCTTGACAAGGCACGAGA 420 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ------------------------------------------------------------ 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            AAATCGAACTACTATATGCATAGCGCATCGGCTTTCTACCATCAGAGATGCTGATAAAAT 480 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGTACGCGGGGGATTGAG 60 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            CATTGTTTTCGACGAGGGACACGTTGTTGAGCAAGGGACACATGATGAACTGATGGCAGT 540 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TAGACTTCTTGAGCCTGTTTTCGTCTGCTAAGTGTGTCCACTCCTCATTTCGGTGGAGAT 120 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TGAAGGTGGCATGTACCGGAGTATGGTAAAAGCACAGGCGATTGATAAAGGCGAAGAGGA 600 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TTGTTCTACGATGTTCACTTCATTGCTAGTCCGGCGAGCTATTTGTACTCGTTGCTATTC 180 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            CACCACACTAGATGATGTGAATCCCACGGAACTCAAACGAGGTGTGTCGCGAGTGGGATC 660 251 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            ACTTCCGTCTAGTTCAAAAAGGTTATTCTGTGCTCTACCTCGACAGTCGATTACGCCATC 240 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GGAGGAAGACACGCATCGTGTCGAAATGGCTAGAGAATCGGCACGACTTCGTCAAAGTAT 720 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TTTGAAGTTATTAAAAGTCGGTCGAACTCTGTTGAGAAGTCCCTTTGTAAGAAATGTTAC 300 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GATCAGCACTTCGACACAGGAGCCGGATTGGGAGATAGAAAGTGCCCGTGACAACATGGT 780 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ------------------------------------------------------------ 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            GACTGTGGAGACGAAACGTGCCTCGGTTAAACTTAAAAATGCAACATTCAAAGATCTGAA 360 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TGAAGAAGGCGCTATGGAAGCCTCTCTCCTCGACATTTTTGGCTACGCCAAGCCAGAACT 840 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            --------------------------------------CTAATACGACTCACTATAGGGC 22 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            GGAGATATTCTCTTTAGCTGGACCGTATAAGTGGAGAATTCTTCTAGGC---CTTTCATT 417 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TCCAATGGCTGGCATTGCCTTGATCTTCACTTTATTRCGTGGACTCACATGGCCGCTGTT 900 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            AAGCAGTGGTATCAACGCAGAGTACGCGGGAGGACTGCCTATGATGTCTATCATTATGGG 82 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            CCTCGGCGTAAGCAGCTCGATTTTCCTGATAACACCTAGAGTGCTGGGAAAACTAATAGA 477 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            CTCTATAATCTACGGAAAACTGTTTCTGTTGCTCTCAAGTCCGGATCCGGAAACTCTCGC 960 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            CAATATTTCACAAAACTTCATGAGTATCACTGGTAACACAACCTCTATCCAACAATTCGA 142 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 252 
Pgp7            TGAGTTCGACGAAACGAAACGAGCCGCTCCAGGATATGAAGATCTATCGCTCAAGATTGC 537 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TAGTGGTAACATCCTCAATTCGATCTTCTTTCWATTGCTCGCCATCGCTTCCGGTATCAC 1020 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            ACATGATGTGATCCAGAACTGCCTTAAATATGTCTACCTYGGYTGCGGAGTATTCACGGC 202 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TAGGTATTTAAAGGACAATCCCATTGCACTGGTTGGGTTGCTGTTTCTTGGAGCTGCTGC 597 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            AACTTTCGCTTCTGGATCACTGTTTGGTATCACCGGCGAAAAGATGGCAATGCGATTACG 1080 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            GGCRACGATTCAGGCAATGTGTTTTCTAACGGTMTGCGARAATCTTGTKAATCAACTCAG 262 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TATAACTGCAAGAGTGTATTGTATGCACACAGCCGGACAACTCATTATAAATGATCTCCG 657 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            AATGGATGTCTTCAAGAATATAATGCGCCAGGATGCTTCCTATTTTGATAATCCGAATCA 1140 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            AAGACAGTTCTTCAAGTCRATTCTTCGTCAAGACATCACGTGGTTCGACAA------RAA 316 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TAAGAAAGTTTTCAATTCGGTTCTACGCCAAGACATCGCCTTCTTCGATAA------AAA 711 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            CAACACAGGCAACTTGACAGCCCATTTGGCTTCGGACACACCGAATGTGCAAGCTGCGAT 1200 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            CAATTCAGGAACTCTYGCCACRAAACTRTTCGACAATCTGGAACGAGTCAAAGAGGGWAC 376 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            CAAAGTGGGCGAAATTGTCTCTCGTCTATCAACTGATGCCCTCATCGTGGGATACTCGGT 771 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            CGACCAACGACTCGCAGAGGTGTTGCAAGGTGTTTGCGCTTTGGTGGCTGGAATTGTCGT 1260 
Pgp2            ------------------------------------------------------------ 
Pgp3            ------------------------------------------------------------ 
Pgp4            MGGYGACAAACTTGGCCTTATGATCCAATTYGTGGCGCAGTTYTTCGGCGGTTTCATCGT 436 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            -GTCCATGAATTTGAGCGATGGTGCAAGAGCTCTCTSACATGCTTAGGCTCAGGCGGTCT 830 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 253 
                                                                             
 
Pgp1            TGCATTTTCCTACGGTTGGAATGTCGCTCCTATTGGCCTAGCCACCGCTCTTCTATTAGT 1320 
Pgp2            ---------------------------TCTAATACGACTCACTATAGGGCAAGCAGTGGT 33 
Pgp3            ------------------------------------------------------------ 
Pgp4            GGCGTTCACTTACGACTGGAAACTYACTCTGATCATGATGTCATTGGCYCCATTCATGAT 496 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            AATGGTTTACACATCTCCGGCTCTCTGCCAAGTGATGTTTGTTGTGATTCCGATTATGGT 890 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TTTCGCTCAATCGTCTGTCGCTCAATATCTGAAGTTCAGAGGACAGAGGGATATGGAGTC 1380 
Pgp2            ATCAACGCAGAGTACGCGGGTGCAAATGCAGTTCGGTAAGAAAATGCGGGACACAGAACT 93 
Pgp3            ----------------------------------------------------------CT 2 
Pgp4            YATTTGTGGAGCWTTCATTGCYAAGTTGATGGCCAGTGCAGCTACTCGGGAAGCCAARAA 556 
Pgp5            ------------------------------------------------------------ 
Pgp6            ------------------------------------------------------------ 
Pgp7            TGGAACTTTCGCCGTTTTCGGTAAGCTGCAACGGAAGTACACTCTCCAAATGCAGGAGGC 950 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TGCAGTGGAAGCCAGTCAGATAGTGACGGAATCAATCTCGAATACACGA----ACGATTC 1436 
Pgp2            TCTGGAGGAGGCTGGCAAGGTTGCATCGCAAGCTGTAGAGAACATCCGC----ACCGTGC 149 
Pgp3            AATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGTACGCGGGGAGACAGTAA 62 
Pgp4            GTACGCCGTGGCGGGAGGAATTGCTGARGAAGTGCTCACHTCWATGAGA----ACTGTKA 612 
Pgp5            -------------GCGGCTATAGCCGAGGAAACGTTCTCGTCCATACGT----ACTGTGC 43 
Pgp6            ------------------------------------------------------------ 
Pgp7            TGTAGCTGGGGCTAATCAGGTGGCAACAGAACGATTRTCGAATGTTCGA----ACGGTTA 1006 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            AAGCACTCTGTAAGGAGGGCTACATGTACGAAGCATACTGTGCTGCAGCACAGGAACCTC 1496 
Pgp2            ATGCCCTGAATCGGCAAGAGCAATTCCATTTCATGTACTGTGAATATCTGAAAGAGCCTC 209 
Pgp3            AGTACTACGGTAATGAGATGTATGAAGTGGATCGTTTCCGAGTTGCAATTGAGAGATTTC 122 
Pgp4            TCGCATTCAACGGACAGCCTTACGAATGCGAGAGGTACGAAAAAGCAYTGGAAGACGGCA 672 
Pgp5            ATGCATTATGTGGTCATAGAAGAGAGCTTACAAGGTTTGAGGCAGCGTTGGAGAAAGGAC 103 
Pgp6            ------------------------------------------------------------ 
Pgp7            GAATGTTGGTTGCCGAAAAGAAGGAACTAGGTGCGTACGCCGACAAGATTTACGACATCT 1066 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            ATAAACGGGCTCTTGTACGAGGCC-TATGGCAGGCGCTGTCCTTAGCGCTGTCAAATAGT 1555 
Pgp2            ATCGGGAGAATCTTTGCCAAACCCACACTTACGGTGGTGTGTTT-GCATTCTCACAATCG 268 
Pgp3            AGTTGGC-TGAATGGCGMTCCAATGCATCCCTGGCTCTGCTAAACTTTCTGCAAAACGGC 181 
Pgp4            AATCGACMGGAATCAAGAAATCCTTGTACATYGGCATTGGYCTCGGGATCACTTTTCTCA 732 
Pgp5            GTAAGACAGGACTTGTCAAATATTTCTATATGGGCGTAGGTGTCGGATTCGGTCAGATGT 163 
Pgp6            ------------------------------------------------------------ 
Pgp7            GGATGATATCGAGAAAAGAAGGTTTGGCTCGTGGTGCCATGTATGGCTCGTTCCAATTCA 1126 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TTCGTTGTGGTGAACTTCGCTATCGCCTACGCTTTTGGACTATGGCTCATACGAAACGAA 1615 
Pgp2            TTACTGTTCTTCATGTATGCGATAGCGTTTTGGATTGGTGCAATCTTCGTGGATAACCAT 328 
Pgp3            ACCATTGGTCTCGGRATGACAGCCGGTTCTATACTTGTCGCTTACTTRGTYACAGTTGAC 241 254 
Pgp4            TCATGTTCTCKTCGTACTGYCTGGCTTTCTGGGTTGGCACGGATTTTGTCTTCAARAATC 792 
Pgp5            GTACCTACGTGTCGTACGCCTTGGCTTTTTGGTACGGTAGCACACTGATCATCAGCGACC 223 
Pgp6            ------------------------------------------------------------ 
Pgp7            CGGGGTAT-------------ATCGCCCTTTCAACCGTACTGTTCTACGGAAGTAACCTT 1173 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            TGGAGTACACCATTTATAGTTTTCCAGGTGATAGAAGCGT-TAA-ACATGGCGTCAATGA 1673 
Pgp2            AGTATGCAACCGATTGATGTCTWCCGAGTGTTTTTCGCGT-TCATGTTCTGCGGTCAAAT 387 
Pgp3            CACGARCTCACGGTAGGAGATTATGTTCTGTTCACCACTTATATTCTACAGCTGTATTCT 301 
Pgp4            AAATGCAAG---GAGGAACTGTKATGACGGTATTCTTCTC-CGTGATGATGGGYTCWATG 848 
Pgp5            CAACATTGGACCGTGGCCGGATTTTCACTGTGTTCTTCGC-GGTGATGTCCGGCTCATCA 282 
Pgp6            ------------------------------------------------------------ 
Pgp7            ATCAGTCAGGGMTTGCTCACTTACGGTGATTTGTCATCGT-TCTGCCTTTATGCCGTTCT 1232 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GCGTGAYGATGG-CCGCCTCATATTTTCCGGAGTATATTCGTGCCCGGATATCAGCAGGG 1732 
Pgp2            GGTCGGCAACA--TCTCCTCATTCATTCCGGACGTTGTGAAAGCTCGCCTAGCTGCATCG 445 
Pgp3            CCATTGAACTTTTTTGGGACAGTGTATAGAACTATTCAAAAGTCTTTCATTGATATGGAG 361 
Pgp4            GCGCTCGGWCAGGCYGGACCRCAATTTGCTGTCCTTGGYACAGCTATGGGTGCYGCTGGG 908 
Pgp5            GCTCYAGGTACCTGCCTCCCATATCTTAACACCATATCAATCGCCCAAGGTGCTGTTCGA 342 
Pgp6            ------------------------------------------------------------ 
Pgp7            CTGTGCAGCGAGTTTGTCAAACATATCTGGTTTTTTCATCGAAATCATGAAGGGYTTGGG 1292 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GTCATGTTCACGATGATGCGACAGCGGCCAAAAATCGACA-ATATGAGTCATCAAGGR-- 1789 
Pgp2            CTCCTGTTTTACCTTATTGAACACCCTACGGAGATCGATA-ATCTATCGGAGGACGGC-- 502 
Pgp3            AATATGTTYGACCTAATGAACGAGGAGGTCGATGTAAGGG---ATGCTCCAAACGCAATT 418 
Pgp4            TCTCTYTATCAGATTATCGMKSGGGAACCAGAAATAGACTCCTACTCCTCCGAAGGAGTT 968 
Pgp5            AGTGTGCTGAAAGTGATCAATAGTCGTCCAAAGATCGATCCATATTCATTGGATGGGATT 402 
Pgp6            ------------------------------------------------------------ 
Pgp7            CGCCAGTTCTAGACTGTTCGAACTTCGCAATACAGTGCCGCGCATCCCTCTTGAGGGA-- 1350 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GATAAACCGGCGCTCAAAGGCGACATAGCGCTGAGAAACGTCTATTTCTCGTATCCGGTA 1849 
Pgp2            ATTAAGAAGAAACTCTCCGGTCATGTTGTATTCCGCAATGTCTATTTCAATTATCCAACC 562 
Pgp3            GAATACCATCCAACGAATGGGCARATTGTAGTGAAAGATCTTACATTCGCCTAC------ 472 
Pgp4            AGGCCATCGAATCTCAAAGGAAAAATCACTGTCTCAAATCTGAAGTTCACTTATCCAACA 1028 
Pgp5            GTGCTGAACAATATGAGAGGATCTATTCGCTTGAAGAACGTACATTTCTCTTACCCATCT 462 
Pgp6            ------------------------------------------------------------ 
Pgp7            GGTATCAARAAGGGAAATGTCGAGGATRCAATCAGATTTGACCGTGTGGCGTTTGCATAT 1410 
Pgp8            ------------------------------------------------------------ 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            CGACGGCGGCAGCTTGTCTTTCAAGGCATGAACCTGAGCGTCCGACATGGACAGACTGTG 1909 
Pgp2            AGAAAACAGATCAGAGTACTTCGTGGATTAAGCTTAGAGATTCAACCCGGTACTACGGTA 622 
Pgp3            AACGAGAACCGTATAGTRCTGAATGACATCTCGTTYGAAGTCGGCAGTGGACAGTCYATC 532 
Pgp4            CGACCAGATGTCCCGATTCTTAAGGGTGTTTCATTTGAAGCGAAACCCGGTGAGACGATA 1088 
Pgp5            AGAAGTACACTCCCGATATTGAGAGGCGTGTCCCTCCAAGTGGCAGCCGGCCAAAAGATC 522 
Pgp6            ------------------------------------------------------------ 
Pgp7            CCGGGACGAGATCCGCTGTTCCACAATATCTCCTTCACAGTWCCGGCTGGTCAAATCACT 1470 
Pgp8            ------------------------------------------------------------ 255 
Pgp9            ------------------------------------------------------------ 
Pgp10           ------------------------------------------------------------ 
Pgp11           ------------------------------------------------------------ 
                                                                             
 
Pgp1            GCACTGGTAKGCGCCAGCGGGTGTGGAAAGAGCACCGTGATACAGCTCGTCGAGAGGTAT 1969 
Pgp2            GCACTGGTTGGTCGATGTGGGTGTGGRAARAGCACCGTGATGGCRTTRTTGGAAAGGTTT 682 
Pgp3            GCATTCGTYGGCCCATCRGGTGGTGGGAARAGTACGTTGATTCGTTTGTTGTTCCGTCTG 592 
Pgp4            GCACTGGTAGGTTCTAGTGGRTGTGGAAARAGYACCATAATTCAGCTGCTACTACGGTAC 1148 
Pgp5            GCCCTGGTGGGTTCAAGYGGGTGTGGAAAGTCGACAATCGTTAATTTGCTGCTGAGATTT 582 
Pgp6            ---------------AGTGGGTGTGGGAAGTCWACAGTGATATCGTTACTTGAAMGGCTT 45 
Pgp7            GCAGTGGTCGGATCGTCYGGTAGCGGWAARTCWACCATCGCAAATCTTYTGTTGAGGCTT 1530 
Pgp8            ---------------AGCGGGTGTGGGAAAAGCACCTCCATTCAGTTAATCGAACGATTC 45 
Pgp9            ---------------AGTGGGTGTGGGAAGAGTACCCTTGTTGGACTACTTCTTCGCTTT 45 
Pgp10           ---------------AGYGGGTGYGGGAAGAGYACCCTCGCCAGTTTATTGATGGGCTAT 45 
Pgp11           ---------------AGCGGGTGTGGTAAGAGTACGCTTATACGTTGTGTAAACCTGCTG 45 
                                  **  * ** **    **              *           
 
Pgp1            TACGACGCCTTGTGTGGCAACGTGAGTATCGACACATACGACATACGTGATCTCTCCATT 2029 
Pgp2            TACAATCAAAGCAGGGGTGTCATCACGGTCGATGGCGAAAACATCAGAAACATGAATATC 742 
Pgp3            TTCGAGTGTCCTGAGGGAACTATTTTCYTCGACGGGAAAGATGTACGACATCTGAAGTTG 652 
Pgp4            TACAATCCTGCAGATGGAAAGATTACAATAGACGGTGTGGAAATCGACAAGATTAATATC 1208 
Pgp5            TACGATCCGACCAGRGGSAAGGTAACCATAGATGACATTGACGTCTGCGATCTCAACGTT 642 
Pgp6            TACGATGCYTTGGACGGTTCTGTGGAAGTTGATGGYAATGATCTWCGCSAAGTRAAYCCY 105 
Pgp7            TACGATCCGGACCGTGGTCATATCATGATTGATGATGTCGATTTGAAACAAACAGATCCT 1590 
Pgp8            TACGATCCTGTGGCTGGTGCTGTGCTGTTCGATGAAGTGGATGCTCGTGAACTGAATTTG 105 
Pgp9            TACGAACAGAAATCGGGAAAGATCTCTATCGATGACGTTCCCATATCCGAACTGAATATC 105 
Pgp10           TACCCGCTAACGGAAGGTGAGATTCGCCTTGATGGTCGTCCATTAAGTTCGCTAAGTCAC 105 
Pgp11           GAGCGCCCAACCGAGGGTAGCGTGCTGGCCGATGGCCAGGA-ACTGACCACGCTGTCAGA 104 
                               **     *       **                             
 
Pgp1            CGTTACGTAAGGGACAACATGGCATTAGTTGGACAGGAGCCGACACTATTCAATGTGACG 2089 
Pgp2            CGTGATCTTCGTGAACAAGTGTGCATCGTCAGTCAGGAACCGACGCTGTTYGAYTGTACG 802 
Pgp3            GTATCGCTGCGTAAACAAATTGGAATCGTACCGCAGGATACGGTACTGTTCAACGATACG 712 
Pgp4            GAATTTCTCCGAAATTACGTTGGAGTAGTGTCACAAGAGCCTATGCTGTTTAACACAACG 1268 
Pgp5            CACAAACTTCGTGAACAAATCGGTGTTGTCAGTCAGGAGCCAGTACTATTTGATGGGACA 702 
Pgp6            ACTCATCTACGTGCCCATATAGCYTTGGTATCGCAAGAGCCGATTCTTTTCGACAGATCM 165 
Pgp7            TCTTACTGGCGACGGCARATTGGAACTGTAGGGCAGGAACCAATATTGTTCTCAACCACG 1650 
Pgp8            AGGCACCTTCGATCACAAATCTCCCTAGCGGGCCAGGAGCCTATACTTTTCAACTATTCC 165 
Pgp9            GAACATCTGAGGAACATCGTAGGAGTCGTGTCTCAGGAGCCGGCGTTGTTTGCTGATACA 165 
Pgp10           AGCGCGCTGCGCCAGGGCGTGGCAATGGTGCAGCAAGATCCGGTGGTGCTGGCGGATACC 165 
Pgp11           ATCCGAGTTGACCAAAGCTCGCCGCCAGATTGGTATGATTTTCCAGCATTTTAACCTGCT 164 
                                           *      * **           *        *  
 
Pgp1            ATACGCGAGAACATCATGTATGGTCTTG---AC------AAATGTTCTCAGGAGGAAATT 2140 
Pgp2            ATCCTTGAGAACATYTGCTATGGACTGG---ACGACCCTAAACCTTCCTACGAGAAGGTG 859 
Pgp3            ATACGGTACAATATCCGCTTTGGTCGCC---------CGTCAGCCACAGACGAGGAGGTT 763 
Pgp4            ATTGAACAGAATATCCGTTATGGACGTG---------AAAAAGTCACAGATGCTGAAATC 1319 
Pgp5            TTATTTGAGAATATTCGAATGGGATATG---------AACACGCTACTATGGAAGAGGTC 753 
Pgp6            ATYCGMGACAACATCCTCTACGGYCTY---CCWCCAGGWTCCGTTAGTGAYGCACAAGTK 222 
Pgp7            ATTCGGGAGAATATYCTCTATGGTGCTGAGTACCCCGATAAAATCACGGAGGCTAAGATA 1710 
Pgp8            ATAAGAGAGAATATTGCGTACGGTTTCG---AG------GAAGCAACTACAGCTCAAATC 216 
Pgp9            GTTGAAAATAATATCCGCTTGGGACGGG---------TGGACATT-TCGCGGCAGGAAAT 215 
Pgp10           TTCCTCGCCAACGTGACGCTGGGGCGGG---------ATATC--T-CCGAAGAACGCGTC 213 
Pgp11           CTCTTCGCG--TACTGTTTTTGGCAACG----------TGGCTCTGCCGCTG--GAGCTG 210 
                 *                   **                            *         
 
Pgp1            GAGCACGCCGCACGTCTCGCCAATATTCATGATTTTATTAATAGCCTTCCT---GAGCGT 2197 
Pgp2            GTCGCTGCGGCAAAAATGGCMAATATYCACAACTTTGTGCTRGGGCTGCCA---GAGGGT 916 
Pgp3            TATGAAGCCGCAAAAGCTGCAATGATTCACGATAAGATCATGACCCTTCCT---GAAGGC 820 
Pgp4            ACGGCGGCACTCCGTAAAGCAAACGCCTACAATTTTGTGCAGTCATTCCCT---GACGGA 1376 
Pgp5            CAGGAAGCTTGTCGTATTGCAAATGCRGCTGATTTTATCAAACGACTTCCG---GACGGT 810 
Pgp6            CACGAAGTCGCTCAACGTGCYAACATTCACAGCTTCATCATAGGMCTGCCT---GATGGM 279 
Pgp7            GAAGAGGCTGCAGAGCAGTCAAACGCTCTCGATTTCATCCAAGCGTTCTCT---GAAAAA 1767 
Pgp8            GAGGATGCCGCTAGACTGGCCAACGCCCACAACTTCATTGTCAAATTGCCA---GCAGGC 273 
Pgp9            GGAAGATTGTTGCAAGATGGCAAATGCGCATGATTTCATCATGAATTTAAGT--CAGGGC 273 
Pgp10           TGGCAGGCGCTGGAAACCGTGCAACTGGCGGAGCTGGCGCGT-AGCATGAGC--GACGGT 270 
Pgp11           GACAACACACCGAAAGACGAGGTCAAACGTCGCGTGACGGAATTGCTGTCATTGGTTGGT 270 
                                                                             
 256 
Pgp1            TACAATACGGTGGTTGGAGCAAAAGGTGCACTGTTGTCGGGCGGTCAAAAGCAGCGCATC 2257 
Pgp2            TAYGACACACGTGTGGGCGAGAAAGGCACACARTTATCGGGCGGGCAGAAGCAGCGAATC 976 
Pgp3            TATGAAACGATGGTTGGTGAGCGGGGATTGAAGCTATCTGGTGGTGAGAAACAACGTGTC 880 
Pgp4            ATTTACACGAACGTTGGTGACCGAGGAACCCAGATGTCTGGTGGCCAAAAGCAACGTATA 1436 
Pgp5            TACGGTACYCGCGTTGGSGAGCGTGGTGTGCAGCTGAGTGGTGGACAAAAACAGCGAATA 870 
Pgp6            TAYAACACGCGTGCAGGAGAAAAGGGRGCGCAGCTRTCTGGKGGGCAGAAACAACGGATC 339 
Pgp7            TTCGATACTATGGTCGGTGAACAGGGATCAATGCTCAGTGGCGGCCAGAAACAGCGAATA 1827 
Pgp8            TACGACACGGTCGTCGGTGAGCGAGGTAGCATGCTGTCCGGTGGCCAAAAGCAGCGAATC 333 
Pgp9            TACCAGACAAGGATAGGAGACGGTGGAGTTCAGCTGTCTGGTGGTCGAAAGCAGCGAGTT 333 
Pgp10           ATTTACACGCCGCTGGGCGAGCAGGGGAATAATCTCTCAGTTGGGCAAAAGCAACTGCTG 330 
Pgp11           CTTGGCGATAAGCATGATGGCTACCCGTCGAATCTTTCCGGTGGGCAGAAACAACGTGTG 330 
                               *  *               *    *  **    ** ** *   *  
 
Pgp1            GCCATCGCTCGTGCTATCGTCAGAGATCCAAAGATACTACTACTTGACGAAGCCACCTCC 2317 
Pgp2            GCGATCGCTCGGGCGTTGATYCGAGATCCACCTATACTTCTTCTTGACGAGGCAACCWSC 1036 
Pgp3            GCGATTGCACGAACCATTCTGAAGAAACCACAGTTTATATTTTTGGACGAAGCAACCAGC 940 
Pgp4            GCCATTGCCCGCGCTTTGGTCAGAGACCCAAAAATTCTTCTACTCGACGAAGCCACATCC 1496 
Pgp5            GCCATTGCTCGTGCRATYATCAARAAYCCACGTATACTYTTGCTCGAYGAAGCAACCWSC 930 
Pgp6            GCCATYGCACRTGCACTTGTTCGGAATCCAAAAATCCTACTACTTGACGARGCCACAWSY 399 
Pgp7            GCAATTGCGAGAGCACTGGTCACGAATCCAAGGATTCTAATCCTCGATGAAGCCACTAGC 1887 
Pgp8            GCAATAGCTCGAGCTGTGATCCGTAACCCGAAAGTTCTTCTATTGGACGAGGCAACCAGT 393 
Pgp9            GCTATAGCTCGAGCTCTGGTGAGAAATCCGCGAATTCTGCTACTGGACGAGGCCACATCC 393 
Pgp10           GCACTGGCGCGCGTGCTGGTCGAGACGCCGCAAATCCTGATCCTTGATGAAGCCACATCC 390 
Pgp11           GCAATTGCCCGTGCGTTAGCCAGCAATCCCAAAGTATTGCTGTGTGACGAAGCAACCAGT 390 
                **  * **        *          **     *  *  *    ** ** ** **     
 
Pgp1            GCCCT 2322 
Pgp2            GCCCT 1041 
Pgp3            GCCCT 945 
Pgp4            GCCCT 1501 
Pgp5            GCCCT 935 
Pgp6            GCCCT 404 
Pgp7            GCCCT 1892 
Pgp8            GCCCT 398 
Pgp9            GCCCT 398 
Pgp10           GCCCT 395 
Pgp11           GCCCT 395 
                ***** 257 
Appendix 2: Clustal W alignment of the translated protein sequences of the 11 partial 
Pgp genes identified from T. circumcincta 
PGP7 has two alignments due to the frame shift that occurs in the nucleotide sequence.  Rf after the Pgp 
name stands for reading frame, with the end number denoting whether the reading frame was 1, 2 or 3. 
 
Pgp1Rf2         YDSLGKSGINAEYAGIPLREYNVRWWRGVVGVVQQEPVIFRATVAENVRMGDDSLSDADV 60 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         ------------------------------------------------------------ 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         ------------------------------------------------------------ 
Pgp7Rf1         ------------------------------------------------------------ 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         EEACKVANALGFIRNLSEGFNTXIGEGAVQLSGGQKQRIAIARALVRNPQILLLDEATSA 120 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         ------------------------------------------------------------ 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         ------------------------------------------------------------ 
Pgp7Rf1         ------------------------------------------------------------ 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         LDTESEHAVQKALDKARENRTTICIAHRLSTIRDADKIIVFDEGHVVEQGTHDELMAVEG 180 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         ------------------------------------------------------------ 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         ------------------------------------------------------YDSLGK 6 
Pgp7Rf1         ----------------------------LIRLTIGQAVVSTQSTRGIETSACFRLLSVST 32 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         GMYRSMVKAQAIDKGEEDTTLDDVNPTELKRGVSRVGSEEDTHRVEMARESARLRQSMIS 240 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         ------------------------------------------------------------ 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         QWYQRRVRGGLSRLLEPVFVCVCPLLISVEICSTMFTSLLVRRAICTR------------ 54 
Pgp7Rf1         PHFGGDLFYDVHFIASPASYLYSLLFTSVFKKVILCSTSTVDYAIFEVIKSR-------- 84 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         TSTQEPDWEIESARDNMVEEGAMEASLLDIFGYAKPELPMAGIALIFTLLRGLTWPLFSI 300 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         ------------------------NTTHYRASSGINAEYAGGLPMMSIIMGNISQNFMSI 36 258 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         ------------------------CYSLPSSSKRLFCALPRQSITPSLKLLKVGRTLLRS 90 
Pgp7Rf1         ---------SNSVEKSLCKKCYDCGDETCLGTKCNIQRSEGDILFSWTVVENSSRPFIPR 135 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         IYGKLFLLLSSPDPETLASGNILNSIFFXLLAIASGITTFASGSLFGITGEKMAMRLRMD 360 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         TG-------NTTSIQQFEHDVIQNCLKYVYLGCGVFTAATIQAMCFLTVCENLVNQLRRQ 89 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         PFVRNVTTVETKRASVKLKNATFKDLKEIFSLAGPYKWRILLGLSFLGVSSSIFLITPRV 150 
Pgp7Rf1         RKQLDFPDNTSAGKTNRVRRNETSRSRIRSIAQDCVFKGQSHCTGWVAVSWSCCYNCKSV 195 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         VFKNIMRQDASYFDNPNHNTGNLTAHLASDTPNVQAAIDQRLAEVLQGVCALVAGIVVAF 420 
Pgp2Rf2         ------------------------------------------------------------ 
Pgp3Rf2         ------------------------------------------------------------ 
Pgp4Rf3         FFKSILRQDITWFDKNNSGT--LATKLFDNLERVKEGTGDKLGLMIQFVAQFFGGFIVAF 147 
Pgp5Rf1         ------------------------------------------------------------ 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         LGKLIDEFDETKRAAPGYEDLSLKIARYLKDNPIALVGLLFLGAAAITARVYCMHTAGQL 210 
Pgp7Rf1         LYAHSRTTHYKSPESFQFGSTPRHRLLRKQSGRNCLSSINCPHRGILGVHEFERWCKSSL 255 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         SYGWN----------VAPIGLATALLLVFAQSSVAQYLKFRGQRDMESAVEASQIVTESI 470 
Pgp2Rf2         -----------------LIRLTIGQAVVSTQSTRVQMQFGKKMRDTELLEEAGKVASQAV 43 
Pgp3Rf2         ------------------------------------------------YDSLGKQWYQRR 12 
Pgp4Rf3         TYDWK----------LTLIMMSLAPFMIICGAFIAKLMASAATREAKKYAVAGGIAEEVL 197 
Pgp5Rf1         ----------------------------------------------------AAIAEETF 8 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         IINDLRKKVFNSVLRQDIAFFDKNKVGEIVSRLSTDALIVGYSVSMNLSDGARALXHAAQ 270 
Pgp7Rf1         TCLGSGGLMVYTSPALCQVMFVVIPIMVGTFAVFGKLQRKYTLQMQEAVAGANQVATERL 315 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         SNTRTIQALCKEGYMYEAYCAAAQEPHKRALVRGLWQALSLALSNSFVVVNFAIAYAFG- 529 
Pgp2Rf2         ENIRTVHALNRQEQFHFMYCEYLKEPHRENLCQTHTYGGVFAFSQSLLFFMYAIAFWIG- 102 
Pgp3Rf2         VRGETVKYYGNEMYEVDRFRVAIERFQLAEWRSNASLALLNFLQNGTIGLGMTAGSILVA 72 
Pgp4Rf3         TSMRTVIAFNGQPYECERYEKALEDGKSTGIKKSLYIGIGLGITFLIMFSSYCLAFWVGT 257 
Pgp5Rf1         SSIRTVHALCGHRRELTRFEAALEKGRKTGLVKYFYMGVGVGFGQMCTYVSYALAFWYGS 68 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         AVWFTHLRLSAKCLLFRLWLELSPFSVSCNGSTLSKCRRLLGLIRWQQNDXRMFERLECW 330 
Pgp7Rf1         SNVRTVRMLVAEKKELGAYADKIYDIWMISRKEGLARGAMYGSFQFTGYIALSTVLFYG- 374 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         LWLIRNEWSTPFIVFQVIEALNMASMSVXMAASYFPEYIRARISAGVMFTMMRQRPKIDN 589 
Pgp2Rf2         AIFVDNHSMQPIDVXRVFFAFMFCGQMVGNISSFIPDVVKARLAASLLFYLIEHPTEIDN 162 
Pgp3Rf2         YLVTVDHELTVGDYVLFTTYILQLYSPLNFFGTVYRTIQKSFIDMENMFDLMNEEVDVR- 131 
Pgp4Rf3         DFVFKN-QMQGGTVMTVFFSVMMGSMALGQAGPQFAVLGTAMGAAGSLYQIIXXEPEIDS 316 259 
Pgp5Rf1         TLIISDPTLDRGRIFTVFFAVMSGSSAXGTCLPYLNTISIAQGAVRSVLKVINSRPKIDP 128 
Pgp6Rf1         ------------------------------------------------------------ 
Pgp7Rf2         LPKRRNVRTPTRFTTSGYREKKVWLVVPCMARSNSRGISPFQPYCSTEVTLSVRXCSLTV 390 
Pgp7Rf1         SNLISQGLLTYGDLSSFCLYAVLCAASLSNISGFFIEIMKGLGASSRLFELRNTVPRIP- 433 
Pgp8Rf1         ------------------------------------------------------------ 
Pgp9Rf1         ------------------------------------------------------------ 
Pgp10Rf1        ------------------------------------------------------------ 
Pgp11Rf1        ------------------------------------------------------------ 
                                                                             
 
Pgp1Rf2         MSHQGDKPA-LKGDIALRNVYFSYPVRRRQLVFQGMNLSVRHGQTVALVXA---SGCGKS 645 
Pgp2Rf2         LSEDGIKKK-LSGHVVFRNVYFNYPTRKQIRVLRGLSLEIQPGTTVALVGR---CGCGKS 218 
Pgp3Rf2         DAPNAIEYHPTNGQIVVKDLTFAYNENR--IVLNDISFEVGSGQSIAFVGP---SGGGKS 186 
Pgp4Rf3         YSSEGVRPSNLKGKITVSNLKFTYPTRPDVPILKGVSFEAKPGETIALVGS---SGCGKX 373 
Pgp5Rf1         YSLDGIVLNNMRGSIRLKNVHFSYPSRSTLPILRGVSLQVAAGQKIALVGS---XGCGKS 185 
Pgp6Rf1         ------------------------------------------------------SGCGKS 6 
Pgp7Rf2         ICHRSAFMPFSVQRVCQTYLVFSSKSRXWAPVLDCSNFAIQCRASLLREVSXREMSRXQS 450 
Pgp7Rf1         -LEGGIKKGNVEDXIRFDRVAFAYPGRD--PLFHNISFTVPAGQITAVVGS---SGSGKS 487 
Pgp8Rf1         ------------------------------------------------------SGCGKS 6 
Pgp9Rf1         ------------------------------------------------------SGCGKS 6 
Pgp10Rf1        ------------------------------------------------------XGCGKX 6 
Pgp11Rf1        ------------------------------------------------------SGCGKS 6 
                                                                       .  :  
 
Pgp1Rf2         TVIQLVERYYDALCGNVSIDTYDIRDLSIRYVRDNMA-----------LVGQEPTLFNVT 694 
Pgp2Rf2         TVMALLERFYNQSRGVITVDGENIRNMNIRDLREQVC-----------IVSQEPTLFDCT 267 
Pgp3Rf2         TLIRLLFRLFECPEGTIFXDGKDVRHLKLVSLRKQIG-----------IVPQDTVLFNDT 235 
Pgp4Rf3         TIIQLLLRYYNPADGKITIDGVEIDKINIEFLRNYVG-----------VVSQEPMLFNTT 422 
Pgp5Rf1         TIVNLLLRFYDPTRGKVTIDDIDVCDLNVHKLREQIG-----------VVSQEPVLFDGT 234 
Pgp6Rf1         TVISLLERLYDALDGSVEVDGNDLRXVNPTHLRAHIA-----------LVSQEPILFDRS 55 
Pgp7Rf2         DLTVWRLHIRDEIRCSTISPSQXRLVKSLQWSDRXVAXXXPSQIFCGFTIRTVVISLMMS 510 
Pgp7Rf1         TIANLLLRLYDPDRGHIMIDDVDLKQTDPSYWRRQIG-----------TVGQEPILFSTT 536 
Pgp8Rf1         TSIQLIERFYDPVAGAVLFDEVDARELNLRHLRSQIS-----------LAGQEPILFNYS 55 
Pgp9Rf1         TLVGLLLRFYEQKSGKISIDDVPISELNIEHLRNIVG-----------VVSQEPALFADT 55 
Pgp10Rf1        TLASLLMGYYPLTEGEIRLDGRPLSSLSHSALRQGVA-----------MVQQDPVVLADT 55 
Pgp11Rf1        TLIRCVNLLERPTEGSVLADGQELTTLSESELTKARR-----------QIGMIFQHFNLL 55 
                                           .                            :    
 
Pgp1Rf2         IRENIMYGLD---KCSQEEIEHAARLANIHDFINSLPER----YNTVVGAKGALLSGGQK 747 
Pgp2Rf2         ILENICYGLDD-PKPSYEKVVAAAKMANIHNFVLGLPEG----YDTRVGEKGTQLSGGQK 322 
Pgp3Rf2         IRYNIRFGRP---SATDEEVYEAAKAAMIHDKIMTLPEG----YETMVGERGLKLSGGEK 288 
Pgp4Rf3         IEQNIRYGRE---KVTDAEITAALRKANAYNFVQSFPDG----IYTNVGDRGTQMSGGQK 475 
Pgp5Rf1         LFENIRMGYE---HATMEEVQEACRIANAADFIKRLPDG----YGTRVGERGVQLSGGQK 287 
Pgp6Rf1         IRDNILYGLPP-GSVSDAQVHEVAQRANIHSFIIGLPDG----YNTRAGEKGAQLSGGQK 110 
Pgp7Rf2         INKQILLTGDGXLELGRNQYCSQPRFGRIXSMVLSTPIKSRRLRKRLQSSQTLSISSKRS 570 
Pgp7Rf1         IRENILYGAEYPDKITEAKIEEAAEQSNALDFIQAFSEK----FDTMVGEQGSMLSGGQK 592 
Pgp8Rf1         IRENIAYGFE---EATTAQIEDAARLANAHNFIVKLPAG----YDTVVGERGSMLSGGQK 108 
Pgp9Rf1         VENNIRLGRV---DISRQEMEDCCKMANAHDFIMNLSQG----YQTRIGDGGVQLSGGRK 108 
Pgp10Rf1        FLANVTLGRD----ISEERVWQALETVQLAELARSMSDG----IYTPLGEQGNNLSVGQK 107 
Pgp11Rf1        SSRTVFGNVALPLELDNTPKDEVKRRVTELLSLVGLGDK----HDGYPSN----LSGGQK 107 
                    :                   .                       .     :*  .. 
 
Pgp1Rf2         QRIAIARAIVRDPKILLLDEATSA------------------ 771 
Pgp2Rf2         QRIAIARALIRDPPILLLDEATXA------------------ 346 
Pgp3Rf2         QRVAIARTILKKPQFIFLDEATSA------------------ 312 
Pgp4Rf3         QRIAIARALVRDPKILLLDEATSA------------------ 499 
Pgp5Rf1         QRIAIARAIIKNPRILLLDEATXA------------------ 311 
Pgp6Rf1         QRIAIAXALVRNPKILLLDEATXA------------------ 134 
Pgp7Rf2         LKNSILWSVNRDQCSVAARNSEQLREHWSRIQGFSSMKPLAP 612 
Pgp7Rf1         QRIAIARALVTNPRILILDEATSA------------------ 616 
Pgp8Rf1         QRIAIARAVIRNPKVLLLDEATSA------------------ 132 
Pgp9Rf1         QRVAIARALVRNPRILLLDEATSA------------------ 132 
Pgp10Rf1        QLLALARVLVETPQILILDEATSA------------------ 131 
Pgp11Rf1        QRVAIARALASNPKVLLCDEATSA------------------ 131 
                   ::   :      :   ::                      260 
Appendix 3: Clustal W alignment of the nucleotide sequences of the 3 partial CYP 
genes identified from T. circumcincta 
CYP1TC          ------------------------------------------------------------ 
CYP2TC          CAAAGAAAAGACGATATCGCATCTGGACAACACACGTTAGATGGTGATGGCAATGATTTT 60 
CYP3TC          ------------------------------------------------------------ 
                                                                             
 
CYP1TC          ------------------------------------------------------------ 
CYP2TC          GTTGATGCCTTCTTTATCAAGATGGAGAAAGATAACAAAGAAGGCCGATCTCCCAACGAA 120 
CYP3TC          -------------------------------GATAGCAATATGTTTGCCGTCGTGATTCT 29 
                                                                             
 
CYP1TC          ---------------------------------TTTGATCTTTG-GATTGCAGGTCAGGA 26 
CYP2TC          TCATACAAAGAAGAGGAGCTGCTCTATGATATATTTGATCTTTG-GATTGCTGGTCAGGA 179 
CYP3TC          TTTCCTGTTATCGTTTGTCGTCTACTACGTATGGTTGTTCTATGCGAACGTGAAACGTTA 89 
                                                  *** *** ** **  *     *   * 
 
CYP1TC          AACCACAATAACTACGCTGGAGTGGGCGTTTTCCTACTTACTACTTAATCCACAGGTAAC 86 
CYP2TC          AACGACAACAATCACAATATTGTGGGGAATGATGCATCTCATCAAAAATCCTGAGGTCAT 239 
CYP3TC          CCCCAAAGGACCAACACCTCTGCCAGTTGTCGGAAATCTTTTG-TCGATCAAC------T 142 
                  * * *  *   **      *   *   *     *  *  *     ***           
 
CYP1TC          AGCACGGGTAGAGGAGGAACTGCTCACGCTCACAAAGGGACAACGCCTACTCTCTATCGT 146 
CYP2TC          GCATAAAATTCGAACAGAGTTGAACACAGTCACTGGTGGCAACAGATTGATCTCCTTATC 299 
CYP3TC          TGCGGAAGCTCAATGATGACTTCGTGCACATATCAAAGGATTATGG-TGATATCTTTACT 201 
                                    *     *    *     **     *  *  * **  *    
 
CYP1TC          GGACAGACCGAACACTCCATACTACAACGCCACTTTGAACGAAGTCCATAGATGCGCTAC 206 
CYP2TC          CGACAGAGAACACACTCACTACCTGAACTGGACAATACTGGAAATACATCGGCTTGCGTC 359 
CYP3TC          GTTTGGC-------TTCCAAAGCCGTATGTGGTGAT-CATGAACTACGACAAT--ATTAA 251 
                     *         **   *     *        *    *** * *              
 
CYP1TC          ATTAGTGCCCATGAATTTGTGGCGTGATACCTCTGAAGATACTGTTGTTGGATCTTATGT 266 
CYP2TC          TATTCTGAATTTGAATCTGTTCCGTAAAACCAAGGAAAATCTCGTTGTCGGTGGACATTC 419 
CYP3TC          GGAGGCGTTCGCGAAAAAAGGAGATGACTTTAACGGACGGTCTGGTCTCTTTCCTGACAC 311 
                      *     ***         * *       * *      * * *        *    
 
CYP1TC          GAT-TCCCAAAGGAACCGCAATCACAGCTCAAATCTCACTCATTATGACTGACGAGAAAT 325 
CYP2TC          TGT-CCCAAAAGGCACTCCAATTGCAGCTGAATTGTCGGTAATAATGCAAGATGAACAAC 478 
CYP3TC          ATTGTACCAAAGCATGCACAATGGAGGCATTGTTTTCTCCCAGGGAGACCTTTGGAAAGA 371 
                  *   * ****      ****    **     * **    *    *      *   *   
 
CYP1TC          ACTTCGAAAATTSCAAAGAGTTCAATCCTGACCGYTATTTCRATGGCAAYAA----ATTG 381 
CYP2TC          GCTTCGAGGAGGCTAACAAGTTCAATCCAGAACGGTATAAACATGGCGGTAAG-ACACTG 537 
CYP3TC          ACAACGACG--TGTATCACTCCAAATACTTCGCGATTTTGGAATGGGAAAGAGCGCAATG 429 
                 *  ***       *        *** *    ** * *    ****     *    * ** 
 
CYP1TC          GAGCAAAAGGTGGTCGCTTTCGGTTTAGGAAAGCGATCCTGTTTGGGTGAATCACTTGCT 441 
CYP2TC          GAACAGCAAGTGATTCCTTTTGGTCTTGGTAAACGATCGTGTATTGGCGAGAATTTGGCA 597 
CYP3TC          GAGGAACAGGTT-TCTCTTTCTGCACAAGAATT---TCTCAATCATATGAACAGCAT-CA 484 
                **  *  * **  *  ****  *     * *     **          **        *  
 
CYP1TC          CARGCAGAACTSTATCTGATCAYYGCRAAC---TTCCTGCTTCKCTACAAAATCTCGGCA 498 
CYP2TC          AGAGCGGAAATTTTCTTGATTTTGGCCAAC---TTGATTTCACGCTACGAAAT------- 647 
CYP3TC          AAAACAAGGATGAAGTTGATCTACGAAGACCATTACAGGTTTTTGTCGGGAACGTTATCA 544 
                    *     *     ****    *   **   *           *    **         
 
CYP1TC          GATCCTCTACATATGCCAAGGACGAAAGCCACAAATGAAATGGGAACCATGAGAAAAC-- 556 
CYP2TC          ------------------------------------------------------------ 
CYP3TC          ACCGAACATTATTCGGATACGGATACAGTTACGATAACAGCGATCGCCTTATGAAAGTGG 604 
                                                                             
 
CYP1TC          CATACCCCTATCACATGCARTT---TGAACKTCGATAAAATGCCTTGACTTTTTTGCTTT 613 
CYP2TC          ------------------------------------------------------------ 
CYP3TC          CGGATACTTTAGCCATATTATTCGATGAAACGAGGAGCAGCAAGATGGTATTTCTAGCTC 664 261 
                                                                             
 
CYP1TC          TCGTTATGCCTTGCTCATTTTTTGTTGTTGTTTATTATGCCTGTATTGTCTCAGTTGTTG 673 
CYP2TC          ------------------------------------------------------------ 
CYP3TC          AACTTATGCCTTTCATA------------------------------------------- 681 
                                                                             
 
CYP1TC          TCTATTTTTTCAACGTGAGCCACCTTCATTTTCGCTGAAAAAACCTGCGAG 724 
CYP2TC          --------------------------------------------------- 
CYP3TC          --------------------------------------------------- 262 
Appendix 4: Clustal W alignment of the translated protein sequences of the 3 CYP 
genes identified from T. circumcincta.   
Rf after the CYP name stands for reading frame, with the end number denoting whether the reading frame 
was 1, 2 or 3. 
 
CYP1TcRf1       ---------------------------------------------------------FDL 3 
CYP2TcRf1       QRKDDIASGQHTLDGDGNDFVDAFFIKMEKDNKEGRSPNESY------KEEELLYDIFDL 54 
CYP3TcRf1       -DSNMFAVVILFLLSFVVYYVWLFYANVKRYPK-GPTPLPVVGNLLSINLRKLNDDFVHI 58 
                                                                         ..: 
 
CYP1TcRf1       WIAGQETTITTLEWAFSYLLLNPQVTARVEEELLTLTKGQRLLS--IVDRPNTPYYNATL 61 
CYP2TcRf1       WIAGQETTTITILWGMMHLIKNPEVMHKIRTELNTVTGGNRLIS--LSDREHTHYLNWTI 112 
CYP3TcRf1       SKDYGDIFTVWLPKPYVVIMNYDNIKEAFAKKGDDFNGRSGLFPDTLYQSMHNGGIVFSQ 118 
                     :     :      ::   ::   .  :   ..  . *:.  : :  :.     :  
 
CYP1TcRf1       NEVHRCATLVPMNLWRDTSEDTVVGSYVIPKGTAITAQISLIMTDEKYFENXKEFNPDRY 121 
CYP2TcRf1       LEIHRLASILNLNLFRKTKENLVVGGHSVPKGTPIAAELSVIMQDEQRFEEANKFNPERY 172 
CYP3TcRf1       GDLWKEQRRVSLQILR----DFGMGKSAMEEQVSLSAQEFLNHMNSIKNKDEVDLRRPLQ 174 
                 :: :    : ::: *    :  :*   : : ..::*:  :   :.   ::  .:.     
 
CYP1TcRf1       FX-GNKLEQKVVAFGLGKRSCLGESLAQAELYLIXANFLLXYKISADPLHMPRTKATNEM 180 
CYP2TcRf1       KHGGKTLEQQVIPFGLGKRSCIGENLARAEIFLILANLISRYE----------------- 215 
CYP3TcRf1       VFVGNVINRTLFGYGYSYDNSD-RLMKVADTLAILFDETRSSKMVFLAQLMPFI------ 227 
                   *: ::: :. :* .  ..  . :  *:   *  :     :                  
 
CYP1TcRf1       GTMRKPYPYHMQFEXRNALTFLLFVMPCSFFVVVYYACIVSVVVYFFNVSHLHFRKNLR 239 
CYP2TcRf1       ----------------------------------------------------------- 
CYP3TcRf1       ----------------------------------------------------------- 
 263 
Appendix 5: Table showing the 355 clusters that were statistically significant under the liberal model following bioinformatic and statistical 
analysis of the sequences generated using Roche 454 sequencing 
The columns show the cluster identity used in the analysis (cluster), the number of reads within that cluster (U reads = unexposed and T reads = exposed), whether gene expression up 
(+) or down (-) regulated compared to unexposed reads (change) and what the putative cluster identity was (BLAST identity). 
 
Cluster  U reads  T reads  Change  BLAST Identity 
803  0  15  +  14-3-3 protein [Caenorhabditis brenneri] ACE74683.1 
552  13  40  +  24 kDa excretory/secretory protein [Haemonchus contortus] AAV83999.1 
1661  0  19  +  60S ribosomal protein L3 [Caenorhabditis briggsae] Q9NBK4 
691  0  19  +  Abnormal cell lineage family member (lin-2) [Caenorhabditis elegans] NP_001024588.1 
798  0  9  +  Abnormal cell Lineage family member (lin-53) [Caenorhabditis elegans] NP_492552.1 
900  0  11  +  ADAM (disintegrin plus metalloprotease) family member (adm-4) [Caenorhabditis elegans] NP_509318.1 
2  77  157  +  ATP synthase F0 subunit 6 [Cooperia oncophora] NP_851326.1 
1105  0  13  +  ATP synthase subunit family member (atp-2) [Caenorhabditis elegans] NP_498111.2 
1729  0  13  +  Bifunctional glyoxylate cycle protein [Caenorhabditis elegans] AAA85857.1 
840  0  9  +  cDNA sequence BC017158 [Brugia malayi] XP_001896227.1 
1771  0  12  +  Chain A, Glutathione Transferase-2, Apo Form [Heligmosomoides polygyrus] 1TW9_A  
1345  0  9  +  Chaperonin Containing TCP-1 family member (cct-8) [Caenorhabditis elegans] NP_500035.2 
858  0  15  +  Chitin-Binding Domain protein family member (cbd-1) [Caenorhabditis elegans] NP_502145.2 
455  5  39  +  Conserved Germline Helicase family member (cgh-1) [Caenorhabditis elegans] NP_498646.1 
1653  0  10  +  C-type single domain activation associated secreted protein [Ostertagia ostertagi] CAO00416.1 
410  982  1531  +  Cytochrome c oxidase subunit I [Cooperia oncophora] NP_851331.1 
117  306  538  +  Cytochrome c oxidase subunit I [Cooperia oncophora] NP_851331.1 264 
Cluster  U reads  T reads  Change  BLAST Identity 
99  422  703  +  Cytochrome c oxidase subunit III [Cooperia oncophora] NP_851329.1 
1260  0  9  +  Delta6-fatty-acid-desaturase [Caenorhabditis elegans] AAC15586.1 
1133  0  9  + 
DNaJ  domain  (prokaryotic  heat  shock  protein)  family  member  (dnj-13)  [Caenorhabditis  elegans]  
NP_496468.1 
649  124  239  +  Elongation FacTor family member (eft-2) [Caenorhabditis elegans] NP_492457.1 
1187  0  13  +  Enhancer of PolyComb-like family member (epc-1) [Caenorhabditis elegans] NP_499642.2 
652  16  73  +  Eukaryotic translation elongation factor 1A [Ancylostoma ceylanicum] DAA05878.1 
918  0  9  +  Exportin (nuclear export receptor) family member (xpo-1) [Caenorhabditis elegans] NP_741567.1 
874  0  12  +  F-box/LRR-repeat protein, putative [Pediculus humanus corporis] EEB16685.1 
1728  0  9  +  GF24664 [Drosophila ananassae] XP_001956296.1 
1266  0  11  +  GJ11426 [Drosophila virilis] XP_002048294.1 
1110  0  10  +  GJ11487 [Drosophila virilis] XP_002048175.1 
1149  0  9  +  GK13711 [Drosophila willistoni] XP_002072638.1 
934  0  31  +  Globin-like ES protein F6 [Ostertagia ostertagi] CAD20463.1 
1082  0  9  +  Groucho/TLE N-terminal Q-rich domain containing protein [Brugia malayi] XP_001901168.1 
969  0  9  +  GTP-binding nuclear protein RAN/TC4 [Brugia malayi] XP_001900408.1 
1671  0  16  +  Heat shock protein 20 [Haemonchus contortus] AAN05752.1 
1739  0  27  +  Heat shock protein 20 [Ostertagia ostertagi] CAG25499.1 
358  0  25  +  Heat shock protein 20 [Ostertagia ostertagi] CAG25499.1 
60  12  38  +  Heat shock protein 20 [Ostertagia ostertagi] CAG25499.1 
630  106  256  +  Heat Shock Protein family member (hsp-16.2) [Caenorhabditis elegans] NP_503507.1 
765  0  10  +  Histone family member (his-35) [Caenorhabditis elegans] NP_505463.1 
925  0  9  +  Hypothetical protein [Brugia malayi] XP_001896639.1 265 
Cluster  U reads  T reads  Change  BLAST Identity 
1705  0  11  +  Hypothetical protein [Leishmania infantum JPCM5] XP_001464917.1 
522  23  64  +  Hypothetical protein [Tetrahymena thermophila SB210] XP_001028745.1 
773  0  9  +  Hypothetical protein B0365.1 [Caenorhabditis elegans] NP_506267.1 
1636  0  12  +  Hypothetical protein BRAFLDRAFT_124962 [Branchiostoma floridae] XP_002225324.1 
1011  0  9  +  Hypothetical protein C05C8.2 [Caenorhabditis elegans] NP_504837.1 
893  0  11  +  Hypothetical protein C07E3.9 [Caenorhabditis elegans] NP_496228.1 
1066  0  10  +  Hypothetical protein C28H8.3 [Caenorhabditis elegans] NP_498283.1 
1740  0  13  +  Hypothetical protein C39D10.7 [Caenorhabditis elegans] NP_509334.2 
1044  0  11  +  Hypothetical protein C50F4.14 [Caenorhabditis elegans] NP_505467.2 
1703  0  14  +  Hypothetical protein CBG00021 [Caenorhabditis briggsae AF16] XP_001666234.1 
1710  0  10  +  Hypothetical protein CBG01069 [Caenorhabditis briggsae AF16] XP_001672943.1 
454  236  395  +  Hypothetical protein CBG01578 [Caenorhabditis briggsae AF16] XP_001671326.1 
1002  0  16  +  Hypothetical protein CBG01670 [Caenorhabditis briggsae AF16] XP_001671249.1 
266  2  32  +  Hypothetical protein CBG02470 [Caenorhabditis briggsae AF16] XP_001679726.1 
623  0  12  +  Hypothetical protein CBG02815 [Caenorhabditis briggsae AF16] XP_001679448.1 
457  162  348  +  Hypothetical protein CBG03358 [Caenorhabditis briggsae AF16] XP_001670763.1 
1719  0  9  +  Hypothetical protein CBG07973 [Caenorhabditis briggsae] CAP27887.1 
502  336  349  +  Hypothetical protein CBG09272 [Caenorhabditis briggsae AF16] XP_001674277.1 
275  130  301  +  Hypothetical protein CBG12450 [Caenorhabditis briggsae AF16] XP_001668445.1 
788  0  10  +  Hypothetical protein CBG12789 [Caenorhabditis briggsae AF16] XP_001668986.1 
687  0  9  +  Hypothetical protein CBG13605 [Caenorhabditis briggsae AF16] XP_001669195.1 
839  0  12  +  Hypothetical protein CBG17994 [Caenorhabditis briggsae AF16] XP_001665645.1 
464  84  284  +  Hypothetical protein CBG18692 [Caenorhabditis briggsae AF16] XP_001669248.1 266 
Cluster  U reads  T reads  Change  BLAST Identity 
1648  0  14  +  Hypothetical protein CBG18692 [Caenorhabditis briggsae AF16] XP_001669248.1 
1669  0  15  +  Hypothetical protein CBG19186 [Caenorhabditis briggsae AF16] XP_001674556.1 
181  0  16  +  Hypothetical protein CBG21168 [Caenorhabditis briggsae AF16] XP_001666373.1 
1094  0  9  +  Hypothetical protein Csp3_JD02.002 [Caenorhabditis sp. PS1010] ACI49174.1 
1690  0  13  +  Hypothetical protein Csp3_JD03.008 [Caenorhabditis sp. PS1010] ACI49199.1 
1633  0  9  +  Hypothetical protein Csp3_JD05.001 [Caenorhabditis sp. PS1010] ACI49216.1 
910  0  11  +  Hypothetical protein F25B4.6 [Caenorhabditis elegans] NP_504496.1 
571  0  10  +  Hypothetical protein F41C3.5 [Caenorhabditis elegans] NP_494846.1 
1664  0  15  +  Hypothetical protein F42A8.3 [Caenorhabditis elegans] NP_495993.2 
1763  0  30  +  Hypothetical protein L3ni51 [Dictyocaulus viviparus] AAT02162.1 
933  0  9  +  Hypothetical protein Y46G5A.13 [Caenorhabditis elegans] NP_496718.1 
1190  0  10  +  Hypothetical protein Y57G11C.9 [Caenorhabditis elegans] NP_502785.2 
1229  0  9  +  Hypothetical protein Y69E1A.1 [Caenorhabditis elegans] NP_502038.1 
1078  0  9  +  Hypothetical protein ZC416.2 [Caenorhabditis elegans] NP_500388.2 
1344  0  9  +  Metalloprotease IV [Ostertagia ostertagi] AAS47831.1 
1134  0  11  +  Myosin heavy chain [Trypanosoma cruzi strain CL Brener] XP_808187.1 
78  197  449  +  NADH dehydrogenase subunit 1 [Cooperia oncophora] NP_851325.1 
666  278  532  +  NADH dehydrogenase subunit 2 [Bunostomum phlebotomum] YP_002725706.1 
412  373  677  +  No hits found 
1686  0  28  +  No hits found 
1783  0  21  +  No hits found 
1008  0  17  +  No hits found 
750  0  16  +  No hits found 267 
Cluster  U reads  T reads  Change  BLAST Identity 
647  338  540  +  No hits found 
721  0  12  +  No hits found 
1780  0  10  +  No hits found 
1726  0  10  +  No hits found 
1632  0  10  +  No hits found 
822  0  10  +  No hits found 
903  0  11  +  No hits found 
310  0  11  +  No hits found 
1775  0  11  +  No hits found 
494  31  73  +  No hits found 
1076  0  9  +  No hits found 
772  0  9  +  No hits found 
957  0  9  +  No hits found 
749  0  9  +  No hits found 
882  0  9  +  No hits found 
889  0  9  +  No hits found 
805  0  9  +  No hits found 
1742  0  9  +  No hits found 
1051  0  9  +  No hits found 
37  11  41  +  Paralysed Arrest at Two-fold family member (pat-10) [Caenorhabditis elegans] NP_491501.1 
1693  0  14  + 
PCNA  (Proliferating  Cell  Nuclear  Antigen)  homolog  family  member  (pcn-1)  [Caenorhabditis  elegans] 
NP_500466.2 
932  0  9  +  Peptidase family M1 containing protein [Brugia malayi] XP_001897028.1 268 
Cluster  U reads  T reads  Change  BLAST Identity 
1135  0  10  +  Predicted protein [Nematostella vectensis] XP_001633893.1 
668  28  91  +  Predicted: hypothetical protein [Monodelphis domestica] XP_001375856.1 
711  0  14  +  Predicted: similar to Aconitase CG9244-PB [Apis mellifera] XP_391994.1 
537  3  24  +  Pre-mRNA cleavage complex II protein Clp1 [Brugia malayi] XP_001895648.1 
1716  0  10  +  Putative hexose transporter 2 [Babesia bovis] ABY75261.1 
1663  0  10  +  Putative secretory protein precursor; HC40 [Haemonchus contortus] AAC03562.1 
753  0  9  +  Putative ubiquitin conjugating enzyme 2 [Oesophagostomum dentatum] CAJ57642.1 
961  0  9  +  Receptor Mediated Endocytosis family member (rme-2) [Caenorhabditis elegans]  NP_500815.2 
1065  0  9  +  Ribosomal protein S9 [Danio rerio] NP_957146.1 
1701  0  11  +  Ribosomal Protein, Large subunit family member (rpl-11.2) [Caenorhabditis elegans] NP_508413.1 
1761  0  10  +  RNA recognition motif domain containing protein [Brugia malayi] XP_001894321.1 
629  490  925  +  rRNA promoter binding protein [Brugia malayi] XP_001891902.1 
1665  0  21  +  Secreted protein 6 precursor [Ancylostoma caninum] AAO63578.1 
793  0  9  + 
SideroFleXiN  (mitochondrial  iron  transporter)  family  member  (sfxn-1.4)  [Caenorhabditis  elegans] 
NP_496493.1 
789  0  9  +  SUMO (ubiquitin-related) homolog family member (smo-1) [Caenorhabditis elegans] NP_490842.1 
1170  0  10  +  Troponin T [Brugia malayi] XP_001902458.1 
1631  0  11  +  Ubiquitin Conjugating enzyme family member (ubc-3) [Caenorhabditis elegans] NP_490882.3 
700  0  10  +  Venom-Allergen-like Protein family member (vap-1) [Caenorhabditis elegans] NP_001024553.1 
287  66  200  +  Vitellogenin [Haemonchus contortus] AF305957_1 
591  65  173  +  Vitellogenin-6; Flags: Precursor [Oscheius brevesophaga] Q94637.1 
2039  9  0  -  Alpha-1,6-mannosyltransferase subunit (Och1), putative [Talaromyces stipitatus ATCC 10500] EED17616.1 
17  24  11  -  Amino  acid  Transporter  GlycoProtein  subunit  family  member  (atgp-2)  [Caenorhabditis  elegans] 269 
Cluster  U reads  T reads  Change  BLAST Identity 
NP_497043.2 
1804  6  0  -  Anaphase-promoting complex subunit 2-like [Brugia malayi] XP_001894849.1 
626  98  73  -  Ancyclostoma-secreted protein-like protein [Ostertagia ostertagi] CAD56659.1 
2233  9  0  -  Argonaute protein [Brugia malayi] XP_001892201.1 
2529  7  0  -  Aspartic protease [Ostertagia ostertagi] CAC14005.1 
2098  7  0  -  BESS motif family protein [Brugia malayi] XP_001900724.1 
1840  8  0  -  Bifunctional glyoxylate cycle protein [Caenorhabditis elegans] AAA85857.1 
87  10  0  -  C. briggsae CBR-ATG-2 protein [Caenorhabditis briggsae] CAP30290.1 
1919  9  0  -  C. briggsae CBR-PRX-11 protein [Caenorhabditis briggsae] CAP27856.1 
447  37  17  -  C. elegans protein F53B2.5, partially confirmed by transcrip [Caenorhbditis elegans] CAA98127.3 
2473  6  0  -  CD151 antigen, putative [Ixodes scapularis] EEC13496.1 
2511  7  0  -  Chitin binding Peritrophin-A domain containing protein [Brugia malayi] XP_001895704.1 
2498  10  0  -  Conserved hypothetical protein [Brugia malayi] XP_001898151.1 
1903  6  0  -  Conserved hypothetical protein [Brugia malayi] XP_001900985.1 
605  29  0  -  C-type single domain activation associated secreted protein [Ostertagia ostertagi] CAO00416.1 
2547  6  0  - 
C-type  single  domain  activation  associated  secreted  protein  ASP3  precursor  [Ostertagia  ostertagi]  
CAO00416.1 
456  172  116  - 
C-type  single  domain  activation  associated  secreted  protein  ASP3  precursor  [Ostertagia  ostertagi] 
CAO00416.1 
646  166  113  - 
C-type  single  domain  activation  associated  secreted  protein  ASP3  precursor  [Ostertagia  ostertagi] 
CAO00416.1 
616  61  31  - 
C-type  single  domain  activation  associated  secreted  protein  ASP3  precursor  [Ostertagia  ostertagi] 
CAO00416.1 270 
Cluster  U reads  T reads  Change  BLAST Identity 
2116  10  0  -  Cyclin, N-terminal domain containing protein [Brugia malayi] XP_001891912.1 
1918  6  0  -  Cyclophylin family member (cyn-1) [Caenorhabditis elegans] NP_506561.1 
1912  6  0  -  DIRP family protein [Brugia malayi] XP_001900735.1 
2567  8  0  -  E5 [Human papillomavirus type 69] BAA90732.1 
2518  24  0  -  Endochitinase [Schizosaccharomyces japonicus yFS275] XP_002171895.1 
1983  11  0  -  Fatty Acid CoA Synthetase family member (acs-16) [Caenorhabditis elegans] NP_498568.1 
1947  6  0  -  FHA domain-containing protein [Myxococcus xanthus DK 1622] YP_632168.1 
2109  9  0  -  Fructose-bisphosphate aldolase 1 [Brugia malayi] XP_001894530.1 
1936  6  0  -  GABA TransAminase family member (gta-1) [Caenorhabditis elegans] NP_501862.1 
2541  15  0  -  Gag-pol polyprotein [Schistosoma mansoni] CAJ00230.1 
435  30  10  -  GEX Interacting protein family member (gei-7) [Caenorhabditis elegans] NP_503306.1 
1964  18  0  -  Globin-like host-protective antigen; Flags: Precursor [Trichostrongylus colubriformis] P27613.1 
2488  10  0  -  Glycerol-3-phosphate dehydrogenase [Ctenolepisma longicaudata] AAR13229.1 
2521  8  0  -  Heat shock protein 20 [Haemonchus contortus] AAN05752.1 
1871  15  0  -  Heat shock protein 20 [Ostertagia ostertagi] CAG25499.1 
651  85  49  -  Heat Shock Protein family member (hsp-16.1) [Caenorhabditis elegans] NP_505354.1 
2060  8  0  -  Heat Shock Protein family member (hsp-16.2) [Caenorhabditis elegans] NP_503507.1 
2212  6  0  -  Helicase conserved C-terminal domain containing protein [Brugia malayi] XP_001901253.1 
2153  8  0  -  Hypothetical protein [Monosiga brevicollis MX1] XP_001743138.1 
1985  9  0  -  Hypothetical protein [Plasmodium falciparum 3D7] XP_001350649.1 
1920  6  0  -  Hypothetical protein Bm1_13905 [Brugia malayi] XP_001894245.1 
2035  11  0  -  Hypothetical protein BRAFLDRAFT_233880 [Branchiostoma floridae] XP_002235185.1 
664  87  72  -  Hypothetical protein C04G2.9 [Caenorhabditis elegans] NP_501838.2 271 
Cluster  U reads  T reads  Change  BLAST Identity 
94  50  34  -  Hypothetical protein C07D8.6 [Caenorhabditis elegans] NP_509242.1 
2013  6  0  -  Hypothetical protein C08H9.2 [Caenorhabditis elegans] NP_001129807.1 
1786  6  0  -  Hypothetical protein C10G11.8 [Caenorhabditis elegans] NP_491811.1 
1905  7  0  -  Hypothetical protein C14B1.10 [Caenorhabditis elegans] NP_497751.1 
1990  7  0  -  Hypothetical protein C16C8.18 [Caenorhabditis elegans] NP_494539.1 
2234  6  0  -  Hypothetical protein CBG00644 [Caenorhabditis briggsae AF16] XP_001678643.1 
2371  6  0  -  Hypothetical protein CBG00694 [Caenorhabditis briggsae AF16] XP_001678605.1 
2475  7  0  -  Hypothetical protein CBG01426 [Caenorhabditis briggsae AF16] XP_001673254.1 
543  354  260  -  Hypothetical protein CBG01578 [Caenorhabditis briggsae AF16] XP_001671326.1 
2503  6  0  -  Hypothetical protein CBG02238 [Caenorhabditis briggsae AF16] XP_001668494.1 
588  8  0  -  Hypothetical protein CBG02304 [Caenorhabditis briggsae AF16] XP_001679863.1 
1927  6  0  -  Hypothetical protein CBG02746 [Caenorhabditis briggsae AF16] XP_001679501.1 
2263  8  0  -  Hypothetical protein CBG03108 [Caenorhabditis briggsae AF16] XP_001679208.1 
2524  11  0  -  Hypothetical protein CBG04059 [Caenorhabditis briggsae AF16] XP_001668188.1 
2015  6  0  -  Hypothetical protein CBG04059 [Caenorhabditis briggsae AF16] XP_001668188.1 
2120  9  0  -  Hypothetical protein CBG04320 [Caenorhabditis briggsae AF16] XP_001678833.1 
2122  9  0  -  Hypothetical protein CBG04454 [Caenorhabditis briggsae AF16] XP_001671526.1 
1948  6  0  -  Hypothetical protein CBG05408 [Caenorhabditis briggsae AF16] XP_001670625.1 
2175  11  0  -  Hypothetical protein CBG08653 [Caenorhabditis briggsae AF16] XP_001673371.1 
1806  13  0  -  Hypothetical protein CBG08658 [Caenorhabditis briggsae AF16] XP_001673367.1 
361  82  67  -  Hypothetical protein CBG08717 [Caenorhabditis briggsae AF16] XP_001669329.1 
2214  7  0  -  Hypothetical protein CBG08774 [Caenorhabditis briggsae AF16] XP_001672562.1 
2520  7  0  -  Hypothetical protein CBG09451 [Caenorhabditis briggsae AF16] XP_001674131.1 272 
Cluster  U reads  T reads  Change  BLAST Identity 
2528  6  0  -  Hypothetical protein CBG09806 [Caenorhabditis briggsae AF16] XP_001665103.1 
1908  10  0  -  Hypothetical protein CBG09896 [Caenorhabditis briggsae AF16] XP_001665184.1 
2378  6  0  -  Hypothetical protein CBG11896 [Caenorhabditis briggsae AF16] XP_001667421.1 
2133  9  0  -  Hypothetical protein CBG12251 [Caenorhabditis briggsae AF16] XP_001666259.1 
1922  8  0  -  Hypothetical protein CBG12316 [Caenorhabditis briggsae AF16] XP_001668329.1 
2157  8  0  -  Hypothetical protein CBG12597 [Caenorhabditis briggsae AF16] XP_001668827.1 
1866  7  0  -  Hypothetical protein CBG13426 [Caenorhabditis briggsae AF16] XP_001678475.1 
2526  8  0  -  Hypothetical protein CBG15925 [Caenorhabditis briggsae AF16] XP_001667359.1 
2132  10  0  -  Hypothetical protein CBG16572 [Caenorhabditis briggsae AF16] XP_001665476.1 
2089  6  0  -  Hypothetical protein CBG17431 [Caenorhabditis briggsae AF16] XP_001676058.1 
2199  6  0  -  Hypothetical protein CBG17919 [Caenorhabditis briggsae] CAP35459.1 
2048  18  0  -  Hypothetical protein CBG17992 [Caenorhabditis briggsae AF16] XP_001665643.1 
1994  7  0  -  Hypothetical protein CBG18189 [Caenorhabditis briggsae AF16] XP_001665804.1 
2522  8  0  -  Hypothetical protein CBG18268 [Caenorhabditis briggsae AF16] XP_001665868.1 
2561  6  0  -  Hypothetical protein CBG19105 [Caenorhabditis briggsae AF16] XP_001674484.1 
1813  7  0  -  Hypothetical protein CBG21198 [Caenorhabditis briggsae AF16] XP_001666345.1 
1837  7  0  -  Hypothetical protein CBG22304 [Caenorhabditis briggsae AF16] XP_001667777.1 
2381  6  0  -  Hypothetical protein CBG24043 [Caenorhabditis briggsae] CAP20747.1 
1961  7  0  -  Hypothetical protein CBG24742 [Caenorhabditis briggsae AF16] XP_001678957.1 
1896  8  0  -  Hypothetical protein D1037.1 [Caenorhabditis elegans] NP_491200.1 
2069  14  0  -  Hypothetical protein F11C1.1 [Caenorhabditis elegans] NP_510159.1 
1923  6  0  -  Hypothetical protein F13H8.7 [Caenorhabditis elegans] NP_495261.1 
499  22  10  -  Hypothetical protein F23B12.4 [Caenorhabditis elegans] NP_001122926.2 273 
Cluster  U reads  T reads  Change  BLAST Identity 
1889  10  0  -  Hypothetical protein F52E1.2 [Caenorhabditis elegans] NP_505170.2 
321  22  9  -  Hypothetical protein F53B6.7 [Caenorhabditis elegans] NP_492409.2 
507  70  40  -  Hypothetical protein F54H12.6 [Caenorhabditis elegans] NP_498737.1 
2523  9  0  -  Hypothetical protein HcanM9_03085 [Helicobacter canadensis MIT 98-5491]  ZP_03656248.1 
65  20  6  -  Hypothetical protein K03E5.2d [Caenorhabditis elegans] ACO15785.1 
1930  15  0  -  Hypothetical protein K09E9.4 [Caenorhabditis elegans] NP_001024780.1 
2554  9  0  -  Hypothetical protein K12G11.6 [Caenorhabditis elegans] CAF31481.2 
1827  23  0  -  Hypothetical protein L3ni51 [Dictyocaulus viviparus] AAT02162.1 
2462  8  0  -  Hypothetical protein M176.4 [Caenorhabditis elegans] NP_496013.2 
2497  11  0  -  Hypothetical protein NEMVEDRAFT_v1g141408 [Nematostella vectensis]  XP_001622397.1 
419  24  2  -  Hypothetical protein PC101070.00.0 [Plasmodium chabaudi chabaudi] CAH88354.1 
84  58  28  -  Hypothetical protein R09E10.6 [Caenorhabditis elegans] NP_501889.1 
116  7  0  -  Hypothetical protein SS1G_07081 [Sclerotinia sclerotiorum 1980 UF-70] XP_001591635.1 
1873  7  0  -  Hypothetical protein T10G3.3 [Caenorhabditis elegans] NP_506346.2 
2224  8  0  -  Hypothetical protein Y110A7A.19 [Caenorhabditis elegans] NP_491536.1 
1812  6  0  -  Hypothetical protein Y1A5A.1 [Caenorhabditis elegans] NP_497801.1 
394  23  6  -  Hypothetical protein Y38F1A.2 [Caenorhabditis elegans] NP_496760.1 
527  27  10  -  Hypothetical protein Y69A2AR.7 [Caenorhabditis elegans] NP_741338.1 
2144  9  0  -  Hypothetical protein ZK1307.8 [Caenorhabditis elegans] NP_496073.1 
2169  6  0  -  Hypothetical protein ZK795.4 [Caenorhabditis elegans] NP_001023622.1 
2551  8  0  -  Hypothetical protein ZK970.8 [Caenorhabditis elegans] NP_001022541.1 
1808  10  0  -  IntraMembrane Protease (IMPAS) family member (imp-2) [Caenorhabditis elegans] NP_502079.1 
14  22  8  -  Kelch-like protein X [Brugia malayi] XP_001898633.1 274 
Cluster  U reads  T reads  Change  BLAST Identity 
1834  6  0  -  Lipid Binding Protein family member (lbp-9) [Caenorhabditis elegans] NP_001033511.1 
1797  6  0  -  Lysozyme family member (lys-10) [Caenorhabditis elegans] NP_501405.1 
2552  7  0  -  Maternal Effect Lethal family member (mel-11) [Caenorhabditis elegans] NP_001021928.1 
2508  7  0  -  Metalloprotease I [Ostertagia ostertagi] CAD28559.2 
2052  7  0  -  MSP domain containing protein [Brugia malayi] XP_001898260.1 
2559  9  0  -  Multiple PDZ domain protein family member (mpz-1) [Caenorhabditis elegans] NP_001122601.1 
2570  26  0  -  No hits found 
243  75  24  -  No hits found 
2531  21  0  -  No hits found 
1799  18  0  -  No hits found 
2516  15  0  -  No hits found 
193  45  18  -  No hits found 
2515  12  0  -  No hits found 
178  33  11  -  No hits found 
2500  11  0  -  No hits found 
2501  10  0  -  No hits found 
2509  10  0  -  No hits found 
2539  10  0  -  No hits found 
608  10  0  -  No hits found 
204  77  52  -  No hits found 
1819  9  0  -  No hits found 
1789  9  0  -  No hits found 
2544  9  0  -  No hits found 275 
Cluster  U reads  T reads  Change  BLAST Identity 
514  9  0  -  No hits found 
1845  8  0  -  No hits found 
2215  8  0  -  No hits found 
2002  7  0  -  No hits found 
569  7  0  -  No hits found 
1921  7  0  -  No hits found 
1976  7  0  -  No hits found 
2560  7  0  -  No hits found 
2198  7  0  -  No hits found 
2077  7  0  -  No hits found 
2171  7  0  -  No hits found 
1928  7  0  -  No hits found 
1856  7  0  -  No hits found 
2566  7  0  -  No hits found 
235  101  87  -  No hits found 
2274  6  0  -  No hits found 
2093  6  0  -  No hits found 
2321  6  0  -  No hits found 
1851  6  0  -  No hits found 
2279  6  0  -  No hits found 
2569  6  0  -  No hits found 
2032  6  0  -  No hits found 
2377  6  0  -  No hits found 276 
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64  6  0  -  No hits found 
2242  6  0  -  No hits found 
2055  6  0  -  No hits found 
2064  6  0  -  No hits found 
2080  6  0  -  No hits found 
2513  6  0  -  No hits found 
2165  6  0  -  No hits found 
1906  6  0  -  No hits found 
1830  6  0  -  No hits found 
1917  6  0  -  No hits found 
2328  6  0  -  No hits found 
2148  6  0  -  No hits found 
2176  6  0  -  No hits found 
612  6  0  -  No hits found 
2272  6  0  -  No hits found 
2542  6  0  -  No hits found 
2091  6  0  -  No hits found 
1999  6  0  -  No hits found 
2117  6  0  -  No hits found 
2143  6  0  -  No hits found 
1931  6  0  -  No hits found 
1878  6  0  -  No hits found 
1965  6  0  -  No hits found 277 
Cluster  U reads  T reads  Change  BLAST Identity 
2268  6  0  -  No hits found 
2155  6  0  -  No hits found 
1816  7  0  -  Paramyosin [Dictyocaulus viviparus] ABO07440.1 
2555  6  0  -  Precursor transthyretin like protein 1 [Ostertagia ostertagi] CAP45649.1 
2510  6  0  -  Predicted protein [Nematostella vectensis] XP_001627195.1 
1824  10  0  -  Predicted: hypothetical protein [Apis mellifera] XP_001121281.1 
353  24  4  - 
Predicted: similar to  AGRin (synaptic protein) homolog  family  member (agr-1) [Hydra magnipapillata] 
XP_002157711.1 
49  101  44  -  Predicted: similar to cell division cycle 2-like 5 isoform 2 [Rattus norvegicus] XP_001053609.1 
2266  6  0  -  Predicted: similar to collagen, type XXVIII [Hydra magnipapillata] XP_002166419.1 
2273  6  0  -  Predicted: similar to conserved hypothetical protein [Tribolium castaneum] XP_971602.1 
1795  7  0  - 
Predicted:  similar  to  DEAD  (Asp-Glu-Ala-Asp)  box  polypeptide  [Strongylocentrotus  purpuratus] 
XP_785431.2 
2478  13  0  - 
Predicted:  similar  to  egg  bindin  receptor  1  precursor,  partial  [Strongylocentrotus  purpuratus] 
XP_001177184.1 
290  113  64  - 
Predicted:  similar  to  hect  (homologous  to  the  E6-AP  (UBE3A)  [Ornithorhynchus  anatinus] 
XP_001514757.1 
2545  6  0  -  Predicted: similar to nahoda CG12781-PA [Danio rerio] XP_698035.3 
620  21  3  -  Predicted: similar to polyubiquitin [Nasonia vitripennis] XP_001599434.1 
2241  6  0  -  Predicted: similar to predicted protein [Hydra magnipapillata] XP_002160784.1 
1933  7  0  -  Predicted: similar to predicted protein, partial [Hydra magnipapillata] XP_002164783.1 
1978  9  0  -  Predicted: similar to Protein phosphatase 1 regulatory subunit 11 [Ciona intestinalis] XP_002120515.1 
1833  7  0  -  Predicted:  similar  to  spen  homolog,  transcriptional  regulator  (Drosophila)  [Equus  caballus]  278 
Cluster  U reads  T reads  Change  BLAST Identity 
XP_001914854.1 
1979  6  0  -  Protein kinase domain containing protein [Brugia malayi] XP_001900551.1 
1988  7  0  -  Protein RIO1 kinase [Trichostrongylus vitrinus] CAR64255.1 
1898  6  0  -  Putative cathepsin B.1 [Ostertagia ostertagi] CAB97364.2 
1874  7  0  -  Putative L3 ES protein [Ostertagia ostertagi] CAH23216.1 
2525  8  0  -  Putative secretory protein precursor; HC40 [Haemonchus contortus] AAC03562.1 
673  47  28  -  Putative secretory protein precursor; HC40 [Haemonchus contortus] AAC03562.1 
1916  16  0  -  Putative serine/threonine phosphatase [Oesophagostomum dentatum] AF496634_1 
140  21  8  -  Regulator of Microtubule Dynamics family member (rmd-2) [Caenorhabditis elegans] NP_741608.1 
1893  6  0  -  RiboNucleotide Reductase family member (rnr-1) [Caenorhabditis elegans] NP_499039.1 
2472  16  0  -  RNA recognition motif domain containing protein [Brugia malayi] XP_001894321.1 
2530  12  0  -  Secreted protein 5 precursor [Ancylostoma caninum] AAO63577.1 
1910  9  0  -  Secreted protein 5 precursor [Ancylostoma caninum] AAO63577.1 
2482  8  0  -  Secreted protein 5 precursor [Ancylostoma caninum] AAO63577.1 
2477  14  0  -  Secreted protein 5 precursor [Ancylostoma ceylanicum] ABB53347.1 
2262  6  0  -  Splicing factor, arginine/serine-rich 4 [Brugia malayi] XP_001902042.1 
669  20  6  -  SXC1 protein [Ostertagia ostertagi] CAC17797.1 
674  31  17  -  SXC1 protein [Ostertagia ostertagi] CAC17797.1 
2070  11  0  -  TBC (Tre-2/Bub2/Cdc16) domain family member (tbc-3) [Caenorhabditis elegans] NP_001023165.1 
1998  7  0  -  Temporarily Assigned Gene name family member (tag-192) [Caenorhabditis elegans] NP_491426.2 
2496  9  0  -  Trypsin-like Protease family member (try-1) [Caenorhabditis elegans] NP_494910.2 
2023  8  0  -  Tubulin alpha chain [Haemonchus contortus]  P50719.1 
2504  6  0  -  Ubiquitin [Lepeophtheirus salmonis] ACO11811.1 279 
Cluster  U reads  T reads  Change  BLAST Identity 
1890  6  0  -  Ubiquitin, putative [Pediculus humanus corporis] EEB18688.1 
418  226  160  -  Vitellogenin [Haemonchus contortus] AF305957_1 
583  64  24  - 
Vitellogenin  structural  genes  (yolk  protein  genes)  family  member  (vit-6)  [Caenorhabditis  elegans]. 
NP_001023274.1 
169  310  233  -  Vitellogenin-6; Flags: Precursor [Oscheius brevesophaga] Q94637.1 
2033  6  0  -  Zinc finger, C2H2 type family protein [Brugia malayi] XP_001901497.1 
1963  7  0  -  Zinc finger, C2H2 type family protein [Brugia malayi] XP_001901967.1 
 
 